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THE SKELETON AND BONE TISSUE
A typical adult human skeleton consists of 206 bones of varying shapes and sizes to match their func-
tions. Why do we have bones? The skeleton provides a frame to support the body and protects our inner 
organs. Without our bony structures, we would be a jelly-fi sh-like mass unable to sit or stand upright. 
Sites where bones connect to each other are called joints and muscles are attached to the bones by 
tendons. Altogether, this musculoskeletal system enables movement. Further, bone acts as a reservoir 
for minerals, such as calcium and phosphorus, salts, and growth factors including insulin-like growth 
factor-I (IGF-I).1, 2 Additionally, the marrow located in the interior of certain bones produces red and 
white blood cells. Finally, in recent years it has become evident that we should regard bone tissue as a 
metabolically active endocrine organ, which produces hormones such as fi broblast growth factor – 23 
(FGF-23)3 and osteocalcin4.
There are two types of bone tissue in the human skeleton, namely cortical and trabecular (Figure 
1). Most human bones consist of an outer shell of cortical bone that surrounds the inner trabecular 
elements. Cortical bone tends to be harder, stiff er and heavier than trabecular bone. Nevertheless, load 
sharing between cortical and trabecular bone compartments varies between skeletal sites; for example 
cortical bone contributes relatively more to bone strength in the femoral necks than it does in the ver-
tebral bodies.5, 6 Bone is a dynamic organ, constantly undergoing remodeling, which involves a coupled 
process of resorption by bone-destroying cells, i.e., osteoclasts and bone formation by bone-building 
cells, i.e., osteoblasts. When osteoblasts become embedded in the matrix that they secrete, they become 
osteocytes, which compose the far majority of all cells in adult bone (Figure 2).3 The bone remodeling 
balance is under control of various stimulatory and inhibitory eff ects at the same time. Mechanical load-
ing through increased Wnt/beta-catenin signaling is a very important stimulatory factor; for instance, 
astronauts lose an average of more than 1% of their bone mass per month when weightless in space. 
Also, hormonal eff ects have a very prominent stimulatory role on bone, including sex steroids, vitamin 
D, parathyroid hormone, calcitonin, the aforementioned IGF-I and insulin.7, 8 Inhibitory factors are, for 
example, exposure to toxic substances, glucocorticoids and infl ammation.9-12 Furthermore, diff erent fac-
tors may infl uence the effi  ciency of aforementioned regulatory processes. For instance, high glucose and 
advanced glycation endproducts (AGEs) may blunt the stimulatory actions of IGF-I on osteoblasts13-15 
and, additionally, they can directly compromise bone material properties.16
	
Figure 1. Cross-sections of a 
normal (left) and an osteopo-
rotic (right) hip bone showing 
cortical and trabecular com-
ponents. Adapted from http://
www.hughston.com/hha/a.
osteo.htm
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Figure 2. Stages of the bone remodeling process depicting bone-destroying cells, i.e., osteoclasts, bone-building 
cells, i.e., osteoblasts, and osteocytes. Source http:\\www.medscape.com
OSTEOPOROSIS AND FRACTURES
Normally, bone resorption and bone formation are well-balanced through regulation by hormones, 
growth factors and cytokines.17 Resorption is necessary for bone repair, as illustrated by the condition 
pycnodysostosis, a form of osteopetrosis due to defective osteoclasts, where patients have an increased 
fracture risk despite a high bone mass.18 However, more commonly, when bone resorption is higher than 
bone formation, this leads to bone loss. Osteoporosis is a disease characterized by low bone mass and 
microarchitectural deterioration of bone tissue, leading to enhanced bone fragility and a consequent 
increase in fracture risk.19 It is the most common metabolic bone disease, with the most common 
skeletal sites of fracture being the spine, hip and wrist (Figure 3).20 Of the population aged 50–84 years, 
approximately 50% are classified as having osteopenia and 20% as having osteoporosis and it has been 
estimated that after the age of 50 years up to 1 in 2 women and 1 in 4 men will suffer a major osteo-
porotic fracture in their remaining lifetime.21, 22 These fractures are associated with a high morbidity and 
mortality.23 Worldwide, osteoporosis causes more than 9 million fractures annually, which is equivalent 
to an osteoporotic fracture every 3 seconds.24 The greatest number of osteoporotic fractures occur in 
Europe, where osteoporotic fractures account for more disability-adjusted life years (DALYs, a measure 
for disease burden) lost than common cancers with the exception of lung cancer.24 Moreover, the death 
rate for all low-trauma fractures in older men and women is increased immediately post-fracture with 
a quarter of hip fracture patients dying within 6 months due to complications, but mortality remains 
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elevated also for many years thereafter.25, 26 Given the “greying” (i.e., ageing) of populations, osteoporotic 
fractures are likely to become an even increasingly important health issue. The annual cost of treating all 
types of fracture has been projected at $17 billion in the United States and is predicted to have increased 
50% by 2025.27
Figure 3. Image representations at the top and radiographs at the bottom for the most common skeletal sites of os-
teoporotic fractures, i.e. the spine, hip and wrist. Parts obtained and adapted from http://www.orthopaedicsurgeon.
com.sg/what-you-need-to-know-about-osteoporosis/ and http://www.medicalmultimediagroup.com/
SKELETAL DIAGNOSTICS
The most well-studied clinical risk factors for osteoporosis and fractures include age, lower body mass 
index,28 smoking,29 alcohol consumption30 and glucocorticoid use31. Additionally, a positive family his-
tory confers an increased risk of fracture.32 The term secondary osteoporosis refers to disorders that are 
strongly associated with osteoporosis;33 these include rheumatoid arthritis, diabetes, hypogonadism 
(including premature menopause), malnutrition and malabsorption. Furthermore, prior fracture34-36 
and bone mineral density37 are particularly strong predictors of future osteoporotic fractures. Several 
clinical risk score calculators are available which enable physicians to calculate the future risk of osteo-
porotic fractures in patients, such as the World Health Organization’s (WHO) fracture risk assessment 
tool (FRAX).38 Although these algorithms represent major advances in clinical practice, clinicians should 
be aware that the calculations do not accommodate all known risk factors and there are more fracture 
determinants remaining to be discovered.39
Dual-energy X-ray absorptiometry (DXA) at the lumbar spine and hip (Figure 4) to measure BMD is a 
routine investigation in osteoporosis, because, as stated before, BMD constitutes one of the strongest 
predictors of future fracture with each standard deviation (SD) decrease of BMD being associated with 
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a two-fold increase in fracture risk.21, 38 The BMD measured is most commonly expressed as the T score, 
the number of standard deviations above or below the mean for a healthy 30 year old adult of the same 
sex and ethnicity as the patient. Subsequently, osteoporosis is defi ned as a T score≤-2.5 and osteopenia 
as a T score≤-1.0 at any skeletal site. No upper reference value has been proposed, as the adverse health 
eff ects of having an increased BMD have been poorly studied. Intriguingly, the far majority of fractures 
occur in individuals without an abnormal clinically assessed bone mineral density.21 In addition, several 
diseases are paradoxically known to be associated with a higher fracture risk despite a higher bone 
mineral density, such as diabetes-related bone disease and degenerative disease. There is increasing 
evidence supporting an association between type 2 diabetes and increased fracture risk, even though 
individuals with type 2 diabetes have on average a high BMD.40-43 Also, the increased BMD in subjects 
with lumbar disc degeneration (LDD) would theoretically protect against fractures, however, a few stud-
ies which examined the relationship between LDD and fractures found confl icting results.44-47 Another 
valuable evaluation in osteoporosis is vertebral fracture assessment on lateral DXA or radiography (Fig-
ure 5). However, there is currently no gold standard for osteoporotic vertebral fracture diagnosis48 and 
several radiological scoring methods exist, each using diff erent criteria for diagnosing and grading frac-
tures. Such grading defi nitions are currently under debate. In addition, there are a number of diff erential 
diagnoses that have to be considered in individuals with vertebral deformities,49 such as Scheuermann’s 
disease and degenerative changes.50 Scheuermann’s disease is a form of osteochondrosis of the spine 
of unknown etiology characterized by increased posterior rounding of the thoracic spine in association 
with structural deformity of the vertebral elements.51, 52 Experimental assessments for osteoporosis are 
being developed in the research setting by either post-processing of radiographic or DXA data or involv-
ing more advanced imaging modalities such as computed tomography (CT) and magnetic resonance 
imaging (MRI) to appraise bone microarchitecture or bone geometry (i.e., biomechanical characteristics 
of a bone’s size and shape).53-59 Finally, an arsenal of biochemical markers derived from serum, urine, 
DNA or bone biopsy sampling have found their way into clinical practice as they are helpful for the initial 
clinical assessment and for the monitoring of treatment.60 Ideally, we would like to further improve and 
Figure 4. Dual-energy X-ray ab-
sorptiometry (DXA) of the total 
body (left panel), at the lumbar 
spine (upper right panel) and femo-
ral neck (lower right panel) to mea-
sure bone mineral density.
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expand our current diagnostic panels to facilitate precision medicine, the customization of healthcare 
tailored to the individual patient.
Figure 5. Radiological imaging by means of lateral radiographs (X-rays) of the thoracolumbar spine to assess the 
presence of osteoporotic vertebral fractures. Arrows indicate osteoporotic vertebral fractures of vertebral levels T7, T9, 
T10 and T12. The simulated patient photo (left panel) is a courtesy of Hannie van den Boogert.
EPIDEMIOLOGICAL STUDIES
Epidemiology is the science of health and disease in populations; epidemiological research investigates 
frequencies of phenomena of health, the occurrence of illness and related states and events.61 To discover 
the causes of diseases in the elderly we should study risk factors of those diseases.62 Most association 
studies presented in this thesis are based on the Rotterdam Study (Figure 6), a prospective population-
based cohort study of determinants of diseases in elderly men and women in Rotterdam city’s district 
of Ommoord.63 Participant enrolment started in 1990 by inviting all inhabitants aged 55 years and over 
to take part in the study, of which 7,983 subjects (response rate 78%) entered the study (RS-I). In 2000, 
3,011 participants (response rate 67%) who had become 55 years of age or moved into the study district 
since the start of the study were added to the cohort (RS-II). In 2006, a further extension of the cohort 
(RS-III) was initiated in which 3,932 subjects (response rate 65%) aged 45 years and over were included. 
The participants were interviewed at home (2 hours) and had an extensive set of examinations (a total 
of 5 hours) in a specially built research facility in the center of the Ommoord district. These clinically 
state-of-the-art examinations were repeated every 3–4 years. Radiological imaging and collection of 
bodily fl uids for molecular and genetic analyses were performed. Additionally, very comprehensive 
patient health information was obtained from pharmacy medication histories, general practitioners’ 
records and hospital registries. The research projects within the Rotterdam Study endeavor to bring light 
to the prevalences, incidences, risk factors, biomarkers, correlates and consequences of various diseases 
including musculoskeletal and endocrine diseases such as osteoporosis and diabetes.
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GENETIC EPIDEMIOLOGy
As mentioned before, one of the most important risk factors for osteoporosis and fractures is a posi-
tive family history, and reinforces that genetics is at the basis of liability to osteoporosis and fractures.64 
Heritability studies have reported estimates of BMD and fractures of up to 66% and 46%, respec-
tively.65, 66 Nucleotides are the building blocks of the genome. One human genome counts roughly 3 
billion (3,000,000,000) nucleotides. The genetic alphabet is made up of the four nucleotide bases letters 
A, T, G and C. When a single letter (base) in the sequence is swapped for another letter, this is called a 
single nucleotide polymorphism (SNP). Only ~1% (~3,000,000) seems to be variable per genome when 
comparing different people.67-70 Because of this limited variability, sets of SNPs tend to co-occur; these 
are called haplotype blocks. Technologies for SNP genotyping include enzyme-based methods (e.g., 
polymerase chain reaction [PCR]-based), hybridization-based methods (e.g., microarrays) and next-gen-
eration sequencing. It has been shown that SNPs underlie differences between people, including the 
variability in disease risks, and recent genome-wide association studies (GWAS) have vastly expanded 
our knowledge in this area.71 For instance, previous GWAS have identified 24 loci that influence BMD 
variation explaining ~3% of trait variance72-78 of which several variants have also been nominally associ-
ated with fracture risk.79, 80
In a typical GWAS a large number of SNPs (thousands to millions) are genotyped by microarrays 
and analyses are run to see if particular areas in the genome (i.e., loci) relate to certain phenotypes in 
Figure 6. Diagram of examination cycles of the Rotterdam Study (RS); five visit cycles have been conducted until 
now and are denoted as ERGO-1 up to ERGO-5. RS-I-1 to RS-I-5 refer to the examinations of the original cohort. RS-
II-1 and RS-II-2 relate to the extension of the cohort with persons in the study district that became 55 years since 
the start of the study or those of 55 years or over that migrated into the study district. RS-III-1 denotes the baseline 
examination of all persons aged 45 years and over living in the study district that had not been examined before in a 
second extension cohort. Examinations RS-I-4 and RS-II-2 feature an identical research program (ERGO-4), and so will 
examinations RS-I-5, RS-II-3, and RSIII-2 share the same program items (ERGO-5).
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hundreds or thousands of people.81 In a standard case-control disease GWAS, SNP allele frequencies are 
compared between disease cases and healthy control subjects to see if certain SNPs are more prevalent 
in persons with the disease of interest (Figure 7).82 As so many tests are performed in a GWAS, by chance, 
false-positives may arise. Therefore, a Bonferroni correction assuming one million independent tests, 
representing the estimated number of haplotype blocks, is applied to the P value threshold for declaring 
statistical signifi cance: α = 5x10−8 (i.e., P=0.05/1,000,000).83 Good practice is to follow-up the initial set 
of promising susceptibility loci identifi ed by discovery GWAS to a meta-analytical replication stage, in 
which the SNPs identifi ed are examined in additional independent studies.84 Apart from developing our 
understanding of disease etiology, expectations are that these genetic markers will be useful in disease 
diagnostics and prediction, form potential drug targets and potentially modulate treatment response.85
AIMS AND OUTLINE OF THIS THESIS
This thesis covers studies that investigate the epidemiology of hormonal and skeletal diseases. We have 
focused on osteoporosis, diabetes-related bone disease and Scheuermann’s disease. The objectives 
were to discover novel risk factors for these conditions, deepen our understanding of known determi-
nants, expand our knowledge about the prevalences of the diseases in the general population, refi ne 
our tools for clinical assessments including diagnostics such as radiological imaging and make the fi rst 
Figure 7.  A schematic representation of a disease case-control genome-wide association study (GWAS). All study 
participants are genotyped to investigate if certain genetic variants are associated with the disease of interest. Then, 
single nucleotide polymorphism (SNP) allele frequencies are compared between people with the disease (cases) and 
healthy control subjects free of the disease being studied. In this example the C allele of a SNP mapping to chromo-
some 16 is associated with the disease, i.e., osteoporotic fractures, as it appears to be more frequent in the group with 
the disease than in the disease-free control group: 70% versus 20%. At the bottom right the results are displayed in a 
“Manhattan plot” where the statistical signifi cance P values for association are mapped on the Y-axis by chromosomal 
position on the X-axis. Each color denotes a specifi c chromosome and each dot represents a single SNP.
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steps from bench-to-bedside and back. Chapter 2 encompasses epidemiological studies of fractures 
and bone mineral density performed in the Rotterdam Study. Chapter 3 brings a comparative appraisal 
of radiological scoring methods for osteoporotic vertebral fractures. Chapter 4 reports various genetic 
epidemiological studies for osteoporotic fracture risk, with the majority being large-scale projects 
executed within the framework of the genetic factors for osteoporosis (GEFOS) and genetic markers 
for osteoporosis (GENOMOS) consortia. Chapter 5 presents a treatise on the future role of personalized 
sequencing in medicine in general.
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 Chapter 2
EPIDEMIOLOGICAL STUDIES OF FRACTURES 
AND BONE METABOLISM

 Chapter 2.1
The eﬀ ect of thiazide and loop 
diuretics on urinary levels of free 
deoxypyridinoline: an osteoclastic bone-
resorption marker
Ruiter R, Oei L, Visser LE, Peltenburg HG, Hofman A, Zillikens MC, Uitterlinden AG, Rivadeneira F, Stricker BH
Journal of Clinical Pharmacy and Therapeutics. 2013;38(3):225-9. PMID: 23442167
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ABSTRACT
What is known and Objective Diuretics can cause changes in calcium levels due to renal effects. 
Moreover, calcium levels can also vary as a result of changes in intestinal absorption and in the activity 
of osteoclastic cells. A marker of osteoclastic bone resorption activity is the level of urinary free de-
oxypyridinoline (FDP). Deoxypyridinoline (DP) acts as a cross-link between adjacent collagen chains to 
provide structural rigidity. Our aim was to investigate the association between use of thiazides and loop 
diuretics and urinary levels FDP.
Methods In this follow-up study, data were obtained from the Rotterdam Study, a large population-
based prospective cohort study. For a subset of 658 participants, urinary levels of FDP were measured at 
baseline. Linear regression analysis was performed to assess the association between the use of thiazides 
and loop diuretics and the urinary levels of FDP.
Results In women, current use of loop diuretics for less than 42 days was associated with an increased 
level of urinary FDP (+3.43 nmol deoxypyridinoline per mmol urinary creatinine; 95% CI: 1.85–5.02) 
compared with no use. However, use for a period of more than 42 days was not associated with an 
increased level of FDP, nor was past use of loop diuretics. For thiazide diuretics, no statistically significant 
associations were found.
Conclusion In women, short-term use of loop diuretics is associated with an increased level of FDP, 
reflecting increased bone resorption by osteoclasts. As the difference disappears with longer term use, 
the clinical significance is unclear and the value of FDP as a biomarker in this setting is not established. 
The molecular mechanism for the observed differences in bone fracture rates with use of diuretics 
remains unclear.
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INTRODUCTION
Thiazides increase serum calcium levels, and use of diuretics has been associated with a decreased risk of 
fractures.1 In 2003, we described that, relative to non-use, current use of thiazides for more than 365 days 
was statistically significantly associated with a lower risk of hip fracture. This lower risk disappeared after 
thiazide use was discontinued.2 In contrast, use of loop diuretics has been associated with decreased 
bone mineral density (BMD)3 and with an increased risk of fractures.4 Although loop diuretics can also be 
used in the treatment of hypertension, they are more frequently used for the management of patients 
with heart failure. More recently, it was investigated whether the risk of fractures varied between use of 
different antihypertensive drugs.5 Analyses were also performed for use of thiazide and loop diuretics. In 
users of thiazide diuretics, fracture rates were significantly lower compared with users of loop diuretics.5
Thiazide diuretics can cause hypercalcemia, mainly through effects on the distal convoluted tubule 
inducing enhanced calcium reabsorption.6 In contrast to thiazides, loop diuretics (e.g., furosemide) cause 
hypocalcaemia due to decreased reabsorption of calcium in the loop of Henle.7 Calcium levels can, how-
ever, also vary by changes in intestinal absorption and by changes in activity of osteoclastic cells. A marker 
of osteoclastic bone resorption activity is the level of urinary free deoxypyridinoline (FDP) crosslinks.8 De-
oxypyridinoline is one of the two pyridinium cross-links that provide structural rigidity to type I collagen, 
which represents 90% of the organic matrix of bone.9 Deoxypyridinoline is only found in significant quanti-
ties in bone,10 and is not absorbed from the diet11 and is not metabolized by the liver. During osteoclastic 
bone resorption, deoxypyridinoline is released into the circulation and is excreted in the urine in free and 
peptide-bound forms.12 However, it has been published that measurement of free cross-links only provides 
similar information to that from the total amounts.13 Hence, it was shown that measurement of urinary FDP 
provides a reasonably accurate estimate of bone resorption.8, 14 In addition, an association between high 
levels of FDP and an increased risk of fractures, independent of BMD, has been demonstrated.15-17
We wished to explore if, in addition to the known renal effects, osteoclastic activity is involved in diuretic-
related effects on bone metabolism. Therefore, we aimed to verify the association between use of thiazides 
and loop diuretics and the urinary levels of FDP. We hypothesized that use of thiazides is associated with 
decreased levels, whereas the use of loop diuretics might be associated with increased levels of FDP. To this 
end, we studied the association in a subgroup of subjects from a large prospective cohort study.
METHODS
Setting
Data were obtained from the Rotterdam Study, a large population-based prospective cohort study. The 
objectives and design were extensively described earlier.18 In summary, as of 1991, inhabitants of the 
suburb Ommoord, aged 55 years or older were invited to participate. Of all 10,275 invited subjects, 7,983 
entered the study (78%).
Baseline examinations consisted of a home interview and a clinical work up at the research center. 
During follow-up, additional interviewing, laboratory assessments, clinical examinations and imaging 
procedures were carried out every 3–4 years. As all pharmacies which serve the Ommoord district are 
on one computer network, detailed information on drug dispensing was available for all participants 
as of January 1, 1991. The vital status of the participants was obtained regularly from the municipal 
population registry. Morbidity and mortality were assessed by information from the general practitioner, 
or, in case of hospitalization, by discharge reports from the medical specialists. The study was approved 
by the Medical Ethics Committee of the Erasmus MC and all participants gave written informed consent.
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For a subset of 658 participants, the urinary levels of FDP were measured at baseline. This subset was 
used for a case-control analysis in which participants with a non-vertebral fracture (N=376) were com-
pared with participants without this type of fracture.19 To ensure a cohort of incident users of diuretics, 
only participants with a prescription-free period of 3 months in the period before baseline were eligible.
Exposure
Use of diuretics (ATC-code C03C) in the Rotterdam Study was categorized into two groups: use of thiazides 
and use of loop diuretics.20 The duration of a prescription was calculated as the total number of units deliv-
ered divided by the prescribed daily number of units. Participants could contribute cumulative exposure 
time to both categories. Cumulative exposure was calculated from start of drug use until the measurement 
of the urinary FDP level (index date). When participants did not use a diuretic on the index date, but did 
use a diuretic in the past, the cumulative number of days of use was calculated until the last day of the last 
prescription; past use since discontinuation was also used as determinant. Participants who did not use a 
diuretic during the study period were used as reference. To assess the effect of dose in current users, the 
average number of ‘defined daily doses’ (DDD) over all previous prescriptions was calculated.20
Outcome
Bone resorption was evaluated by the measurement of FDP in the first morning void of an overnight 
fasting urine. Urine samples were collected at baseline and stored until measurement at -20°C. Urinary 
FDP was determined by an automated chemiluminescence immunoassay (ACS: 180 DPD, Chiron Diag-
nostics, Medfield, MA, USA).21 To correct for dilution, results were normalized against urinary creatinine 
and expressed as nmol deoxypyridinoline per mmol urinary creatinine (nmol/mmol).22
Covariables
The following covariables were assessed as potential confounders and/or effect modifiers: age, sex, body 
mass index (BMI; kg/m2), smoking status (no, current or past smoking), diabetes mellitus and presence 
of an earlier myocardial infarction, stroke or non-vertebral fracture. Of these, height, weight and the 
presence of a non-vertebral fracture were assessed at baseline at the research center. Other factors were 
assessed via an interview at baseline. In addition, the effect of use of other drugs known to have an effect 
on the calcium level on the index date was assessed. Use of the following drugs (ATC-code) was assessed 
as present use (yes/no) at the index date: corticosteroids for systemic use (H02), thyroid therapy (H03), 
drugs affecting bone structure and mineralization (M05B), estrogens and/or progestagens (G03C, G03D, 
G03F), drugs involved in calcium homeostasis (H05), antithrombotic agents (B01AA or B01AB), vitamin A 
and/or D (A11C), retinoids for systemic treatment (D10BA01), certain antineoplastic and immunomodu-
lating agents (ciclosporin [L04AD01], methotrexate [L01BA01, L04AX03] and ifosfamide [L01AA06]), 
antiepileptics (N03A), antidepressants (N06A), thiazolidinediones (A10BG), statins (C10), antivirals for 
treatment of HIV infections (J05AR), nitric oxide (R07AX01) and beta-blocking agents (C07).20
Statistical analyses
Linear regression analysis was performed to assess the association between the use of thiazides and 
loop diuretics and the urinary levels of FDP. Covariables that changed the point estimate by more than 
10%, or covariables which were considered to be clinically relevant, were included in the full model.23 A 
stepwise model was used to include all other potential relevant confounders.
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As levels of FDP differ between men and women, analysis was stratified for sex. Differences between 
the groups were tested for significance with ANOVA and for categorical variables with a Chisquared test.
The effect of current use or past use of thiazides and loop diuretics was assessed. Current use, deter-
mined as cumulative days of use of diuretics at the date of collection of the urine sample, was compared 
with never use at the date of collection of the urine sample. Current use was categorized in current use for 
1–42 days, current use for 43–365 days and current use for more than 365 days. The cut-off point of 42 days 
was used as in the first 6 weeks of thiazide use, a decrease in circulating volume can occur; after 42 days, the 
circulating volume in most patients is within normal limits again.2 Although in our analyses, FDP levels were 
normalized against urinary creatinine levels, this decrease in circulating volume might potentially influence 
this ratio. Past use, determined as cumulative days of use of thiazides and loop diuretics assessed at the 
date of collection of the urine sample, was compared with never use at the date of collection of the urine 
sample as well. Past use was categorized in past use after discontinuation for more than 120 days before 
the index date, between 60 and 120 days before the index date and for less than 60 days before the index 
date. These time frames were chosen because they were used in an earlier study.2
The effect of dose was assessed in current users as average cumulative dosage at the date of collec-
tion of the urine sample. Analyses were performed using SPSS software (IBM SPSS statistics, version 170; 
New York, NY, USA); all P values are two sided and were considered significant if P<0.05.
RESULTS
For 658 participants in the Rotterdam Study, the urinary levels of FDP were measured at baseline. How-
ever, for 120 participants, a prescription-free period of 3 months could not be obtained leaving 538 
participants for the analysis. As can be seen from Table 1, the majority of the participants were female; 
there were, however, no statistically significant deviations between the different drug categories. Age 
did differ between the different drug users, with users of loop diuretics being older than those using 
thiazide diuretics or those not using any diuretic.
Table 1. Baseline characteristics for current users of thiazides and loop diuretics compared with those not using 
diuretics (N,% unless otherwise stated).
No diuretic
(N=461)
Thiazide
(N=50)
Loop diuretic
(N=26)
Female sexa 373 (80.9) 47 (94.0) 20 (76.9)
Age at start (years, SD)b 71.8 (9.1) 73.7 (9.0) 81.2 (7.2)
BMI (SD)c 26.0 (4.0) 28.2 (3.4) 27.5 (3.8)
Stroke at baselinea 18 (3.9) 3 (6.0) 1 (3.8)
MI at baselinea 31 (6.7) 5 (10.0) 7 (26.9)
Diabetes at baselinea 39 (8.5) 9 (18.0) 4 (15.4)
Smokinga Current 88 (19.1) 10 (20.0) 6 (23.1)
Former 159 (34.5) 15 (30.0) 11 (42.3)
Never 209 (45.3) 24 (48.0) 7 (26.9)
Missing 5 (1.1) 1 (2.0) 2 (7.7)
History of a non-vertebral fracturea 220 (47.7) 24 (48.0) 13 (50.0)
Mean average dosage (SD) NA 0.81 (0.27) 1.33 (1.80)
Mean average duration (SD) NA 42.7 (27.2) 36.2 (23.9)
aP value not significant following Chi-squared test. bP value following ANOVA significant.
cP value following ANOVA not significant.
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In crude analyses (men + women), current use of loop diuretics was associated with an increased level 
of FDP (+2.27 nmol deoxypyridinoline per mmol urinary creatinine; 95% CI: 1.23–3.32). Use of thiazides 
was statistically non-significantly associated with a decreased level of FDP (-0.29 nmol deoxypyridinoline 
per mmol urinary creatinine; 95% CI: -1.08–0.50). In Table 2, the effects of past use and current use of 
thiazides and loop diuretics on the FDP levels, per mmol urinary creatinine, are shown. Results were 
adjusted for age and BMI, which were the only two variables that changed the point estimate by more 
than 10% for thiazide diuretics as well as loop diuretics. Using stepwise modelling, we further included 
the covariates regarding previous myocardial infarction and use of beta-blocking agents for both diuret-
ics. Adjustment for smoking status, the presence of a previous stroke, the diabetic status of the patient 
and use of other drugs than beta-blocking agents known to have an effect on the calcium level was 
not deemed necessary using this approach. As mentioned in the methods section, our intention was to 
stratify results for men and women; however, as numbers for men were too low, these analyses were not 
performed. The adjusted results for women, categorized on duration, are shown in Table 2. In women, 
current use for less than 42 days of loop diuretics was associated with an increased level of FDP (+3.43 
nmol deoxypyridinoline per mmol urinary creatinine; 95% CI: 1.85–5.02). However, use for a period of 
43–365 days was not associated with an increased level of FDP, nor was past use of loop diuretics. In 
contrast, the use of thiazides was not associated with a change in FDP levels.
Table 2. The effects of past use and current use of thiazides and loop diuretics on the free deoxypyridinoline levels 
per mmol urinary creatinine.
Diuretic Duration of (past) use Women
N Change in level with 95% CI
Thiazides No use Reference
Current use for < 42 days 23 −0.74 (−1.85; 0.37)
Current use for 43–365 days 24 0.27 (−0.81; 1.35)
Current use for > 365 days 0 NA
Past use since < 60 days 9 0.23 (−1.47; 1.93)
Past use since 60–120 days 3 +1.59 (−1.31; 4.49)
Past use since > 120 days 23 +0.01 (−1.09; 1.11)
Loop diuretics Current use for < 42 days 11 +3.43 (1.85; 5.02)a
Current use for 43–365 days 9 +1.08 (−0.58; 2.75)
Current use for > 365 days 0 NA
Past use since < 60 days 9 +1.50 (−0.37; 3.38)
Past use since 60–120 days 1 +0.36 (−4.51; 5.23)
Past use since > 120 days 6 +0.57 (−1.64; 2.78)
aP value <2.5×10-5. Results are adjusted for age, BMI, previous myocardial infarction and use of beta-blocking agents.
Dosage analyses were performed in current users of diuretics. In women, neither the dosage of thiazides 
(change in DDD -0.09 nmol deoxypyridinoline per mmol urinary creatinine; 95% CI -0.28–0.16) nor the 
dosage of loop diuretics (change in DDD +0.30 nmol deoxypyridinoline per mmol urinary creatinine; 
95% CI -0.27–1.17) was associated with the levels of FDP.
Post-hoc power analyses were performed to verify whether we had sufficient power for especially the 
thiazide analyses. Using a P value of 0.05, and given the number of predictors in the model, the observed 
R2 of the model and the samples sizes in the different models used, the power in women for the thiazide 
analyses was >0.80 and for the loop diuretics analyses, power was 0.67.
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DISCUSSION
Short-term use for less than 42 days of loop diuretics is associated with an increased level of FDP, reflect-
ing increased bone resorption by osteoclasts. Longer term use was not associated with increased levels 
nor was past use of these drugs associated with a deviation in the urinary levels of FDP. For users of 
thiazides, no statistically significant associations were found. Moreover, no dose-dependent associations 
could be described.
When it is hypothesized that the use of drugs has an instant effect on the excretion of FDP, the lack of 
association with past use of loop diuretics can be explained. However, the absence of a relationship with 
longer duration of current use cannot readily be explained. The cut-off point for short-term use was 42 
days (for thiazide diuretics), a decrease in circulating volume can occur during this period. With longer 
term use, the circulating volume in most patients returns to normal limits again.2 This would explain 
relatively higher urinary levels of FDP during the first 42 days of use of thiazides and might possibly 
explain why associations could not be observed in our study. However, the fact that in our analyses, 
FDP levels were normalized against creatinine levels would argue against this hypothesis. Moreover, 
whether a similar mechanism could explain the lack of association between long-term use of loop 
diuretics and urinary deoxypyridinoline levels remains questionable as for loop diuretics, this decrease 
in circulating volume after 42 days has not been described. Population-based cohort studies may be 
affected by selection bias, information bias and confounding. Selection bias probably did not occur 
as cases with a non-vertebral fracture were ascertained independent of their diuretic exposure status 
within a large population-based cohort study. However, with regard to the external validity, the analyses 
were performed in a subgroup of this cohort and these analyses could only be performed in women. 
We had too few men, and hence inadequate statistical power, to test the associations in men. However, 
when pooled analyses were performed, with adjustment for sex, the point estimate for short term use 
of loop diuretics remained statistically significant (data not shown). Another limitation of our study is the 
relatively limited number of users of diuretics. Information bias is unlikely as all information was gathered 
prospectively and without knowledge of the research hypothesis. With regard to confounding, we were 
able to adjust for several potential confounding factors, which did not change the point estimate. 
Confounding by indication could also be present. Recently, heart failure has been reported to be associ-
ated with an increase in rate of major fractures (independent of traditional risk factors and BMD).24 After 
adjustment for use of loop diuretics, this association weakened but remained statistically significant.24 
Therefore, the association described in our study could also be explained by confounding by indication. 
However, in our opinion, this is less likely as in earlier studies, including a randomized controlled trial, use 
of loop diuretics was associated with increased bone turnover; as well as with decreased BMD and with 
increased risk of fractures.3, 4, 25, 26
Loop diuretics increase the excretion of calcium.7 Calcium reabsorption in the thick ascending limb 
of the loop of Henle results from a positive lumen potential. Loop diuretics block the Na-K-chloride 
transporter, which decreases the positive lumen potential, and consequently diminishes calcium reab-
sorption.7 To compensate, the decrease in serum calcium induces an increase in parathyroid hormone, 
which subsequently stimulates the intestinal absorption of calcium as well as the absorption from bone 
through increased activity of osteoclasts.6 Our finding of increased levels of FDP is therefore consistent 
with the hypothesis that the use of loop diuretics has an impact on the osteoclastic activity.
However, we could not find a statistically significant association between change in urinary levels of 
FDP and the use of thiazide diuretics. The use of thiazide diuretics reduces urinary calcium excretion and 
consequently, thiazides have been associated with increased serum calcium levels.7 Thiazide diuretics in-
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crease calcium reabsorption in the distal tubule by increasing the activity of the Na+/Ca2+-ATPase on the 
basolateral membrane, subsequently lowering the Ca2+ concentration so that more Ca2+ is reabsorbed 
from the lumen. This increase arises from an increase in proximal calcium reabsorption in parallel with an 
increase in reabsorption of sodium and water, hypothesized to be caused by the parathyroid hormone.7 
The increased calcium level may result in decreased intestinal calcium absorption and suppression of 
the osteoclastic activity.7 In addition, it has been suggested that thiazides in vitro also directly inhibit 
osteoclastic activity, and consequently bone resorption.27 However, others could not confirm this.28 In 
our study, the hypothesized lower osteoclastic activity could not be explained by decreased levels of 
urinary excretion of FDP. This may suggest that other (yet unknown) factors are involved in the associa-
tion between thiazides, calcium levels and osteoclastic activity. As numbers of subjects in our study were 
low, this might also be explained by insufficient power.
In a large Cochrane meta-analysis on the relationship between thiazides and risk of hip fracture, 
marked heterogeneity was found.29 Part of this variation could be explained by the use of multiple 
diuretics.30 We aimed to analyze the association between use of multiple diuretics and the effect on 
levels of FDP, but as only 10 participants used multiple diuretics, these analyses could not be performed. 
In addition, the effect of use of diuretics other than loop diuretics and thiazides could not be evaluated 
due to low numbers. Although our findings seem to be consistent with the hypothesis that the use of 
loop diuretics has an impact on the osteoclastic activity, we cannot exclude the possibility that other 
factors may influence the possible association between the use of loop diuretics and the increased risk 
of fractures.4
CONCLUSION
Short-term use of less than 42 days of loop diuretics is associated with an increased level of FDP, reflect-
ing increased bone resorption by osteoclasts. Whether the increased levels of FDP are induced directly 
by the loop diuretics, indirectly via decreased serum calcium levels, through a compensatory increase in 
parathyroid hormone, or via other mechanisms, requires further exploration. Also, the impact of comor-
bidity and other drugs used on the bone needs to be further evaluated. The value of FDP as an additional 
biomarker for the assessment of bone resorption in diuretic-induced effects on bone metabolism is not 
yet established.
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ABSTRACT
Objective To investigate the relation between lumbar disc degeneration (LDD) and all type of osteopo-
rotic (OP) fractures including vertebral.
Methods This study is part of the Rotterdam study, a large prospective population-based cohort study 
among men and women aged 55 years and over. In 2,819 participants spine radiographs were scored 
for LDD (osteophytes and disc space narrowing (DSN)) from L1 till S1, using the Lane atlas. Osteoporotic 
(OP) fracture data were collected and verified by specialists during 12.8 years. We considered two types 
of vertebral fractures (VFx): Clinical VFx (symptomatic fractures recorded by medical practitioners) and 
Radiographic VFx (using the McCloskey–Kanis method). Meta-analysis of published studies reporting 
an association of LDD features and VFx was performed. Differences in bone mineral density (BMD) 
between participants with and without LDD features were analyzed using ANOVA. Risk of OP-fractures 
was analyzed using Cox regression.
Results In a total of 2385 participants, during 12.8 years follow-up, 558 suffered an OP-fracture. Sub-
jects with LDD had an increased OP fracture risk compared to subjects without LDD (HR: 1.29, 95% CI: 
1.04–1.60). LDD-cases have between 0.3 and 0.72 standard deviations more BMD than non-cases in all 
analyzed regions including total body BMD and skull BMD (P<0.001). Only males with LDD had increased 
risk for OP-fractures compared to males without LDD (adjusted-HR: 1.80, 95% CI: 1.20–2.70, P=0.005). 
The risk was also higher for VFx in males (HR: 1.64, 95% CI: 1.03–2.60, P=0.04). The association LDD–OP-
fractures in females was lower and not significant (adjusted-HR: 1.08, 95% CI: 0.82–1.41). Meta-analyses 
showed that the risk of VFx in subjects with LDD has been studied only in women and there is not 
enough evidence to confidently analyze the relationship between LDD-features (DSN or/and OPH) and 
VFx due to low power and heterogeneity in phenotype definition in the collected studies.
Conclusions Male subjects with LDD have a higher osteoporotic fracture risk, in spite of systemically 
higher BMD.
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INTRODUCTION
Lumbar disc degeneration (LDD) and osteoporosis are two age-related skeletal diseases which are very 
prevalent in elderly and known to be related to pain, increased morbidity and disability in this popula-
tion.1, 2 In Europe, the mean prevalence of vertebral fractures (VFx) in women between 60 and 64 years 
is 17% and this increases up to 35% when they are aged 75 years or more.1 Both, osteoporotic (OP) 
fractures and LDD occur also in men however, it has been more studied in women.3, 4
The relationship between LDD and bone health is unclear. As it has been previously shown, the pres-
ence of LDD is associated with higher spine bone mineral density (BMD).5-7 In addition, LDD has been 
found associated with higher BMD of the femoral neck, which suggests a systemic increased BMD in 
subjects affected by LDD.5, 6, 8 In this respect LDD behaves very similar to knee or hip osteoarthritis (OA), 
where also an increased systemic BMD has been found.9, 10
In theory, the higher BMD found in subjects with LDD should corresponds to lower fracture risk 
compared to subjects without LDD. However, the few studies examining the relationship between LDD 
and vertebral fractures (in women) found conflicting results.7, 11-14 In part this might be explained by the 
different radiological definitions used for LDD (based on the presence of osteophytes (OPH) and/or disc 
space narrowing (DSN)) and vertebral fractures (scored by different methods). Additionally, there are 
no studies examining the relationship between LDD and all types of OP fractures which would indicate 
whether the increased BMD found in LDD cases corresponds to a decreased fracture risk.
Therefore, we investigated the relation between LDD and all type of osteoporotic fractures including 
vertebral, in a large prospective cohort that includes men and women. In addition, we performed a 
systematic review of previously published studies.
METHODS
The Rotterdam study
This study is part of the Rotterdam study (RS), a large prospective population-based cohort study among 
men and women 55 years of age and older. The study design and rationale are described elsewhere 
in detail.15 The objective of the study is to investigate the determinants, incidence and progression of 
chronic disabling diseases in the elderly. The baseline measurements were conducted between 1990 
and 1993. In total, 7,983 participants were examined. The current study was performed in 2,385 study 
participants for whom data on incident vertebral fractures, BMD and LDD was available. The medical eth-
ics committee of Erasmus University Medical School approved the study and written informed consent 
was obtained from each participant.
Data collection for potential risk factors
Home interviews on medical history were performed by trained interviewers. Smoking habit was cat-
egorized binary as current or former versus never. The lower limb disability index used was composed of 
the mean score from six different questions regarding activities of daily living, using a modified version 
from the Stanford Health Assessment Questionnaire.16
At baseline measurement, medical information and physical examination including height and 
weight were obtained. Body mass index (BMI) was calculated by dividing weight by height squared (kg/
m2). Radiographic assessment of LDD Each vertebral level from L1 to S1 was reviewed for the presence 
and severity of osteophytes (OPH) and vertebral narrowing (disc space narrowing (DSN)), using the Lane 
atlas.3, 4 In this atlas the categories are as follows: grade 0=none; grade 1=mild; grade 2=moderate; and 
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grade 3=severe. DSN was defined as present when there was a grade 1 narrowing at two or more ver-
tebral levels. Because of the small proportion of subjects without osteophytes, we used a higher cut-off 
value for this feature; OPH was positive when there were osteophytes of at least grade 2 at two or more 
vertebral levels. When DSN and OPH were both positive and present at 2 or more levels, the participant 
was assigned as “LDD case”. The definition suggested for LDD was previously found as the best related to 
clinical symptoms including lumbar pain.17 A severity score for each participant was calculated adding 
the individual scores of DSN and OPH (1–3) of all intervertebral levels.
BMD measurements
DXA BMD (g/cm2) of the right proximal femur and lumbar spine was measured at baseline using a Lunar 
DPX-L densitometer (Lunar Radiation Corp., Madison, WI, USA). Total body scans were performed at the 
third follow-up visit (mean follow-up 6.5 years) using a ProdigyTM fan-beam densitometer (GE Lunar 
Corporation Madison, WI) and analyzed with EncoreTM software. The software employs an algorithm 
that divides body measurements into areas corresponding to total body, head, trunk, arms and legs. 
Other methodological details have been described previously.18
Assessment of osteoporotic fracture
Follow-up started either on January 1, 1991 or at the time of inclusion into the study. For this analysis, 
follow-up ended either at January 1, 2007 or, when earlier, at the participant’s death or loss to follow-up. 
For ~80% of the study population, medical events were reported through computerized general prac-
titioner diagnosis registers. For the remaining 20%, research physicians collected data from the general 
practitioners’ medical records of the study participants. All collected fractures were verified by reviewing 
discharge reports and letters from medical specialists. Fracture events were coded independently by 
two research physicians according to the International Classification of Diseases, 10th revision (ICD-10). 
Finally, an expert in osteoporosis reviewed all coded events for final classification. Fractures coded as 
incident vertebral fractures were considered clinical fractures if they were identified on radiographs 
when subjects with symptoms (principally pain) visited the medical practitioner. All fractures that were 
considered not osteoporotic (fractures caused by cancer and all hand, foot, skull, and face fractures) were 
excluded. The period of follow-up was calculated as the time from enrollment in the study to the first 
fracture, death, or the end of the planned follow-up period, whichever occurred first. The participants 
were followed for the occurrence of fracture for approximately 12.8 years ( ± 3.1 SD yr).
Assessment of prevalent and incident radiographic vertebral fracture
Radiographic vertebral fracture: both at baseline, between 1990 and 1993, and at the second follow-up 
visit, between 1997 and 1999, a trained research technician obtained lateral radiographs of the thora-
columbar spine of subjects who were able to come to the research center. The follow-up radiographs 
were available for 2819 individuals, who survived an average of 6.3 years after their baseline center 
visit and who were still able to come to our research center. All follow-up radiographs were evaluated 
morphometrically in Sheffield by the McCloskey–Kanis method, as described previously.19 If a vertebral 
fracture was detected, the baseline radiograph was evaluated as well. If the fracture was already pres-
ent at baseline, it was considered a prevalent fracture. All vertebral fractures were confirmed by visual 
interpretation by an expert in the field to rule out artifacts and other etiologies, such as pathological 
fractures.20 Participants with missing data on one or more risk factors were excluded (N=434).
- 43 -
Lu
m
ba
r d
isc
 d
eg
en
er
at
io
n 
an
d 
os
te
op
or
ot
ic
 fr
ac
tu
re
s
2.2
Literature study
Relevant articles were identified by a systematic search using the database of PubMed with the words 
[“spine osteoarthritis” or “spine OA” or “disc degeneration”] and [fracture] as keywords in the title or 
abstract. The following inclusion criteria applied for this review are: (1) listed in PubMed, (2) publica-
tion in the English language, (3) study in humans, (4) the article represents original data, (5) subjects 
with and without disc degeneration features are compared in the study in relation to vertebral and/or 
osteoporotic fractures and (6) the full-text article was available. Methodological quality assessment is 
found in the Supplementary material.
Statistical analysis
We compared the baseline characteristics of the study population and the FN- and LS-BMD between the 
LDD cases and controls using analysis of variance (ANOVA). Categorical variables were analyzed using 
chi squared test. Cox’s proportional hazards regression was used to assess association between LDD and 
OP fractures (or only clinical vertebral fractures). The analyses were adjusted by gender (or stratified by 
gender), age, BMI, lower limb disability and FN-BMD as continuous variables. Departure from additive 
effect of the risk factors was tested using interaction terms in the model. All these analyses were made 
using SPSS V. 15.0.Meta-analyzed results and forest plots included in the literature study were obtained 
using the Comprehensive Meta-analysis Software Version 2, Biostat, Englewood NJ (2005). Power calcu-
lations were done with PS version 2.1.31.
RESULTS
Study population
Characteristics of the cohort comprising 2,385 participants with data for the two major outcomes: LDD 
and vertebral fracture are shown in Table 1. At baseline, 362 participants had LDD (moderate OPH and 
mild-DSN) in two or more intervertebral levels. Subjects with LDD were older and heavier than controls. 
Also, LDD subjects had 0.72 and 0.32 SD higher LS- and FN-BMD at baseline compared to controls (Fig-
ure 1, P<0.001 for both FN and LS-BMD differences). Additionally, Figure 1 shows that total body-BMD 
and skull-BMD (measured at a later time point) were also significantly increased in subjects with lumbar 
disc degeneration. All BMD analyses were adjusted for age, gender, BMI, and lower limb disability. The 
number of prevalent radiographic vertebral fractures was not different in the LDD group compared to 
the group without LDD after adjustment for age and gender (Table 1, P=0.83). The mean LDD severity 
score was higher in males than in females (mean=6.6 (SD=4.3) for males and 5.9 (SD=4.4) for females 
(P<0.001, adjusted for age and BMI)). However, there was no statistically significant association between 
LDD-severity score and all type of OP-fractures (P=0.13).
Osteoporotic fracture risk
During 12.8 (SD=3.12) years of follow-up, 558 participants suffered an osteoporotic (OP) fracture. Sub-
jects with LDD had an increased risk of OP fractures compared to subjects without LDD (HR: 1.29, 95% 
CI:1.04–1.60). The risk slightly decreased after adjustment for age, gender, BMI, lower limb disability and 
FN-BMD (HR: 1.24 (0.99–1.55)). We found a significant interaction between gender and LDD on fracture 
risk suggesting differences in OP fracture risk between genders (P for interaction term: 0.03). Therefore, 
we stratified the analysis according to gender and observed that only males with LDD had an increased 
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OP fracture risk (Table 2, adjusted HR: 1.80 (1.20–2.70), P=0.005 for males and HR: 1.08, 95% CI: 0.82–1.41, 
P=0.59 for females).
Clinical vertebral fracture
After the follow-up time, 21% of participants having fractures (N=116) had a clinically defined vertebral 
fracture. Participants with LDD had an increased hazard of having a clinical vertebral fracture during the 
follow-up (Table 2, adjusted-HR: 1.64, 95% CI: 1.03–2.60, P=0.04). As it was for overall OP-fractures, the 
hazard for a clinical vertebral fracture was higher only for males with LDD (HR: 2.34, 95% CI: 1.09–5.04 in 
males and 1.39, 95% CI: 0.78–2.50 for females).
Radiographic vertebral fracture
During 6.3 years of follow-up, 106 participants had an incident radiographic-vertebral fracture. After 
adjustment for age, gender, BMI, FN-BMD and prevalent radiographic vertebral fracture, subjects with 
Table 1. Baseline characteristic for subjects according to LDD features in two or more levels.
Variables Controls* N=2,023 (82) LDD** N=362 (18) P value
Female 1161 (57) 207 (57) 0.9
Age (years) 63.7 (5.7) 65.9 (6.2) <0.001
BMI (kg/m2) 26.2 (3.7) 26.9 (3.8) 0.04
FN-BMD (g/cm2) 0.88 (0.13) 0.91 (0.14) <0.001
Total-BMD (g/cm2) 1.10 (0.12) 1.12 (0.13) 0.001
Head-BMD (g/cm2) 1.93 (0.28) 2.01 (0.29) <0.001
Smoking (current/former) 1367 (68) 233 (64) 0.18
Lower limb disability 0.16 (0.38) 0.21 (0.33) <0.001
Falling (yes) 241 (12) 52 (14.5) 0.29
Prevalent radiological VFx* 88 (6.6) 22 (7.4) 0.83
Abbreviations: LDD: Lumbar disc degeneration, **defined as mild disc space narrowing (DSN) and moderate/severe 
osteophytes (OPH) in two vertebral levels. *Controls: Participants with less than 2 levels affected by DSN and OPH 
per level. Values presented are mean and standard deviations (SD) for each continuous variable and numbers and 
percentage (%) for categorical variables. BMI (body mass index), smoking, LLD (lower limb disability), falling and 
prevalent radiographic-vertebral fracture (VFx) comparisons were adjusted for age and gender. All bone mineral 
density (BMD) analyses were adjusted for age, gender, BMI and LLD.
Figure 1. Bone mineral density (BMD; Z-scores) differences between subjects with lumbar disc degeneration (LDD) 
and without LDD in four different regions: lumbar spine (LS), femoral neck (FN), and total body and skull. Estimates 
were adjusted by age, gender, height and BMI. **P value ≤0.001. Total body-BMD and skull-BMD were measured in a 
subset of 1,649 participants at a second follow-up.
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LDD had 2.14 increased odds of having a radiographic vertebral fracture. However, this was not statisti-
cally significant and the broad confidence interval revealed low power in the analysis (95% CI: 0.82–5.58, 
P=0.12). Hence, we reviewed the existent literature on the relationship between LDD and (vertebral) 
fractures.
Results of the literature study: separate LDD features and risk for radiographic 
vertebral fractures
From 36 studies selected on bases of the search terms in abstract/title, a total of 28 studies were ex-
cluded because the abstract clearly showed that the study did not analyze the studied relationship LDD/
spine OA-fracture. Based on the criterion 4 studies were excluded: no comparison was made between 
subjects with and without disc degeneration in relation to vertebral and/or osteoporotic fractures (cri-
teria e). A total of five studies (four from the literature search + current results from our study) analyzing 
the relation LDD and radiographic vertebral fractures were included in this review (Supplementary Table 
1). There were no studies analyzing the relation of LDD with other types of fractures in accordance with 
the selection criteria previously explained. Further details of the selection procedure of studies can be 
found in the Supplementary material. From these five selected studies, two were done in the same 
population therefore, only the most recent “longitudinal prospective” (Sornay-Rendu et al.) was included 
in the meta-analysis.12 These studies fulfilled the inclusion criteria requirements and methodological 
quality assessment, including adjustment for age, gender, BMI and BMD in the analysis. Only one study 
(Roux et al.) did not perform BMD adjustment in the analysis of vertebral fracture risk.11
All selected studies were done in postmenopausal women, one of them in women with osteopo-
rosis.11 In all studies, radiographic-LDD features were evaluated from the first till fifth lumbar segment 
(L1–L5). LDD was defined as the presence of osteophytes (OPH), or disc space narrowing (DSN) in at 
least one intervertebral level. A detailed description of the studies and definition of LDD and vertebral 
fracture assessment is presented in Supplementary Table 1.
Table 3 shows the results of the studies reviewed. Prevalence of at least minimal/mild osteophytes in 
the studied populations differs between 56 and 90% (Table 3). In the study of Roux et al. there was also 
a protective effect of OPH for vertebral fractures, however in that study, the association was not adjusted 
for BMD; what seems to modify the relationship of osteophytes–vertebral fractures (Table 2). Post-hoc 
power calculation demonstrated that to have 80% power to detect OR N=1.2 having an incidence of 
radiographic vertebral fractures of around 5%, a sample size of around 4,200 participants would be 
Table 2. Risk of vertebral and osteoporotic fracture in participant with lumbar disc degeneration (LDD).
N.LDD/N Clinical vertebral fractures (HR & 95% CI) Osteoporotic fractures (HR & 95% CI)
Unadjusted P Adjusted risk P Unadjusted P Adjusted risk P
All (362/2,385) 1.53 (0.98–2.40) 0.06 1.64 (1.03–2.60) 0.04 1.29 (1.04–1.60) 0.02 1.24 (0.99–1.55) 0.06
Males 1.41 (0.68–2.90) 0.36 2.34 (1.09–5.04) 0.03 1.88 (1.27–2.79) 0.002 1.80 (1.20–2.70) 0.005
Females 1.22 (0.71–2.10) 0.47 1.39 (0.78–2.50) 0.26 1.11 (0.85–1.43) 0.45 1.08 (0.82–1.41) 0.59
Risk for osteoporotic and clinical vertebral fractures in participants with Lumbar disc degeneration (LDD) defined as 
categorical variable according to the presence of at least mild disc space narrowing (DSN ≥ 1) and moderate/severe 
osteophytosis (OPH≥2) per intervertebral level in at least two intervertebral levels. Lumbar disc degeneration was 
evaluated only at lumbar spine (L1–L5). Risk of vertebral and osteoporotic fracture are hazard ratio (HR) and 95% 
confidence interval (CI) unadjusted or adjusted for baseline characteristics (gender, age, BMI, lower limb disability, 
femoral neck bone mineral density (FN-BMD)). Number of clinical vertebral fractures=116; number of osteoporotic 
fractures=558.
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Table 3. Results of the reviewed studies for association of LDD and risk of vertebral fractures.
Reference Definition of VFx N. of 
VFx
OR (confidence interval) 
unadjusted risk
OR (confidence interval) 
(BMD adjusted)
P adj.
Arden13 Quantitative 
McCloskey
41 Not shown LS-OPH: 0.46 (0.21–0.99) <0.05
Thoracic-OPH: 3.57 (1.55–8.24)
Sornay-Rendu14 Semi-quantitative 
Genant
48 Lumbar spine Lumbar spine Not shown
OPH≥1: 0.8 (0.4–1.6) 1.0 (0.5–2.1)
DSN≥1: 3.4 (1.5–7.8) 3.5 (1.5–8.3)
OA grade 2: 1.6 (0.9–2.3) 1.7 (0.9–3.2)
Sornay-Rendu12 Semi-quantitative 
Genant
42 LS-DSN: Not shown LS-DSN: 3.27 (1.19–8.98) Not shown
LS and thoracic spine LS and thoracic spine
DSN≥1: 6.88 (1.64–28.9) DSN≥1: 6.59 (1.36–31.94)
OPH≥1: 1.39 (0.18–10.7) OPH≥1: 0.94 (0.10–8.97)
OA grade 2: 1.57 (0.81–3.01) OA grade 2: 0.92 (0.42–1.99)
**Roux11 Semi-quantitative 
Genant
215 DSN≥1: 0.83 (0.55–1.26) DSN≥1: 0.67 (0.43–1.04) 0.071
OPH≥1: 0.45 (0.21–0.99) OPH ≥1: 0.38 (0.17–0.86) 0.02
LS-DSN≥2: 0.86 (0.56–1.33) LS-DSN≥2: 0.74 (0.47–1.16) 0.191
DSN≥1: 1.26 (0.72–2.20) DSN≥1: 1.27 (0.71–2.26) 0.42
This study Quantitative 
McClosckey
108 OPH≥1: 1.10 (0.43–2.84) OPH≥1: 1.27 (0.48–3.34) 0.63
OA grade 2: 1.00 (0.57–1.74) OA grade 2: 1.05 (0.59–1.87) 0.86
LDD: 1.14 (0.61–2.15) LDD: 1.14 (0.57–2.29) 0.7
Figure 2. Meta-analysis of lumbar disc degeneration features and their relation with vertebral fractures in wom-
en. Values are odds ratios (OR) and 95% confidence intervals. Abbreviations: DSN≥1=mild disc space narrowing, 
OPH≥1=minimal or mild osteophytes. Studies were included when they had similar adjustments.
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needed. Consequently, confidence intervals are wide and associations of separate features of combined 
LDD definition did not reveal conclusive evidence (Figure 2, OR: 0.70, 95% CI: 0.39–1.25, P: 0.23 and OR: 
1.05, 95% CI: 0.75–1.46, P: 0.79 for the presence of at least mild osteophytes and disc space narrowing, 
respectively).
DISCUSSION
This study shows that individuals affected with lumbar disc degeneration (LDD), in spite of having a 
systemically higher BMD, are not protected of osteoporotic fractures. Contrarily, male subjects with 
LDD had an increased risk for osteoporotic fractures, including clinical vertebral fractures. Results of the 
meta-analysis of the literature showed that LDD has been studied only in women for its association with 
radiographic vertebral fractures. Additionally, this is the first study analyzing the association of LDD with 
all type of fractures in males and females. The results of the meta-analysis were not conclusive regarding 
the relation of separate LDD features (osteophytes and disc space narrowing) and risk of radiographic 
vertebral fractures in females.
We found a higher systemic BMD in participants with LDD. Participants with LDD had a higher BMD 
not only in lumbar spine (where BMD measurements are known to be influenced by the presence of 
osteophytes), but also in femoral neck, total body and skull. This is in line with previous findings of 
higher BMD in LDD patients not only in lumbar spine but also in other body regions.6, 7 Measurement of 
skull-BMD has been shown to be less subjective to change during aging and influence of environmental 
and mechanical factors (strain and weight bearing).21 Higher skull-BMD in subjects with LDD suggests 
that a systemically higher BMD might be present before LDD.
In spite of higher BMD in participants with LDD, we found a higher osteoporotic fracture risk. It is 
possible that the increased BMD in subjects with LDD is not enough to compensate for other detri-
mental effects of disc degeneration on trunk stability and flexibility that might result in an increased 
fracture risk. Loading on the spine is determined by a person’s height, weight, muscle forces, and activity, 
but can also be affected by intervertebral disc degeneration.22-24 Loss of disc height and its properties 
produce high tensile strains in the endplate and they have been shown as causal factors for “failure 
of the vertebra”.25, 26 Additionally, disc degeneration can affect other structures (vertebra itself, muscles 
and ligaments) producing modification in the distribution of compressive and tensional forces through 
the column that in normal conditions are evenly distributed. Ligaments of the anterior region have 
changes as a consequence of LDD, causing its remodeling and thickening.27, 28 Consequently ligaments 
lose elasticity and the trunk’s flexibility decreases; this becomes evident during aging where the range 
of spine movement is severely affected. Individuals with LDD have more stiffness in trunk and lower legs 
that could increase the reaction time during falling and other demanding occupational activities which 
are major situations where fractures occur in elderly.29, 30
We found a higher osteoporotic fracture risk in males. Severity of LDD was higher in males, principally 
because of higher severity of disc space narrowing. Additionally, there is some evidence for an associa-
tion between disc space narrowing and lower back pain especially in men proportionally increasing 
with a higher number of affected intervertebral disc spaces.17 However, severity itself did not explain the 
increased OP fracture risk in males. Neither was the risk explained by other factors such as lower limb 
disability, which was found to be higher in males with LDD and other common risk factors including age 
and falling risk. In older males (N=65 years), clinical vertebral fractures are caused by no known trauma 
or by low-energy trauma. It is known that most fractures occur in men with normal BMD and clinical 
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vertebral fractures are particularly common in the oldest men.31 Clinical vertebral fractures have been 
also related to important comorbidities, negative effects on quality of life and increased mortality.32-34
The systematic review showed some important aspects. Previous studies analyzing the association 
between LDD and fractures have been done only in females, the majority had small sample size and 
they defined LDD using only separate features. There were also important methodological differences 
between these studies in type (cross-sectional versus longitudinal) and fracture assessment. In spite of 
trying to meta-analyze the results of studies included in this review, using homogeneous definitions, 
power was still insufficient to draw significant conclusion on the relation of separate LDD features and 
radiological vertebral fractures.
The review made evident that there is a need for consensus in the definition of radiological LDD. In 
our opinion, more stringent radiological definitions are needed; some studies only consider osteophytes 
to define LDD. Osteophytes are a common feature in older populations and its prevalence depends 
of how stringent the definition is, reaching 90% for the presence of minimal/mild osteophytes. The 
presence of disc space narrowing and osteophytes (at least moderate) in the same intervertebral level 
should be considered when LDD is defined because it has been shown to be more clinically relevant; 
this combination of radiological definition was found to best correlate with clinical symptoms: lumbar 
pain and stiffness.17, 29
There are strengths and limitations in this study. This study is unique in examining the relation of LDD, 
osteoporotic and vertebral fractures in a large prospective cohort that includes males and females. In 
addition, the composed definition of several radiographic features used in this study is an advantage 
because it is more stringent and clinically relevant. We also examined separate LDD features in order to 
compare results with earlier published studies. However, we concluded that even after the meta-analysis 
the number of radiographic vertebral fractures was insufficient to get conclusive evidence in the relation 
of radiographic vertebral fractures with separate LDD features.
CONCLUSION
To conclude, we consider that subjects with LDD in spite of having higher systemic BMD are at higher 
risk of osteoporotic fractures, especially males for whom LDD seems more severe. The exact mechanisms 
to explain this association merits further investigation, considering that both, LDD and clinical vertebral 
fractures are common, associated with comorbidities and decreasing quality of life.
ACKNOWLEDGMENTS
This study is funded by the European Commission Seventh framework program TREAT-OA (grant 
200800), The Netherlands Society for Scientific Research (NWO), Research Institute for Diseases in the 
Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organization for 
Scientific Research (NWO) project no. 050-060-810, and the Netherlands Consortium for Healthy Ageing 
(NCHA). The Rotterdam study is funded by the Erasmus Medical Center and Erasmus University, Rot-
terdam, the Netherlands Organization for the Health Research and Development (ZonMw), the Research 
Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry 
for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam.
- 49 -
Lu
m
ba
r d
isc
 d
eg
en
er
at
io
n 
an
d 
os
te
op
or
ot
ic
 fr
ac
tu
re
s
2.2
REFERENCES
 1. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002 May 
18;359(9319):1761-7.
 2. Engel CC, von Korff M, Katon WJ. Back pain in primary care: predictors of high health-care costs. Pain. 1996 
May-Jun;65(2-3):197-204.
 3. Lawrence JS. Disc degeneration. Its frequency and relationship to symptoms. Ann Rheum Dis. 1969 
Mar;28(2):121-38.
 4. Miller JA, Schmatz C, Schultz AB. Lumbar disc degeneration: correlation with age, sex, and spine level in 600 
autopsy specimens. Spine (Phila Pa 1976). 1988 Feb;13(2):173-8.
 5. Jones G, Nguyen T, Sambrook PN, Kelly PJ, Eisman JA. A longitudinal study of the effect of spinal degenerative 
disease on bone density in the elderly. J Rheumatol. 1995 May;22(5):932-6.
 6. Livshits G, Ermakov S, Popham M, Macgregor AJ, Sambrook PN, Spector TD, et al. Evidence that bone 
mineral density plays a role in degenerative disc disease: the UK Twin Spine study. Ann Rheum Dis. 2010 
Dec;69(12):2102-6.
 7. Schneider DL, Bettencourt R, Barrett-Connor E. Clinical utility of spine bone density in elderly women. J Clin 
Densitom. 2006 Jul-Sep;9(3):255-60.
 8. Miyakoshi N, Itoi E, Murai H, Wakabayashi I, Ito H, Minato T. Inverse relation between osteoporosis and spondy-
losis in postmenopausal women as evaluated by bone mineral density and semiquantitative scoring of spinal 
degeneration. Spine (Phila Pa 1976). 2003 Mar 1;28(5):492-5.
 9. Bergink AP, Uitterlinden AG, Van Leeuwen JP, Hofman A, Verhaar JA, Pols HA. Bone mineral density and verte-
bral fracture history are associated with incident and progressive radiographic knee osteoarthritis in elderly 
men and women: the Rotterdam Study. Bone. 2005 Oct;37(4):446-56.
 10. Hart DJ, Cronin C, Daniels M, Worthy T, Doyle DV, Spector TD. The relationship of bone density and fracture to 
incident and progressive radiographic osteoarthritis of the knee: the Chingford Study. Arthritis Rheum. 2002 
Jan;46(1):92-9.
 11. Roux C, Fechtenbaum J, Briot K, Cropet C, Liu-Leage S, Marcelli C. Inverse relationship between vertebral 
fractures and spine osteoarthritis in postmenopausal women with osteoporosis. Ann Rheum Dis. 2008 
Feb;67(2):224-8.
 12. Sornay-Rendu E, Allard C, Munoz F, Duboeuf F, Delmas PD. Disc space narrowing as a new risk factor for 
vertebral fracture: the OFELY study. Arthritis Rheum. 2006 Apr;54(4):1262-9.
 13. Arden NK, Griffiths GO, Hart DJ, Doyle DV, Spector TD. The association between osteoarthritis and osteopo-
rotic fracture: the Chingford Study. Br J Rheumatol. 1996 Dec;35(12):1299-304.
 14. Sornay-Rendu E, Munoz F, Duboeuf F, Delmas PD. Disc space narrowing is associated with an increased 
vertebral fracture risk in postmenopausal women: the OFELY Study. J Bone Miner Res. 2004 Dec;19(12):1994-9.
 15. Hofman A, van Duijn CM, Franco OH, Ikram MA, Janssen HL, Klaver CC, et al. The Rotterdam Study: 2012 
objectives and design update. Eur J Epidemiol. 2011 Aug;26(8):657-86.
 16. Lawton MP, Moss M, Fulcomer M, Kleban MH. A research and service oriented multilevel assessment instru-
ment. J Gerontol. 1982 Jan;37(1):91-9.
 17. de Schepper EI, Damen J, van Meurs JB, Ginai AZ, Popham M, Hofman A, et al. The association between lum-
bar disc degeneration and low back pain: the influence of age, gender, and individual radiographic features. 
Spine (Phila Pa 1976). 2010 Mar 1;35(5):531-6.
 18. Burger H, van Daele PL, Algra D, van den Ouweland FA, Grobbee DE, Hofman A, et al. The association between 
age and bone mineral density in men and women aged 55 years and over: the Rotterdam Study. Bone Miner. 
1994 Apr;25(1):1-13.
 19. McCloskey EV, Spector TD, Eyres KS, Fern ED, O’Rourke N, Vasikaran S, et al. The assessment of vertebral defor-
mity: a method for use in population studies and clinical trials. Osteoporos Int. 1993 May;3(3):138-47.
 20. van der Klift M, de Laet CE, McCloskey EV, Johnell O, Kanis JA, Hofman A, et al. Risk factors for incident vertebral 
fractures in men and women: the Rotterdam Study. J Bone Miner Res. 2004 Jul;19(7):1172-80.
 21. Turner AS, Maillet JM, Mallinckrodt C, Cordain L. Bone mineral density of the skull in premenopausal women. 
Calcif Tissue Int. 1997 Aug;61(2):110-3.
Ch
ap
te
r 2
.2
- 50 -
 22. Pollintine P, Dolan P, Tobias JH, Adams MA. Intervertebral disc degeneration can lead to “stress-shielding” 
of the anterior vertebral body: a cause of osteoporotic vertebral fracture? Spine (Phila Pa 1976). 2004 Apr 
1;29(7):774-82.
 23. Polga DJ, Beaubien BP, Kallemeier PM, Schellhas KP, Lew WD, Buttermann GR, et al. Measurement of in vivo 
intradiscal pressure in healthy thoracic intervertebral discs. Spine (Phila Pa 1976). 2004 Jun 15;29(12):1320-4.
 24. Adams MA, Dolan P. Spine biomechanics. J Biomech. 2005 Oct;38(10):1972-83.
 25. Fields AJ, Lee GL, Keaveny TM. Mechanisms of initial endplate failure in the human vertebral body. J Biomech. 
2010 Dec 1;43(16):3126-31.
 26. Hulme PA, Boyd SK, Ferguson SJ. Regional variation in vertebral bone morphology and its contribution to 
vertebral fracture strength. Bone. 2007 Dec;41(6):946-57.
 27. Iida T, Abumi K, Kotani Y, Kaneda K. Eff ects of aging and spinal degeneration on mechanical properties of 
lumbar supraspinous and interspinous ligaments. Spine J. 2002 Mar-Apr;2(2):95-100.
 28. Fujiwara A, Tamai K, An HS, Shimizu K, Yoshida H, Saotome K. The interspinous ligament of the lumbar spine. 
Magnetic resonance images and their clinical signifi cance. Spine (Phila Pa 1976). 2000 Feb 1;25(3):358-63.
 29. Scheele J, de Schepper EI, van Meurs JB, Hofman A, Koes BW, Luijsterburg PA, et al. Association between 
spinal morning stiff ness and lumbar disc degeneration: the Rotterdam Study. Osteoarthritis Cartilage. 2012 
Sep;20(9):982-7.
 30. Grisso JA, Kelsey JL, Strom BL, Chiu GY, Maislin G, O’Brien LA, et al. Risk factors for falls as a cause of hip fracture 
in women. The Northeast Hip Fracture Study Group. N Engl J Med. 1991 May 9;324(19):1326-31.
 31. Freitas SS, Barrett-Connor E, Ensrud KE, Fink HA, Bauer DC, Cawthon PM, et al. Rate and circumstances of 
clinical vertebral fractures in older men. Osteoporos Int. 2008 May;19(5):615-23.
 32. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos 
Int. 2000;11(7):556-61.
 33. Oglesby AK, Minshall ME, Shen W, Xie S, Silverman SL. The impact of incident vertebral and non-vertebral 
fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results 
from the teriparatide randomized, placebo-controlled trial in postmenopausal women. J Rheumatol. 2003 
Jul;30(7):1579-83.
 34. Adachi JD, Ioannidis G, Olszynski WP, Brown JP, Hanley DA, Sebaldt RJ, et al. The impact of incident vertebral 
and non-vertebral fractures on health related quality of life in postmenopausal women. BMC Musculoskelet 
Disord. 2002 Apr 22;3:11.
 Chapter 2.3
Dissecting the relationship between high-
sensitivity serum C-reactive protein and 
increased fracture risk: the Rotterdam 
Study
Oei L, Campos-Obando N, Dehghan A, Oei EHG, Stolk L, van Meurs JBJ, Hofman A, Uitterlinden AG, Franco OH, 
Zillikens MC, Rivadeneira F
Osteoporosis International. 2014 Apr;25(4):1247-54. PMID: 24337661
Ch
ap
te
r 2
.3
- 52 -
ABSTRACT
Summary Serum high-sensitivity C-reactive protein (CRP) is an inflammatory biomarker. We investigated 
the relationship between CRP and bone health in the Rotterdam Study. Serum high-sensitivity CRP 
was associated with fracture risk and lower femoral neck bending strength. Mendelian randomization 
analyses did not yield evidence for this relationship being causal.
Introduction Inflammatory diseases are associated with bone pathology, reflected in a higher fracture 
risk. Serum high-sensitivity C-reactive protein CRP is an inflammatory biomarker. We investigated the 
relationship between CRP and bone mineral density (BMD), hip bone geometry and incident fractures 
in the Rotterdam Study, a prospective population-based cohort.
Methods At baseline, serum high-sensitivity CRP was measured. A weighted genetic risk score was 
compiled for CRP based on published studies (29 polymorphisms; Illumina HumanHap550 Beadchip ge-
notyping and HapMap imputation). Regression models were reported per standard deviation increase 
in CRP adjusted for sex, age and BMI. Complete data was available for 6,386 participants, of whom 1,561 
persons sustained a fracture (mean follow-up, 11.6 years).
Results CRP was associated with a risk for any-type of fracture (hazard ratio [HR]=1.06; 95% confidence 
interval [CI]: 1.02–1.11), hip fractures (HR=1.09; 1.02–1.17) and vertebral fractures (OR=1.34; 1.14–1.58). 
An inverse relationship between CRP levels and section modulus (-0.011 cm3; -0.020 to -0.003 cm3) 
was observed. The combined genetic risk score of CRP SNPs was associated with serum CRP levels 
(P=9×10-56), but not with fracture risk (HR=1.00; 0.99–1.00; P=0.23).
Conclusions Serum high-sensitivity CRP is associated with fracture risk and lower bending strength. 
Mendelian randomization analyses did not yield evidence for this relationship being causal. Future stud-
ies might reveal what factors truly underlie the relationship between CRP and fracture risk.
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INTRODUCTION
Chronic inflammatory diseases are frequently associated with bone loss, usually translated as a higher 
fracture risk.1, 2 Independent of the type of inflammatory process the effects arise due to alterations on 
the bone remodeling cycle, through direct (e.g., pro-inflammatory cytokines like TNF-alpha stimulating 
osteoclastogenesis through regulation of RANKL expression in osteoblasts or inhibiting bone formation 
through DKK1 action); or indirect mechanisms (e.g., it is well-established that the remodeling cycle is 
controlled by mechanical strains and a variety of endocrine and immunological mechanisms.3
The most commonly measured inflammatory serum biomarker is C-reactive protein (CRP), a protein 
found in the blood which levels rise in response to inflammation.4 To date, several publications have 
reported on serum CRP levels in relation to BMD,2, 5-9 non-vertebral fractures,2, 8 radiographic vertebral 
fractures and bone microarchitecture at the distal radius.8 To our knowledge, there have been no studies 
investigating CRP in relation to hip bone geometry. In summary, some,5-7, 9 but not all, studies have found 
serum CRP to be associated with lower BMD; a few studies with fracture data found an increased risk for 
higher CRP levels,2, 8 which intriguingly appeared independent of BMD or trabecular microarchitecture.8 
Nonetheless, the causal mechanism is largely unknown.
Observational studies are well-suited to identify risk factors, it is, however, difficult to establish causal 
relationships, because they are prone to confounding and reverse causation.10 Analytical techniques are 
available to assess causality in observational data using genotypes as instrumental variables. If we know 
of genetic determinants closely linked to a particular disease risk factor, where the genetic determinants 
do not have direct effects on the disease, it can be reasonably assumed that these genetic determinants 
fully represent the risk factor and are themselves not affected by confounding factors.11 This approach, 
which is based on the fact that genotypes are transmitted randomly from parents to offspring during 
meiosis (Mendel’s second law), is called the Mendelian randomization approach.12 The heritability of 
serum CRP levels has been estimated to range between 25% to 40%,13-15 suggesting that genetic factors 
are influencing variation in CRP levels. So far, 18 genetic loci have been identified by genome-wide 
association studies (GWAS) as associated at genome-wide significant level with serum CRP levels and 
explaining approximately 5% of the trait variance.16 An example of a well-conducted Mendelian ran-
domization study is the report by Zacho et al. examining the relationship between polymorphisms in 
the CRP gene and ischemic vascular disease.17
Our study’s aim was to investigate the relationship between serum high-sensitivity CRP levels and 
bone health using data from the Rotterdam Study, a prospective population-based cohort. First, we 
performed association analyses between CRP and different bone-related outcomes, such as fracture risk, 
bone mineral density (BMD) and hip geometry. Secondly, we explored the potential causality of serum 
CRP levels on the skeletal outcomes using a Mendelian randomization approach by applying regression 
of CRP-SNP genotypes on the fracture risk outcome.
METHODS
The Rotterdam Study
The Rotterdam Study is a prospective population-based cohort that aims to investigate the determi-
nants of chronic diseases and disability in Dutch men and women. Both the objectives and the study 
design have been described previously.18 The study targets investigations on endocrine diseases like 
osteoporosis amongst others. In short, all inhabitants aged 55 years and over of the Ommoord district 
in the city of Rotterdam in The Netherlands were invited to participate from January 1990 onwards (re-
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sponse rate 78%). Between 1990 and 1993, a baseline home interview on medical history and risk factors 
for chronic diseases and medication use was taken by trained interviewers. Falling was assessed using 
structured personal interviews and falling frequency was recorded as never, less than once a month, and 
more than once a month. Smoking habits were coded as “current”, “former”, and “never”. Subsequently, 
participants were invited to the research center for clinical examination. During the baseline visit height 
and weight were measured with indoor clothing and no shoes. Body mass index (BMI) was calculated 
as weight (in kg)/height (in m2).
Serum CRP measurement
At the baseline visit, high-sensitivity CRP was measured in non-fasting frozen serum samples of 6,658 
study participants using a rate near-infrared particle immunoassay (Immage Immunochemistry System, 
Beckman Coulter, Fullerton, CA, USA). This system measures concentrations from 0.2 to 1.440 mg/l, with 
a within-run precision <5.0%, a total precision <7.5%, and a reliability coefficient of 0.995. More details 
are described elsewhere.19
Skeletal assessments
All events, including incident fractures and death were reported by general practitioners (GPs) in the 
research area (covering 80% of the cohort) by means of a computerized system. All reported events 
were verified by two trained research physicians, who independently reviewed and coded the informa-
tion. Subsequently, all coded events were reviewed by a medical expert for final classification. Subjects 
were followed from their baseline visit until January 1, 2007 or until a first fracture or death occurred. 
In addition, during the second follow-up visit between 1997 and 1999 all Rotterdam Study participants 
underwent lateral spine radiographic screening. Spinal radiographs obtained at the follow-up visit 6.3 
years after baseline were evaluated morphometrically for the presence of prevalent vertebral fractures 
in Sheffield, UK, using the McCloskey-Kanis method as described previously.20, 21 Femoral neck (FN) and 
lumbar spine (LS) BMD were measured at baseline by dual-energy X-ray absorptiometry (DXA), using a 
Lunar DPX-L densitometer (Lunar Radiation Corporation, Madison, WI, USA).22 Hip structural analysis23 was 
used to measure hip bone geometry from the DXA scans of the femur narrow-neck region as described 
previously.24 One intensively trained interview assistant carried out a one hour home interview includ-
ing the Stanford Health Assessment Questionnaire (HAQ) 25 to assess lower limb disability, as described 
previously.26 Briefly, it measures the ability or disability and difficulty to perform different categories of 
daily life activities, such as rising, walking, bending and getting in and out of a car, summarized in an 
index ranging from 0 (no impairment) to 3 (severe impairment).
Genotyping
The Rotterdam Study participants were genotyped using the Illumina (Hayward, CA, USA) Infinium Hu-
manHap550 Beadchip in the Genetic Laboratory of Erasmus MC Department of Internal Medicine, The 
Netherlands, following manufacturers’ protocols and quality control standards. Further single nucleotide 
polymorphism (SNP) imputations were performed based on the HapMap CEU reference panel (release 
22, build 36).27, 28 The genotypes of the 29 variants reported to be associated with CRP levels were ex-
tracted from the GWAS dataset.16
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Statistical analysis
All effect estimates are reported per standard deviation of increase in CRP. Additionally, CRP values were 
log-transformed to account for the non-normal distribution and effect estimates expressed per unit log-
transformed CRP (Results presented in Supplementary Materials). Risk of incident any-type of fractures 
was evaluated for association with CRP levels in Cox proportional hazard regression models. Proportional 
hazards assumption was tested via Schoenfeld residuals. The association with risk of vertebral fractures 
was assessed in logistic regression models. The relationships between CRP levels and continuous 
measures of BMD and hip bone geometry parameters were tested in linear regression models. Models 
for fracture, BMD and hip geometry were corrected for potential confounders, including: sex, age and 
BMI; fracture analyses had additional adjustments for myocardial infarction, prevalent type 2 diabetes 
mellitus, dementia, prevalent cancer, lower limb disability, use of systemic corticosteroids and risk of 
falling. In addition, the fracture analyses were adjusted for femoral neck and lumbar spine BMD. Change 
in effect estimates of 10% or more and/or loss of statistical significance after correction was examined. 
To further study relationships with confounders, analyses were performed stratified across gender and 
smoking status, and across age and BMI tertiles. Potential interaction of CRP levels with both BMD and 
BMI was tested by adding an interaction term to the models, to explore if an effect of CRP on fracture 
risk dependent on BMD levels could be detected. Subsequently, we performed stratified analyses per 
unadjusted and age-adjusted BMD tertiles.
For the Mendelian Randomization approach a weighted genetic risk score was constructed for each 
subject using all SNPs reported as associated with serum CRP levels (Supplementary Table 1)16. The 
cumulative effect of the CRP SNPs was tested in relation to CRP levels and risk of fracture by including 
the allele score on the statistical models. To declare a causal relationship, the following requirement 
should be met: βCRP gene scorefor serum CRP×βserum CRP for fracture≈βCRP gene score for fracture. In addition, association statistics 
were computed for each SNP separately and to account for multiple testing the significance threshold 
was corrected according to Bonferroni (0.05/29=0.002 with corresponding 99.8% confidence intervals). 
SPSS statistics software version 20 (IBM, Armonk, NY, USA) and R software version 3.0.1 (R Foundation for 
Statistical Computing, Vienna, Austria) were used for the analyses.
Table 1. Population baseline characteristics.
Age (years) 69.1 (8.9)
Height (m) 1.67 (0.09)
Weight (kg) 73.1 (12)
CRP (mg/L) 3.31 (6.69)
Log-transformed CRP 0.61 (1.04)
Femoral neck BMD (g/cm2) 0.87 (0.14)
Lumbar spine BMD (g/cm2) 1.09 (0.2)
Use of corticosteroids (%) 1.9
Current smoking (%) 23.1
Data presented as mean (SD) or percentages from the total study population (N=6,386) assessed at baseline (%). 
CRP=C-reactive protein; BMD=bone mineral density.
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RESULTS
Association between serum CRP and fracture risk
Complete data was available for 6,386 participants (59% women), of whom 1,561 persons sustained 
a fracture during a mean follow-up duration of 11.6 years (SD=4.5 years; incidence=0.024 / person 
years). Serum CRP levels were significantly associated with increased risk of any-type of fracture (hazard 
ratio [HR] per unit increase in log-CRP: 1.06; 95% confidence interval [CI]: 1.02-1.11; P=0.005) (Table 2). 
For the gender-stratified analyses effect estimates did not all reach statistical significance, but were of 
similar magnitude (male HR=1.11; 95% CI: 1.02-1.22; P=0.02; female HR=1.05; 95% CI: 1.00-1.11; P=0.05). 
Furthermore, the main analysis was repeated stratifying according to age tertiles, where the effect was 
found foremost in the oldest age category (Table 3). Additional adding of potential confounders (myo-
cardial infarction, prevalent type 2 diabetes mellitus, dementia, prevalent cancer and lower limb dis-
ability; systemic corticosteroids use; risk of falling) did not essentially change the results (HR=1.06; 95% 
CI: 1.01-1.11; P=0.018; P=0.03; HR=1.07; 95% CI: 1.02-1.12; P=0.003). The skeletal site-specific fracture risk 
analyses showed that the effect was particularly strong at the hip (HR=1.09; 95% CI: 1.02-1.17; P=0.008) 
and at the spine (OR = 1.34; 95% CI: 1.14-1.58; P=0.0004), but not clearly present with wrist fractures 
(HR=1.06; 95% CI: 0.97-1.16; P=0.21). As observed for any type of fracture, correction of the associations 
with hip and vertebral fracture were not affected by the inclusion of covariates in the models. Analyses 
adjusting for smoking status (HR=1.06; 95% CI: 1.01-1.11; P=0.01) or stratifying according to smoking 
status did not display strong differences between groups (“never smokers”: HR=1.07; 95% CI: 1.01-1.14; 
P=0.03; “past smokers”: HR=1.09; 95% CI: 0.99-1.19; P=0.08; “current smokers”: HR=1.07; 95% CI: 0.90-1.27; 
P=0.47). The interaction term CRP*BMI was not significant; stratification by BMI tertiles did not show any 
differences in the analysis with log-transformed CRP (Supplementary) but there seemed a trend towards 
greater effects in the higher BMI tertiles in the analyses per standard deviation of CRP (Table 3). Neither 
was the association between CRP and fracture free survival attenuated by adjustment of analyses for 
FN-BMD or LS-BMD (HR=1.08; 95% CI: 1.03-1.13; P=0.003; HR=1.07; 95% CI: 1.02-1.13; P=0.003). However, 
CRP and FN-BMD were weakly interacting with each other to affect the risk of fracture (beta-coefficient: 
-0.46; P=0.08), which was more obvious in the analyses per log-transformed unit of CRP (Supplemen-
tary). Indeed, the association with fracture was strongest in the lowest FN-BMD tertile (Table 3). The 
Table 2. Association statistics between serum high-sensitivity CRP and fracture risk.
Outcome
Any-type of fracture
Total sample size 
(number of cases)
Hazard ratio per unit 
increase in log-CRP
95% Confidence 
interval
P value
Model 1 6,386 (1,561) 1.06 1.02–1.11 0.005
Model 1 Hip fracture 6,386 (390) 1.09 1.02–1.17 0.008
Model 1 Wrist fracture 6,386 (363) 1.06 0.97–1.16 0.21
Model 1 Vertebral fracture 3,246 (359) 1.34a 1.14–1.58a 0.0004
Model 2 Any-type of fracture 5,399 (1,311) 1.08 1.03–1.13 0.003
Model 3 Any-type of fracture 5,420 (1,324) 1.07 1.02–1.13 0.003
Model 4 Any-type of fracture 6,234 (1,529) 1.06 1.01–1.11 0.018
Model 5 Any-type of fracture 6,304 (1,542) 1.07 1.02–1.12 0.003
Model 1: adjusted for age, sex and BMI; Model 2: adjusted for age, sex, BMI and FN-BMD; Model 3: adjusted for age, 
sex, BMI and LS-BMD; Model 4: adjusted for age, sex, BMI, myocardial infarction, prevalent type 2 diabetes mellitus, 
dementia, prevalent cancer and lower limb disability and use of systemic corticosteroids; Model 5: adjusted for age, 
sex, BMI and risk of falling. FN-BMD=femoral neck bone mineral density; LS-BMD=lumbar spine bone mineral density.
aOdds ratios for prevalent radiographic vertebral fractures.
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interaction term CRP*LS-BMD did not reach statistical significance (beta-coefficient: -0.02; P=0.92), yet, 
the association seemed strongest again in the lower ranges of LS-BMD (Table 3).
Association between serum CRP and fracture risk in relation to BMD and hip bone 
geometry
Next, we analyzed the relationship between serum CRP and hip bone geometry, correcting for potential 
confounding by sex, age and BMI. Serum CRP was neither statistically significantly associated with FN-
BMD (-0.003 g/cm2; per unit log-CRP increase; 95% CI: -0.006–0.001 g/cm2; P=0.16) nor with LS-BMD 
(-0.002 g/cm2; -0.008–0.003 g/cm2; P=0.37) in our study sample. Hip bone geometry data was available 
for a subset of 4,528 participants. There was a significant inverse relationship between serum CRP levels 
and section modulus (-0.011 cm3 per standard deviation increase; -0.020 to -0.003 cm3; P=0.009). For nar-
row neck width we found a significant inverse association in the analysis per log-transformed unit of CRP 
(Supplementary) but this could not be replicated in the analysis per standard deviation increase of CRP 
(-0.05 mm; 95% CI: -0.10–0.002 mm; P=0.21). In line with no association with BMD levels there was also 
no significant association with cortical thickness (-0.0005 mm; -0.001–0.0002 mm; P=0.18). Increased CRP 
levels were associated with a weak increase of the buckling ratio instability index though not achieving 
statistical significance (+0.08 mm; -0.02 mm–0.18 mm; P=0.13); the buckling ratio instability index is 
the composite of narrow neck width and cortical thickness. When re-running the association analysis 
between CRP and hip fracture for the subset of participants with hip bone geometry data available and 
entering the hip bone geometry parameters analyzed the risk estimate did not change (HR=1.11; 95% 
CI: 1.03–1.20; P=0.007 to HR=1.12; 95% CI: 1.04–1.22; P=0.005).
Mendelian Randomization approach
The combined weighted genetic risk score for CRP was highly significantly associated with serum CRP 
levels in our study (β = 0.011, P=2×10-13) and explained 3% of the variance in serum CRP levels. However, 
this score did not show a significant association with fracture risk (HR=1.00; 95% CI: 0.99–1.00; P=0.23). 
Clearly, the requirement of βCRP gene score for serum CRP x βserum CRP for fracture ≈ βCRP gene score for fracture was not met as 
0.011×0.063=0.0007≠-0.004. Neither did association testing for each of the individual 29 SNPs demon-
strate any significant effect for fracture (Table 4).
Table 3. Association analyses between serum CRP and any-type of fracture per tertile of age, bone mineral density 
or body mass index.
Stratification category First tertile Second tertile Third tertile
Age <64 years: 0.95 [0.75–1.20] 64-73 years: 1.05 [0.99–1.12] >73 years: 1.08 [1.02–1.15]
Body mass index <24.5 kg/m2: 1.05 
[0.96–1.14]
24.5-27.5 kg/m2: 1.07 
[1.00–1.13]
>27.5 kg/m2: 1.12 
[0.99–1.27]
Femoral neck bone mineral 
density
<0.80 g/cm2: 1.10 
[1.01–1.20]
0.80-0.92 g/cm2: 1.07 
[1.00–1.14]
>0.92 g/cm2: 1.05; 
[0.87–1.26]
Age-standardized femoral 
neck bone mineral density
1.12 [1.00–1.26] 1.06 [0.98–1.14] 1.09 [0.93–1.27]
Lumbar spine bone 
mineral density
<1.00 g/cm2: 1.07 
[1.02–1.13]
1.00-1.16 g/cm2: 1.08 
[0.95–1.23]
>1.16 g/cm2: 1.06 [0.91–1. 
24]
Age-standardized lumbar 
spine bone mineral density
1.06 [1.01–1.13] 1.07 [0.94–1.21] 1.03 [0.89–1.21]
Hazard ratio per unit increase of log C-reactive protein with corresponding 95% confidence intervals between brack-
ets.
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DISCUSSION
In this study we report an association between serum CRP levels and any-type of fracture risk for both 
men and women. Our skeletal-site specific analyses showed effects on at least hip fractures and radio-
graphic vertebral fractures. Using a Mendelian Randomization approach we did not find any evidence 
for a causal relation. Moreover, even though the association is independent of BMD, it appears to be 
strongest for individuals with the lowest levels of BMD. Further, we show that higher CRP levels are 
associated with a lower bending strength (section modulus) of the hip.
Our results from the CRP gene weighted score for fracture risk are in line with the previously proposed 
hypothesis that complex interactions between inflammation and other factors modulating bone metab-
olism are likely.2 Circulating high-sensitivity CRP levels may be a surrogate for unrecognized confounders 
that affect fracture risk, but it remains difficult to pinpoint which these unrecognized confounders are. 
CRP levels are known to be increased in multiple conditions, including infections, autoimmune diseases, 
Table 4. Association statistics of individual CRP SNPs with any-type of fracture risk.
SNP Beta-coefficient for fracture 99.8% confidence interval
rs12037222 0.03 -0.11 – 0.17
rs4420065 0.06 -0.06 – 0.19
rs4129267 0.00 -0.12 – 0.12
rs13962 -0.09 -0.28 – 0.09
rs2794520 0.05 -0.09 – 0.18
rs12239046 -0.02 -0.14 – 0.11
rs1260326 0.01 -0.12 – 0.14
rs1030023 0.01 -0.12 – 0.13
rs6734238 0.10 -0.02 – 0.22
rs4705952 0.00 -0.16 – 0.16
rs16889362 -0.09 -0.31 – 0.13
rs195522 0.04 -0.09 – 0.17
rs6901250 0.00 -0.13 – 0.13
rs13233571 0.02 -0.16 – 0.21
rs9987289 0.02 -0.19 – 0.23
rs4410870 -0.02 -0.15 – 0.10
rs10086637 -0.19 -0.45 – 0.07
rs6486122 0.00 -0.13 – 0.13
rs10745954 -0.01 -0.13 – 0.11
rs1183910 0.03 -0.10 – 0.16
rs4903031 -0.02 -0.17 – 0.12
rs340029 0.07 -0.05 – 0.20
rs10521222 -0.02 -0.33 – 0.29
rs1558902 -0.03 -0.15 – 0.10
rs2847281 0.02 -0.11 – 0.14
rs10460119 -0.06 -0.19 – 0.07
rs4420638 0.10 -0.10 – 0.31
rs1800961 0.02 -0.31 – 0.35
rs2836878 0.07 -0.06 – 0.20
A 99.8% confidence interval corresponds to a correction for 29 independent tests.
- 59 -
C-
re
ac
tiv
e 
pr
ot
ei
n 
an
d 
fra
ct
ur
e 
ris
k
2.3
some malignancies,4, 29 and chronic conditions such as obesity and atherosclerosis and therefore predict 
cardiovascular disease30 and type 2 diabetes mellitus19, 31. Our association analyses between serum CRP 
and fracture risk have been corrected, to the best of our means, for potential confounders but these 
corrections did not essentially modify the associations. This lack of a causal relationship of CRP with 
fracture is similar to the outcome of a large-scale study scrutinizing the association between CRP and 
clinical cardiovascular events, i.e., incident cases of myocardial infarction and coronary heart disease. 
After applying the same methodology we used in our study, this well-powered effort also found that 
neither the individual CRP SNPs nor the combined weighted genetic risk score show consistent or 
genome-wide significant associations with disease risk.16 Another group has investigated three tagging 
SNPs associated with CRP levels in relation to insulin resistance, serum glucose, and diabetes, where the 
researchers also did not find any conclusive evidence for causality.32
As stated before, CRP is elevated in inflammatory diseases. Rheumatoid arthritis,33, 34 inflammatory 
bowel disease35 and spondylarthropathies36-38 have been found associated with increased risk of fracture 
and decreased BMD. In systemic lupus erythematosus BMD has been found to be decreased as well, and 
on top of that, hip bone geometry differences have been detected including an increased buckling ratio 
and decreases in bending (section modulus) and axial (cross-sectional areas).39 Our present study also 
found decreases in section modulus and possibly femoral neck width, but not BMD. These differences 
did not explain the increase in hip fracture risk. For type 2 diabetes mellitus we have found earlier in 
the same Rotterdam Study cohort that patients have increased fracture risk, but increases in BMD with 
a decreased cortical buckling ratio.40, 41 More specifically, recent work in the Study of Women’s Health 
Across the Nation (SWAN) showed that CRP levels were inversely associated with hip geometry strength 
indices (a finding in line with those of our study) which partially explained the increased fracture risk 
observed in SWAN.42
The association of these inflammatory diseases with increased fracture risk has frequently been 
reported to be independent of BMD.34, 36 On the other hand, the relationship between CRP levels and 
BMD is less clear. Several studies have reported an inverse relationship between serum CRP and BMD,5-7, 9 
while others have not clearly observed the same relation2, 8. In our study, the effect estimates between 
serum CRP and BMD were negative but not statistically significant. We found that the increased fracture 
risk in relation to CRP remains after accounting for BMD, which is supported by previous results from 
the STRAMBO study.8 In addition, in the same study higher hs-CRP levels were associated with a poor 
trabecular, but not cortical, microarchitecture at the distal radius as assessed by pQCT in men aged 72 
years an older but not in younger men. However, this again was shown not to fully explain the positive 
association between CRP level and fracture risk. These heterogeneous and multi-factorial observations 
are in line with the complex nature of bone metabolism and fracture risk.
Our findings suggest that cumulative effects of inflammation may eventually manifest predominantly 
in those elderly individuals with the frailest bones. The decline in femoral neck BMD with age, involves 
cortical thinning and widening of the bone width.23 This is a homeostatic process preserving bone 
strength (section modulus) through subperiosteal apposition. Our results and those of others postulate 
that chronic inflammation undermines this compensatory physiological process.39, 40 The underlying 
mechanisms underlying the geometrical differences observed remain to be elucidated. Further, experi-
mental studies have demonstrated that inflammatory cytokines stimulate osteoclastic bone resorption43 
and suppress osteoblast function (bone formation).44 Another very important (potentially) contributing 
factor is glucocorticoid use,45 which is frequently indicated for the treatment of inflammatory diseases. 
Negative effects of steroids include both direct and indirect skeletal effects, displayed in decreases in 
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BMD and altered bone geometry.46, 47 Our correction for glucocorticoid use indicates they are respon-
sible for a fraction but not all of the effect of CRP levels on fracture risk. Finally, skeletal loading might be 
altered in patients with inflammation, because of pain, fatigue, metabolic wasting and steroid-induced 
myopathy39 for which CRP levels can be a marker of such statuses.
Strengths of our study are the long follow-up duration and availability of various outcomes and co-
variables in a large prospective population-based study which includes both men and women. Serum 
CRP at baseline was measured by the high-sensitivity assay increasing the accuracy of the assessment. 
Additionally, this is to our knowledge the first study with to investigate the relationship of CRP with hip 
bone geometry. Yet, our study has some limitations. Causal inference is largely dependent on study 
power. Even though the instrumental variables (genetic markers) are strongly associated with CRP levels, 
the compound effect of the included CRP SNPs tested explain ~3-5% of the variance in serum CRP 
levels; this was the best we could achieve based on our current knowledge of genetics of CRP.16 A post-
hoc power calculation based on data from a simulation-based study by Pierce et al.48 indicates that the 
power of our study is limited ranging between 0.11–0.36. Therefore, even though the effect estimates 
of the relation between the genetic score for CRP-levels and fracture risk is convincingly supports the 
null (HR=1.0; 95% CI: 0.99–1.00) hypothesis, lack of causality cannot be definitely concluded considering 
power limitations.
If the relationship between elevated CRP and increased fracture risk is indeed not causal, then inter-
ventions focused only on lowering CRP levels are not expected to lower fracture risk.
Future studies might be able to reveal which (set) of the conditions that are associated with elevated 
CRP can explain the relationship between CRP and fracture risk. In our study the effect seems to be stron-
gest, or perhaps even restricted, to individuals with the lowest ranges of BMD, probably an indication 
of co-morbidity. Nevertheless, we cannot exclude inflammation can turn out to be more detrimental to 
bones that are already compromised. Finally, DXA-based bone geometry represents 2D assessments of 
a 3D structure, whose measurement relies on several assumptions and several of the parameters are not 
independent of BMD. Unfortunately, we currently do not have more optimal measurements like QCT or 
MRI available, which accurately measure the underlying bone geometry.
In conclusion, serum high-sensitivity CRP levels are associated with increased incident fracture risk. 
Nevertheless, there is not enough evidence for this relationship being causal. Finally, it is suggested that 
high serum CRP may also be associated with lower bending strength at the hip.
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ABSTRACT
Type 2 diabetes mellitus (T2DM) influences bone metabolism, but the relation of T2DM with bone 
mineral density (BMD) remains inconsistent across studies. The objective of this study was to perform a 
meta-analysis and meta-regression of the literature to estimate the difference in BMD (g/cm2) between 
diabetic and non-diabetic populations, and to investigate potential underlying mechanisms. A literature 
search was performed in PubMed and Ovid extracting data from articles prior to May 2010. Eligible 
studies were those where the association between T2DM and BMD measured by dual energy X-ray 
absorptiometry was evaluated using a cross-sectional, cohort or case–control design, including both 
healthy controls and subjects with T2DM. The analysis was done on 15 observational studies (3,437 
diabetics and 19,139 controls). Meta-analysis showed that BMD in diabetics was significantly higher, 
with pooled mean differences of 0.04 (95% CI: 0.02–0.05) at the femoral neck, 0.06 (95% CI: 0.04–0.08) at 
the hip and 0.06 (95% CI: 0.04–0.07) at the spine. The differences for forearm BMD were not significantly 
different between diabetics and non-diabetics. Sex-stratified analyses showed similar results in both 
genders. Substantial heterogeneity was found to originate from differences in study design and pos-
sibly diabetes definition. Also, by applying meta-regression we could establish that younger age, male 
gender, higher body mass index and higher HbA1C were positively associated with higher BMD levels 
in diabetic individuals. We conclude that individuals with T2DM from both genders have higher BMD 
levels, but that multiple factors influence BMD in individuals with T2DM.
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INTRODUCTION
Osteoporosis and diabetes are both common human diseases. Albright and Reifenstein reported their 
coexistence in 1948,1 but hitherto the association between them remains unclear. Due to the different 
pathogenesis of type 1 and type 2 diabetes mellitus (T2DM), it is not surprising that there is no uniform 
entity of diabetic bone disease as such. While decreased bone mineral density (BMD) has consistently 
been observed in type 1 diabetes mellitus patients,2, 3 studies on BMD investigated in T2DM showed 
contradictory results with higher, lower or similar values in comparison with healthy control subjects.4-7 
These inconsistent findings may be related to vast differences in study design, BMD measurement 
technology, differences in site of BMD examination, selection of patients, and presence or absence of 
complications.
It is well known that advanced age is a risk factor for bone loss and osteoporosis.8, 9 Some of the at-
tributed mechanisms include increased production of inflammatory cytokines and cellular components, 
incremental osteoclast precursors generation and decreased bone preservation due to gonadal failure 
resulting in lower tissue production of sex steroids.10 Advanced age is also associated with increased fall 
frequency, lack of exercise, use of drugs that negatively influence bone metabolism and renal function 
such as drugs prescribed for diabetes and hypertension.
Gender also appears to have an important effect on the relation between BMD and T2DM. Barrett-
Connor11 found that older women with T2DM had higher BMD levels at all sites compared to those with 
normal glucose tolerance, but this effect was not observed in men. It has also been suggested that 
obesity and hyperinsulinemia can lead to lower bone turnover in diabetic women,7, 12 so that the adverse 
effects of estrogen deficiency on bone mass are attenuated and delayed after menopause.
Many studies have shown a difference in population characteristics between type 2 diabetic patients 
and healthy controls.6, 11, 13, 14 Diabetic study participants tend to have a higher body mass index (BMI) 
or weight, increased insulin levels, less physical exercise, higher alcohol consumption and they usually 
smoke more. The use of diuretics is more common in diabetes. These characteristics might influence 
bone metabolism independently of diabetes. Paradoxically, an increased risk of osteoporotic fracture in 
T2DM has been repeatedly demonstrated and this was independent of BMD.13, 15 This association with 
fracture adds uncertainty around the actual association between diabetes mellitus and BMD.
The aim of our study was to perform meta-analysis of published articles exploring differences between 
type 2 diabetics and healthy individuals in BMD levels measured at four anatomical sites. In addition, we 
evaluated factors influencing BMD variation like sex, age, BMI and glucose control (HbA1C levels) for 
which a meta-regression was performed to evaluate potential mechanisms by which T2DM influences 
BMD variation.
METHODS
Search strategy
A systemic search for all literature that was published in May 2010 or earlier was performed using 
Pubmed and Ovid online (1950 to present with daily update). The search used MeSH terms ‘‘diabetes 
mellitus’’ and (‘‘osteoporosis’’ OR ‘‘bone density’’ or ‘‘bone mass’’).
Study selection
Studies were considered eligible for the meta-analysis if (1) they evaluated the association between 
T2DM and BMD, (2) they were of a cross-sectional, cohort or case–control design, (3) they included 
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healthy subjects without DM as controls, (4) they reported gender-stratified statistics on both individuals 
with and without T2DM, (5) BMD was measured by dual energy X-ray absorptiometry (DXA) and (6) BMD 
measurements were expressed as an absolute value in g/cm2. In the cases that more than one article 
presented data from the same study population, the study with more complete reporting of data was 
selected.
Studies in nonhuman populations, review articles, experimental studies, case reports or studies that 
lacked controls, studies on type 1 or other types of DM, studies that had no clear definition of T2DM, 
studies that measured BMD measured by computed tomography, ultrasound or single X-ray absorpti-
ometry were all regarded as ineligible.
Only published results were used and papers in all languages were considered. We supplemented 
electronic searches by hand-searching reference lists of relevant articles and reviews. The abstracts 
and titles of primitive collections were initially browsed and all observational studies were extracted. 
Potentially relevant articles were then considered by double checkout. Disagreements were resolved by 
discussion between at least two reviewers.
Data
Quality-scoring varies in meta-analyses of observational studies and no criteria have been interna-
tionally accepted to date. Consequently, we appraised each article included in this analysis with the 
guidelines of the MOOSE group16. Some key points were: clear definition of study population, clear and 
internationally accepted criteria of diagnosing diabetes, description of the coefficient of variation for 
BMD measurements, consecutive selection of cases, random selection of controls and identification of 
important confounders. We required that at least 2 studies per site-specific BMD outcome should be 
available to perform a meta-analysis.
Mean and its standard deviation (SD) of BMD measurements at the calcaneus, femoral neck, total 
hip, spine and forearm in both diabetics and non-diabetics were extracted to explore the pooled mean 
difference estimation. If repeated measurements were available in cohort studies we extracted only the 
measurements at baseline (or the earliest available measurement) as being a cross-sectional study. The 
mean and standard deviation had to be unadjusted due to large variance of adjusted factors between 
different studies. If there were statistically significant age differences between patients and controls and 
the age-adjusted mean and deviation could be found, these data were used; if these were not found 
the study was excluded. In addition, we performed meta-analysis including the maximally adjusted 
estimates from studies where available. If sample size of either group in comparison was less than 30, it 
was not used in our analysis. Gender was considered to be a determinant for subgroup analysis.
If studies lacked SD estimates but provided P value, standard error (SE), confidence interval (CI) that 
related to the mean difference, we estimated SDs using the following methods17:
1. From SE to SD: the following formula was used:
2. From CI to SD: SE=(upper limit - lower limit)/3.92 (if 95% CI), then replaced in formula.
- 69 -
As
so
ci
at
io
n 
be
tw
ee
n 
bo
ne
 m
in
er
al
 d
en
sit
y a
nd
 ty
pe
 2
 d
ia
be
te
s m
el
lit
us
2.4
3. From P value to SD: the corresponding t-value according to P value was obtained from a table of the 
t-distribution with the degrees of freedom given by Ncase+Ncontrol–2 (where Ncase, Ncontrol are the sample 
sizes); then, assuming 
(where MD is mean difference between case and control); we finally replaced SE in the formula:
(where SD is the average of the SDs of the case and control arms);
Analyses
The weighted mean difference estimates of BMD in g/cm2 comparing diabetes with controls were 
calculated as Der-Simonian and Laird estimators using random effects models. As secondary analyses 
inverse variance fixed effect models were applied. Publication bias was tested using funnel plots. Tests 
for heterogeneity were performed by applying the Cochran Q test and estimating the degree of incon-
sistency index (I2)18. Sources of heterogeneity were investigated by sensitivity analyses stratifying on 
study design, by excluding studies: on Asian populations, presenting large differences in BMI between 
cases and controls, and/or having BMD measurements assessed by different densitometers. All analyses 
were conducted with the use of Review Manager, version 5.0 (Revman, The Cochrane Collaboration; 
Oxford, UK) and Comprehensive Meta-analysis version 2 (Biostat, Inc., Englewood, USA). To estimate the 
effects of gender, age, BMI and HbA1C on the BMD measured at the different sites a meta-regression 
analysis was performed using STATA 11.0 (StataCorp LP, USA).
RESULTS
Figure 1 shows a flow diagram describing the study selection process. The initial search yielded 1,161 
research reports, of which 222 were excluded for having the same title or authors; 788 were excluded 
due to not eligible study design (including non-human studies, review articles, case reports, comment, 
letter, experimental study, and/or fracture-only outcome). Additional 109 studies were found irrelevant 
to the original research question and excluded because the disease of interest was either type 1 or ges-
tational DM (81 studies); or for not measuring bone mass using DXA, i.e. by single X-ray absorptiometry, 
CT or ultrasound (28 studies). Of the 42 remaining studies, 11 either lacked non-diabetic controls at all 
or did not report means and standard deviations in non-diabetic controls19-29. In addition, six studies had 
small sample sizes (N<30) in either group of comparison30-35. The study population of two studies was 
used in follow-up reports.4, 36 In three studies there was a big age difference between individuals with 
diabetes and those without diabetes, but the investigators did not adjust for it.37-39 One study matched 
cases and controls by age and BMI and presented data only on post-matching.40 The original articles of 
four articles could not be retrieved.41-44 All of these aforementioned studies were excluded. One study 
cited as reference in one of the research reports was traced and satisfied the inclusion criteria.45 In one 
research report the results of gender-specific BMD analyses was mentioned, but not listed in detail.14 
We contacted the researchers and were able to retrieve this information. The study of Perez et al. found 
a significantly increased calcaneal BMD in female but not in males subjects with diabetes.46 No meta-
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analysis was attempted for this site since this was the only study that evaluated BMD at the calcaneus. 
Since no SD’s for male comparison groups could be retrieved for the paper by Barrett-Connor et al. 
we were not able to include these results for men. As we extracted only a single measure and didn’t 
examine repeated measurements, cohort studies were analyzed as cross-sectional using the baseline 
or earliest available measurement. A total of 15 observational studies (9 case–control, 6 cross-sectional) 
were included in our meta-analysis (3,437 diabetics and 19,139 controls).5-7, 11, 12, 14, 45, 47-54 Table 1 indicates 
the quality evaluation of all studies. We did not observe indication of publication bias on the Funnel Plots 
(data not shown), with the effect magnitude of larger studies being closer to and smaller studies largely 
equally distributed at both sides of the summary estimate.
Figure 1.  Flow diagram of the study-selection process. DM diabetes mellitus, CT computed tomography, US ultra-
sound.
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Table 2 shows study population characteristics and the reported effect of covariates on the association 
between BMD and T2DM. Out of five studies performed in the US, one had included Mexican–American 
women6 and one had white and black participants51. One study was done in Eastern Asia7 and another 
two in Eastern Europe53, 54. The remaining eight studies collected data in Western Europe and Ocea-
nia. Participants in all study populations were aged 25 years and over and approximately 70 % were 
middle-aged or older. In addition, Table 2 shows that the most common covariates considered by the 
studies were BMI or weight, cigarette smoking, alcohol use, physical activity, diuretic use, calcium intake, 
estrogen use (women), menopause status (women), age at menarche (women), insulin level, HbA1C 
and alkaline phosphatase. Table 3 shows the population characteristics of the source studies by gender.
Table 4 presents BMD levels in diabetics and non-diabetics at four skeletal sites across the different 
studies, also including subgroup analysis by gender. At the femoral neck, all studies except for Yaturu 
et al.5 and Majima7 found a higher BMD in subjects with diabetes. At the total hip, all referred studies 
showed significantly higher BMD in diabetics. At the lumbar spine, almost all of the studies reported 
a higher BMD in diabetics. These differences were statistically significant in the vast majority. At the 
forearm there were no significant differences between diabetics and non-diabetics in all analyses. No 
major differences between genders were found.
Some reports concluded that the association remained significant despite the fact that the effect size 
decreased remarkably after correcting for aforementioned covariates.6, 11, 12, 14, 48, 54 In others, the associa-
tion disappeared or even shifted in the opposite direction after adjustment for covariates, particularly in 
the case of BMI or weight.5, 49, 51, 52 We performed meta-analysis for maximally adjusted estimates where 
available, which did not significantly alter previously calculated mean differences. Nearly all studies found 
that BMI was positively correlated with BMD. There was some evidence suggesting that other factors 
such as insulin levels also had a positive correlation with BMD.7 In contrast, HbA1C levels had positive,7 
negative51 or no correlation50 with BMD. In a follow-up study, Schwartz51 found that after adjustment for 
covariates white women with T2DM lost on average more BMD per year than those without DM.
Table 5 shows meta-analysis results of pooled mean differences and corresponding 95% confidence 
intervals of BMD values between diabetic and non-diabetic individuals. In the pooled meta-analyses the 
Table 3. Population characteristics of the source studies by gender.
Female Male
Study Age 
(years)
BMI 
(kg/m2)
HbA1C
(%)
Serum 
creatine 
(μmol/L)
Disease 
duration 
(years)
Age 
(years)
BMI 
(kg/m2)
HbA1C
(%)
Serum 
creatine 
(μmol/L)
Disease 
duration 
(years)
Barrett-Connor11 76.0 26.3 6.7 99.7 NA 76.0 26.3 6.7 99.7 NA
Tuominen48 63.3 25.3 9.8 NA NA 63.3 25.3 9.8 NA NA
Kao6 54.3 33.0 NA NA NA 54.3 33.0 NA NA NA
Dennison49 64.8 26.6 NA NA NA 64.8 26.6 NA NA NA
Bridges50 62.8 31.4 8.9 NA 10.1 62.8 31.4 8.9 NA 10.1
de Liefde14 69.6 25.8 NA 96.2 NA 69.6 25.8 NA 96.2 NA
Majima7 62.8 23.6 7.8 66.3 NA 62.8 23.6 7.8 66.3 NA
Schwartz51 (white) 73.7 NA 7.2 NA 7.4 73.7 NA 7.2 NA 7.4
Schwartz51 (black) 74.0 NA 8.2 NA 9.5 74.0 NA 8.2 NA 9.5
Rakic52 66.0 29.0 7.4 94.0 8.7 66.0 29.0 7.4 94.0 8.7
Yaturu5 67.5 30.1 NA 106.1 NA 67.5 30.1 NA 106.1 NA
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differences were 0.04 (95% CI: 0.02–0.05) at the femoral neck, 0.06 (95% CI: 0.04–0.08) at the hip, 0.06 
(95% CI: 0.04–0.07) at the spine, and -0.003 (95% CI: -0.02–0.02) at the forearm, respectively. In the sex-
stratified analysis these differences were most pronounced for females, being 0.04 (95% CI: 0.03–0.06), 
0.07 (95% CI: 0.04–0.11), 0.07 (95% CI: 0.05–0.09), 0.01 (95% CI: -0.02–0.03) at the femoral neck, hip, spine, 
and forearm, respectively. In males these differences were statistically significant at the hip 0.04 (95% CI: 
0.01–0.08) and spine 0.05 (95% CI: 0.02–0.07). The meta-analysis result in males was non-significant at the 
femoral neck 0.03 (95% CI: 0.00–0.05) and forearm -0.01 (95% CI: -0.04–0.02). This information is displayed 
in more detail in the forest plots of Figures 2, 3, 4, and 5.
Table 5. Pooled mean differences of BMD comparing diabetes with non-diabetes.
Site Groups Number 
of studies
Sample 
size (case/
control)
Mean difference of 
BMD (g/cm2)
P value Heterogeneity
I2 (%) Q test P 
value
Femoral neck Total 12 2,720/12,707 0.04 [0.02, 0.05] <0.00001 83 <0.0001
Female 10 1,234/5,752 0.04 [0.03, 0.06] <0.00001 71 0.0002
Male 7 1,486/6,955 0.03 [0.00, 0.05] 0.09 87 <0.0001
Hip Total 3 1,143/7,282 0.06 [0.04, 0.08] <0.00001 78 0.0002
Female 3 777/6,610 0.07 [0.04, 0.11] <0.00001 82 0.001
Male 2 366/672 0.04 [0.01, 0.08] 0.007 63 0.07
Spine Total 12 2,833/17,677 0.06 [0.04, 0.07] <0.00001 66 <0.0001
Female 11 1,583/11,354 0.07 [0.05, 0.09] <0.00001 62 0.003
Male 6 1,250/6,323 0.05 [0.01, 0.07] 0.008 74 0.002
Forearm Total 6 918/1,013 −0.003 [−0.02, 0.02] 0.90 88 <0.0001
Female 5 601/652 0.01 [−0.02, 0.03] 0.68 93 <0.0001
Male 4 317/361 −0.01 [−0.04, 0.02] 0.44 79 0.003
The weighted mean difference estimates of BMD were calculated as DerSimonian and Laird estimators using random 
effects models Tests for heterogeneity were performed by applying the Cochran Q test.
The heterogeneity (Q) tests showed significant differences between individual studies (P<0.01) at all 
sites in the total group and sex-specific analyses (Table 5). Still, point estimates and statistical significance 
from fixed effects models were very similar to those derived from random effects models. We further 
performed sensitivity analyses to identify potential sources of the observed heterogeneity. Subgroup 
analyses per study design (case–control/cross-sectional) showed that case–control studies had effect 
estimates with larger variation around the pooled estimate thereby increasing the heterogeneity. For 
the femoral neck BMD analysis the largest source of heterogeneity was traced back to one study by 
Yaturu et al.5 This study include only men and observed a positive relation with lumbar spine and a 
negative one for femoral neck; after removing this study the I2 statistic dropped from 81 to 57%. An-
other study in Asians also displayed estimates in the opposite direction for different outcomes though 
not significant7. Removing seven studies with significantly different BMI between diabetes and non-
diabetes5, 12, 14, 47, 50, 51, 54 or six studies that did not use a densitometer manufactured by Hologic incorpora-
tion (USA)5, 12, 14, 48, 50 from the analyses showed no significant influence on the observed heterogeneity, 
except for the femoral neck BMD analysis, but this was largely attributable to the large heterogeneity 
brought in by the Yaturu et al. study5.
The results of a meta-regression on BMD by sex, age, BMI and glucose control (HbA1C levels) is pre-
sented in Table 6 for individuals from the diabetic group of the studies. Being a woman was associated 
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with significantly lower BMD levels at all four anatomical sites, as compared to men. Age was negatively 
associated with BMD at hip but positively at the lumbar spine. Higher BMI was a strong determinant 
of higher BMD at the femoral neck and lumbar spine, with no apparent effect on forearm BMD. Higher 
HbA1C levels (reflecting lesser glucose control) resulted in higher BMD at the femoral neck and total hip.
Figure 2.  Forest plot for mean femoral neck bone mineral density. Difference in means (g/cm2) and 95% confidence 
interval for femoral neck bone mineral density between comparison groups with and without type 2 diabetes mel-
litus, stratified per study and gender. Diamonds represent joint estimate for subgroups of available studies for women 
(upper) and men (middle), respectively. Pooled estimate for all studies displayed with the diamond at the bottom.
Figure 3. Forest plot for mean hip bone mineral density. Difference in means (g/cm2) and 95% confidence interval 
for hip bone mineral density between comparison groups with and without type 2 diabetes mellitus, stratified per 
study and gender. Diamonds represent joint estimate for subgroups of available studies for women (upper) and men 
(middle), respectively. Pooled estimate for all studies displayed with the diamond at the bottom.
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Figure 4. Forest plot for mean spine bone mineral density. Difference in means (g/cm2) and 95% confidence interval 
for spine bone mineral density between comparison groups with and without type 2 diabetes mellitus, stratified per 
study and gender. Diamonds represent joint estimate for subgroups of available studies for women (upper) and men 
(middle), respectively. Pooled estimate for all studies displayed with the diamond at the bottom.
Figure 5. Forest plot for mean forearm bone mineral density. Difference in means (g/cm2) and 95% confidence 
interval for forearm bone mineral density between comparison groups with and without type 2 diabetes mellitus, 
stratified per study and gender. Diamonds represent joint estimate for subgroups of available studies for women 
(upper) and men (middle), respectively. Pooled estimate for all studies displayed with the diamond at the bottom.
Ch
ap
te
r 2
.4
- 80 -
DISCUSSION
Our study provides insights into the inconsistently reported relationship between T2DM and BMD. In 
line with what is suggested by the majority of reviewed studies our meta-analysis concluded that overall 
individuals with T2DM have about 25–50% SD higher BMD compared to nondiabetic control subjects.
In this study we found no strong evidence for skeletal site specificity of this association. Subjects with 
T2DM had elevated BMD at the femoral neck, hip, and spine. No major differences in BMD at the forearm 
were seen but there are no obvious biological reasons we can attribute to them. This lack of association 
with forearm BMD may be the consequence of limited sample size. We also found no strong evidence 
suggesting there is sex-specificity in the observed BMD differences between diabetics and nondiabetics. 
BMD differences seem larger in women than in men but power limitations can also play a role. We did 
find considerable heterogeneity influencing the association as reflected by a high I2 statistic. This large 
heterogeneity could most probably stem from a large variation in types of study design, diagnostic 
definitions and individual characteristics that were not considered by each study. We did sensitivity 
analyses trying to find sources of heterogeneity and concluded that study design and Asian ethnicity are 
a likely, but not sufficient sources to explain the observed heterogeneity. In contrast, differences in DXA 
manufacturers and levels or correction for BMI do not seem to be an important source of heterogeneity.
Our study has limitations. We procured including all eligible studies to the best of our capacities but 
at least four studies were not able to be traced back. Sensitivity analyses considering such studies did 
not essentially change our results or conclusions. Variation in the definition of T2DM was present across 
studies with some combining selfreports and blood glucose tests, while others only used blood glucose 
tests. Studies which relied either on selfreports, population screening or which used register data will be 
subject to potential disease misclassification bias. Similarly, differences in mode of diagnosis can affect 
the prevalence of disease across studies and, hence, influence the power for detecting BMD differences. 
Disease duration can also be an important confounder, but uniform assessment for this co-variable 
was not possible across studies. Another drawback is that not all studies reported on or adjusted for 
covariates. Yet another potential source for heterogeneity that we could not control for are differences 
in glucose control and prevalence of diabetic complications. Nevertheless, the meta-regression done for 
BMD on the group of diabetic individuals across studies shows that in addition to BMI, HbA1C levels also 
has a significant positive effect on BMD measured at any site.
Since May 2010 about 134 articles have been published on the topic of which we could identify two 
that would have met our inclusion criteria55, 56. These were studies based on Chinese populations show-
ing opposite results with one concluding type 2 diabetics had higher BMD55 while the other56 concluded 
diabetics had lower BMD and higher risk of osteoporosis.
Mechanisms that might account for an association between T2DM and increasing BMD are plentiful 
and largely unclear. We discuss below from a clinical perspective the most important factors which can 
influence the relationship between T2DM and BMD.
Table 6. Meta-regression results for BMD for individuals from the diabetic group of the studies.
Site Gender (female–male) Age (years) BMI (kg/m2) HbA1C (%)
Femoral neck −0.114 ± 0.012* 0.002 ± 0.002 0.022 ± 0.002* 0.045 ± 0.013*
Hip −0.119 ± 0.021* −0.015 ± 0.003* – 0.117 ± 0.024*
Spine −0.164 ± 0.018* 0.030 ± 0.006* 0.029 ± 0.004* 0.241 ± 0.090*
Forearm −0.150 ± 0.050* 0.001 ± 0.013 −0.001 ± 0.006 −0.062 ± 0.052
Values are regression coefficients ± SEM, *P value <0.05
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Obesity
Historically, overweight and hyperinsulinemia have been postulated as two important features of T2DM 
which are positively correlated with BMD. Yet, we saw that in a considerable number of the included 
studies the correction for BMI did not essentially modify the association. There are several complex 
pathways by which obesity may influence the relation between diabetes and BMD. Body fatness may 
have an impact on the accuracy of DXA-based BMD measures as demonstrated in obese diabetic 
patients.57 Yet, such measurement error should be negligible considering that this phenomenon can 
either under or overestimate the values and have been shown to have low impact on the accuracy of 
the BMD measurement.58 On the other hand, adipose tissue releases a wide variety of adipokines that 
have been implicated either directly or indirectly in the regulation of bone remodeling.59 Plasma leptin 
concentrations have been shown to be higher in diabetic men than in healthy controls.60 Leptin induces 
bone growth by stimulating osteoblast proliferation and differentiation in vitro61-63 and it has also been 
shown to inhibit osteoclastogenesis through reducing RANK/RANKligand production and increasing 
osteoprotegerin64, 65. Other adipokines such as adiponectin and resistin are also expressed in osteoblasts 
and osteoclasts.66, 67 The effects of these adipokines on bone metabolism remain largely ambiguous but 
differentiation from mesenchymal progenitor cells to osteo- or adipocytes may play a role.67-70 Some 
reports indicate that circulating adiponectin71 and resistin levels72 are reduced in diabetes in line with a 
recent report demonstrating that higher adiponectin levels are associated with lower BMD73.
Hyperinsulinemia
Some of the reviewed studies indicated that insulin levels could mediate in part a positive association 
between T2DM and elevated BMD. Individuals with T2DM usually have an excess of insulin. Physiologi-
cally, insulin has an anabolic effect on bone due to its structural homology to IGF-1 by interacting with 
the IGF-1 receptor which is present on osteoblasts74. The IGF-1 signaling pathway is crucial for bone 
acquisition75: both human and mouse studies have demonstrated a significant positive association 
between IGF-1 and BMD76, 77. From this perspective it can be hypothesized that hyperinsulinemia could 
have a mitogenic effect on osteoblasts and their differentiation by stimulating the IGF-1 signaling path-
way. Some indirect influences of insulin on bone formation could possibly be mediated by osteogenic 
factors such as amylin, osteoprotegerin, sex steroids and sex hormone-binding globulin (SHBG).
Medication use
Thiazide use which is expected to be higher in diabetic individuals has also been associated with higher 
BMD at different skeletal sites.78, 79 Similarly, statin use (also more prevalent in diabetics) is also associated 
with higher BMD.80, 81 Nevertheless, several of the included studies controlled for medication use, and 
thus it is unlikely that this alone can explain the observed associations. On the other hand medication 
use can well be a source of the large heterogeneity observed in the meta-analysis.
Paradoxically increased fracture risk
For many of the aforementioned mechanisms resulting in higher BMD it is rather difficult to fit their 
role in the paradoxically increased fracture risk. It has been well established that diabetic patients have 
impaired bone healing after fracture.82 This probably indicates a compromise of both osteoclastic82 and 
osteoblastic cell lineages,83 and possibly also on bone remodeling. Indeed, a recent study by Burghardt 
et al. using high-resolution peripheral quantitative computed tomography (HR-pQCT) reported up to 
twice the cortical porosity observed in type 2 diabetes patients as compared to controls.84 The results 
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of this pilot investigation provide a potential explanation for the inability of standard BMD measures 
to explain the elevated fracture incidence in patients with T2DM presenting with higher BMD levels. 
Specifically, the findings suggest that T2DM may be associated with an inefficient redistribution of bone 
mass and insufficient compensation for increased body mass, which may result in impaired bending 
strength. In addition, bone strength might be compromised through different mechanisms, such as 
increased production of non-enzymatic cross-links within collagen fibers, accumulation of advanced 
glycation end products,85 higher serum glucose levels that can negatively influence bone matrix proper-
ties86 or indirectly as a consequence of sarcopenia87. Finally, patients with diabetes have increased fall 
risk, which can arise as a consequence of sarcopenia, retinopathy and/or neuropathy. Very recently, it 
has been shown how T2DM underestimates the risk of fracture at a given BMD level,88 reason why the 
diabetic status is needed to be considered in risk fracture algorithms89, 90.
CONCLUSION
Our meta-analysis showed that diabetic individuals have higher BMD levels than non-diabetics in-
dependent of the skeletal site of measurement, gender, age, BMI or medication use. In addition, by 
applying a meta-regression we could establish that younger age, male gender, higher BMI and higher 
HbA1C are positively associated with higher BMD levels in diabetic individuals. The potential mechanisms 
underlying these associations remain complex suggesting that several influential factors need to be 
considered while interpreting the association between T2DM and BMD. Large prospective studies are 
needed to establish the mechanisms underlying this association, and most importantly the relationship 
with fracture risk, the most adverse consequence of osteoporosis.
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complications of inadequate glucose 
control: the Rotterdam Study
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ABSTRACT
Objective Individuals with type 2 diabetes have increased fracture risk despite higher bone mineral 
density (BMD). Our aim was to examine the influence of glucose control on skeletal complications.
Research design and methods Data of 4,135 participants of the Rotterdam Study, a prospective popu-
lation-based cohort, were available (mean follow-up 12.2 years). At baseline, 420 participants with type 2 
diabetes were classified by glucose control (according to HbA1C calculated from fructosamine) resulting 
in three comparison groups: adequately controlled diabetes (ACD; N=203; HbA1c<7.5%), inadequately 
controlled diabetes (ICD; N=217; HbA1C≥7.5%) and no diabetes (ND; N=3,715). Models adjusted for sex, 
age, height, and weight (and femoral neck BMD) were used to test for differences in bone parameters 
and fracture risk (hazard ratios [HR]; [95% CI]).
Results The ICD group had 1.1–5.6% higher BMD, 4.6–5.6% thicker cortices and -1.2 to to -1.8% narrower 
femoral necks than ACD and ND, respectively. Participants with ICD had 47–62% higher fracture risk than 
individuals without diabetes (HR 1.47; [1.12–1.92]) and ACD (HR 1.62; [1.09–2.40]); whereas those with 
ACD had a risk similar to those without diabetes (HR 0.91; [0.67–1.23]).
Conclusions Poor glycemic control in type 2 diabetes is associated with fracture risk, high BMD, and 
thicker femoral cortices in narrower bones. We postulate that fragility in apparently “strong” bones in 
ICD can result from micro-cracks accumulation and/or cortical porosity reflecting impaired bone repair.
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INTRODUCTION
Type 2 diabetes and osteoporosis are common diseases with increasing prevalence in the aging popula-
tion. Due to their associated morbidity and mortality the conditions cause a high health burden to 
Western societies.1-3
There is increasing evidence supporting an association between type 2 diabetes and increased 
fracture risk, even though individuals with type 2 diabetes have high bone mineral density (BMD).4-6 One 
of these studies was based on the Rotterdam Study, where de Liefde et al. showed that individuals with 
type 2 diabetes had 69% increased fracture risk than those without diabetes despite having higher BMD 
at the femoral neck and lumbar spine.7 Results from a joint effort by three large prospective observa-
tional studies indicated that the fracture risk for any given femoral neck BMD T score and age is increased 
in type 2 diabetes patients compared to those without diabetes.5 Recently, the World Health Organiza-
tion’s fracture risk assessment tool (FRAX) has been shown to underestimate osteoporotic fracture risk in 
individuals with diabetes, reason why diabetes as a risk factor will be considered for inclusion in future 
iterations of FRAX.8 These findings suggest that factors other than BMD may be underlying the higher 
fracture risk observed in diabetes patients, and that in fact the BMD measurement does not reflect the 
actual tendency of patients with type 2 diabetes to develop bone fragility. We recently meta-analyzed 
published studies that compared BMD in type 2 diabetes to no diabetes, where by meta-regression we 
established that higher HbA1C is associated with higher BMD across type 2 diabetes groups.6
Our aim was to investigate if the intricate relationship between BMD, bone geometry and fractures in 
type 2 diabetes is influenced by glucose control. Using data from the Rotterdam Study, a large prospec-
tive population-based study in elderly Dutch individuals, we examined bone parameters and incident 
fracture risk across groups of diabetes with adequate and inadequate glucose control as compared to 
the rest of the population without diabetes.
METHODS
Ethics statement
The Medical Ethics Committee of the Erasmus Medical Centre has approved the Rotterdam Study, and 
informed consent was obtained from all participants.
The Rotterdam Study
The Rotterdam Study is a prospective population-based cohort studying the determinants of chronic 
diseases and disability in Dutch men and women. Both the objectives and the study design have been 
described previously.9 The study targets investigations on endocrine diseases like osteoporosis and 
diabetes amongst others. In short, all inhabitants aged 55 years and over of the Ommoord district in the 
city of Rotterdam in The Netherlands were invited to participate from January 1990 onwards (response 
rate 78%). Between 1990 and 1993, a baseline home interview on medical history, risk factors for chronic 
diseases and medication use and information on age at menopause was taken by trained interviewers. 
Falling was assessed using structured personal interviews by trained medical research nurses. A faller 
was defined as an individual with a history of one, two or more falls without precipitating trauma (e.g., 
car accident or sport injury) in the 12 months preceding the baseline interview. Falling frequency at 
baseline was recorded as “never”, “less than once a month”, and “more than once a month”. Follow up 
data was collected using different questionnaire at second and third follow-up. Smoking habits were 
coded as “current”, “former”, and “never”. A trained dietician used an extensive, validated semi-quantitative 
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food-frequency questionnaire to assess alcohol intake, which was reported in standard alcoholic drinks 
(9.8625g/12.5 cc of alcohol) per day. Subsequently, participants were invited to the research center for 
clinical examination. During the baseline visit height and weight were measured with indoor clothing 
and no shoes. Body mass index (BMI) was calculated as weight (in kg)/height (in m2). Information on 
medication use included use of anti-diabetic medication, diuretics, hormonal replacement therapy and 
systemic corticosteroids.
Laboratory investigations
Creatinine was measured using standard laboratory methods. Serum insulin and sex steroids (including 
testosterone, E1, E2, SHBG, DHEAS) levels were determined in plasma samples using radioimmunoassay’s 
purchased from Diagnostic Systems Laboratories, Inc. (Webster, TX) and Medgenix diagnostics (Brus-
sels, Belgium), respectively. Fasting serum insulin levels were measured only in those individuals using 
anti-diabetic medication and the small fraction of exogenous insulin users were not excluded from the 
analysis. Fructosamine serum levels were measured by colorimetry and reported in µmol/l; fructosamine 
measurements in the Rotterdam Study had an interassay coefficient of variation (CV) of 3.0.10 HbA1C was 
computed at baseline from fructosamine levels using the following formula as described previously11: 
HbA1c=0.017*Fructosamine [µmol/L]+1.61.
Assessment of type 2 diabetes
All participants, except those on anti-diabetic medication, underwent an oral glucose tolerance test 
(OGTT) with a 37.5% oral glucose solution (75 g of glucose) in a non-fasting state. Blood samples were 
drawn by venipuncture before and 2 hours after the OGTT. Serum glucose levels were measured using 
glucose hexokinase. Diabetes was defined as anti-diabetic medication use or a pre-load or post load 
serum glucose levels above 11.1 mmol/l. Medical profiles were checked to exclude type 1 diabetes 
cases (e.g., restriction to those who reported having diabetes at or after the age of 30) 7. From the 4,135 
included participants 420 (10.2%) were classified as having type 2 diabetes at baseline according to 
both OGTT and anti-diabetic medication use. Inadequate glucose control in diabetes was defined as a 
serum HbA1C level≥7.5% (58 mmol/mol) measured at baseline. This way, three comparison groups were 
defined including no diabetes (N=3,715), adequately controlled diabetes with serum HbA1C level <7.5% 
(N=203) and inadequately controlled diabetes with serum HbA1C level≥7.5% (N=217).
Ophthalmic examinations
Visual acuity was measured at 3-m distance using Lighthouse Distance Visual Acuity Test which is a 
modified Early Treatment Diabetic Retinopathy Study chart.12 For best-corrected visual acuity (BCVA), 
optimal refraction was obtained subjectively after objective autorefraction (Topcon RM-A2000, Topcon 
Optical Company, Tokyo, Japan). After pharmacologic mydriasis participants underwent fundus pho-
tography, covering a 35-degree field centered on the macula of both eyes. For the assessment of Visual 
impairment two sets of commonly used criteria for categorization of blindness and low-vision were 
applied based on: 1) World Health Organization (WHO) criteria 13: with blindness defined as BCVA <0.05 
(Snellen, 20/400) in the better eye and low vision defined as 0.05 (20/400) ≤ BCVA < 0.3 (20/60) in the 
better eye; and 2) the most commonly used criteria in the United States (US) defining blindness as 
BCVA<0.1 (20/200) in the better eye and low vision as 0.1 (20/200) ≤ BCVA < 0.5 (20/40) in the better eye. 
Retinopathy at baseline, was defined as the presence of cotton wool spots, evidence of laser treatment 
for retinopathy or the presence of one or more dot/blot hemorrhages or microaneurysms.
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Bone mineral density and hip structural analysis
Femoral neck and lumbar spine BMD was measured by dual-energy X-ray absorptiometry (DXA), using 
a Lunar DPX-L densitometer (Lunar Radiation Corporation, Madison, WI, USA).14 Hip structural analysis15 
was used to measure hip bone geometry from the DXA scans of the femur narrow neck region. BMD, 
and bone width (outer diameter) was measured directly from mineral mass distributions15 Estimates of 
mean cortical thickness and endocortical diameter were obtained by modeling the narrow neck region 
as a circular annulus, which assumes a proportion of cortical/trabecular bone of 60/40. Section modulus 
was calculated as CSMI/dmax, where dmax is the maximum distance from the center of mass to the medial 
or lateral surface. Buckling ratios were computed as dmax divided by estimated mean cortical thickness. 
Data on bone geometry and glucose controls were available for 3,339 individuals including those with-
out diabetes (N=2,995), with adequately controlled diabetes with serum HbA1C level<7.5% (N=157) and 
with inadequately controlled diabetes with serum HbA1C level≥7.5% (N=187).
Incident fracture assessment
All events, including fractures and death were reported by general practitioners (GPs) in the research 
area (covering 80% of the cohort) by means of a computerized system. All reported events were 
verified by two trained research physicians, who independently reviewed and coded the information. 
Subsequently, all coded events were reviewed by a medical expert for final classification. Subjects were 
followed from their baseline visit until January 1, 2007 or until a first fracture or death occurred resulting 
in a mean fracture follow-up of 12.2 years (SD=4.2 years).
Statistical analysis
Mean differences in continuous baseline characteristics, BMD and geometry parameters were tested 
adjusted for age, sex, height and weight using analysis of variance (ANOVA) and (post-hoc) independent-
samples T-test of subgroups. Baseline characteristics that were counts were analyzed with Pearson’s 
chi-squared and Fisher’s exact tests. Cox proportional hazard regression models were used to estimate 
the risk of fracture in a model adjusted for sex, age, height and weight. In addition, the fracture analyses 
were adjusted for femoral neck BMD. Differences in beta-coefficients between groups were tested with 
a Z-test. Potential confounders were tested by adding them to the models, including: serum creatinine, 
serum insulin, use of diuretics, systemic corticosteroid use, alcohol intake, smoking status and falling 
frequency in the year preceding baseline visit. We evaluated if the change in effect estimate was 10% 
or more and if statistical significance was lost. The role of anti-diabetic medication use was evaluated 
in a sensitivity analysis by running the regression model after excluding individuals who were using 
anti-diabetic medication. S-plus software was used to generate Kaplan-Meier curves and to test for 
proportionality of hazards. If not stated otherwise SPSS 15 was used for the analyses.
RESULTS
Baseline characteristics by status of glycemic control
The baseline characteristics of the three comparison groups are shown in Table 1. On average, indi-
viduals with diabetes were older, had a higher BMI, higher serum insulin and creatinine levels, and used 
diuretics more frequently than ND. Individuals classified as ICD had the highest insulin levels, highest 
frequency of retinopathy and used anti-diabetic medication more frequently. In female participants, age 
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at menopause, frequency of hormone-replacement therapy, and serum sex steroid levels did not differ 
significantly between women in any of the comparison groups (data not shown).
Association with BMD and hip bone geometry
Overall participants with diabetes had higher BMD than those without diabetes at the lumbar spine 
and femoral neck (Table 1). ICD had between 1.1% to 5.6% higher BMD (g/cm2) at both the femoral 
neck (0.89) and lumbar spine (1.14) as compared to ACD (femoral neck: 0.88, P=0.26; lumbar spine: 
1.10, P=0.02) and ND (femoral neck: 0.86, P=0.00006; lumbar spine: 1.08, P=0.00003). In addition, bone 
geometry parameters of the narrow neck region assessed in a subset of the sample (N=3,319) were 
studied across glucose-control comparison groups (Table 2). As expected from the results from the 
lumbar spine and the femoral neck region, the mean narrow neck BMD (g/cm2) was also the highest 
in individuals with ICD. As compared to ND, individuals with ICD had 5.6% thicker cortices than ND 
(P=0.00002) and 4.6% thicker cortices than ACD (P=0.02). No significant difference in cortical thickness 
was observed between ND and ACD (P=0.48). Differential effects were also seen for neck width, where 
individuals with ICD had -1.8% narrower femoral necks than ND (P=0.0004) and -1.2% narrower femoral 
necks than ACD, though this difference did not achieve statistical significance (P=0.10). The narrow 
neck width in individuals with ACD showed no significant differences from those observed in ND. No 
significant differences in bending strength (section modulus) were observed across comparison groups. 
In contrast, shorter necks with thicker cortices suggest higher cortical bone stability (lower buckling 
ratios), and ICD individuals had -6.8% significantly lower buckling ratios (higher cortical bone stability) 
than those observed in individuals from ACD (P=0.005) and ND groups (P=0.0001). To further evaluate 
Table 1. Baseline characteristics of study participants stratified by comparison group.
Mean (SD)
Comparison groups
ANOVA P valueND (N=3,715) ACD (N=203) ICD (N=217)
Age (years)a 68.2 (7.7) 71.9 (7.6) 68.5 (7.8) <0.05
Height (meter) a 1.67 (0.09) 1.65 (0.09) 1.67 (0.10) NS
Weight (kg) a 73.1 (11.6) 73.8 (12.5) 74.2 (11.4) NS
Body mass index (kg/m2) a 26.3 (3.7) 27.0 (4.2) 26.9 (4.0) <0.05
Serum insulin (pmol/l) a 85.9 (99.0) 109.5 (109.5) 199.9 (266.0) <0.05
Serum creatinine (µmol/l) a 82.1 (20.3) 85.7 (22.5) 89.2 (21.6) <0.05
Females (%)b 59.7 61.6 53.0 NS
Use of diuretics (%)b 13.1 22.8 24.4 <0.05
Use of corticosteroids (%)b 1.86 3.47 2.76 NS
Use of anti-diabetic drugs (%)b 0.0 20.8 34.8 <0.05
Current smoking (%)b 24.8 31.0 22.7 NS
Ever smoking (%)b 42.3 38.0 46.5 NS
Recent fall (%)b 17.2 19.5 18.1 NS
History of myocardial infarction (%)b 13.6 13.6 17.2 NS
Retinopathy (%)b 6.5 11.0 19.5 <0.05
Visual impairment WHO/U.S. (%)b 2.3/1.1 4.0/1.5 4.7/1.4 NS/NS
Lumbar spine BMD (g/cm2)c 1.08 (0.003) 1.10 (0.01) 1.14 (0.01) <0.05
Femoral neck BMD (g/cm2) c 0.86 (0.002) 0.88 (0.009) 0.89 (0.008) <0.05
Data presented as mean (SD). WHO, World Health Organization. aUnadjusted means with SDs. bPercentages from total 
assessed at baseline. cSex-, age-, height- and weight- adjusted means with SEs.
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the relationship between cortical thickness, femoral neck width and glucose control, we examined the 
relationship across age tertiles (Figure 1). The observed diff erences were particularly prominent in the 
oldest tertile where individuals with ICD had 8.1% thicker cortices than ND (P=0.001) and 9.3% thicker 
than ACD (P=0.08). Similarly, neck width of ICD individuals in this older tertile had -2.5% narrower necks 
than ND (P=0.003) and, though not statistically signifi cant, -1.2% narrower necks than ACD (P=0.31).
Table 2. Hip structural analysis (bone geometry) parameters stratifi ed by glucose control groups.
Measurement
Comparison groups ANOVA
ND (N=3,715) ACD (N=125) ICD (N=115) P value
Narrow neck BMD (g/cm2) 0.69 ± 0.002 (0.68–0.69) 0.69 ± 0.009 (0.68–0.71) 0.72 ± 0.008 (0.71–0.74) 0.0002
Cortical thickness (mm) 1.31 ± 0.004 (1.30–1.32) 1.32 ± 0.02 (1.28–1.35) 1.38 ± 0.02 (1.35–1.41) 0.0001
Neck width (cm) 3.20 ± 0.004 (3.19–3.21) 3.18 ± 0.02 (3.15–3.22) 3.14 ± 0.02 (3.11–3.17) 0.001
Section modulus (cm3) 1.118 ± 0.004 (1.111–1.126)1.124 ± 0.018 (1.089–1.158)1.125 ± 0.016 (1.094–1.157) 0.89
Cortical buckling ratio 13.99 ± 0.06 (13.88–14.11) 14.00 ± 0.3 (13.51–14.49) 13.04 ± 0.2 (12.59–13.49) 0.0003
Values are mean ± SEM (95% CIs) adjusted for age, sex, height and weight.
 
Figure 1. Adjusted means of narrow neck width (top bar chart) and cortical thickness (bottom bar chart) in relation 
to glucose control by age tertiles: youngest 55.0–63.6 years of age; middle 63.6–71.4 years of age; oldest >71.4 years 
of age. Kaplan-Meier curve per comparison group showing the adjusted cumulative hazards for fracture using follow-
up time as timescale. Cox proportional hazard model: ICD vs. no diabetes HR 1.47 (95%CI 1.12–1.92); P=0.005, ACD vs. 
no diabetes HR 0.91 (0.67–1.23); P=0.54. Cumulative hazard ratio adjusted for femoral neck BMD, age, sex, height and 
weight. Light gray, ND; dark grey or dashed, ACD; black, ICD.
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Fracture-free survival analysis
Tables 3 and 4 shows the site-specific fracture incidence rates and hazard ratios stratified by glucose 
control. During follow-up, 1,068 subjects experienced at least one incident fracture, including 253 
individuals presenting with a hip fracture and 257 individuals with a wrist fracture. Individuals in the 
ICD group had an increased fracture risk compared to ACD (HR: 1.62; 95% CI: 1.09–2.40) and ND (HR: 
1.47; 1.12–1.92); while those with ACD had a HR of 0.91 (0.67–1.23) as compared to ND. Kaplan-Meier 
fracture-free survival curves are shown in Figure 1. The analysis of fracture subtypes showed a similar 
trend for wrist (Colles’ distal forearm) fracture as that observed for all-types of fracture; while the pattern 
for hip fracture risk was inconsistent (Tables 3 and 4).
Table 3. Site-specific fracture incidence rates stratified by glucose control groups.
Comparison groups
ND ACD ICD
(3,715 subjects; 
46,130 person-years)
(203 subjects; 
2,165 person-years)
(217 subjects; 
2,134 person-years)
Type of fracture Cases Incidence Cases Incidence Cases Incidence
All types 967 0.0241 44 0.0230 57 0.0311
Hip 227 0.0050 15 0.0072 11 0.0052
Wrist 232 0.0052 9 0.0042 16 0.0078
Table 4. HRs stratified by glucose control groups.
Type of fracture
Cox analysis of fracture-free survival
ICD vs. ACD ICD vs. ND ACD vs. ND
HR 95% CI P value HR 95% CI P value HR 95% CI P value
Basic model 1.54 (1.04–2.29) 0.03 1.31 (1.00–1.71) 0.05 0.85 (0.63–1.15) 0.29
All types BMD adjusted 1.62 (1.09–2.40) 0.02 1.47 (1.12–1.92) 0.005 0.91 (0.67–1.23) 0.54
Basic model 0.83 (0.38–1.81) 0.64 0.96 (0.52–1.75) 0.89 1.15 (0.68–1.94) 0.60
Hip BMD adjusted 0.93 (0.42–2.02) 0.85 1.16 (0.63–2.13) 0.63 1.25 (0.74–2.12) 0.40
Basic model 2.12 (0.94–4.80) 0.07 1.59 (0.95–2.64) 0.07 0.75 (0.38–1.46) 0.40
Wrist BMD adjusted 2.23 (0.99–5.06) 0.05 1.71 (1.03–2.86) 0.04 0.77 (0.39–1.50) 0.44
Basic model, adjusted for age, sex, height and weight; BMD-adjusted model, adjusted for age, sex, height, weight and 
femoral neck BMD.
Even though mean BMD was higher in individuals with diabetes, being the highest in the ICD group, 
lower femoral neck BMD was significantly associated with increased fracture risk across all study groups: 
ND (HR: 1.60 per SD decrease; 95% CI: 1.46–1.75), ACD (HR: 2.72 per SD decrease; 95% CI: 1.76–4.20) and 
ICD (1.54; 1.11–2.14). The association was less strong in ICD individuals suggesting that they fracture at 
a higher BMD threshold. We tested for sex interaction finding that the increase in fracture risk was sig-
nificantly stronger in women (P=0.02). ICD vs. ACD (HR women: 2.08; 1.31–3.30; HR men: 0.72; 0.33–1.56); 
ICD vs. ND (HR women: 1.64; 1.20–2.22; HR men 1.09; 0.62–1.92).
The effect of inadequate glucose control on fracture risk, BMD or bone geometry was not essen-
tially changed by any of the confounders tested. For example, falling more than once a month was 
independently and highly significantly associated with fracture risk (HR: 1.80; 1.18–2.74) as expected, 
but when added to the model the risk estimates for the diabetes comparison groups remained similar 
(ICD vs. ACD effect estimate -0.9% and ICD vs. ND effect estimate -1.4%). Also, serum creatinine as a 
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measure of kidney function was independently significantly associated with fracture risk (HR: 0.89 per 
SD increase in serum creatinine; 95% CI: 0.81–0.98), but when added to the model the estimates for the 
diabetes comparison groups remained statistically significant and essentially the same magnitude (ICD 
vs. ACD effect estimate +2.0% and ICD vs. ND effect estimate -6.4%). The elevated HR for fracture risk in 
the inadequately controlled group remained after excluding individuals who were using anti-diabetic 
medication. In addition, further adjustment of the analyses for serum insulin levels in a subset of the 
study population did not essentially alter the effect estimates. Finally, following the classification used 
in de Liefde et al.7 we examined the group without diabetes classified by presence of impaired glucose 
tolerance (IGT, pre-load or post-load OGTT serum glucose from 7.8 to 11.1 mmol/L) and observed no 
differences in BMD or bone geometry parameters. In contrast, individuals without diabetes and an 
impaired glucose tolerance test had 0.80 (95% CI: 0.66–0.97) decreased risk for any-type of fracture as 
compared to individuals without diabetes and no impaired glucose tolerance, a finding that requires 
further evaluation in future studies.
DISCUSSION
To our knowledge, this is the first study examining glucose control in subjects with type 2 diabetes in 
relation to BMD, bone geometry parameters and fracture risk. ICD individuals have higher BMD at the 
lumbar spine and femoral neck, with thicker cortices and smaller bone diameter at the femoral neck. 
This hip bone geometry configuration results in lower estimates of femoral narrow neck instability and 
no differences in bending strength. ICD individuals present stronger geometry associated with a lower 
risk of fracture.16, 17 However, we found that ICD individuals have an increased fracture risk compared to 
individuals with ACD and individuals without diabetes. This association did not seem to be influenced 
by potential confounders or arising from diabetes complications (extra-skeletal risk factors) like risk of 
falling at baseline, decline in renal function, nor by the use of systemic corticosteroids or diuretics. The 
discrepancy between BMD and geometrical findings with fracture incidence observed here could be 
attributed to weaker material causing failure at lower stress or biomechanical skeletal properties, which 
cannot be detected by DXA assessments.
Our study has several strengths. First, this is a large prospective population-based study including 
4,135 participants with long and comprehensive follow-up of more than 12 years on average. Second, 
we had various co-variables available for analyses, including the fracture incidence, bone geometry 
parameters at baseline and various other determinants of fractures. Third, classification of type 2 dia-
betes was robustly determined taking into account OGTT and anti-diabetic medication use. The broad 
availability of assessments in our study enabled extensive analyses. Yet, our study has limitations. The 
age of onset of diabetes was unknown, nor can we be sure about the duration of the glucose control 
assessment beyond the three to four months around the fructosamine measurement. Similarly, deriving 
HbA1C from fructosamine may result in a somewhat different classification of glycemic control. Yet, it has 
been shown that fructosamine is as or even more strongly associated with microvascular conditions 
than HbA1C, with excellent assay reliability.10, 18 In addition, hip structural properties and risk of falling 
during follow-up were assessed with different methods than at baseline, so we were less able to infer 
relationships with incident fractures that occurred many years after the baseline visit. Falling risk is a 
potential confounder, because patients with diabetes have increased risk of falling.19 We showed that 
risk of falling at baseline does not explain the association with increased fracture risk. Nevertheless, we 
cannot exclude that during follow-up falling frequency and subsequent fracture risk can increase as a 
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consequence of diabetes complications (i.e., retinopathy, neuropathy), which we show is higher in the 
inadequately controlled group of individuals with diabetes. Alternatively, insulin users with low HbA1C 
levels are reported to fall more, likely as a consequence of hypoglycemia.20 We propose that even with 
a similar risk for falling, individuals in the group of ICD would have (when falling) higher propensity to 
fracture given their unfavorable skeletal properties.
Interestingly, ICD individuals actually seem to have a stronger bone geometry, which would protect 
against fractures. Unfortunately, no bone geometry parameters for sites other than the femoral neck 
were available in our study; neither did we have access to techniques such as peripheral quantitative 
computed tomography (pQCT) scanning allowing a three-dimensional assessment of bone structure 
and microarchitecture. Others have shown before that bone strength in patients with type 2 diabetes 
may be compromised despite a higher BMD21-23 and as a result of altered adaptation to loading.21 Sex-
specific differences may exist reflecting differential patterns of bone apposition between sexes (bone 
dimorphism). A direct interaction between estradiol and insulin-like growth factor-I (IGF-I) in the deter-
mination of periosteal apposition has been proposed24 and serum IGF-I levels are negatively associated 
with increased risk for prevalent vertebral fractures in postmenopausal women but not in men with type 
2 diabetes25. Yet, our sex-specific analyses are restricted because of a lower power setting in men, partly 
due to survival bias and lower incidence of fractures. A final caveat to bear in mind in relation to the 
applicability of our findings is that our study population consisted of Dutch individuals of Northeastern 
European background. Additional studies in multiple settings with sufficiently large sample sizes are 
required.
Some studies evaluated the relationship between glycemic control and fracture risk finding con-
flicting results.26-30 A study by Ivers et al. in 3,654 Australian middle-aged subjects found that fasting 
blood glucose >7mmol/l, disease duration >10 years, insulin treatment, and the presence of diabetic 
retinopathy were associated with increased risk of all fractures.27 On the other hand, Melton et al. found 
no association of fracture risk with baseline fasting plasma glucose level, yet the follow-up time was 
limited 29. None of these studies measured HbA1C (a better indicator of diabetes control) which correlates 
strongly with disease severity. In a study in Japanese men28 Kanazawa et al. found that obese individuals 
with HbA1C>9 and higher BMD had 3 times increased risk of vertebral fracture than non-obese men 
with diabetes. In another study, Forsen et al.26 used a similarly high cut-off of HbA1C >9.5 for diabetic 
subjects from a large Norwegian population (N=35,444) and found no association. Yet, they did find 
that fracture risk was higher in subjects with disease duration greater than 5 years and being treated 
with insulin. A threshold of HbA1C >7% was used by Strotmeyer et al. to define poor glycemic control for 
diabetics, in a study in 3,075 older white and black adults from the Health ABC study.30 Individuals with 
diabetes had 1.6 increased risk of fracture (after correction for BMD) but, longer disease duration, and 
insulin use were not significantly different. Therefore, different HbA1C thresholds can make a difference in 
the definition of glucose control and the relationship with fracture. In our study, we used a 7.5% cut-off 
(closest to the median/mean HbA1C in our data) which has been proposed for patients of old age (mean 
age in our study was 69 years), those with co-morbidities and in those with established cardiovascular 
complications,31 in line with the established relationship between diabetes control, (cardiovascular) 
complications and mortality32.
Our data on hip bone geometry shows how individuals with ICD have persistently thicker cortices 
than ND and ACD (Figure 2). In addition, a lesser tendency to undergo physiological bone expansion 
(periosteal apposition) is also inferred from narrower bone diameters in individuals with ICD. A recent 
study by Burghardt et al.,33 using high-resolution pQCT (HR-pQCT), reported that the cortical porosity 
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in type 2 diabetes patients was up to twice that of controls. Our fi ndings are compatible with those 
described by Ahlborg et al.,34 where impaired bone remodeling is suggested by a lack of cortical thin-
ning, with consequent lack of compensatory bone expansion. Since such diff erences in geometry are 
accentuated at older ages, we postulate that an accumulation of micro cracks and/or cortical porosity 
in time may well be the consequence of impaired bone repair or decreased bone remodeling. Taken 
together, these results suggest an ineffi  cient redistribution of bone in ICD. This confi guration can pre-
dispose individuals with ICD to increased bone fragility as a result of increased micro-cracks and/or 
cortical porosity. Additional studies using HR-pQCT to evaluate bone properties in type 2 diabetes while 
considering glucose control are thus warranted.
Figure 2. Cartoon depicting the diff erences in bone geometry across glucose control groups for a cross-section of 
the femoral neck. Individuals with ICD have thicker cortices and narrower neck width than those without diabetes 
and ACD. With lower instability of cortical bone (lower buckling ratios) the accumulation of micro-cracks and cortical 
porosity become a possibility to explain bone fragility and fracture susceptibility. Drawing is not to scale.
The exact mechanisms underlying these bone parameters in ICD remain to be elucidated. Neverthe-
less, it can be hypothesized that the following factors may play a role: the accumulation of advanced 
glycation end (AGE) products,35 impaired bone healing,36 altered body composition (e.g., sarcopenia37), 
increased production of non-enzymatic cross-links within collagen fi bers negatively infl uencing bone 
matrix properties,38 etc. Probably both osteoclastic39 and osteoblastic40 cell lineages are compromised, 
knowing that bone remodeling involves both bone resorption and formation. From this perspective, the 
narrower neck width observed in ICD may well refl ect alterations in the diff erentiation and/or function of 
the osteoblastic lineage. Considering the known anabolic eff ects of insulin-like growth factor-I (IGF-I) and 
insulin on bone and periosteal expansion,41-43 it can be expected that the altered insulin-IGF-I-growth 
hormone axis (lower bio-availability of IGF-I) present in ICD44-46 may also contribute to the observed 
geometrical alterations we observed. Also, follow-up studies focusing on the actual metabolic pathways 
involved in such mechanisms are thus also needed.
Our fi ndings indicate that the detrimental eff ects of chronically elevated glucose levels on bone 
should be added to the more well-known complications of inadequately regulated diabetes, such as 
retinopathy, nephropathy, micro- and macro- cardiovascular disease. Furthermore, a high BMD in inad-
equately controlled diabetes may in fact refl ect a skeletal complication of the disease. If so, evaluation of 
BMD and the most commonly used clinical risk factors might be inadequate for predicting fracture risk 
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in ICD, who (due to their high BMD) are unlikely to be diagnosed with osteoporosis and increased risk of 
fracture. Similarly, our data showed that individuals with type 2 diabetes who are adequately controlled 
have a similar fracture risk as ND. This indicates that the first line of action for fracture prevention in 
diabetes is targeting adequate glycemic control. However, results from a randomized trial published 
very recently did not find changes in fracture or fall risk between standard glycemia and intensive glyce-
mia47. Nevertheless, average follow-up until now was merely 3.8 (SD 1.3) years so inference of long-term 
effects, i.e., from long-standing control and diminishing carry-over of pre-treatment glycemic exposure, 
is not yet possible. Type 2 diabetes can seriously affect patients’ quality of life, especially in the presence 
of diabetes-related complications.48 Bone fractures occurring on top of these altered conditions might 
further increase the health burden already observed in individuals with inadequate glucose control of 
their diabetes. Randomized controlled trials could reveal if certain anti-diabetic drugs associated with 
increased risk of fracture (i.e., thiazolidinediones) are a case of confounding by indication (inadequate 
glucose control);49 or alternatively, if skeletal specific interventions to activate remodeling (e.g., vibration 
plate) could indeed benefit the bone health of individuals with diabetes.
CONCLUSION
Increased fracture risk in type 2 diabetes is driven by poor glycemic control and occurs in the presence 
of higher BMD, and thicker femoral cortices in narrower bones. We postulate that fragility in the appar-
ently strong bones of ICD is the consequence of an accumulation of micro-cracks (cortical porosity) 
that reflects sustained impairment of bone repair. This should be investigated in future research. We 
recommend that fracture risk assessments in ICD should not be based on BMD alone, since high BMD 
could actually reflect a complication of inadequate glycemic control. Reassessment of risk factors (par-
ticularly BMD) is needed for the prevention of this skeletal complication in ICD. Finally, maintaining more 
stringent parameters of glycemic control can emerge as the first line of action to prevent fractures and 
their subsequent deleterious consequences on the quality of life of individuals with diabetes.
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ABSTRACT
Diabetes and osteoporosis are both common diseases with increasing prevalences in the aging popula-
tion. There is increasing evidence corroborating an association between diabetes mellitus and bone. 
This review will discuss the disease complications of diabetes on the skeleton, highlighting findings from 
epidemiological, molecular, and imaging studies in animal models and humans. Compared to control 
subjects, decreased bone mineral density (BMD) has been observed in type 1 diabetes mellitus, while 
on average, higher BMD has been found in type 2 diabetes; nonetheless, patients with both types of 
diabetes are seemingly at increased risk of fractures. Conventional diagnostics such as DXA measure-
ments and the current fracture risk assessment tool (FRAX) risk prediction algorithm for estimating risk 
of osteoporotic fractures are not sufficient in the case of diabetes. A deterioration in bone microarchitec-
ture and an inefficient distribution of bone mass with insufficiency of repair and adaptation mechanisms 
appear to be factors of relevance. A highly complex and heterogeneous molecular pathophysiology 
underlies diabetes-related bone disease, involving hormonal, immune, and perhaps genetic pathways. 
The detrimental effects of chronically elevated glucose levels on bone should be added to the more 
well-known complications of diabetes.
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INTRODUCTION
Diabetes and osteoporosis are common diseases with increasing prevalences in the aging population. 
There is growing evidence corroborating that diabetes mellitus influences the skeletal metabolism. De-
creased bone mineral density (BMD) and increased fracture risk have fairly consistently been observed 
in type 1 diabetes mellitus patients.1 This review will primarily focus on type 2 diabetes. Contradictory re-
sults with higher, lower or similar values for BMD observed in persons with type 2 diabetes compared to 
control subjects have been reported across individual and relatively small studies with diverse designs.2-5 
Nevertheless, several lines of evidence arising from meta-analytical efforts suggest that individuals with 
type 2 diabetes have generally higher BMD levels at the femoral neck, hip and spine than persons 
without diabetes, independently of gender or body mass index (which is usually higher in subjects 
with type 2 diabetes and discussed in further detail below).1, 6 The between-study heterogeneity was 
very high and originated at least in part from differences in design and possibly diabetes definition 
across studies. Nonetheless, meta-regression of the results across studies showed that younger age, 
male gender, higher body mass index and higher hemoglobin A1c (HbA1C) were positively associated 
with higher BMD levels in individuals with type 2 diabetes.
Higher fracture risk despite a higher bone mineral density in type 2 diabetes
Based on evidence in non-diabetics, higher levels of BMD should be protective against fracture; this 
association seems somewhat different in type 2 diabetes.2, 7-9 Using data from the prospective Rotterdam 
Study cohort, De Liefde et al. were among the first to show that individuals with type 2 diabetes have 
69% higher risk of non-vertebral fractures than those without diabetes despite having higher BMD at 
the femoral neck and lumbar spine.9 The aforementioned meta-analysis by Vestergaard et al. found 
summary estimates for hip fracture risk of 6.9 in type 1 and 1.4 in type 2 diabetes compared to subjects 
without diabetes, respectively.1 Schwartz and colleagues established in a meta-analysis based on three 
prospective observational studies with adjudicated fracture outcomes (Study of Osteoporotic Fractures; 
Osteoporotic Fractures in Men Study; and Health, Aging, and Body Composition study) that in type 2 
diabetes patients the fracture risk was higher for a given BMD and age as compared with participants 
without diabetes, and most importantly, that the World Health Organization’s fracture risk assessment 
tool (FRAX) underestimates osteoporotic fracture risk in individuals with diabetes;8 similar work by 
Giangregorio et al. in the Canadian Manitoba Bone Density Program illustrated how diabetes as a risk 
factor is necessary to be considered for inclusion in future iterations of FRAX10. Even though most of the 
work has been done in populations of European background, similar relationships have been observed 
across different ethnicities, particularly in relation to increased risk of vertebral fractures.11-13
Many studies have shown a difference in population characteristics between type 2 diabetic patients 
and healthy controls.3, 9, 14, 15 In these studies, diabetic study participants tend to be older, have a higher 
body mass index (BMI) or weight, increased insulin levels, less physical exercise, higher alcohol con-
sumption and they usually smoke more and more often. Also, the use of diuretics is more common 
in diabetes, and particularly loop diuretics (e.g. furosemide) may be associated with decreased BMD 
and increased risk of fractures through increasing urinary calcium excretion and osteoclastic bone 
resorption,16 while thiazides are associated with higher BMD and lower fracture risk.17, 18 Further, use of 
anti-diabetic thiazolidinediones has been reported to increase fracture risk.19 Patients with diabetes fall 
more often, which can be a consequence from suffering from suboptimal physical fitness, neuropathy, 
retinopathy or sarcopenia.20 Alternatively, insulin users with low HbA1C levels are reported to fall more, 
likely as a consequence of hypoglycemia.21 These characteristics might influence bone metabolism 
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and fracture risk, nevertheless, statistical analyses with corrections in aforementioned studies suggest 
independence of the differences in BMD and fracture risk from these measured confounders3, 9, 14, 15 such 
as risk of falling9, 14.
Relation of diabetes regulation with fracture risk
Some studies evaluating the relationship between glycemic control based on fasting blood glucose and 
fracture risk have found conflicting results. Other factors that do seem to matter are use of insulin and 
disease duration. Among these studies is an investigation by Ivers et al.22 which found that fasting blood 
glucose greater than 7 mmol/L, disease duration longer than 10 years, insulin treatment, and the pres-
ence of diabetic retinopathy were associated with increased risk of all-type of fractures. The oral glucose 
tolerance test (OGTT) remains the gold standard for distinguishing diabetes mellitus (pre-glucose load 
or post-glucose load challenge serum glucose level of 11.1 mmol/l or higher) and impaired glucose 
tolerance (pre-glucose load or post-glucose load challenge serum glucose level from 7.8 mmol/l to 11.1 
mmol/l).23 In the Rotterdam Study subjects with type 2 diabetes and impaired glucose tolerance were 
both found to have higher BMD, whereas contrary to those with impaired glucose tolerance, patients 
with type 2 diabetes had higher fracture risk, particularly those on anti-diabetic medication.9 Never-
theless, HbA1C is a better indicator than serum glucose for long-term diabetes control and is therefore 
considered the main parameter in clinical practice.
Higher HbA1C reflects a higher average plasma glucose concentration over a prolonged period, in the 
order of weeks. We observed in Rotterdam Study data that poor glycemic control based on an HbA1C 
cut-off of 7.5% (58 mmol/l) in type 2 diabetes is associated with higher all-type of fracture risk, higher 
BMD, and thicker femoral cortices in narrower bones.24 Intriguingly, different HbA1C thresholds were 
applied in various studies, possibly due to heterogeneity in effects and study population. Similar to 
our observations, the Atherosclerosis Risk in Communities (ARIC) Study found that type 2 diabetes was 
significantly and independently associated with increased risk of fracture. In this study, an increased 
risk of fracture of 1.87 times was observed among persons treated with insulin and an increased risk of 
1.63 times among persons with diagnosed diabetes with HbA1C ≥8% (64 mmol/l) as compared to those 
individuals with HbA1C below 8%.25 Kanazawa et al. found that obese Japanese men with type 2 diabetes 
and HbA1C of 9% and above had three times increased risk of vertebral fracture than men with diabetes 
but normal BMI, despite equal or higher BMD.26 Strotmeyer et al. found that older white and black adults 
with type 2 diabetes in the Health ABC study had 1.6 increased risk of fracture.13 However, when compar-
ing diabetes patients with and without fractures, poor glycemic control (threshold of HbA1C 7% (53 
mmol/l)), longer disease duration, and insulin use were not significantly different. Forsén et al.(26) found 
that fracture risk was higher in Norwegian subjects with disease duration longer than 5 years and insulin 
use, but failed to demonstrate any effect on fractures using a high cutoff of HbA1C 9.5% (80 mmol/l). Yet, 
this cut-off was very high and a consequent lack of study power cannot be ruled out.
Pathophysiology
A highly complex and heterogeneous molecular pathophysiology seems to underlie fracture risk in 
diabetes-related bone disease. One of the factors that have been found detrimental are advanced glyca-
tion endproducts (AGEs). AGEs are generated by the sequential non-enzymatic addition of carbohydrate 
molecules to protein amino groups.27 AGEs accumulate in various tissues including bone,28, 29 kidney 
and coronary arteries.30 This may result in development of diabetic complications through increased 
inflammation, interference with normal tissue function and cellular damage. Pentosidine is one of the 
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well-known AGEs, and accumulation of pentosidine in cortical and trabecular bone is negatively as-
sociated with bone strength.28, 29, 31 Histopathological analyses comparing bone samples from femoral 
neck fracture cases with post-mortem controls revealed a higher extent of hydroxylation and higher 
pentosidine content.32, 33 Furthermore, Yamamoto et al. showed that individuals with type 2 diabetes 
suffering from vertebral fractures have increased serum levels of pentosidine,34 while higher levels of 
the endogenous secretory receptor for AGEs (esRAGE), acting as a decoy receptor binding AGEs, have 
protective effects on fracture risk in diabetes35. esRAGE is the most prevalent splice variant of RAGE, 
while the most common form is full-length RAGE,36 which possesses a transmembrane domain and is 
therefore able to transduce signals as a membrane-bound receptor.37 Seemingly, full-length RAGE has a 
role in bone remodeling by regulating osteoclast function possibly through integrin signaling and bone 
mass given that mice lacking RAGE have increased bone mass and BMD and decreased bone resorptive 
activity in vivo.38
Insulin levels could mediate in part a positive association between type 2 diabetes and elevated 
BMD. Individuals with type 2 diabetes usually have an excess of insulin and those with worse glucose 
control have the highest serum levels.24 Physiologically, insulin has an anabolic effect on bone due to its 
structural homology to insulin-like growth factor-I (IGF-I) by interacting with the IGF-I receptor present 
on osteoblasts.39 The IGF-I signaling pathway is crucial for bone acquisition and bone remodeling.40 
Lower concentrations of serum IGF-I levels are associated with the presence of and a higher number 
of prevalent vertebral fractures in postmenopausal women with type 2 diabetes.41, 42 Additionally, novel 
data from a mouse study with osteoprogenitor-selective ablation of the insulin receptor suggest that 
insulin receptor malfunction itself may directly lead to biomechanical microarchitecture alterations 
in both cortical and trabecular bone.43 Furthermore, there is evidence that insulin receptor signaling 
promotes the differentiation of osteoblasts and enhances production and activation of osteocalcin.44, 45
Osteocalcin is an osteoblast-specific secreted protein that regulates hydroxyapatite size and shape 
through its vitamin-K-dependent, gamma-carboxylated form, thereby reflecting bone remodeling and, 
in particular, bone formation.46 Metabolic roles of osteocalcin have been identified in animal studies, 
including increasing insulin secretion and sensitivity.47 The regulation of insulin sensitivity by osteocalcin 
may be either direct or indirect, via the adipocyte-derived hormone adiponectin (discussed below).46 
Osteocalcin has also been found to be negatively correlated with HbA1C as a marker of glycemic control 
in type 1 and type 2 diabetes.26 Osteocalcin knock-out mice display glucose intolerance and insulin re-
sistance with a concomittant slight increase in bone density.48 In bone and serum, osteocalcin is incom-
pletely carboxylated (undercarboxylated osteocalcin) and it is this uncarboxylated form that has been 
negatively implicated in energy metabolism and glucose control in both mice and humans.45, 47 Higher 
undercarboxylated osteocalcin may be linked to increased risk of hip fracture,49 where calcium and 
vitamin D2 suppletion was able to normalize the undercarboxylated osteocalcin levels.50 The underlying 
mechanism is largely unknown; It is known that 1,25-dihydroxyvitamin D enhances the transcription of 
osteocalcin by means of the gene possessing a vitamin D-responsive element51 but whether vitamin D 
might directly influence the γ-carboxylation reaction of osteocalcin remains unclear.52, 53 Cardiovascular 
disease including atherosclerosis is more common in type 2 diabetes mellitus; studies carried out so far 
suggest that abdominal aortic calcification is more common in diabetics.54 In Asian women it has been 
observed that osteocalcin significantly correlated with aortic calcification, which again is associated with 
a threefold increased risk of vertebral fractures.55
Adipokines are cell signaling proteins secreted by adipose tissue and include for instance leptin, 
adiponectin and resistin. The release of these adipokines leads to a chronic subinflammatory state that 
Ch
ap
te
r 2
.6
- 108 -
could play a central role in the development of insulin resistance and type 2 diabetes.56 It has been 
observed that plasma leptin concentrations are higher in obese persons with diabetes than in healthy 
controls.57 Leptin induces bone growth by stimulating osteoblast proliferation and differentiation58-60 
and it has also been shown to inhibit osteoclastogenesis through reducing RANK/RANK-ligand pro-
duction and increasing osteoprotegerin.61, 62 Plasma leptin concentrations have been found inversely 
related with BMD in cross-sectional studies.63-65 Further, higher leptin levels were associated with a lower 
prevalence of fracture in some cohorts,66 though the effect may not be as clear in individuals aged 70 to 
79 years from the Health Aging and Body Composition Study.67 Some reports indicate that circulating 
adiponectin and resistin levels are reduced in diabetes.68 Adiponectin is expressed in osteoblasts and 
osteoclasts69 and adiponectin seems to influence differentiation from mesenchymal progenitor cells 
into osteocytes or adipocytes, yet the effects on bone metabolism remain unclear.70, 71 After adjustments 
of measures of body fat, each doubling of adiponectin is associated with a 2-3% decrease in BMD,72 
and higher adiponectin levels may be a risk factor for increased fracture risk.67 The gut-derived peptide 
hormone ghrelin has been shown to modulate osteoblast differentiation and function, both directly and 
perhaps also through regulation of the growth hormone–insulin-like growth factor axis, and through 
interaction with leptin ghrelin has a role in modulating bone structure.73 A systematic review and 
meta-analysis by Biver et al. concluded that the most relevant adipokines influencing BMD and fracture 
risk are indeed leptin and adiponectin, whereas no convincing data are available for resistin, visfatin or 
gut-derived ghrelin.74
The role of inflammation in the pathogenesis of type 2 diabetes, as touched upon before, and associ-
ated complications is now well established.75 C-reactive protein (CRP) is an extremely sensitive marker 
of systemic inflammation produced mainly by the liver under the stimulation of macrophage- and 
adipocyte-derived proinflammatory cytokines, principally interleukin-6 (IL-6).76 Elevated levels of CRP 
are described in persons with type 2 diabetes; however, it is not clear if they are related to the presence 
of obesity, diabetes, or both.77 Studies in general populations have found lower BMD,78, 79 lower hip geo-
metrical bending strength80 and an increased risk of fracture80, 81 for higher CRP levels, which intriguingly 
appeared to be independent of BMD or trabecular microarchitecture.82 Some studies explicitly indicate a 
relationship between CRP and complications of diabetes,83-86 nonetheless, evidence is lacking for a direct 
mechanism and CRP may very well merely be a marker of the ongoing inflammation.80, 87-89
Shared genetic factors between diabetes and bone disease
A genome-wide association study (GWAS) meta-analysis for gene expression levels in relation to type 2 
diabetes as the phenotype of interest including 1,175 case-control microarrays showed a significantly 
differential gene expression of osteopontin (OPN), also known as phosphoprotein 1 (SPP1) or bone 
sialoprotein I (BSP-I).90 This same investigation brought forward that osteopontin is a ligand for the most 
prominent top hit of this genome-wide screening being the immune-cell receptor CD44; and that the 
expression profiles of CD44 and osteopontin are frequently coordinately dysregulated, especially in 
adipose tissue. The gene encoding osteopontin maps to the 4q22.1 locus, which has frequently ap-
peared as a femoral neck-BMD and lumbar spine-BMD locus in large-scale meta-analyses and contains 
many bone-active genes.91-94 Osteopontin is an extracellular structural protein in bone able to bind 
strongly to calcium crystals.95 It has been proposed that osteopontin is an important factor in bone 
remodeling,96 which may be by anchoring osteoclasts to the mineral matrix of bones.97 In addition, 
osteopontin enhances B lymphocyte proliferation and immunoglobulin production, and is chemotactic 
for many immune cell types including macrophages, dendritic cells, and T cells.98 Osteopontin null 
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mice of all ages display a bone phenotype probably mediated by altered osteoclast activity, protecting 
them from developing osteoporosis.99 Fascinatingly, wild type mice exposed to a high-fat diet exhibit 
increased plasma osteopontin levels with elevated expression in macrophages recruited into adipose 
tissue, while on the other hand, obese osteopontin null mice exhibit decreased markers of inflammation 
with less macrophage infiltration into adipose tissue, display improved insulin sensitivity and are seem-
ingly protected from the effects of diet-induced obesity on body composition or energy expenditure.100 
Altogether this suggests a key role for osteopontin in the development of age-related osteoporosis and 
the link of obesity to the development of insulin resistance and possibly type 2 diabetes.
A GWAS meta-analysis targeting copy number variations (CNV), which are a type of structural variants 
of the genome in which large (>1 kb) segments of the genome are either lost or duplicated, found 
evidence that a deletion in the 6p25.1 locus predisposes to risk of all-type of fracture.101 The deletion 
is located in an intergenic region in the subtelomeric region of chromosome 6p in the proximity of 
the Peroxisomal D3,D2-EnoylCoA Isomerase (PECI) gene which codes for an enzyme relevant for the 
metabolism of fatty acids. PECI was first cloned by using pooled antisera from autoimmune diabetes 
patients.102 The increased risk seen with individuals with the 6p25del may be mediated by co-morbidity 
with diabetes, yet, more studies are needed to convincingly replicate the potential association of this 
copy number variant with fracture risk and elucidate the underlying functional mechanism.
The association between BMD, type 2 diabetes and glycemic traits103 was also tested in the context of 
pleiotropic relations by members of the Genetic Factors of Osteoporosis (GEFOS) and Meta-Analyses of 
Glucose and Insulin-related traits (MAGIC) consortia. None of the BMD single nucleotide polymorphisms 
(SNPs) reached the a priori P-value threshold corrected for multiple testing, except a SNP at the ITGA1 
locus. This marker was found associated with type 2 diabetes, serum insulin levels, β-cell function and 
glucose tolerance. Null ITGA1 mice have impaired fracture healing and cartilage remodeling,104 although 
it is not yet clear what role this gene product has on BMD or bone structure.
Bone geometry
Our data on hip bone geometry in the Rotterdam Study showed that individuals with inadequately 
controlled diabetes have persistently thicker cortices in narrower femoral necks than those with ad-
equately controlled diabetes or those without diabetes.24 A lesser tendency to undergo physiological 
bone expansion (periosteal apposition), i.e. a process in which a limited amount of bone mass is ef-
ficiently redistributed, could be inferred from narrower bone diameters in these individuals. This led us 
to propose that changes in microarchitecture (i.e. microcracks and cortical porosity) could be underlying 
the increased risk of fractures observed in inadequately controlled diabetics. A peripheral quantitative 
computed tomography (pQCT) investigation in the Osteoporotic Fractures in Men study found that par-
ticipants with type 2 diabetes displayed greater volumetric bone mineral density (vBMD) but a smaller 
bone area at both the distal tibia and radius, which resulted in a bone strength which was particularly 
low relative to body weight105. As described by Ahlborg et al.,106 a process of rapid physiological bone 
expansion occurs in women after menopause, highlighting a complex interplay of hormones such as 
estradiol, IGF-I and insulin.107, 108 Considering the known anabolic effects of IGF-I and insulin on bone 
and periosteal expansion, it can be expected that the altered insulin–IGF-I–growth hormone axis (lower 
bioavailability of IGF-I) may also contribute to the observed geometrical alterations observed in inad-
equately controlled diabetes, as a lack of periosteal apposition and bone repair. Since such differences in 
geometry are accentuated at older ages, we previously postulated that an accumulation of microcracks 
with time may well be an skeletal complication of inadequately controlled diabetes resulting in impaired 
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bone repair, decreased bone remodeling, high BMD and increased risk of fracture.24 There is a growing 
body of evidence for deterioration of bone microarchitecture in type 2 diabetes leading to a porous 
skeleton susceptible to fracture. Burghardt et al. applied a novel derivative of cortical porosity for high-
resolution peripheral quantitative computed tomography (HR-pQCT) and reported that the cortical 
porosity in type 2 diabetic patients is up to twice that of controls at the radius.109 Subsequently, Patsch et 
al. compared type 2 diabetes patients with fragility fractures to patients diabetes with diabetes without 
fractures and controls with and without fractures.110 The investigators showed nicely that the cortical 
porosity is specific to those type 2 diabetes patients that fracture. Similarly, The trabecular bone score 
(TBS) is a measure of bone texture that can be derived from DXA, which correlates with 3D parameters 
of bone microarchitecture.111 One of the first studies utilizing this invention demonstrated that TBS is 
lower at the lumbar spine in diabetes-related bone disease.112 The results of these investigations provide 
a potential explanation for the inability of standard DXA measures to explain the elevated fracture inci-
dence in patients with diabetes presenting with higher BMD and apparently stronger bone geometry.
Recently researchers have started to examine bone marrow fat composition, regarding presence and 
types of hydrogen bonds, where unsaturated fats contain at least one double bond and saturated fats 
have the maximum number of hydrogens bonded to carbons. The radiological research group of Dr. 
Link has demonstrated in their combined quantitative computed tomography (QCT) and magnetic 
resonance (MR) spectroscopy studies that the prevalence of fragility fractures is associated with lower 
unsaturation levels and higher saturation levels of bone marrow fat, in which the participants with 
diabetes with fractures have the lowest marrow unsaturation and highest saturation.113 In contrast to 
controls without diabetes, higher mean vertebral bone marrow fat content is significantly correlated 
with visceral adipose tissue and HbA1C in persons with type 2 diabetes, representing worse metabolic 
profiles.114 The concept of high-saturated fat-associated adipose inflammation and insulin resistance 
have been proposed; however, underlying molecular mechanisms remain to be elucidated.
Reference point indentation115, 116 allows minimally invasive measurements of bone material properties 
of human bone in vivo by microindentation, which is correlated with risk of osteoporotic fractures.117, 118 
Recently, Farr et al. showed that patients with type 2 diabetes have reduced serum markers of bone 
turnover and lower bone material strength at the tibia than age-matched, controls without diabetes.119 
Further, in this same study the average HbA1C level over the previous ten years was negatively correlated 
with bone material strength,119 supporting the contention recognizing the skeleton as another impor-
tant target tissue subject to diabetic complications.24
Therapeutic options
Not only are patients with diabetes at increased risk for fractures, they are prone to impaired bone 
healing after fracture as well.120 In usual fracture healing serum concentrations of biomarkers such as 
alkaline phosphatase, IGF-I and osteocalcin peak in the first few weeks of recovery121, 122 and decrease 
again thereafter, but possibly in disturbed consolidation these levels remain elevated for an even longer 
time.123 An experimental study using the diabetic Zucker (fa/fa) rat model with creation of femoral 
defects demonstrated that administration of parathyroid hormone (PTH) could partially reverse the 
adverse skeletal effects of diabetes on bone defect.124
Systematic screening for complications and fall prevention efforts, along with calcium and vitamin 
D repletion and adequate physical activity, represents the mainstay of fracture prevention in patients 
with diabetes. Nonetheless, we should mention that the controversy regarding the anti-fracture efficacy 
versus the side-effect profile of calcium supplements in general is still unresolved.125-127 A few meta-
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analyses with different methodologies have been published on this topic to date yielding conflicting 
results,128-131 of which the investigation by Bolland et al. suggested an increased risk of myocardial infarc-
tion (MI) and possibly stroke in men and women together for calcium supplements, particularly without 
co-administered vitamin D.128 These specific potential side effects of calcium supplements may be of 
particular importance in patients with diabetes as they are already at increased risk of cardiovascular 
disease complications, however, no studies have been performed in this area yet. As discussed above, 
the current FRAX risk score underestimates fracture risk in patients with diabetes, which leads to under-
treatment of the diabetic individuals that are actually at increased fracture risk. Anti-catabolic drugs 
(raloxifene, bisphosphonates, denosumab) might be effective, but on the basis of pathophysiological 
evidence that suggests low bone formation in the aforementioned research in model organisms,124 
osteo-anabolic therapies such as teriparatide might represent an important therapeutic option for 
diabetes-related bone disease.132 More studies including randomized controlled trials in this area are 
needed.
CONCLUSION
The detrimental effects of diabetes on bone should be added to the more well-known complications 
of diabetes. A deterioration in bone microarchitecture and an inefficient distribution of bone mass 
with insufficiency of repair and adaptation mechanisms in combination with increased risk of falling 
all lead to an elevated fracture risk as skeletal complications of diabetes. Improved risk prediction with 
epidemiological determinants and integration of novel biochemical and imaging biomarkers will be 
necessary to correctly and timely diagnose those individuals at increased risk. More research is needed 
to unravel the pathophysiology underlying diabetes-related bone disease, which may eventually con-
tribute to preventative and curative therapies.
Strength of Evidence
The evidence outlined in this review includes studies in humans and animals. Animal studies cited are 
mostly knockout mice experiments. Human studies include observational studies of varying sizes, meta-
analyses summarizing these results, and a few randomized controlled trials of generally smaller sample 
sizes. At present, it may not be very well possible to grade the evidence; replication studies in this field 
are desirable.
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ABSTRACT
Our understanding of the genetic control of skeletogenesis and bone remodeling is expanding, and 
normally, bone resorption and bone formation are well balanced through regulation by hormones, 
growth factors and cytokines. Osteoporosis is considered a systemic disease characterized by low bone 
mass and microarchitectural deterioration of bone tissue. Consequent increased bone fragility results 
in higher fracture risk. The most common osteoporotic fractures are located in the spine and they form 
a significant health issue. A large variety of systemic diseases are associated with risk of osteoporotic 
vertebral fractures, illustrating its multi-factorial etiology. Prevalences of these conditions vary from com-
mon to extremely rare and incidence peaks differ according to etiology. This review appreciates different 
aspects of osteoporotic vertebral fractures as part of systemic disease, including genetic, immunologic, 
inflammatory, metabolic and endocrine pathways. It seems impossible to be all-comprehensive on this 
topic, nevertheless, we hope to provide a reasonably thorough overview. Plenty remains to be eluci-
dated in this field, identifying even more associated diseases and further exposing pathophysiological 
mechanisms underlying osteoporotic vertebral fractures.
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INTRODUCTION
Osteoporosis is considered a systemic disease characterized by low bone mass and microarchitectural 
deterioration of bone tissue, leading to enhanced bone fragility and a consequent increase in fracture 
risk. Our understanding of the genetic control of skeletogenesis and bone remodeling is expanding. 
Normally, bone resorption and bone formation are well balanced and regulated by hormones, growth 
factors and cytokines. Various internal and external factors are known to contribute to the risk of osteo-
porosis, illustrating the multi-factorial etiology of the condition. The most well-known clinical risk factors 
for osteoporosis and fractures include age, lower body mass index,1 immobility,2-4 smoking,5 alcohol 
consumption,6 and glucocorticoid use7. In addition, a positive family history confers an increased risk of 
fracture8. The term secondary osteoporosis refers to disorders that are strongly associated with osteopo-
rosis;9 these include diseases with systemic inflammation like rheumatoid arthritis, inflammatory bowel 
disease, chronic obstructive pulmonary disease (COPD), but also diabetes, hypogonadism (including 
premature menopause), malnutrition and malabsorption. Medication use may also predispose to 
elevated fracture risk, but, this is beyond the scope of this review. This list is all-but comprehensive and, 
undoubtedly, many more risk factors and associated diseases are to be discovered.
Vertebral fractures are the most common osteoporotic fractures and they are often a first manifesta-
tion of osteoporosis. These fractures represent a significant health issue10, 11 as they are associated with 
a high morbidity, including but not limited to acute and chronic pain, loss of independence, height 
loss, kyphosis, depression, higher risk of additional future vertebral and non-vertebral fractures,12-17 and 
increased mortality18, 19. There may be skeletal-site specific effects of fracture determinants, meriting the 
study of vertebral fractures apart from non-vertebral fractures, as we will discuss later in this review. Risk 
factors that have been specifically validated for incident vertebral fractures include: prevalent vertebral 
fractures, older age, female gender, lower body height and weight, smoking history and use of a walk-
ing aid.20, 21 Very recently, Schousboe et al. pioneered in prediction models for osteoporotic vertebral 
fractures in older men22 and women23, and although promising yielding area under the receiver operat-
ing curves of up to 0.69, validation in independent studies is needed and future research may identify 
additional risk factors that enhance prediction of incident osteoporotic vertebral fractures.
This review appreciates different aspects of osteoporotic vertebral fractures as part of systemic dis-
ease, touching on genetic, metabolic and inflammatory pathways and organ system dysfunction.
Structural vertebral deformities and fractures
Several methods for radiological assessment of vertebral fractures exist, but a gold standard is lacking.24 
Traditionally conventional radiography has been the imaging modality of choice. Yet, two advantages 
of dual-energy X-ray absorptiometry (DXA) over conventional radiography for vertebral fracture as-
sessment are the lower radiation dose and capture of the whole spine in one image with virtually no 
divergent radiation beam issues, particularly because DXA imaging resolution has improved drastically 
with the introduction of state-of-the-art machinery. Another novel add-on to DXA is the trabecular bone 
score (TBS), a measure of bone texture, which correlates with 3D parameters of bone microarchitecture 
reflecting bone quality and which is partly independent from DXA-measured lumbar spine bone mineral 
density (LS-BMD).25 In any case, a number of differential diagnoses remain that complicate the diagnosis 
of vertebral fractures, including degenerative diseases, anatomical variation and anomalies.26 More is 
becoming clear about these conditions and the possible presence or absence of an interrelationship 
with osteoporosis and associated fractures, as discussed in the following section. Therefore, we start the 
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review by discussing the definition of osteoporotic vertebral fractures and mimickers of that should not 
be confused with vertebral fractures.
Non-fracture deformities represented by anatomical variation and developmental abnormalities have 
been reviewed extensively by Ferrar et al.27 From a lateral view, the spine has a natural curvature. Ver-
tebrae in the mid-thoracic region are more wedge-shaped, causing a mild kyphosis. Lumbar vertebrae 
have a relatively shorter posterior height and tend to be biconcave resulting in a normal lordotic curve. 
Some individuals have developmentally smaller or shorter vertebrae, particularly in anterior height 
found most commonly in the mid-thoracic region. This is thought to be due to congenital variation or 
as the result of inhibited growth of the vertebral body during childhood or adolescence, and it is also 
thought that these variants should not be regarded as fractures.28 In so-called ‘‘step-like’’ or “step-off” 
endplates the central endplate is deeper with an abrupt transition to the more normal periphery. This 
is in contrast to the appearance of the fractured endplate in osteoporosis, in which, a smooth, concave 
depression extends from corner to corner of the vertebral body.27 These “step-off” endplates seem to be 
the consequence of a growth retardation in the central portion of the endplate due to central circulatory 
stasis. In contrast, the periphery of the growth plate has a different blood supply through short arteries, 
in which vaso-occlusion and microinfarction may lead to avascular necrosis and further developmental 
disruption of the vertebral body.29 Diseases that have been listed as associated with these observations 
are Gaucher’s disease, hemolytic anemias including hereditary spherocytosis, sickle cell, and thalassemia 
hemoglobinopathies.30 The cortical margins of the inferior endplates of predominantly lumbar vertebral 
bodies L3 to L5 frequently have paired parasagittal concavities when viewed in the frontal projection, 
resembling the curvature of an aimed bow.31 When viewed in the lateral projection, the concavities are 
superimposed and lie in the posterior portion of the vertebral body, and could then be confused with 
fractures.27 This aspect, called “Cupid’s bow” is considered a normal anatomic variant. Histologic exami-
nation in cadavers showed thickened bone in the Cupid’s bow endplate with annular fibers inserting 
into this region, which was detected at multiple lumbar and thoracic levels, with the highest frequency 
in the lower lumbar spine.32 Furthermore, the endplates tend to become progressively deeper with 
lower vertebral level and another commonly seen normal variant is a deep inferior endplate. Another 
developmental variation is represented by balloon discs, where there is an occurrence of an unusually 
concave disc-vertebral border at multiple levels. A Japanese study has reported a prevalence up to 14% 
in the healthy population, with an association with male gender and height, but a lack of a relation with 
back pain or age;33 yet, to our knowledge no replication and validation studies have been published.
A specific example of an anatomical anomaly of the vertebrae that could be confused with verte-
bral fractures is Scheuermann’s disease. With reported prevalence rates of up to 10%, the disease is 
frequently mentioned in the differential diagnosis of osteoporotic vertebral fractures.27 It is a form of 
osteochondrosis of the spine characterized by increased posterior rounding of the thoracic spine in 
association with structural deformity of the vertebral elements.34, 35 Scheuermann’s disease often first 
appears during adolescence at the time of puberty, resulting in permanent vertebral distortion and back 
pain in many cases. The etiology is unknown, but genetics most likely plays a significant role;36 genetic 
surveys are underway. Scheuermann’s disease is diagnosed on the basis of radiographic criteria of which 
those defined by Sørensen and Sachs are the most commonly applied: a thoracic kyphosis greater 
than 45°; at least three adjacent wedge-shaped vertebral bodies of 5° or more; endplate irregularities 
with possible vertebral elongation; disc space narrowing. In addition, Schmorl’s nodes are thought to 
be a common but not obligate manifestation of Scheuermann’s disease.37-40 Although coexistence of 
Scheuermann’s disease with osteoporotic vertebral fractures may occur, it is thought that the disorders 
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should be distinguished as clinical disease treatments differ.41 Nonetheless, very little data exists on a 
possible connection between the two diseases. A few studies with small patient numbers have been 
conducted a long time ago, of which some suggest that patients with Scheuermann’s disease have 
generalized lower bone mineral density (BMD).42, 43 Some suggest this is a transient effect that resolves 
at adulthood,44 whereas no effect at all was found by others45. However, no investigations have looked 
into osteoporotic vertebral fracture risk in Scheuermann’s disease.
More generally speaking, the vertebral endplates are thought to contain the adjacent intervertebral 
discs and evenly distribute applied loads to these discs and the bony material of the vertebral bodies 
themselves. Consequently, sclerosis or ossification of the endplate may impact the nutritional supply 
and hydration of the intervertebral disc. Similar to Scheuermann’s disease, also with aging, degenerative 
alterations may take place such as lumbar disc degeneration.46 Lumbar disc degeneration and osteo-
porosis are two age-related skeletal diseases that are highly prevalent in the elderly.47, 48 Intriguingly, it 
has been previously shown, that the presence of lumbar disc degeneration is associated with higher 
BMD.49-51 In theory, the higher BMD found in subjects with lumbar disc degeneration should correspond 
to lower fracture risk compared to subjects without the condition. However, a systematic review that 
was published recently on this topic demonstrated that although subjects with lumbar disc degenera-
tion have systematically higher BMD, at least at the lumbar spine, femoral neck, skull, and total body. 
In spite of this systematically higher BMD, persons with lumbar disc degeneration are at higher risk of 
osteoporotic fractures. This particularly applies to males in whom lumbar disc degeneration seems more 
severe. Possibly, these observations could be explained by direct and indirect effects. Loss of disc height 
and deterioration of its biomechanical properties produce high tensile strains in the vertebral endplate 
which may be causally related to “failure of the vertebra”.52, 53 Furthermore, individuals with lumbar disc 
degeneration have more stiffness in the trunk and lower legs, which could increase the reaction time 
during falling and other demanding occupational activities.54, 55 The exact mechanisms to explain the 
associations merit further investigation.
From an antero-posterior view, a few percent of the general population has a sideways curvature of 
their spine, that is, scoliosis. A scoliosis is diagnosed with a Cobb angle of more than 10⁰ in the frontal 
plain.56, 57 Presence of scoliosis may impede DXA-BMD measurement and assessment for vertebral frac-
tures.27, 58 Scoliosis can be categorized into several groups according to the etiology. First, scoliosis may 
occasionally be of congenital origin, arising during embryonic development and oftentimes it is then 
part of a syndrome.59 Second, adolescent idiopathic scoliosis embodies a substantial proportion of the 
cases and it is the most common pediatric skeletal disease. The etiology of adolescent idiopathic sco-
liosis remains largely unknown, but population and twin studies strongly suggest a contribution from 
genetic factors.60 So far, findings from linkage and candidate gene association studies involved genes 
related to connective tissue structure, bone formation/metabolism, melatonin signaling pathways, 
puberty and growth, and axon guidance pathways, but these results remain to be replicated.61 Two 
genome-wide association studies (GWAS) containing a replication phase have been published until now 
and described associations with loci containing the candidate genes ladybird homeobox 1 (LBX1) and 
G protein–coupled receptor 126 (GPR126), of which the functions remain to be elucidated further. Bone 
quality deterioration and lower bone mass have been recounted as a systemic phenomenon at the hip, 
spine and other peripheral sites in a significant percentage of adult idiopathic scoliosis patients.58, 62-65. 
Whether this decrease in bone mass is associated with an increased risk of osteoporotic spine fractures 
or not has not yet been investigated prospectively. Thirdly, the clinically most prominent groups in adult 
scoliosis are primary and secondary degenerative scoliosis.66 In the so-called primary degenerative 
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scoliosis (‘‘de novo’’ form) there is an asymmetric disc degeneration and facet joint degeneration, mostly 
located in the thoracolumbar or lumbar spine, which is associated with aging.67 Secondary degenerative 
scoliosis may appear as a consequence of pelvic obliquity due to a leg length discrepancy, hip pathology 
or a neuromuscular problem. Finally, osteoporotic vertebral fractures may bring about an asymmetric 
configuration with the appearance of kyphosis, scoliosis, or both.66
Systems genetics of vertebral fractures
As mentioned previously, one of the most important risk factors for osteoporosis and fractures is a posi-
tive family history.68 Previous studies have reported estimates of heritability of BMD and fractures of up 
to 66% and 46%, respectively.69, 70 Furthermore, a recent report has formally quantified that there is a 
mixture of shared and specific genetic influences for distinct DXA-BMD traits, where the strength of 
genetic variants may differ in their association and magnitude of effect across different skeletal sites, 
or, moreover, some loci seem to act in certain skeletal locations, whereas they are irrelevant to others.71 
Such a difference in genetic basis had previously been proposed for LS-BMD versus femoral neck BMD 
(FN-BMD) in GWAS.72 Although the occurrence of fracture is the most important clinical outcome in 
osteoporosis, identifying genetic determinants contributing to the risk of fracture has been difficult 
because of its multifactorial nature and occurrence late in life. For this reason, correlated intermediate 
phenotypes such as BMD measured by DXA have attracted the interest of researchers in the field of 
genetics of osteoporosis. The most recent GWAS meta-analysis concluded that the identified genetic 
factors related to LS-BMD and FN-BMD as measured by DXA cluster in three key biological pathways 
being mesenchymal stem cell differentiation, Wnt signaling and RANK–RANKL–OPG (receptor activa-
tor of nuclear factor kappa-B–receptor activator of nuclear factor kappa-B ligand–osteoprotegerin).73 
Mesenchymal stem cells are multipotent stromal cells that can differentiate into a variety of cell types, 
including osteoblasts (bone-forming cells), chondrocytes (cartilage cells), and adipocytes (fat cells). 
Wnt signaling consists of a group of signal transduction pathways made of proteins that pass signals 
from extracellularly through cell surface receptors to the inside of the cell. It plays an essential role 
in development and maintenance of a multitude of organs and tissues including bone, contributing 
fundamentally in osteoblastogenesis.74 The RANK–RANKL–OPG system is crucial for well-balanced bone 
remodeling through well-orchestrated activation of osteoclasts by osteoblasts.75 Another critical process 
highlighted in this study was endochondral ossification, the accumulation of intracellular calcium by 
chondrocytes to form calcified bone tissue in the developing skeleton.
A growing number of GWAS have revealed genetic loci for fracture risk of any type.73, 76, 77 A study 
by Liu et al. has obtained heritability estimates of prevalent moderate and severe vertebral fractures 
(semi-quantitative (SQ) grade ≥2) as assessed on computed tomography (CT) ranging between 
43% and 53%, and increasing to approximately 69% when adjusting for volumetric BMD (vBMD) and 
cross-sectional area (CSA).78 The very first GWAS for radiographic vertebral fractures discovered a single 
nucleotide polymorphism (SNP) on chromosome 16q24 at genome-wide significant level.79. The SNP 
maps to a region previously found associated with DXA LS-BMD in two large meta-analyses.72, 73. From 
a biomedical perspective, deletions/mutations in this 16q24 locus are implicated in a combination of 
birth defects that includes vertebral defects in both humans and mice.80 Furthermore, the neighboring 
forkhead box C2 (FOXC2) candidate gene encodes a transcription factor essential for axial skeletogenesis 
in mice.81 However, this GWAS association could not be convincingly replicated by de novo genotyping 
the specific marker in a large-scale global replication effort, displaying a high degree of heterogeneity 
of effects.79 It was speculated that apart from the possibility of the signal being a false positive associa-
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tion in the discovery, phenotype definition issues as discussed in the previous subchapter may have 
undermined establishment of a firm correlation. For instance, it is thought that many mild vertebral 
deformities represent non-fracture deformities such as degenerative changes. Indeed, in the study by 
Liu et al., after adding mild grade 1 vertebral deformities into the analyses, the heritability was much 
lower (aforementioned 43% to 69% dropping to 19% to 27%) with a lower intra-reader agreement 
(kappa =0.56–0.59 versus kappa=0.68–0.72 for grade ≥2).78
There are a multitude of additional candidate genes that could be screened for in unusual clinical cases 
presenting with vertebral fractures, for instance genetic mutations that are known to cause monogenic 
forms of osteoporosis or osteogenesis imperfecta, for example: COL1A1,82COL1A2, LRP5,83WNT1,84LGR4,85, 
PLS386, CRTAP, FKBP10, LEPRE1, PLOD2, PPIB, SERPINF1, SERPINH1 and SP787.
Immunologic, metabolic and endocrine factors with respect to vertebral fractures
Chronic inflammation is associated with bone loss, and even low grade sub-clinical inflammation has 
been reported to increase fracture risk.88 Bone loss in patients with inflammatory diseases is thought 
to be due to direct effects of inflammation, poor nutrition, reduced lean body mass, immobility and 
the side-effects of treatments, especially glucocorticoids.89 Inflammatory diseases can increase bone 
resorption, decrease bone formation, but most commonly affect both these processes resulting in an 
uncoupling of bone formation from resorption resulting in bone loss. This will be detrimental to the total 
quantity of bone mass and the spatial distribution at macro- and micro-architectural levels90. The most 
commonly measured inflammatory serum bio-marker is C-reactive protein (CRP), a protein found in the 
blood which levels rise in response to inflammation. CRP levels have been found associated with fracture 
risk including radiographic vertebral fractures91, 92. Particular autoimmune diseases in which increased 
risk of spinal fractures have been confirmed by research data are: rheumatoid arthritis,93-96 systemic lupus 
erythematosus,97, 98 sarcoidosis,99 inflammatory bowel disease100, 101 and spondylarthropathies102-104.
Metabolic and endocrine factors with respect to vertebral fractures
Systemic glucocorticoids have been prescribed world-wide for various diseases since decades, such 
as the aforementioned autoimmune diseases. Prednisone is the most commonly prescribed synthetic 
corticosteroid. Although these steroids are a highly effective treatment, they are known to have severe 
adverse effects on for example the musculoskeletal and gonadal systems,105, 106 particularly when admin-
istered in high doses and for prolonged periods. Natural glucocorticoids are produced by the adrenal 
glands and are of vital importance. Cushing’s disease refers to pituitary disease and Cushing’s syndrome 
includes exogenous administration and for instance, adrenal overproduction. Both endogenous and ex-
ogenous hypercortisolism induce osteoporosis and fractures, and as glucocorticoids preferentially affect 
trabecular bone, the spine is seriously put at risk. Chronic glucocorticoid therapy has unequivocally been 
linked to BMD loss at the spine and vertebral fracture risk.107 Although rarer, clinical but also subclinical 
endogenous hypercortisolism, has repeatedly been connected to lower LS-BMD,108 worse bone quality 
as quantified by TBS,109 incident and prevalent vertebral fractures110, 111.
Diabetes mellitus affects bone metabolism. It has been demonstrated that patients with type 
1 diabetes have low BMD112 and elevated prevalence of non-spine and asymptomatic vertebral 
fractures,113 and these fractures are associated with the presence of type 1 diabetes independently of 
BMD114. Furthermore, both men and women with type 2 diabetes have a higher fracture risk115 despite 
a paradoxically systematically higher DXA-BMD at the femoral neck, hip and spine;116 an effect which 
seems to be modified by the degree of glucose regulation117. The increased fracture risk is most likely 
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through compromised bone microarchitecture.118-122 Schwartz et al. established recently that the current 
World Health Organization’s fracture risk assessment tool (FRAX) underestimates osteoporotic fracture 
risk in individuals with diabetes;123 reason why diabetes as a risk factor will be considered for inclusion 
in future iterations of FRAX124, 125. It has been observed in different ethnicities that patients with type 2 
diabetes may have an increased risk of vertebral fractures independent of BMD or diabetic complication 
status.126, 127 A highly complex and heterogeneous pathophysiology seems to underlie vertebral fracture 
risk in diabetes-related bone disease. Elevated levels of advanced glycation endproducts (AGEs) have 
been found detrimental,128 and higher levels of the endogenous secretory receptor for AGEs (esRAGE), 
acting as a decoy binding AGEs, have protective effects on vertebral fracture risk in diabetes129. Other 
studies showed that lower concentrations of serum insulin-like growth factor-I (IGF-I) levels were as-
sociated with a higher number of prevalent vertebral fractures in postmenopausal women with type 2 
diabetes.130, 131
IGF-I is a hormone similar in molecular structure to insulin and is a primary mediator of the effects 
of growth hormone. IGF-I is required for the anabolic effects of growth hormone on bone132, 133 and, 
specifically in men, free IGF-I levels are positively related with LS-BMD134. Furthermore, there is an in-
creased prevalence of radiological spinal deformities in adult patients with growth hormone deficiency, 
particularly in those patients with untreated disease and longer disease duration.135 Yet, in acromegaly, a 
disorder caused by excess growth hormone production by the pituitary gland, an increased prevalence 
of radiological spinal deformities has also been observed.136 It has been postulated that the increased 
frequency of diabetes mellitus in acromegaly may partially explain the higher vertebral fracture risk.137 
However, a very high prevalence of vertebral fractures has also been demonstrated in acromegaly 
patients with long-term controlled disease, independently of BMD.138
Osteoporosis is most prevalent in aging women over the age of 50 yr as the hormonal protec-
tive influence of sex steroids such as estrogens on bone health dissipates with the onset of meno-
pause.20, 21 Therefore, early or premature menopause is a major risk factor for vertebral fractures.21 In 
aging premenopausal women, the rate of mineral loss is greater and faster at the trabecular than at 
the cortical level, and the accelerated phase of trabecular bone loss during menopause also occurs 
at a greater rate at the trabecular compartment than at the cortical bone.139 This has a major impact 
on the spine, as trabecular bone constitutes the greatest part of vertebral bone mass and strength,140 
and it may contribute to the occurrence of vertebral fractures already early on in the disease process 
of osteoporosis. Furthermore, osteoporosis is being recognized increasingly in men, and undiagnosed 
clinical hypogonadism is a common cause of osteoporosis in men141. Also, an increasing number of 
patients with cancer acquire hypogonadism as breast and prostate malignancies are treated with anti-
hormonal therapies, such as aromatase inhibitors and anti-androgens; additionally, gonadal damage 
may occur as an adverse effect of radiation and chemotherapy.142-144 It has been demonstrated that 
menopausal transition and treatment with aromatase inhibitors result in decreases in BMD and TBS and 
higher prevalences of vertebral fractures, particularly in those women with the lowest levels of estradiol 
and the highest levels of sex hormone-binding globulin (SHBG)145-147. Comparably, men with prostate 
cancer on androgen deprivation therapy suffer from more spine fractures.148, 149 Intriguingly, vertebral 
fracture risk in hypogonadism does not seem to be mediated by testosterone but seem dependent on 
estradiol levels as well150. Finally, pregnancy and lactation can cause irreversible bone loss, which may 
cause vertebral fractures from young up to old age.151, 152 Levels of the hormone prolactin are normally 
high during pregnancy and lactation, and prolactin exerts negative feedback on estrogen production 
in women and testosterone production in men. Prolactin-secreting adenomas account for about half of 
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all pituitary adenomas and are associated with vertebral fractures in at least men, probably by inducing 
secondary hypogonadism.153
Finally, thyroid hormones are primarily responsible for the regulation of metabolism. Long-standing 
untreated hyperthyroidism and over suppletion with thyroid hormones have long been known to reduce 
BMD and elevate risk of fractures of the spine up to nine times compared to euthyroid controls.154-156 This 
effect may partially be reversible after treatment of the thyroid disorder.
Miscellaneous systemic conditions associated with risk of vertebral fractures
It seems impossible to be all-comprehensive on this topic; we will briefly mention a few more conditions 
associated with vertebral fractures in this final subchapter.
Surely, problems in mineral and calcium homeostasis through parathyroid hormone (PTH) and 
vitamin D metabolism are associated with vertebral fracture risk.157-159 TBS is compromised in hyper-
parathyroidism.160-162 Increased rates of vertebral fractures have been found in chronic kidney disease, 
where the association with tertiary hyperparathyroidism is weak at most and the causal mechanisms 
seem complex, but vascular calcification appears to be related to chronic kidney disease-mineral bone 
disorder (CKD-MBD).163-165 In a study by Szulc et al. severe abdominal aortic calcification and vertebral 
fracture, both assessed using DXA, were positively associated independently of bone mineral density.166 
High prevalences of radiological vertebral fractures in HIV-infected patients have been reported, which 
might be attributable to higher rates of diabetes mellitus, renal insufficiency and steroid use in this 
group.167, 168
Furthermore, decreases in DXA-BMD have been linked to chronic lung disease mortality independent 
of other risk factors for low BMD in chronic obstructive pulmonary disease (COPD) such as smoking, low 
BMI or use of corticosteroids.169 COPD is among the most common chronic lung diseases and mainly 
is a smoking-related disorder affecting millions of people worldwide.170 Systemic manifestations of the 
disease include exercise intolerance, skeletal muscle impairment, osteoporosis and hormonal imbal-
ance.171 These problems may arise due to inactivity, systemic inflammation, hypoxia and corticosteroid 
treatment. Many studies have reported on a relationship between COPD and vertebral fractures;172-176 
however, it is uncertain whether the effect of COPD on vertebral fractures is independent from smok-
ing177.
In chronic liver disease and transplantation patients lower BMD, more spinal and peripheral fractures 
may be found, although it is still unclear whether these effects are explained through confounders such 
as immunosuppressive medications, hypogonadism, lower levels of IGF-I or lifestyle factors including 
vitamin D deficiency, malnutrition, alcohol abuse and decreased outdoor activity.178-182 Hyponatremia, 
that is, a reduced serum sodium concentration, is the most common electrolyte disorder in hospitalized 
patients and has a multifactorial etiology such as diuretic medication use, hyperglycemia in diabetes, liver 
cirrhosis and cardiac decompensation. Mild hyponatremia in the elderly has been found associated with 
an increased risk of vertebral fractures and incident non-vertebral fractures but not with DXA-BMD.183
Finally, we will list a few rare diseases associated with vertebral fractures. Systemic mastocytosis is a 
clonal disorder of abnormal mast cells which release the allergy mediator histamine and can accumu-
late in bone marrow, which has been linked to vertebral fractures in some cases.184, 185 The autosomal 
recessive genetic disorder cystic fibrosis is characterized by abnormal transport of chloride and sodium 
across epithelial cells, leading to thick and viscous secretions. This condition has been linked to higher 
prevalences of osteopenia, osteoporosis, and vertebral fractures in multiple studies as well.186-191
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CONCLUSION
Vertebral fractures are associated with high morbidity, mortality, and costs, and radiological diagnosis is 
not always straightforward. A great variety of systemic diseases are associated with risk of osteoporotic 
vertebral fractures, illustrating its multi-factorial etiology and underscoring its systemic origin. We have 
reviewed genetic, immunologic, metabolic, and endocrine contributing factors. Prevalences of these 
conditions vary from common to extremely rare, and incidence peaks differ according to etiology. Plenty 
remains to be elucidated in this field, identifying even more associated diseases and further exposing 
pathophysiological mechanisms underlying osteoporotic vertebral fractures.
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ABSTRACT
Introduction Osteoporosis is the most common metabolic bone disease; vertebral fractures are the 
most common osteoporotic fractures.
Methods Several radiological scoring methods using different criteria for osteoporotic vertebral fractures 
exist. Quantitative morphometry (QM) uses ratios derived from direct vertebral body height measure-
ments to define fractures. Semi-quantitative (SQ) visual grading is performed according to height and 
area reduction. The algorithm-based qualitative (ABQ) method introduced a scheme to systematically 
rule out non-fracture deformities and diagnoses osteoporotic vertebral fractures based on endplate 
depression. The concordance across methods is currently a matter of debate.
Results This article reviews the most commonly applied standardized radiographic scoring methods 
for osteoporotic vertebral fractures, attaining an impartial perspective of benefits and limitations. It pro-
vides image examples and discusses aspects that facilitate large-scale application, such as automated 
image analysis software and different imaging investigations. It also reviews the implications of different 
fracture definitions for scientific research and clinical practice.
Conclusion Accurate standardized scoring methods for assessing osteoporotic vertebral fractures are 
crucial, considering that differences in definition will have implications for patient care and scientific 
research. Evaluation of the feasibility and concordance among methods will allow establishing their 
benefits and limitations, and most importantly, optimize their effectiveness for widespread application.
- 143 -
Ra
di
ol
og
ic
al
 sc
or
in
g 
m
et
ho
ds
 o
f o
st
eo
po
ro
tic
 v
er
te
br
al
 fr
ac
tu
re
s
3.1
INTRODUCTION
Osteoporosis is the most common metabolic bone disease and vertebral fractures are the most common 
type of osteoporotic fractures1. These fractures are associated with significant morbidity,2-7 mortality,8, 9 
and high health-care costs. Given the ageing of populations, osteoporotic vertebral fractures are likely 
to become an increasingly important health issue. The costs of osteoporotic vertebral fractures were 
estimated to be € 1.5 billion in Europe in 201010 and US$ 1.1 billion in the United States in 2005, and they 
are expected to have increased by more than 50% by 2025.11
The etiology of osteoporotic vertebral fractures is believed to be multi-factorial, influenced by genetic 
and environmental factors.12, 13 Osteoporosis is a disease characterized by low bone mass and micro-
architectural deterioration of bone tissue, leading to enhanced bone fragility and a consequent increase 
in fracture risk.14 Bone mineral density (BMD) and age are strongly predictive for most osteoporotic 
fractures, whereas other risk factors may vary according to fracture site.15 Compared with non-vertebral 
fractures, which usually occur after a fall, it has been suggested that only ~10-15% of osteoporotic ver-
tebral fractures are preceded by a fall, with many resulting from low-grade trauma apparently derived 
from insignificant everyday activities.16
Importantly, vertebral fractures are strong predictors of future osteoporotic fractures, including both 
non-vertebral and new vertebral fractures.17-20 Vertebral fractures can be relatively asymptomatic in some 
cases, still, asymptomatic vertebral fractures remain strong predictors of subsequent risk of fractures and 
fracture-associated mortality,21 reason why radiological detection may be even more valuable. In clinical 
practice, therefore, prevalent osteoporotic vertebral fractures are considered as a strong indication for 
anti-osteoporotic treatment.22 Yet, previous studies have shown that only one third of the patients with 
vertebral fractures come to clinical attention23 and that vertebral fractures are commonly underreported 
in radiological practice.24-27 The latter implies that applying standardized assessment methods of osteo-
porotic vertebral fractures might be beneficial to decrease reader subjectivity.
Currently, there is no gold standard for osteoporotic vertebral fracture diagnosis.28 Several radiological 
scoring methods for osteoporotic vertebral fractures exist, each using different criteria for diagnosing 
and grading the fracture. Such grading definitions are currently under debate. This article will review 
different scoring methods for diagnosing osteoporotic vertebral fractures by discussing the benefits 
and limitations of the most commonly applied radiographic scoring methods. We will also discuss the 
role of alternative imaging techniques for assessing these fractures. In addition, this review will illustrate 
how prevalence of osteoporotic vertebral fractures is influenced by different scoring methods. Finally, 
application of scoring methods in research and patient care will be discussed.
Vertebral fracture assessment by radiography
Radiography is the standard imaging modality used for initially assessing vertebral fractures. Usually 
separate anteroposterior and lateral projections of the thoracic and lumbar spine are acquired, some-
times supplemented by additional views focused at the thoracolumbar junction. However, in the 
scientific research setting, occasionally only lateral radiographs are obtained. Radiographic capture is 
rapid, image quality is mostly high and radiation dose is relatively low especially compared to CT. It 
is important that the spine is positioned parallel to the table to enable good assessment of vertebral 
endplates. Imperfect centering and collimation of the X-ray beam may, however, cause oblique projec-
tion and incorrect exposure, resulting in poor image quality.29 Also, because the X-ray beam is conical, 
oblique projection is worst at the film areas furthest from the center. This distortion may hinder correct 
appraisal of vertebral body shape and can in some situations wrongly suggest a biconcave shape.30 
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Because of superimposition of the overlying shoulder girdle, the upper thoracic spinal region cannot be 
clearly visualized in many cases. The iliac wings of the pelvis can also exert a similar hindrance effect on 
images of the lower lumbar spine. In addition, superposition of the ribs and pulmonary vasculature on 
the thoracic vertebrae may occasionally confound the vertebral body margins on the image.
Scoring methods
Measurements of vertebral shape
The first published standardized assessment methods use quantitative morphometry (QM), which 
entails direct measurement of vertebral body shape. With six-point morphometry, points are placed in 
the superior and inferior endplates at the anterior, middle and posterior aspects of the vertebral body. 
For example, two of the more recent and commonly applied QM scoring methods are those described 
by Eastell-Melton31 and McCloskey-Kanis32. In these methods anterior, central, and posterior vertebral 
body heights are first measured on a lateral radiograph and ratios between these heights are calculated. 
These ratios are then used to classify vertebral fractures, using cutoff values based on standard deviation 
reductions from normal-population means derived from epidemiological studies (Figure 1). Depending 
on which of the three heights are diminished, the Eastell-Melton31 method distinguishes three types of 
fractures (i.e., wedge, biconcavity, or compression) and the McCloskey-Kanis method further classifies 
the wedge type into anterior and posterior.32 Using ratios instead of absolute heights is preferable, as 
anatomical structures farther away from the film may be falsely magnified, depending on the distance 
of the X-ray tube from the subject. Also, vertebral height is partly associated by a person’s body height.31 
It is considered essential to appraise these ratios relative to population reference data, as it has been 
shown that the derived vertebral height ratios are normally (Gaussian) distributed.32 In addition, several 
of these methods relate the values to adjacent vertebra within the same individual, as each vertebra 
has a different size.33 Although QM measurements appear more objective and reproducible than visual 
methods, they are more laborious and time-consuming to acquire. This is an important consideration for 
large-scale epidemiological research as well as for its implementation in clinical practice.
Semi-quantitative (SQ) method
Currently, the most widely used standardized grading method is the visual SQ method (i.e., according to 
Genant34). It is commonly applied as a surrogate gold standard in research.35 Vertebral fractures are SQ 
graded by trained readers, who estimate the percentage of height and/or area reduction subjectively, 
without direct measurement. Vertebral deformities are graded according to shape and severity (Figure 
1). The deformity’s shape is classified on the basis of anterior height loss (i.e., wedge), middle height 
loss (i.e., biconcave), or posterior and anterior height loss (i.e., crush). Severity of vertebral deformities 
is graded according to the extent of height and area loss, as mildly deformed, moderately deformed, 
and severely deformed (Table 1). Next, a spinal fracture index (SFI) can be calculated by summing the 
individual vertebral body grades. Genant et al.34 have noted that height and area loss determined by 
morphometry alone fails to capture several other important characteristics of vertebral fracture, includ-
ing endplate deformity, buckling of cortices, lack of parallelism of endplates and loss of vertical continu-
ity of vertebral morphology.
Algorithm-based qualitative (ABQ) method
The more recent ABQ method by Jiang et al. diagnoses osteoporotic vertebral fractures on the basis of 
endplate depression, regardless of vertebral height reduction (Figure 2).36 The key assumption is that the 
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Figure 1. Six-point quantitative morphometry (QM) and semi-quantitative (SQ) method. P, posterior; C, central; A, 
anterior. (A) Normal thoracic vertebrae. (B) Mild wedge deformity of T8 and (C) severe wedge deformities of T12 and 
L1. (D) Mild wedge deformity of T6, moderate wedge deformity of T7 and moderate biconcave deformities of T8, T9 
and T10. (E) Crush deformity of L3 in an individual with confirmed history of spinal trauma; Severe vertebral body frac-
ture is seen with slight bulging of the posterior vertebral body margin. This fracture morphology is usually traumatic.
Table 1. Semi-quantitative grading of severity of vertebral fractures according to Genant.34
Fracture severity Grade
Reduction of:
Height* Area
Normal 0
Uncertain or borderline 0.5
Mild 1 20-25% 10-20%
Moderate 2 25-40% 20-40%
Severe 3 ≥40% ≥40%
*Anterior, middle, and/or posterior height
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Figure 2. Algorithm-based qualitative (ABQ) method. (A) Superior endplate depression of T11. (B) Inferior endplate 
depression of L3. (C) Superior and inferior endplate depression of L3.
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endplate is always deformed in vertebral fractures, and therefore endplate depression has perfect speci-
ficity for vertebral fracture. The fracture occurs primarily at the center of the endplate, and thus it follows 
that the endplate is centrally depressed in all types of vertebral fracture (i.e., concave, wedge, and crush). 
In addition, vertebral height may appear to be decreased as a result of oblique image projection, certain 
diseases and anatomical variants that can mimic vertebral fractures. To deal with this misclassification, 
ABQ uses a flowchart to systematically rule out non-fracture deformities by examining certain radiologi-
cal features. A skilled ABQ reader is needed to differentiate accurately between vertebral fractures and 
non-fracture deformities. If images are of poor quality, vertebral fractures with subtle endplate changes 
can easily be missed.
Non-radiographic imaging techniques
Vertebral fractures can also be detected and graded on radiological imaging investigations other than 
conventional radiography. Although developed for radiography, which remains the most commonly 
used technique for vertebral fracture assessment, the scoring methods described above can also be 
applied to other radiological techniques.
Dual-energy X-ray absorptiometry (DXA) at the lumbar spine and hip to measure BMD is a routine 
investigation in osteoporosis, because BMD constitutes one of the strongest predictors of future 
fracture.37, 38 Several studies have shown that the risk of incident vertebral fractures doubles for each 
SD reduction of lumbar spine BMD.37, 39 Note, however, that many fractures occur when BMD is in the 
osteopenic or normal range of values.37 In addition to artefacts (i.e., osteophytes, calcifications), BMD 
measurements of the lumbar spine may be falsely elevated in the presence of vertebral fractures be-
cause impacted fracture or fracture healing result in higher areal BMD.40 The World Health Organization’s 
FRAX® tool can be used to calculate the 10-year fracture risk for individual patients, using validated risk 
factors (with or without femoral neck DXA BMD).41 The clinical risk factors used in the calculation include 
age, gender, height, weight, previous low trauma fracture (including vertebral fractures), parental hip 
fracture, oral glucocorticoid therapy, rheumatoid arthritis, current smoking, alcohol consumption of 
more than 3 units per day, secondary causes of osteoporosis. In recent years, the use of densitometers 
has extended beyond BMD assessment, to identify vertebral fractures from DXA images. The so-called 
lateral densitometric vertebral fracture assessment (VFA) is gaining popularity due to the considerable 
improvement in image resolution, and is currently offering complementary and independent informa-
tion about fracture risk (Figure 3a).42 The implementation of fan-beam technology in the DXA devices 
has allowed capturing the whole spine in one image, with virtually no divergent beam issues due to 
parallax effect. Also, VFA has a low radiation dose, making it very suitable for screening in the clinical 
setting. For those more recently introduced DXA devices with a rotating C-arm, the lateral examination 
can even be done without moving the patient from the supine position used for the BMD measure-
ments. In addition, the rotating C-arm may enable three-dimensional DXA scans, allowing the direct 
measurement of geometric parameters of the vertebrae.43 It has been demonstrated that image quality 
can differ greatly between types of densitometers.44 Still, radiographs have superior spatial resolution, 
which facilitates identification of more subtle abnormalities.45
Unlike two-dimensional radiography, computed tomography (CT) and magnetic resonance imag-
ing (MRI) offer three-dimensional visualization of the vertebra (Figure 3B). In addition, CT and MRI can 
differentiate between old and recent vertebral fractures, by assessing the integrity and shape of the 
cortical margins (Figure 3c). MRI does not use ionizing radiation and can demonstrate bone marrow 
edema which distinguishes recent from old fracture (Figure 3d). The images produced by CT have a 
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Figure 3. Non-radiographic imaging modalities. (A) 
Lateral VFA shows a biconcave deformity of T12. (B) 
Three-dimensional visualization of the thoracolumbar 
spine with CT. (C) Midline sagittal CT reformation shows 
an osteoporotic vertebral fracture of L1 (arrow), in addi-
tion to degenerative changes and endplate irregularities 
at multiple levels. (D) MRI: Sagittal short tau inversion 
recovery (STIR) sequence shows endplate deformity, 
height reduction, and bone marrow edema at the T11, 
L3, and L4 levels (arrows), indicating recent osteoporotic 
vertebral fractures.
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much higher spatial resolution than those of MRI and DXA. It has been shown that sagittal reforma-
tions need to be used to demonstrate vertebral fractures on CT.21 Despite the introduction of several 
dose reduction techniques, the ionizing radiation exposure of CT is still substantial, which is a major 
disadvantage of the imaging technique, especially in the research setting.46 CT scout images may also 
be used for assessing vertebral fractures.47 Novel quantitative and high-resolution CT techniques are 
being developed to enable separate analysis of trabecular and cortical bone compartments.48, 49 High-
resolution MRI can be used to assess bone trabeculation in the extremities, but this application of MRI 
at the spine is more challenging.50 Drawbacks of MRI are, however, the long imaging time and high 
costs. Hence, MRI is usually used for other conditions that specifically require MRI, such as spinal cord 
compression and paraspinal soft tissue abnormalities.51, 52 If a malignant etiology for vertebral fracture is 
suspected, then MRI or CT have advantages over conventional radiography.53, 54
Image analysis software
Automated image analysis software packages (e.g., SpineAnalyzer®, Optasia Medical Ltd, Cheadle, 
UK55) have been developed to facilitate efficient and standardized vertebral fracture scoring of large 
datasets.56, 57 The software can handle lateral spine radiographs, VFA or CT scout films. So far, software 
packages have been dedicated to recording QM and SQ.
Instead of having to manually define vertebral contours and height, users only need to place one 
point in the center of each vertebra to define vertebral level. Next, vertebral contours are identified by 
the software using automated segmentation techniques and vertebral height is measured (Figure 4A). 
A table with percentage height loss and presence or absence of deformity per vertebral level based on 
QM and SQ is generated (Figure 4B), after which the data can be exported to a database. The data that 
can be saved include the exact coordinates of the endplates anteriorly, centrally, and posteriorly. This 
information can be valuable in the research setting, where analysis of crude vertebral heights could be 
meaningful to explore optimization of current vertebral fracture definitions. Relatively inexperienced 
users are deemed to be capable of using the software after a brief training.58 These software packages 
can be further improved by incorporating population reference data for QM and by reducing the need 
for manual adjustment of vertebral contour definition, a procedure that is still required routinely. Auto-
mated VFA packages are nowadays integrated in DXA equipment.
Differential diagnosis
There are a number of differential diagnoses that have to be considered in individuals with vertebral 
deformities.59 In the 1960s, Hurxthal described several criteria for vertebral measurements.30 Basically, 
all artefacts that can interfere with vertebral height measurement should be considered by the reader. 
Hook-shaped protuberances at the posterosuperior (called uncinate process by some) and posteroinfe-
rior borders of the vertebrae, any Schmorl’s nodes and osteophytes should be excluded from vertebral 
height measurement. Six-point morphometry alone is unable to distinguish fractures and vertebral 
deformities due to other causes. In the description of the SQ method34 several conditions that can mimic 
vertebral fracture such as scoliosis and vertebral body remodeling due to degenerative disc disease, are 
listed. Moreover, the ABQ method introduced a very comprehensive decision-making algorithm, which 
provides a guideline for systematically assessing various non-fracture deformities.35
Normal anatomical variation in the shape of individual vertebrae and of the spinal column as a 
whole should be taken into account. Viewed laterally, the spine has a natural curvature. Vertebrae in 
the mid-thoracic region are more wedge-shaped, causing a mild kyphosis. Lumbar vertebrae tend to 
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be biconcave rather than wedge-shaped, and this gives rise to a normal lordotic curve, because of 
the relatively shorter posterior height. In addition, some adults have vertebrae that have longstanding 
short anterior height in developmentally small thoracic vertebrae.35 Therefore, the normal spine shape 
must be known if SQ and ABQ readers are to avoid false-positive fracture diagnosis. Some QM methods 
Figure 4. Image analysis software (examinations with SpineAnalyzer®). (A) Automated contour detection. (B) Auto-
mated analysis of shape abnormality.
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that compare ratios to population reference data may classify short vertebral height correctly as non-
fracture. In addition, the anterior vertebral wedge angle has been shown to increase concurrently with 
age-related degenerative change. Degenerative signs include degenerative disc disease, osteophytes 
and endplate irregularities (Figure 5A). The ABQ method incorporates additional differential diagnoses 
including previous (e.g., during childhood) fractures, metabolic diseases (e.g., osteomalacia), and de-
velopmental anomalies, including anterior step deformity (depressions in the anterior portion of the 
vertebral endplate) in thoracic vertebrae, balloon disc, or cupid’s bow with deep inferior endplates in 
the lumbar vertebrae.35
A frequent condition that resembles vertebral fractures is Scheuermann’s disease. Radiographic crite-
ria of Scheuermann’s disease are a thoracic kyphosis greater than 45 degrees and at least three adjacent 
wedge-shaped vertebral bodies of 5 degrees or more.60, 61 Vertebral wedging is frequently associated 
with endplate irregularity and Schmorl’s nodes. Elongated vertebrae and disc space narrowing can 
also be found in Scheuermann’s disease (Figure 5B). This vertebral wedging may be mistaken for mild 
vertebral fractures by QM or SQ, and Schmorl’s nodes may mimic endplate depression. Occasionally, 
but most importantly, osteoporotic vertebral fractures need to be distinguished from those resulting 
from malignant etiologies, such as metastases (most commonly of primary breast, kidney, prostate, or 
lung neoplasms), multiple myeloma, or primary bone tumors.53 In the majority of osteoporotic vertebral 
fracture cases, posterior margins of vertebrae maintain a straight or concave shape whereas in malignant 
etiologies the posterior margin is often convex.
Traumatic fractures should also be distinguished from the typically low-grade trauma osteoporotic 
fractures. Posterior height loss was regarded as posterior wedge in the McCloskey-Kanis method32 and 
as crush deformity in SQ34. However, fractures involving the posterior vertebral part are typically at-
tributable to malignancy or high-energy trauma,62 rather than to low trauma, which is most common 
in osteoporosis.
Inter- and intra-observer agreement of scoring methods
Inter- and intra-observer agreement seem to vary considerably within and between scoring methods. 
However, agreement is about precision of a study and may not necessarily relate to its validity. Neverthe-
less, there are several aspects that need to be considered when comparing methods. Point-placement in 
SQ and QM is said to be somewhat subjective, and hence inclined to influence fracture discrimination. 
This is particularly pertinent in the presence of borderline deformities. Also, reproducibility of SQ and 
ABQ scoring may to some extent depend on the reader’s training and experience.34, 44, 63
Kim et al. have evaluated intra- and inter-reader agreement of a semi-automated quantitative mor-
phometry software algorithm on lateral CT scout views.58 They found intraclass correlation coefficients 
of 0.96 to 0.98 for vertebral heights; while kappa statistics were 0.59 to 0.69 for intra-reader and 0.67 for 
inter-reader agreement. Agreement for vertebral fracture classification was worse than agreement for 
height measurements. This was explained by the small variation of height measurement around fracture 
classification thresholds. Such clinically insignificant variation in height measurement can actually lead 
to two different fracture classifications in a considerable number of cases. Furthermore, kappa scores did 
not improve much even when the fracture definition was changed to include only moderate and severe 
fractures (i.e., deformity ≥25%).
Several publications have evaluated the inter- and intra-observer agreement of SQ alone and com-
pared with QM methods.34, 36, 63-65 Kappa statistics reported for SQ inter-observer agreement ranged from 
0.51 to 0.80 and from 0.76 to 0.93 for intra-observer agreement, respectively. The kappas for agreement 
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between SQ and several QM methods have been reported to be lower, ranging from 0.23 to 0.59, 
with some improvement when fracture definition included only moderate and severe fractures (i.e., 
deformity ≥25%). Obviously, the agreement between different QM methods will depend on the fracture 
threshold chosen. Recently, semi-automated QM reading using Genant’s criteria by a non-radiologist 
was compared with conventional SQ grading performed by experienced radiologists, finding a kappa 
for agreement of 0.78.66
Figure 5. Conditions that mimic vertebral fractures. (A) Degenerative changes. Very mild anterior vertebral wedging 
of two mid-thoracic vertebral bodies is seen along with mild spondylotic changes at the anterior vertebral margins. 
Note that the endplates are intact and only show mild degenerative irregularities. (B) Scheuermann’s disease. In ad-
dition to marked endplate irregularity, mild anterior wedging of multiple midthoracic vertebrae is seen, resulting in 
increased thoracic kyphosis.
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Ferrar et al. have examined inter-observer agreement for ABQ diagnosis of prevalent vertebral fracture 
in approximately 200 elderly women, finding kappa statistics of 0.74 for inter-reader agreement.63 In 
general, the ABQ method has displayed low to moderate concordance with other methods. Jiang et 
al. found kappa statistics between 0.39 and 0.64 comparing ABQ with the QM methods developed by 
Eastell-Melton and McCloskey.36 Also, ABQ has been compared with SQ observing kappa statistics of 
0.30 to 0.58.67
Influence of scoring methods on vertebral fracture prevalence and incidence
All methods assess osteoporotic vertebral fractures with different criteria, which results in different 
estimates of the prevalence of the disease.36, 68 For example, QM and SQ would not diagnose vertebral 
fractures in the case of endplate depression without reduced vertebral height (Figure 6A). Conversely, 
ABQ would not diagnose a QM-based vertebral fracture with reduced height but intact endplates (Fig-
ure 6B). In general, SQ would yield a higher number of fractures than when applying QM, asserting that 
SQ would be more sensitive particularly for the detection of mild deformities.68 However, Melton et al. 
have demonstrated that depending on the morphometric definition used, the prevalence of vertebral 
fractures ranged from 3 to 90% in their study.69 Of all the methods, the ABQ reading results in the lowest 
estimations of vertebral fracture prevalence. The question remains if the higher estimates from other 
methods are actually due to false-positive classification of non-fracture deformities.36
Research implications
Misclassification of vertebral fractures may result in non-differential information bias, leading to dilution 
of observed effects. As a consequence, true associations in studies may go undetected. This ascertain-
ment bias can occur both in case-control studies (including clinical trials investigating drug effects) and 
in observational studies. Therefore, scoring methods should procure the optimal classification of true 
vertebral fractures.
Figure 6. Discrepancy between scoring methods. (A) Vertebral fractures diagnosed with ABQ L2 and L3 based on 
endplate depression, classified as normal with QM because of normal vertebral height. (B) Vertebral fracture of T12 
diagnosed with QM, based on height reduction, classified as normal with ABQ because of intact endplates.
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Large-scale application of standardized scoring can be difficult, with purely morphometric approaches 
being laborious, while the other methods will require thorough training of observers. In very large stud-
ies, especially population-based studies with an expected low prevalence of vertebral fracture cases, a 
technician triage system may reduce the work burden of scoring thousands of radiographs.65, 68, 70 Firstly, 
trained research technicians can triage radiographs as definite vertebral fracture, uncertain fracture, or 
definite normal. Finally, an expert reader may review the difficult cases and confirm vertebral fractures. 
Also, a stepwise evaluation process combining morphometry and qualitative assessment represents a 
possible procedure to achieve a final diagnosis of vertebral osteoporosis.71
To date, there have been few large-scale comparisons of vertebral fracture assessment methods. 
We are currently applying both ABQ and software-assisted QM methods to radiographs from the Rot-
terdam Study (all image examples included in the present article originate from this study). This study 
is a prospective population-based cohort, which has been studying disease and disability in more than 
15,000 individuals aged 45 and over since 1990.72 Within the on-going research program, radiographs 
of approximately 11,000 participants are available, with a follow-up duration of maximally 15 years. An 
aim of the study is to compare the methods applied for identifying vertebral fractures. In addition, data 
on numerous outcomes and risk factors are available, including a comprehensive assessment of clinical 
fractures, BMD, and genetic determinations.
Clinical implications
It is estimated that only about one third of all vertebral fractures come to clinical attention.23 However, 
assessment of vertebral fracture status, in addition to BMD, provides practical and relevant clinical infor-
mation to aid the prediction of subsequent fracture risk.73 Symptomatic and non-symptomatic vertebral 
fractures are both associated with decreased quality of life2-7 and increased mortality risk8, 9. In the case of 
vertebral fracture, pharmacologic therapy is considered necessary to prevent the occurrence of future 
osteoporotic fractures.74 However, as all interventions have costs and potential side effects; correct 
assessment of vertebral fractures is of utmost importance. Over- and underdiagnosis can have major 
consequences, particularly at the population level. Misdiagnosis of osteoporotic vertebral fractures will 
result in under- or overtreatment of patients and subsequently unnecessary costs, increased morbidity 
and higher mortality.
Current definitions used by vertebral fracture scoring methods seem to be based on arbitrary cutoffs. 
At most, some QM methods have been established by deriving standard deviations from measurements 
in a sample of healthy individuals, but variation from the mean is not necessarily abnormal. The clas-
sifications show association with osteoporosis-related outcomes such as BMD and the risk of future 
non-vertebral and new vertebral fractures.17, 36, 65, 70, 75 Yet, from a more clinically oriented perspective the 
definition of vertebral fractures should be based on cutoffs that were defined based on their ability to 
predict relevant outcomes, such as future osteoporotic fractures. This will require the optimal combina-
tion of true- and false-positive ratios that yield the greatest expected utility for the patient at acceptable 
costs to society. For optimal appraisal of future osteoporotic fracture risk it might prove necessary to 
refine currently available vertebral fracture scoring after comprehensive comparative studies and inte-
grate more quantitative information that can be derived from imaging, for example: three-dimensional 
reconstruction of vertebral shape, BMD, measurements able to appreciate integrity of the endplates and 
microarchitecture.
In conclusion, standardized and accurate scoring methods for osteoporotic vertebral fractures are 
desirable. There are several radiological scoring methods for osteoporotic vertebral fractures, which 
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can be characterized as quantitative, qualitative, or semi-quantitative. Also, these standardized scoring 
methods can be implemented for different imaging modalities. The scoring methods each use differ-
ent definitions for the diagnosis of vertebral fracture and the classification of severity. Such differences 
have implications for patient care and scientific research. Accurate diagnosis of vertebral fractures and 
differentiation from non-fracture deformities is an important aspect that depends on the expertise of 
the reader. Future evaluation of the concordance between methods will allow establishing their benefits 
and limitations, and most importantly, optimize their effectiveness for application in clinical and research 
scenarios.
KEy POINTS
– Several scoring methods using different criteria for assessing osteoporotic vertebral fractures exist.
– Standardized osteoporotic vertebral fracture assessment should be applicable to different radiologi-
cal investigations.
– Accurate assessment of osteoporotic vertebral fractures is essential for proper patient management.
– Optimizing feasibility of scoring methods enables wide-spread use in scientific research.
– Assessment of concordance between methods is important for application in patient care.
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ABSTRACT
Vertebral fractures are often a first presentation of osteoporosis, therefore, accurate diagnosis is needed 
to identify high risk patients to prevent future fractures. Several methods for radiological assessment 
of vertebral fractures exist, but a gold standard is lacking. The aim of our study was to analyze differ-
ences in prevalences when applying two assessment methods for osteoporotic vertebral fractures in 
the population-based Rotterdam Study, an ongoing prospective cohort study. The algorithm based 
qualitative (ABQ) method mainly judges endplate integrity, while quantitative morphometry (QM) based 
methods evaluate vertebral height loss. Trained research assistants assessed lateral spine radiographs 
(T4-L4), using either ABQ or software-assisted QM (SpineAnalyzer® (SA), applies Genant’s classification). 
With ABQ, radiographs were triaged as normal, uncertain or definite fracture. Definite and uncertain ver-
tebral fractures were re-assessed by a musculoskeletal radiologist. Radiographs were assessed for 2,827 
participants aged 45-89 years. With SA, the prevalence was 18.9% (95% CI: 17.4%–20.3%), compared 
to 3.1% (95% CI: 2.5%–3.8%) with ABQ. Both methods agreed that 80.0% were normal and 1.9% had 
deformities. 16.9% were assessed as SA deformities but not ABQ fractures; 1.2% were judged fractured 
according to ABQ but not SA. With ABQ, most fractures were found at the thoraco-lumbar junction, 
lumbar (T11-L3) and mid-thoracic (T7-T9) regions. With SA, most deformities were at the middle (T7,T8) 
and lower thoracic regions (T11,T12). The distribution of deformity severity was 70.5% mild, 27.3% 
moderate, 2.3% severe. Shape of deformity was 95.2% wedge, 2.5% biconcave and 2.3% crush. Most 
ABQ fractures concerned the superior endplate. The superior endplate was more frequently affected at 
the thoraco-lumbar junction and lumbar regions (T11-L3), while more inferior endplate fractures were 
seen at the mid-thoracic spine (T7-T8). In conclusion, osteoporotic vertebral fractures prevalence rates 
differ significantly between methods. Both QM and ABQ classify a considerable number of deformities 
that were assessed as normal by the other.
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INTRODUCTION
Of all osteoporotic fractures, vertebral fractures are the most common type.1 Vertebral fractures have 
been synonymous with the diagnosis of osteoporosis since its earliest description as a metabolic bone 
disorder.2 Furthermore, osteoporotic fractures are a major health problem worldwide because of the as-
sociated morbidity3-5 and mortality6, 7. Given the ageing of populations, osteoporotic vertebral fractures 
are likely to become an en even increasingly important health issue. The costs of osteoporotic vertebral 
fractures were estimated to be € 1.5 billion in Europe in 20108 and US$ 1.1 billion in the United States in 
2005 and are expected to have increased by more than 50% by 20259.
Vertebral fractures may occur in absence of trauma or after only minimal trauma, such as bending, 
lifting or turning.1 Clinically detected vertebral fractures only concern one third of radiographically 
detected vertebral fractures.10 In other words, two thirds of vertebral fractures do not come to medical 
attention, nevertheless, these fractures are associated with back pain, functional limitations4 and mortal-
ity6 as well. These vertebral fractures can only be detected by screening imaging examinations. Vertebral 
fractures are often a first presentation of osteoporosis, therefore, accurate diagnosis is important to 
identify high risk patients to prevent future fractures. It has been shown that women with preexisting 
vertebral fractures have four times greater risk of subsequent vertebral fractures than those without prior 
fractures, with this risk increasing with the number of prior vertebral fractures.11-13 Again, it is important 
to detect these fractures, since anti-osteoporotic therapy has been proven effective in reducing the risk 
of both non-vertebral and vertebral fractures.14, 15
However, the identification of a vertebral fracture on a radiograph is complicated. Several methods 
for radiological assessment of vertebral fractures exist, but a gold standard is lacking.16 Quantitative 
morphometry (QM) based methods evaluate vertebral height loss by measuring the distance between 
points placed in the superior and inferior endplates at the anterior, middle and posterior aspects of 
the vertebral bodies. Next, ratios between these heights are calculated to classify vertebral fractures, 
using cutoff values based on standard deviation reductions from normal-population means derived 
from epidemiological studies. Alternatively, the Spine Analyzer® software package17 employs Genant’s 
classification18 to define vertebral deformities. Finally, the algorithm based qualitative (ABQ) method by 
Jiang et al.19 mainly judges endplate integrity, regardless of vertebral height reduction. The key assump-
tion is that the endplate is always deformed in vertebral fractures, and therefore endplate depression 
has perfect specificity for vertebral fracture. In addition, vertebral height may appear to be decreased as 
a result of oblique image projection, certain diseases, and anatomical variants that can mimic vertebral 
fractures.18-21 To deal with this misclassification, ABQ uses an algorithm to systematically rule out non-
fracture deformities by examining certain radiological features.
The aim of our study was to analyze differences in prevalences and fracture location between meth-
ods. We applied two methods, i.e., ABQ and SpineAnalyzer® (SA) software-assisted QM, for assessing 
vertebral fractures in the population-based Rotterdam Study, an ongoing prospective cohort study in 
elderly persons.
METHODS
The Rotterdam Study
The Rotterdam Study is a prospective population-based cohort studying the determinants of chronic 
diseases and disability in Dutch men and women. Both the objectives and the study design have been 
described previously.22 The study targets investigations on endocrine diseases like osteoporosis amongst 
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others. It includes 14,926 inhabitants aged 45 years and over of Rotterdam city’s Ommoord district in The 
Netherlands. The present report describes results obtained from the Rotterdam Study-III cohort, which 
started follow-up in 2006. In short, a baseline home interview on medical history and risk factors for 
chronic diseases and medication use was taken by trained interviewers. Subsequently, participants were 
invited to the research center for clinical examination.
Vertebral fracture assessment
X-ray examinations of the spine were obtained by a digitized Fuji FCR system (FUJIFILM Medical Sys-
tems).We applied two methods for assessment of osteoporotic vertebral fractures on the radiographs. 
Two teams of trained research assistants assessed lateral spine radiographs (T4-L4), using either ABQ or 
software-assisted QM (SpineAnalyzer®, Optasia Medical Ltd, Cheadle, UK).
Each of the assistants applied only one of the two methods. With ABQ, radiographs were triaged as 
normal, uncertain or definite fracture, according to intactness of the endplates. Definite and uncertain 
vertebral fractures were re-assessed by a musculoskeletal radiologist. Additionally, endplate fracture 
localization was recorded (superior, inferior, or both endplates fractured). SpineAnalyzer® software can 
automatically identify vertebral shape to calculate the exact heights of the vertebrae. After labeling 
the vertebrae of interest by placing thirteen points at the center of each vertebral body from L4 to T4, 
SpineAnalyzer® will place six morphometry points around each labeled vertebra, corresponding to the 
four corners of the vertebral body and the middle. The analyst can make manual adjustments to these 
six morphometry points to fine-tune their exact locations for accurate measurements. The morphom-
etry points are used to assess reductions in anterior, middle and posterior heights of the vertebrae. The 
SpineAnalyzer® software output provides a classification for deformities of shape (wedge, biconcave, 
crush) and severity (mild, moderate, severe) for deformities with a vertebral height reduction of at least 
20% according to Genant’s classification scheme for osteoporotic vertebral fractures18.
Additional measurements
During the baseline visit height and weight were measured with indoor clothing and no shoes. Body 
mass index (BMI) was calculated as weight (in kg)/height (in m2). Femoral neck and lumbar spine BMD 
were measured by dual-energy X-ray absorptiometry (DXA), using a Lunar DPX-L densitometer (Lunar 
Radiation Corporation, Madison, WI, USA)23. BMD was measured directly from mineral mass distribu-
tions24.
Statistical analysis
We compared fracture prevalences and distribution according to vertebral level for QM and ABQ. For 
QM, SpineAnalyzer® software calculates height reduction and corresponding ratios automatically. 
Height loss less than 20% is considered normal. Mild fracture (grade 1) is defined as height loss between 
≥20% and <25%, moderate fracture (grade 2) between ≥25% and <40% and severe fracture (grade 3) 
≥40%18. As some believe that most of the grade 1 or mild deformities are not osteoporotic vertebral 
fractures,21, 25, 26 we performed secondary analyses by shifting the cut-off of 20% height loss to more 
conservative thresholds. The wedge ratio is calculated by dividing anterior height by posterior height 
(hA/hP). Biconcavity is calculated by dividing mid height by posterior height (hM/hP). The calculation of 
crush fractures makes use of adjacent vertebral heights, as described before18. Agreement between the 
diagnostic approaches for the identification of prevalent vertebral fractures was analyzed using kappa 
(ĸ) statistics. The ĸ value takes into account the proportion of agreement ascribable to chance alone and 
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can range from 0 (no agreement) to 1 (complete agreement); values greater than 0.8 are considered 
satisfactory and values lower than 0.6 poor. SPSS 20 and R software were used for the analyses.
RESULTS
Radiographs were assessed for 2,827 participants (43% men) aged 45-89 years (mean 57, Figure 1). With 
SA, a prevalence of 18.9% (95% CI: 17.4%–20.3%) was found, compared to 3.1% (95% CI: 2.5%–3.8%) 
with ABQ. Of all individuals, 80.0% (N=2,261) were identifi ed as having no fractures, while 1.9% (N=55) 
were labeled as cases according to both methods. 16.9% (N=478) were assessed as having deformities 
according to SA but not ABQ; 1.2% (N=33) were judged fractured according to ABQ but not SA. The 
concordance between ABQ and SA was poor (ĸ=0.13).
Fracture distribution according to vertebral levels and shape
In Figure 2, the distribution of osteoporotic vertebral fractures per vertebral level assessed according to 
ABQ and SA is illustrated. With ABQ, most fractures were found at the thoraco-lumbar junction, lumbar 
Figure 1.  Age at baseline distribution within the Rotterdam Study-III cohort population, stratifi ed by gender.
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(T11-L3) and mid-thoracic (T7-T9) regions (illustrated separately in Supplementary Figure 1). With SA, 
most deformities were at the middle (T7,T8) and lower thoracic regions (T11,T12) (illustrated separately 
in Supplementary Figure 2). The frequencies for SA deformities’ classification of severity was 70.5% mild, 
27.3% moderate, 2.3% severe; shape of deformity was 95.2% wedge, 2.5% biconcave and 2.3% crush 
(Table 1, Supplementary Figures 3 and 4). Most ABQ fractures concerned the superior endplate (58.3% 
of all ABQ fractures), 29.6% were at the inferior endplates and 12.2% were represented by biconcave 
fractures. The superior endplate was more frequently affected at the thoraco-lumbar junction and 
lumbar regions (T11-L3), while more inferior endplate fractures were seen at the mid-thoracic spine 
(T7-T8) (Figure 3).
Figure 2.  Distribution of osteoporotic vertebral fractures per vertebral level assessed according to the algorithm-
based qualitative (ABQ) method and SpineAnalyzer® (SA) software-assisted quantitative morphometry.
Table 1. Frequencies of severity and shape of deformities assessed according to SpineAnalyzer® (SA) software-assist-
ed quantitative morphometry.
Shape
TotalWedge Biconcave Crush
Severity 20-25% 541 14 8 70.5%
25-40% 205 5 8 27.3%
>40% 15 1 2 2.3%
Total 95.2% 2.5% 2.3% 799
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Varying the cut-off  for vertebral height loss
As some believe that most of the grade 1 or mild deformities are not true osteoporotic vertebral 
fractures21, 25, 26, we tried to shift the cut-off  of 20% height loss to more conservative thresholds (Table 
2). Indeed we see an increase in the net agreement between methods, mostly because the deformi-
ties with height loss but intact endplates are now regarded as normal; but at the same time there is a 
decrease in concordance for the fractures positive for the ABQ criteria. Taken altogether, the ĸ statistic 
was optimal at a threshold of 30%. The fracture prevalence according to height cut-off s of 25% and 40%, 
respectively, is displayed by vertebral level distribution in Figure 4.
Figure 3. Distribution of osteoporotic vertebral fractures per vertebral level by aff ected superior and/or inferior end-
plates, assessed according to the algorithm-based qualitative (ABQ) method.
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Figure 4.  Distribution of osteoporotic vertebral fractures per vertebral level assessed with the algorithm-based 
qualitative (ABQ) method and SpineAnalyzer® (SA) software-assisted quantitative morphometry applying diff erent 
cut-off s for vertebral height loss to classify fractures. In SpineAnalyzer® (SA) software-assisted quantitative morphom-
etry readings, moderate fracture (grade 2) is defi ned as height loss between ≥20% and <25% and severe fracture 
(grade 3) as height loss ≥40%.
DISCUSSION
Osteoporotic vertebral fractures prevalence rates are signifi cantly diff erent when applying SpineAna-
lyzer® software-assisted QM or ABQ, because they each classify a considerable number of deformities 
that were assessed as normal by the other, resulting in poor between-method agreement statistics. In 
the current Rotterdam Study III cohort, we found that the prevalence of osteoporotic vertebral fractures 
according to QM was almost seven times higher than for ABQ in the same dataset (18.9% versus 3.1%). 
Agreement statistics improved when applying more lenient vertebral height cut-off s for QM, but this 
is most probably at the expense of sensitivity. The optimal agreement statistic was observed with a 
cut-off  of 30%, however, this agreement would still be considered poor. The fracture distribution over 
the vertebral column was bimodal for both methods in our cohort, with maxima at the mid-thoracic 
and lower thoracic regions with the thoraco-lumbar junction, where ABQ had a more evenly spread 
distribution covering the middle lumbar regions in addition. Most ABQ fractures concerned the superior 
endplate and this type of fracture occurred more frequently in the lower spinal column, while in the 
higher spinal levels fractures were more equally distributed among the superior and inferior endplates. 
When assessing QM morphometry, the far majority of deformities were classifi ed as mild wedges.
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Our study is the first to compare SpineAnalyzer® software-assisted QM and ABQ. Our vertebral fracture 
prevalence estimate for the ABQ method seems comparable to previous findings in similar popula-
tions, taking into account that we investigated a relatively younger population including both men and 
women.19, 27-29 To our knowledge, our study is the first (population-based) prevalence study conducted 
with SpineAnalyzer® software-assisted QM. We have assessed vertebral levels T4 to L4 as these are the 
most common sites for osteoporotic fractures. The bimodal fracture distribution over the vertebral col-
umn was obvious for both methods in our cohort, with maxima at the mid-thoracic and lower thoracic 
regions including the thoraco-lumbar junction. This dispersal is conform previous observations with 
other assessment methods.30, 31 However, some argue that the more pronounced mid-thoracic peak 
with QM is to a great extent due to normal anatomical variation (i.e., short vertebral height) and old 
traumatic fractures,32 which on the contrary ABQ would be able to discriminate.20, 21, 33 Ferguson et al. 
hypothesized an increased fracture risk in the aging spine for the superior endplate because of the 
observation from biomechanical studies that the superior endplate is generally thinner than the inferior 
endplate and that sacral and inferior lumbar endplates are stronger than superior lumbar endplates,34 
which we now establish by the discovery that most ABQ fractures concerned the superior endplate in 
our study.
Several comparative studies putting other combinations of assessment methods side by side have 
been reported before, but only a few have specifically evaluated SpineAnalyzer® software or ABQ. 
SpineAnalyzer® software-assisted QM reading by a non-radiologist has been found to agree pretty well 
with conventional SQ grading performed by experienced radiologists, finding a kappa for agreement 
of 0.78.35 ABQ has been compared to QM (Eastell-Melton and McCloskey definitions) finding kappa 
statistics between 0.39 and 0.64.19 Most notably, the lowest agreement found to date is between ABQ 
and Genant’s SQ methods, observing kappa statistics of 0.30 to 0.58.21 The between-method agreement 
statistics we found are even lower than these evaluative studies. SpineAnalyzer® software-assisted QM 
and ABQ seem extreme poles apart. ABQ primarily regards endplate depression regardless of vertebral 
height loss, which is the sole criterion for QM-based fractures. From previous experience we could in-
deed expect low agreement between ABQ and any method applying Genant’s criteria,21 possibly on top 
of that, more discordance originates from the lack of non-fracture deformity triage when solely applying 
SpineAnalyzer® software. This could have been further amplified because we have examined a relatively 
young and generally healthy population where we might expect more of these (mild) vertebral non-
fracture deformities.
Table 2. Concordance and discordance between SpineAnalyzer® (SA) software-assisted quantitative morphometry 
and algorithm-based qualitative (ABQ) methods readings of the same cohort on participant level.
Concordant Discordant
KappaABQ + / SA + ABQ - / SA - ABQ + / SA - ABQ - / SA +
Cut-offa
20% 55 (1.9%) 2,261 (80.0%) 33 (1.2%) 478 (16.9%) 0.13
25% 41 (1.5%) 2,587 (91.5%) 47 (1.7%) 152 (5.4%) 0.26
30% 30 (1.1%) 2,702 (95.6%) 58 (2.1%) 37 (1.3%) 0.37
35% 20 (0.7%) 2,728 (96.5%) 68 (2.4%) 11 (0.4%) 0.33
40% 12 (0.4%) 2,734 (96.7%) 76 (2.7%) 5 (0.2%) 0.22
aDifferent vertebral height loss cut-offs for SpineAnalyzer® software-assisted quantitative morphometry (QM) were 
applied and compared to the algorithm-based qualitative (ABQ) method reading.
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Nonetheless, it should be noted that agreement statistics concern precision of a study and may 
not necessarily relate to its validity. QM would not diagnose vertebral fractures in the case of endplate 
depression without reduced vertebral height, and conversely, ABQ would not diagnose a QM-based 
vertebral deformity with reduced height but intact endplates. More research is needed to clarify which 
of these discordant cases are clinically relevant and which are not at all and should for that reason be 
regarded as false-positives.
Our aim is to objectively compare radiological assessment methods for osteoporotic vertebral frac-
tures. Strengths of our study are that we systematically applied two very different assessment methods 
by two independent teams of trained readers in a very large population-based setting. This proved to 
be very labor-intensive and on top of that, extra consensus meetings, supervision by musculoskeletal 
radiologists and double readings were performed. Although radiographs were assessed by well-trained 
reader teams, it was not feasible to have all radiographs assessed by musculoskeletal radiologists. We 
are aware that more subtle fractures could have been missed. As the Rotterdam Study is deemed rep-
resentative of the general Dutch middle-aged to elderly population, we believe that our results may be 
extrapolated to other settings as well.
The semi-automated SpineAnalyzer® software-assisted QM method proved to be an excellent record-
ing tool for research purposes, providing a standardized data output.36 Surprisingly, ABQ was in our 
experience even more time-efficient, but this method requires more intensive initial training. Quantita-
tive assessment is based on morphometry alone, which may result in inclusion of deformities into the 
phenotype definition that are not truly vertebral fractures, reason why one may choose to put the term 
“deformities” instead of “fractures” for cases defined by QM. Yet, we experienced that further triage for 
both methods requires a lot of extra effort involving extra double-reading of up to thousands of par-
ticipants. Further standardization and automation of this triage procedure with clear-cut classification 
criteria would be very helpful.
Vertebral fractures are often a first presentation of osteoporosis and should be regarded as an op-
portunity to trace individuals at high risk of more future fractures and other related adverse health 
outcomes. Accurate vertebral fracture diagnosis is needed to identify these patients with high risk for 
future fractures to optimize patient management, as many effective treatment options are available.14, 15. 
Contrariwise, at times individuals without true vertebral fractures are unnecessarily treated with medica-
tion (e.g., bisphosphonates), associated with high costs and potential adverse effects.37 Improvement of 
radiological vertebral fracture definition, clearer criteria for non-fracture deformities differential diagno-
sis38 and more wide-spread and consistent application of an optimal method may improve clinical care.
In the future, our work can be extended to projects of more epidemiological nature as thousands 
of health measurements are available on the Rotterdam Study cohorts which can be correlated to the 
vertebral fracture assessments reported here.22 Precise and accurate ascertainment of osteoporotic ver-
tebral fractures seems necessary to optimize the yield of such association studies.39 We have undertaken 
meticulous phenotyping, so with some extra efforts we could expand on our ABQ differential diagnoses 
and SpineAnalyzer® morphometric raw data. For example, different cut-offs and vertebral fracture defini-
tions could be linked to various clinically relevant outcomes. Furthermore, the remaining Rotterdam 
Study cohorts, which in total will yield ~11,000 subjects aged 45 years and over, will be assessed for the 
presence of osteoporotic vertebral fractures. In addition, our measurements could serve as population 
reference data.
In conclusion, we procured an impartial comparison of osteoporotic vertebral fracture assessment 
methods in the large population-based Rotterdam Study, with extensive recording of distribution ac-
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cording to vertebral shape and severity. Osteoporotic vertebral fractures prevalence rates are significantly 
different when applying either software-assisted QM or ABQ. Both QM and ABQ identify a considerable 
number of deformities that were assessed as normal by the other. Further work is needed to reveal 
which of the discordant cases are actually clinically relevant and which are not.
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ABSTRACT
Vertebral fractures are a recognized hallmark of osteoporosis. Trabecular bone score (TBS) is a new 
technique applied to dual-energy X-ray absorptiometry (DXA) images of the lumbar spine used to as-
sess vertebral microarchitecture. We aimed to examine the association of TBS and risk of prevalent and 
incident vertebral fractures in a large population based study of Dutch elderly women. We included 
a selection of 3,128 women from the three Rotterdam Study cohorts (RS-I, RS-II RS-III) to evaluate the 
association of TBS and vertebral fractures. Cross-sectional radiographic assessments and DXA scans (GE-
Lunar Prodigy, Madison) of the lumbar spine were available for RS-I (N=258 cases, 1,152 controls), RS-II 
(62 cases, 314 controls) and RS-III (N=223 cases, 1,119 controls), while incident clinical vertebral fracture 
information was available for RS-I (N=12 cases, 950 controls) and RS-II (N=9 cases, 471controls). TBS was 
derived using the TBS iNsight software (Medimaps, Pessac). Logistic- and Cox- regression models cor-
rected for age, height and weight were used to obtain risk estimates per SD decrease in TBS for prevalent 
and incident vertebral fractures, respectively. Overall lower TBS scores were significantly associated with 
30% increased risk for prevalent vertebral fractures per SD decrease in TBS in the pooled analysis (OR 
1.30 95% CI: [1.16–1.45; P<0.001) of the RS-I (OR 1.44 95% CI: [1.24–1.67]; P=1.17x10-6), RS-II (OR 1.13 
95% CI: [0.83–1.55]; P=0.438) and RS-III (OR 1.25 95% CI: [1.07–1.47]; P=0.006) cohorts. The combined 
analysis of incident vertebral fractures in RS-I and RS-II did not show a significant association (HR 1.40 
95% CI: [0.90–2.20]; P=0.139). Adjustment for covariates including lumbar spine BMD did not modify 
the risk estimates. In conclusion, trabecular bone scores are strongly associated with prevalent vertebral 
fractures in women independent of BMD.
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INTRODUCTION
Vertebral fractures are known to be the most common osteoporotic fractures .1 Of all osteoporotic frac-
tures, vertebral fractures are the most common type.2 Osteoporotic vertebral fractures are a major health 
problem worldwide because of the associated morbidity,3-5 disability (such as back pain and functional 
limitations in mobility) and mortality6, 7. Given the ageing of populations, these fractures are likely to 
become an even increasingly important health issue. The costs of osteoporotic vertebral fractures were 
estimated to be € 1.5 billion in Europe in 20108 and US$ 1.1 billion in the United States in 2005 and are 
expected to increase by more than 50% by 20259.
Early detection and, ideally, prediction of future fractures is important for patients, since anti-
osteoporotic therapy has been proven effective in reducing the risk of both non-vertebral and vertebral 
fractures.10, 11 In clinical practice dual-energy X-ray absorptiometry (DXA) is used to diagnose osteoporo-
sis, providing accurate estimates of bone mass through the evaluation of bone mineral density (BMD). 
However, BMD is not always an accurate predictor of fracture.12 Over 50% of fractures occur in individuals 
whose BMD is above the osteoporosis threshold of a T score of -2.5.13 One reason may be that bone 
mass is not the only contributor to bone strength; BMD provides an assessment of the quantity of bone 
but does not provide information on bone quality, another important parameter underlying fracture 
susceptibility. Consequently, evaluating other bone parameters, such as bone microarchitecture, could 
significantly enhance the assessment of bone strength and fracture risk.14
The trabecular bone score (TBS) is a new type of measurement that can be applied to DXA images.15 
It is a measure of bone texture, which correlates with 3D parameters of bone microarchitecture. TBS is 
based on the measurement of the experimental variogram derived from a gray-level DXA image. TBS 
can reflect the structural condition of the bone microarchitecture as it is strongly positively correlated 
with the number and connectivity of trabeculae, and negatively correlated with the space between 
trabeculae.14 A high TBS value means that bone microarchitecture is dense, well-connected and with 
little spaces between trabeculae. Conversely, a low TBS value means that the microarchitecture of bone 
is incomplete and poorly connected with wide spaces between trabeculae.16 Bousson et al. showed 
that this new index emphasizes the failure of the BMD T score to fully capture the fragility fracture risk, 
but still, there is no sufficient evidence that a TBS measurement alone provides reliable information on 
the status of the bone microarchitecture for a given patient.17 Therefore, additional studies will have 
to be performed to assess the advantages and limitations of the TBS. It has also been demonstrated 
that TBS is relevant for the assessment of secondary osteoporosis.15, 18-22 Finally, there is some indication 
that spine TBS can predict major osteoporotic fractures independent of spine BMD. Combining the TBS 
microarchitecture index with BMD from conventional DXA has been suggested to improve fracture 
prediction16 reason why a large prospective meta-analysis is underway.
The aim of our study was to examine the association of TBS with risk for vertebral fracture in women 
from the population-based Rotterdam Study, an ongoing prospective cohort study in Dutch elderly 
individuals. We analyzed prevalent X-ray assessed vertebral fractures and incident clinical vertebral 
fractures occurring during follow-up.
METHODS
The Rotterdam Study
The Rotterdam Study is a prospective population-based cohort studying the determinants of chronic 
diseases and disability in Dutch elderly. Both the objectives and the study design have been described 
Ch
ap
te
r 3
.3
- 176 -
previously.23 The study targets investigations on endocrine diseases like osteoporosis amongst others. 
Inhabitants aged 45 years and over of the Rotterdam city’s Ommoord district in The Netherlands were 
invited to participate. Trained interviewers performed a baseline home interview on medical history 
and risk factors for chronic diseases and medication use. Subsequently, participants were invited to the 
research center for clinical examination. Our study sample comprised 3,128 women with DXA scans and 
vertebral fracture assessments. We only studied women, as at the time of measurement the TBS assess-
ments were not optimized for use in men. During the baseline visit height and weight were measured 
with indoor clothing and no shoes. Body mass index (BMI) was calculated as weight (in kg) divided by 
height (in m2).
DXA measurements of BMD and TBS
Lumbar spine BMD was measured by DXA, using a Lunar DPX-L densitometer (Lunar Radiation Corpora-
tion, Madison, WI, USA)24. BMD was measured directly from mineral mass distributions25. Additionally, 
TBS was measured in all participants with the DXA scans at the Bone Disease Unit at the University of 
Lausanne (Lausanne, Switzerland) blinded to clinical parameters and outcomes using the TBS iNsight 
software (version 1.9; Medimaps, Geneva, Switzerland). TBS was evaluated by determining the variogram 
of the trabecular bone projected image, calculated as the sum of the squared gray-level differences 
between pixels at a specific distance and angle. TBS was then calculated as the slope of the log-log 
transform of this variogram. The mean value of the individual measurements for L1–L4 represents the 
lumbar spine TBS (unit less).14 TBS scores were not calibrated and were analyzed as standardized residu-
als (mean=0, SD=1) adjusted for age, height and weight. Subjects with BMI>35 kg/m2 were not included 
in the study because TBS measurements in morbidly obese persons are not accurate.
Vertebral fracture assessment
Radiographic images of the spine were acquired using a digitized radiography system (Fuji FCR, FU-
JIFILM Medical Systems). We applied two methods for assessment of osteoporotic vertebral fractures 
on the radiographs. Trained research assistants assessed lateral spine radiographs (T4-L4) by means of 
software-assisted quantitative morphometry (QM) (SpineAnalyzer®, Optasia Medical Ltd, Cheadle, UK). 
This software can automatically identify vertebral body contour and shape to calculate the heights of 
the vertebrae. After labeling the vertebrae of interest by placing points at the center of each vertebral 
body from T4 to L4, SpineAnalyzer® will place six morphometry points around each labeled vertebra, 
corresponding to the four corners of the vertebral body and the middle. The analyst can make manual 
adjustments to these six morphometry points to fine-tune their exact locations. The morphometry 
points are then used to assess reductions in anterior, middle and posterior heights of the vertebrae. The 
SpineAnalyzer® software output provides a classification for deformities of shape (wedge, biconcave, 
crush) and severity (mild, moderate, severe). Deformities with a vertebral height reduction less than 20% 
are considered normal and vertebral fractures were defined as height loss ≥20% according to Genant’s 
classification scheme for osteoporotic vertebral fractures26. A random sample and uncertain vertebral 
fractures of in total approximately 10% were re-assessed by a musculoskeletal radiologist. Fracture events 
occurring during follow-up were obtained from computerized records of the general practitioners and 
hospital registries, which were regularly checked by research physicians who reviewed and coded the 
fracture information.13 Subjects were followed from their baseline visit until 1 January 2007 or until a first 
vertebral fracture or death occurred.
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Statistical analysis
Logistic- and Cox- regression models corrected for age, height and weight were used to obtain risk 
estimates per SD decrease in TBS for prevalent and incident vertebral fractures, respectively. The area 
under the curve for prevalent and incident vertebral fractures was determined. For this purposes we 
used SPSS software (IBM SPSS Statistics 20).
RESULTS
The characteristics of participants of the Rotterdam Study cohort included in the analysis of TBS and risk 
for vertebral fractures are shown in Table 1 by fracture case status. Both TBS and BMD mean levels were 
significantly lower in fracture cases than non-cases (P<0.001). The Pearson correlation between mean 
spine TBS and mean spine BMD was between 0.25 and 0.30 across studies (Figure 1).
Table 1. Characteristics of the participants with prevalent radiographic fracture assessments in the Rotterdam Study 
cohorts.
Prevalent radiographic vertebral fractures TOTAL
Rotterdam Study I
(RSI-4)
Rotterdam Study II
(RS II-2)
 Rotterdam Study III
(RS III-1)
Rotterdam Study I + II + III
Controls 
(N=1,152)
Cases 
(N=258)
Controls 
(N=314)
Cases
(N=62)
Controls 
(N=1,119)
Cases
(N=223)
Controls 
(N=2,669)
Cases
(N=556)
Age 74.65 (5.86) 77.54 (5.95) 66.64 (5.91) 71.48 (7.81) 56.63 (6.55) 58.78 (7.72) 65.59 (10.49) 68.94 (11.27)
Height 160.89 (6.24) 159.37 (6.47) 161.85 (5.95) 159.81 (6.49) 164.20 (6.27) 164.40 (6.07) 162.49 (6.41) 161.54 (6.75)
Weight 70.22 (10.66) 66.80 (10.52) 70.66 (10.39) 70.44 (10.21) 71.16 (10.86) 72.35 (11.59) 70.69 (10.72) 69.55 (11.24)
TBS_new 1.20 (0.11) 1.17 (0.12) 1.25 (0.11) 1.22 (0.12) 1.29 (0.11) 1.25 (0.13) 1.25 (0.12) 1.21 (0.13)
TBS_old 1.20 (0.11) 1.16 (0.12) 1.25 (0.11) 1.22 (0.12) 1.29 (0.11) 1.25 (0.13) 1.25 (0.12) 1.21 (0.13)
BMD 1.05 (0.19) 0.99 (0.18) 1.07 (0.17) 1.06 (0.18) 1.17 (0.18) 1.14 (0.19) 1.11 (0.19) 1.06 (0.20)
Mean (SD). BMD refers to mean lumbar spine bone mineral density (L1-L4). TBS refers to mean spine trabecular bone 
score (L1-L4). TBS_old denotes the trabecular bone score without and TBS_new with exclusion of fractured vertebral 
bodies.
 
Figure 1.  Scatter plot of mean spine TBS and mean spine BMD in RS cohorts.
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Radiographs were assessed for 3,128 participants of whom 543 were diagnosed with fracture resulting 
in a vertebral fracture prevalence of 17.4%. Lower TBS scores were associated with increased odds for 
prevalent vertebral fractures in RS-I (OR 1.44 95% CI: [1.24–1.67]; P=1.17x10-6), RS-II (OR 1.13 95% CI: 
[0.83–1.55]; P=0.438) and RS-III (OR 1.25 95% CI: [1.07–1.47]; P=0.006) per SD decrease. Incident clinical 
vertebral fractures occurring during follow-up (mean 3.03, SD 0.11 years) for RS-I and RS-II participants 
were available (combined sample size=1,442, 21 events). The combined analysis of incident vertebral 
fractures in RS-I and RS-II was not signifi cant (HR 1.40 95% CI: [0.90–2.20]; P=0.139). Additional adjust-
ment for lumbar spine BMD did not essentially change these risk estimates. Similarly, the sensitivity 
analyses where in case of the occurrence of a fracture at L1-L4 the TBS was calculated excluding the 
level of the fractured vertebral body yielded essentially no diff erent results. The areas under the ROC 
curves were calculated for prevalent vertebral fractures in models including age, height and weight 
(area=0.59, 95% CI: 0.56–0.62). Inclusion of LS-BMD and TBS independently in the model resulted in areas 
under the ROC curve of 0.60 (95% CI: 0.57–0.62) and 0.61 (95% CI: 0.59–0.64), respectively. The area under 
ROC curve after including both LS-BMD and TBS was 0.61 (95% CI: 0.58–0.64) (Figure 2A). For incident 
vertebral fractures, areas under the curves of the initial model were 0.65 (95% CI: 0.54–0.77); 0.66 (95% CI: 
0.55–0.76) when including LS-BMD; 0.67 (95% CI: 0.56–0.79) including TBS and 0.67 (95% CI: 0.56–0.79) 
after inclusion of both LS-BMD and TBS (Figure 2B).
 
Figure 2. Receiver operating characteristic (ROC) curve for (A) prevalent vertebral fractures and (B) incident vertebral 
fractures. Adjustments for: Model 1: age, height, weight; Model 2: bone mineral density, age, height, weight; Model 3: 
trabecular bone score, age, height, weight; Model 4: trabecular bone score, bone mineral density, age, height, weight.
DISCUSSION
This is to our knowledge the fi rst study examining the trabecular bone score (TBS) in relation to vertebral 
fracture risk cross-sectionally and prospectively across multiple cohorts. Our research revealed that 
decreases in TBS are strongly and signifi cantly associated with increased risk of vertebral fractures. Every 
SD decrease in TBS was signifi cantly associated with an increase of ~30% in risk of prevalent vertebral 
fractures, but not signifi cantly associated with increased risk for incident vertebral fractures. Further-
more, the TBS associations with vertebral fractures are independent of DXA-based lumbar spine BMD 
and their combination negligibly improves risk prediction. TBS seems a promising quantitative imaging 
parameter and might fi nd its way to fracture risk prediction and clinical care, given the fact that it can be 
easily derived from DXA scans.
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TBS was introduced in 2008 as a measure of bone texture that correlates with bone microarchitecture 
parameters, such as bone volume fraction and mean bone thickness, and together or independent of 
BMD will better predict fracture risk.27 It has been shown that the trabecular number (TbN) decreases 
in the lumbar spine with age (−3.6 % per decade between 30 and 90 years old) and that the trabecular 
separation (TbSp) increases by 4.9 % per decade for all regions of lumbar spine.28 Importantly, TBS can 
differ between two 3D microarchitectures that exhibit the same amount of bone, but different trabecu-
lar characteristics.14, 27 A high correlation has been observed between TBS from DXA and connectivity 
density (CD) from μCT, with TBS explaining about 67.2% of the variance in connectivity density.14 In our 
studies, the correlation between TBS and LS-BMD was relatively low, similar to the results described 
before.29, 30 Our results showed that TBS, as evaluated at the spine L1-L4 by DXA, can discriminate 
subjects with prevalent vertebral fractures from those without, independently of the BMD at L1–L4. 
We also showed that BMD and TBS measured at the lumbar spine have similar discrimination ability 
for the prediction of prevalent vertebral fractures, with both TBS and LS-BMD predicting slightly better 
than LS-BMD alone. For prediction of incident vertebral fractures, TBS had better discrimination ability 
than LS-BMD, and was similar to TBS and LS-BMD together. These results are in line with few studies 
showing that lower LS-TBS values were predictive of all types of fragility fractures with an effect of similar 
magnitude as that reported for LS-BMD. Yet, some of these studies showed that the addition of TBS to 
age and lumbar spine BMD adds limited information on vertebral fracture risk prediction 30, 31, which is 
in agreement with our findings. In other studies, matching vertebral fracture cases and controls on BMD 
still showed significant differences in TBS.32-34 In such scenario, the diagnostic value of combining BMD 
and TBS will be higher compared with that of BMD alone. This contention has been shown by some 
studies reporting incremental improvement in fracture prediction in postmenopausal women after 
combining the TBS trabecular texture index with BMD.16, 35 Additionally, TBS has been shown to identify 
66-70% of women with all-type of fracture who were not diagnosed with osteoporosis (T score <-2.5) 
using BMD alone.29 Despite some controversial findings across studies, our results support the state-
ment that TBS predicts vertebral fractures independently of LS-BMD. A large prospective meta-analysis 
examining this contention is now underway with the objective of scrutinizing the need of incorporating 
TBS in individual fracture risk assessment tools.36 Finally, a major advantage of the TBS and vertebral 
morphometry measurements used in our study is that their semi-automated operability and even post-
hoc use allow large-scale and efficient implementation in research and eventually in clinical practice.37, 38
Our study has some limitations. We performed a cross-sectional evaluation of the association of TBS 
and prevalent vertebral fractures. Hence, we cannot directly imply any causative association between 
reduced TBS and prevalent vertebral fracture. Nevertheless, incident vertebral fractures were also indica-
tive for the association with TBS. However, larger collections of cases are needed to assess the effect on 
fracture incidence. Further, for the analysis of prevalent fractures we cannot determine the impact of 
fracture processes occurring on the vertebral bodies where TBS is measured. Nevertheless, we expect 
this not to play a significant role as excluding the vertebral bodies with fracture from the analysis did not 
essentially change the results. Examining differences in TBS values between vertebral bodies where the 
fracture occurs and those with no fracture will provide additional insight to the observed associations.
More insight into the factors underlying vertebral fracture risk would be helpful to possibly target 
high-risk sub-groups with preventative interventions before they even fracture. In addition to conven-
tional risk factors,39 the field of genetics of osteoporotic vertebral fractures should be explored given the 
fact that heritability estimates up to 69% have been reported40. However, directly identifying genetic 
determinants contributing to the risk of vertebral fractures has proven difficult due to its heterogeneity 
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in definition, multifactorial nature and occurrence late in life.41 Most previous genetic epidemiology 
studies were aimed at the genetics of areal bone mineral density,42 unable to differentiate genetic 
determinants from bone microstructural traits even though the genetic variants associated with cortical 
and trabecular bone parameters may differ.43 Future genome-wide association studies GWAS studies 
should be performed for TBS, as analyzing a quantitative trait may prove more powerful than the clinical 
endpoint of fracture as a dichotomous outcome.
In conclusion, TBS is associated with risk for prevalent vertebral fractures independent of BMD in 
Dutch women. TBS, as evaluated from standard DXA scans directly, potentially complements BMD in 
the prediction of osteoporotic vertebral fractures. More studies, preferably of a prospective nature, are 
necessary to fully evaluate the potential role of TBS as a complementary risk factor for fracture.
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Multi-functionality of computer-
aided quantitative vertebral fracture 
morphometry analyses
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ABSTRACT
Osteoporotic vertebral fractures are an increasingly active area of research. Oftentimes assessments are 
performed by software-assisted quantitative morphometry. Here, we will discuss multifunctionality of 
these data for research purposes. A team of trained research assistants processed lateral spine radio-
graphs from the population-based Rotterdam Study with SpineAnalyzer® software (Optasia Medical Ltd, 
Cheadle, UK). Next, the raw coordinate data of the two upper corners of T5 and the two lower corners 
of T12 were extracted to calculate the Cobb’s kyphosis angle. In addition, two readers performed inde-
pendent manual measurements of the Cobb’s kyphosis angle between T5 and T12 for a sample (N=99). 
The mean kyphosis angle and its standard deviation were 53° and 10° for the SpineAnalyzer® software 
measurements and 54° and 12° by manual measurements, respectively. The Pearson’s correlation coef-
ficient was 0.65 [95% confidence interval (CI): 0.53–0.75; P=2×10–13]. There was a substantial intraclass 
correlation with a coefficient of 0.64 (95% CI: 0.51–0.74). The mean difference between methods was 
1° (95% CI: –2°–4°), with 95% limits of agreement of –20°–17° and there were no systematic biases. In 
conclusion, vertebral fracture morphometry data can be used to derive the Cobb’s kyphosis angle. Even 
more quantitative measures could be derived from the raw data, such as vertebral wedging, interverte-
bral disc space, spondylolisthesis and the lordosis angle. These measures may be of interest for research 
into musculoskeletal disorders such as osteoporosis, degenerative disease or Scheuermann’s disease. 
Large-scale studies may benefit from efficient capture of multiple quantitative measures in the spine.
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INTRODUCTION
The complaint of back pain is highly prevalent and is among the most common medical conditions.1 
These pain symptoms may impair function and movement of the spinal column, and therefore, back 
pain is one of the main reasons for healthcare expenditure around the world.2 Nevertheless, no specific 
pathology can be identified in up to 85% of patients,3 as currently employed imaging biomarkers display 
very limited correlation with symptoms1, 2, 4 and a better understanding of spine pathology is necessary.
Vertebral fractures are the most common osteoporotic fractures and represent a significant health is-
sue5 as they are associated with a loss of quality of life,6 mortality7 and a considerable financial burden8, 9.
Hyperkyphosis, i.e., excessive curvature of the spine in the sagittal (anteroposterior) plane, is associ-
ated with advanced age10 and is commonly attributed to osteoporotic vertebral fractures11. Additionally, 
the kyphosis angle is independently associated with decreased mobility, increased propensity to fall 
and mortality.12, 13 Other differential diagnoses that display wedging of vertebral bodies, i.e., structural 
changes involving loss of anterior height, are anatomical variation, degenerative changes or Scheuer-
mann’s disease.14, 15
Osteoporotic vertebral fractures are an increasingly active area of research, especially in the light of 
the aging of populations. Oftentimes the presence of spine fractures is assessed by means of software-
assisted quantitative morphometry,16 which can automatically identify vertebral body margins on digital 
radiography, dual energy X-ray absorptiometry and computed tomography. Some of these software 
packages allow saving of the quantitative spatial information, for example SpineAnalyzer® software 
(Optasia Medical Ltd, Cheadle, UK). This data could be used to derive more quantitative measures than 
osteoporotic vertebral fractures, such as vertebral wedging, dimensions of the intervertebral disc space, 
spondylolisthesis, kyphosis and lordosis. In this brief report we present an added functionality of these 
quantitative data for research purposes, illustrated by the example of the Cobb’s kyphosis angle.
METHODS
Study sample
The Rotterdam Study is a prospective population-based cohort studying the determinants of chronic 
diseases, including osteoporosis, and disability in Dutch men and women. Both the objectives and the 
study design have been described previously.17 It includes 14,926 inhabitants aged 45 years and over 
of Rotterdam city’s Ommoord district in The Netherlands. The present report describes results obtained 
from the Rotterdam Study-III cohort baseline visit, which started follow-up in 2006. The Medical Ethics 
Committee of the Erasmus University Medical Center has approved the Rotterdam Study.
Radiographic assessments
During the periodical research center visits, radiographic examinations of the spine were obtained us-
ing a digitized Fuji Computed Radiography system (FUJIFILM Medical Systems). All radiographs were 
acquired digitally according to a standardized protocol, with a focus to detector distance of 120 cm. 
A team of trained research assistants processed lateral spine radiographs (vertebral levels T4–L4) with 
SpineAnalyzer® software (Optasia Medical Ltd, Cheadle, UK).18 SpineAnalyzer® software can automatically 
identify vertebral body margins on digital radiography, determine the exact heights of the vertebrae, and 
calculate the shape and degree of height reduction. After labeling the vertebrae of interest by placing 
thirteen points at the center of each vertebral body from T4 to L4, the software will automatically outline 
each labeled vertebra with six morphometry points, corresponding to the four corners of the vertebral 
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body, as well as the mid-point of the superior and inferior endplate. The analyst can make manual adjust-
ments to these six morphometry points to fi ne-tune their exact locations for accurate measurements, 
and thereafter, the pixel coordinates of these points are saved. We extracted the raw coordinate data of 
the two upper corners of T5 and the two lower corners of T12 to calculate the Cobb’s kyphosis angle. 
For comparison, two readers (A.A.M. and S.S.) performed independent manual measurements of the 
Cobb’s kyphosis angle between T5 and T12 (Figure 1) for a sample of N=99, which had vertebral wedg-
ing at a minimum of three levels and presence of vertebral body endplate irregularities, as described 
previously.19 The analyses presented in this report concern the sample of N=99 subjects analyzed with 
both SpineAnalyzer® and the manual measurements of the Cobb’s kyphosis angle between T5 and T12.
Figure 1. Measurement of the Cobb’s kyphosis angle (α) between T5 and T12.
Statistical analysis
The Cobb’s kyphosis angle was calculated from the raw coordinates by the formula: α=β1+β2=arctan(ΔyI/
ΔxI)+arctan(ΔyII/ΔxII)=arctan[(y1–y2)/(x1–x2)]+arctan[(y3–y4)/(x3–x4)] (Figure 2). We computed the Pear-
son’s correlation coeffi  cient r and corresponding t-test statistic between the calculations derived from 
the SpineAnalyzer® software and the manual measurements for the Cobb’s kyphosis angle. In addition, 
the intraclass correlation coeffi  cient (two way mixed, consistency and agreement) with the matching 
F-test statistic was determined and classifi ed according to Landis and Koch.20 Finally, we evaluated if 
the diff erences between measurements was diff erent from 0 by a t-test and mapped the results in a 
Bland-Altman plot including calculation of the interval between the 95% limits of agreement by taking 
the mean diff erence plus and minus 2 standard deviations21 to further evaluate the agreement between 
the measurements. SPSS statistics software version 20 (IBM, Armonk, NY, USA) and R software version 
3.0.1 (R Foundation for Statistical Computing, Vienna, Austria) were used for the analyses.
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Figure 2. X-Y coordinate plot in pixels of vertebral levels T4–T12 (left panel); zoom-in focused on T5 (upper right 
panel) and zoom-in focused on T12 (bottom right panel). Calculation of the Cobb’s kyphosis angle (α) between T5 
and T12 from vertebral fracture morphometry analyses coordinates. The Cobb’s kyphosis angle (denoted as α) was 
calculated from the raw coordinates by the formula: α=β1+β2 shown in the left panel; in the upper right panel it is 
shown that β1=arctan(ΔyI/ΔxI)=arctan[(y1–y2)/(x1–x2)] and in the bottom right panel it is shown that β2=arctan(ΔyII/
ΔxII)=arctan[(y3–y4)/(x3–x4)].
RESULTS
The mean kyphosis angle between the superior endplate of T5 and the inferior endplate of T12 of the 
sample as determined by the SpineAnalyzer® software measurements was 53° with a standard deviation 
of 10° and the mean kyphosis angle by manual measurements was 54° with a standard deviation of 12°. 
The Pearson’s correlation coefficient r between the manual measurements and the calculations derived 
from the SpineAnalyzer® software was 0.65 [95% confidence interval (CI): 0.53–0.75; P=2×10–13] (Figure 3). 
There was a substantial intraclass correlation with a coefficient of 0.64 for both consistency and absolute 
agreement (95% CI: 0.51–0.74 P=5×10–13 and P=4×10–13, respectively). The mean difference between 
methods was 1° (95% CI: –2°–4°) and not different from 0 (P=0.4). The interval between the 95% limits 
of agreement was –20°–17° where approximately half the individuals (47%) showed a difference of less 
than 5° and about three quarters less than 10° between the techniques (76%). The Bland-Altman plot 
did not show systematic biases of proportional error, dependency of variation on the magnitude of 
measurements, extreme outliers, systematic under- or overestimation (Figure 4).
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Figure 3. Correlation between the manual measurements (X-axis) and the calculations derived from the SpineAna-
lyzer® software (Y-axis) of the Cobb’s kyphosis angle in degrees between T5 and T12; Pearson’s correlation coefficient 
r=0.65 [95% confidence interval (CI): 0.53–0.75; P=2×10–13].
Figure 4. Bland-Altman plot of the average of (X-axis) and the mean difference (Y-axis) of the manual measurements 
minus the calculations derived from the SpineAnalyzer® software of the Cobb’s kyphosis angle in degrees. The dashed 
lines represent the mean plus two standard deviations and the mean minus two standard deviations, respectively.
- 189 -
Co
m
pu
te
r-
ai
de
d 
qu
an
tit
at
iv
e 
ve
rt
eb
ra
l f
ra
ct
ur
e 
m
or
ph
om
et
ry
 a
na
ly
se
s
3.4
DISCUSSION
In the present study we have shown that quantitative vertebral morphometry data derived from lateral 
spine radiographs from the population-based Rotterdam Study with SpineAnalyzer® software can be 
used to calculate the Cobb’s kyphosis angle. The agreement of this method with independent manual 
measurements was substantial and there were no systematic biases.
There have been multiple publications comparing different methods for the measurement of Cobb’s 
kyphosis angle and reports of the inter-observer variation. Our results are comparable, but with some-
what lower inter-observer agreement, with the findings of previous comparative studies of other meth-
ods for kyphosis angle measurement.22-24 However, the interval between the 95% limits of agreement 
we found in our study sample was rather broad, which is an indication of how far apart measurements 
by the two methods were for most individuals and this limits clinical applicability. It has previously been 
found that measurement error is primarily due to intra-observer error rather than inter-observer error.25
There are several commercially available software packages available for vertebral quantitative mor-
phometry, of which we applied SpineAnalyzer®. A variety of custom or in-house developed software 
tools are also being used in the research community. These software algorithms do not always exploit 
automated vertebral detection, but this is not a requirement for our method to calculate Cobb’s angle. 
Even when vertebral body identification is performed manually, the calculation as presented in this 
paper is possible, provided that the exact pixel coordinates of the superior endplate of T5 and infe-
rior endplate of T12 are available. In addition to kyphosis measurement, more quantitative measures 
could be derived from the raw morphometry data, such as vertebral wedging,26, 27 intervertebral disc 
space28-30 (Figure 5) and the lordosis angle31. Several methods for the assessment of the dimensions of 
the intervertebral disc space have been proposed and comprise calculations with the measurements 
of anterior, central and posterior distances between vertebral endplate, disc diameter and disc areas;30 
in addition, inter-vertebral disc angles can be computed. Theoretically, measures of spondylolisthesis 
could be derived, although obtaining flexion-extension films might be preferable. These measures may 
be of interest to researchers investigating musculoskeletal disorders such as osteoporosis, degenerative 
disease or Scheuermann’s disease. Extending the work flow to more vertebral levels and to capture more 
detailed morphological shapes is desirable. For example, the lumbar lordosis angle is usually calculated 
between T12 and S1 or L5,31 lumbar disc degeneration is most commonly observed at L4-L5 and L5-S132 
and spondylolisthesis is most prevalent at levels L4-L5 and L5-S1 as well,33 which would in fact be the 
most interesting levels to study from the perspective of degeneration. These levels are, however, usually 
disregarded by most vertebral morphometry software packages for osteoporotic fractures, because 
these fractures are rare in the lower lumbar spine. Moreover, information on endplate fractures, Schmorl’s 
nodes and osteophytes cannot be inferred from six point morphometry data, but Spineanalyzer® offers 
additional 95 point morphometry. However, this registration of 95 points per vertebra has not been 
studied and validated comprehensively yet and extra manual adjustments of the point placements on 
the radiographs may be necessary. A limitation of morphometry analyses is that it would not be able to 
capture qualitative imaging features such as vertebral endplate irregularities and diffuse idiopatic skel-
etal hyperostosis (DISH). Shortcomings of 2-dimensional radiographical imaging in the current context 
include failure to represent soft tissues, distortion due to oblique projection of the conical X-ray beams29 
and superimposition of overlying anatomical structures like the shoulder girdle, the iliac wings of the 
pelvis, the ribs and pulmonary vasculature.
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Figure 5. Deriving parameters of vertebral wedging (upper panel, current example concerns wedging of T7) and 
intervertebral disc space height (bottom panel, current example concerns the intervertebral disc space between T10 
and T11).
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Large-scale studies may benefit from efficient capture of multiple quantitative measures in the spine. In 
the future we intend to perform large-scale epidemiological studies with these data in the Rotterdam 
Study, for example to explore the etiology and associations with health outcomes of degenerative 
changes. The etiology of these spine diseases is largely unknown. Heritability plays a significant role in 
various spine diseases with estimates ranging between ~19% and 74%.34, 35 A better understanding of 
the genetic susceptibility and epidemiological risk factors for spine diseases has the potential to identify 
underlying biological mechanisms, improve risk prediction and lead to novel disease interventions.
In conclusion, utilization of vertebral fracture morphometry data to derive the Cobb’s kyphosis 
angle is relatively reliable. Even more quantitative measures could be derived from the raw data, such 
as vertebral wedging, intervertebral disc space, spondylolisthesis and the lordosis angle, and these 
parameters may be of interest to research into different musculoskeletal disorders such as osteoporosis 
or degenerative disease. Efficient capture of multiple quantitative measures in the spine may particularly 
benefit high-throughput studies and these investigations could contribute to a deeper understanding 
of spine conditions.
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ABSTRACT
Study Design Observational population-based study.
Objective To determine the prevalence of radiographical Scheuermann’s disease in a Dutch population 
and evaluate the consistency of diagnostic criteria.
Background Scheuermann’s disease is a form of osteochondrosis characterized by increased poste-
rior rounding of the thoracic spine with structural vertebral deformity. Different expert opinion–based 
radiological criteria exist, yet these have not been validated. The prevalence in the general population 
reported ranged from 1% to 10%.
Methods Lateral spine radiographs of 2,753 Rotterdam Study participants (aged 45–89 years) were as-
sessed for Scheuermann’s disease using Sørensen and Sachs’ radiographical criteria in 2 phases. Cohen 
κ statistics were calculated for interrater agreement. Prevalence estimates were calculated and sex dif-
ferences were tested with Pearson χ2 test. We evaluated whether varying the kyphosis angle criterion 
would change the prevalence estimate.
Results A total of 677 (24.6%) individuals had endplate irregularities and 140 (5.1%) individuals had 
vertebral wedging. Abnormalities were significantly more prevalent among males (P<0.05). The inter-
rater agreement κ statistics were 78.8% for vertebral wedging and 79.4% for endplate irregularity. A total 
of 127 individuals had both criteria, of which 111 had a kyphosis angle greater than 45°, resulting in a 
prevalence of 4.0% (95% confidence interval [CI]: 3.3%–4.7%). The disease prevalence was 4.5% in males 
versus 3.6% in females, yet this difference was not statistically significant (P=0.23). Adjustment of the 
kyphosis angle criterion from 45° to 40° or 35° increased the number of cases marginally, corresponding 
to prevalence estimates not significantly different from the estimates using original criteria (4.2% [95% 
CI: 3.3%–4.7%] and 4.4% [95% CI: 3.6%–5.2%]).
Conclusion Our results revealed a prevalence of 4.0% of radiographical Scheuermann’s disease in Dutch 
individuals aged 45 years and older. Although there is no current “gold standard” for the radiographical 
definition, standardized scoring of independent features resulted in substantial interobserver agree-
ment, and different applications of diagnostic criteria did not significantly alter the classification.
Level of Evidence: 3
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INTRODUCTION
Scheuermann’s disease is a form of osteochondrosis of the spine and is characterized by increased pos-
terior rounding of the thoracic spine in association with structural deformity of the vertebral elements.1 
Previous prevalence estimates of Scheuermann’s disease vary widely, ranging between 0.4% and 10%.1-6 
Scheuermann’s disease is diagnosed on the basis of radiographical criteria, yet, there is no diagnostic 
“gold standard.” The criteria by Sørensen and Sachs are the most commonly applied7, 8 but different radio-
graphical diagnostic criteria exist.9 These different radiographical criteria include endplate irregularity, 
thoracic kyphosis greater than 35°9 or 45°,10 and at least 17, 9 or 310 adjacent wedged vertebral bodies 
each of 5° or more in magnitude1, 11 (Figure 1). Also, Schmorl’s nodes are thought to be a common but 
not obligate manifestation of Scheuermann’s disease.12 When different criteria are used inconsistently, 
the estimates of disease prevalence may differ widely and seem unreliable.
Therefore, the purpose of our study was to determine the prevalence of Scheuermann’s disease and 
its radiographical criteria in the Dutch population across sexes and to evaluate the consistency of the 
diagnostic criteria.
Figure 1.  Lateral radiograph showing Scheuermann’s disease with marked endplate irregularities and mild anterior 
wedging of multiple midthoracic vertebrae, resulting in increased thoracic kyphosis.
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METHODS
The Rotterdam Study is a prospective population-based cohort study that started in 1990 in Ommoord, 
a suburb of Rotterdam, the Netherlands. The main objective of the Rotterdam Study is to investigate 
the prevalence, incidence, and risk factors for chronic disease and disability in elderly individuals aged 
55 years and older. After approximately 1 decade, the Rotterdam Study was expanded with a younger 
cohort (RS-III), including participants aged 45 years and older living in the same suburb. A detailed 
description of the Rotterdam Study has been reported previously.13 The Medical Ethics Committee of 
the Erasmus University Medical Center has approved the Rotterdam Study.
A trained research technician obtained standing lateral radiographs of the thoracolumbar spine of 
individuals visiting the research center. All radiographs were acquired digitally according to a standard-
ized protocol, with a focus to detector distance of 120 cm (Fujifilm Medical Systems, Stamford, CT). A 
DICOM viewer was used for radiographical assessment.
To diagnose Scheuermann’s disease, the radiographical criteria of Sørensen7 and Sachs et al.8 were 
applied in 2 phases (Table 1). A.A.M. and S.S., research assistants trained by a musculoskeletal radiologist 
(E.H.G.O.), scored the radiographs. To determine the level of agreement, a randomly selected subset 
(N=154) was assessed by both readers. The musculoskeletal radiologist (E.H.G.O.) acted as a third reader 
by assessing inconclusive radiographs to resolve discrepancies. In the first phase, we triaged potential 
cases from normal radiographs on the basis of 2 criteria: vertebral wedging at a minimum of 3 levels 
and presence of vertebral body endplate irregularities. Because Schmorl’s nodes are actually focal 
indentations of the vertebral endplate,12 we scored these as endplate irregularities. We defined poten-
tial cases as those with consecutive vertebral wedging in combination with endplate irregularity. In 
the second phase, we reevaluated all these potential cases by measuring the thoracic kyphosis angle 
between thoracic vertebral levels T5 and T12. We defined a kyphosis angle of 45° or more to diagnose 
the Scheuermann’s disease cases.10 In addition, we evaluated the impact of varying the kyphosis angle 
criterion on prevalence estimation of Scheuermann’s disease by adjusting from 45° to 40° or 35°. Finally, 
we reassessed the levels of vertebral wedging and endplate irregularities in more detail. All radiographs 
fulfilling these criteria were reassessed by the other reader (A.A.M. or S.S.) to verify the diagnosis of 
Scheuermann’s disease.
Table 1. Radiographical assessment of diagnostic criteria in 2 phases.
Phases Data Type Criteria Specifications
1 Qualitative Vertebral body endplate irregularities One or more vertebral levels
Qualitative Vertebral wedging At least 3 adjacent vertebral levels 5° or more per 
vertebra
2 Quantitative Kyphosis angle Between thoracic levels T5 and T12 45° or more in 
total
Statistical analysis
Frequencies of each of the independent radiological diagnostic criteria were assessed per vertebral and 
per patient levels, and the prevalence of Scheuermann’s disease was determined in the study popula-
tion. A random subset of radiographs was scored by both readers (A.A.M. and S.S.), and Cohen κ statistics 
for interrater agreement were calculated for this sample and graded according to Landis and Koch.14 
Sex-specific and sex-combined prevalence estimates were calculated and sex differences were tested 
with Pearson χ2 test. Analyses were performed with SPSS statistics software version 20 (IBM, Armonk, NY).
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RESULTS
Lateral spine radiographs were available and assessed for 2,753 participants (mean age, 57 years; range, 
45–89 years). After triage, we identified 677 (24.6%) cases with endplate irregularities and 140 (5.1%) 
cases with vertebral wedging (Table 2). The Cohen κ statistics were 78.8% for vertebral wedging and 
79.4% for endplate irregularity. We investigated whether the occurrence of endplate irregularities and 
vertebral wedging differed between sexes. We found a higher prevalence of endplate irregularities 
among males than in females, but this difference was borderline statistically significant (P=0.06). Also, 
we observed a significantly higher prevalence of vertebral wedging among males than among females 
(P=0.02). In addition, most endplate irregularities occurred at thoracic and vertebral level 8 (Figure 2), 
and vertebral wedging was most common at the midthoracic region (Figure 3). Subsequently, 127 
participants were classified as having both endplate irregularities and vertebral wedging (Table 2). The 
frequency of having both endplate irregularity and vertebral wedging was significantly higher in males 
than in females (5.6% vs. 3.9%; P=0.04).
Table 2. Frequencies of the radiological diagnostic criteria of Scheuermann’s disease.
Variable Males (N=1,187) Females (N=1,566) Total (N=2,753) P*
Endplate irregularity 313 (26.4%) 364 (23.2%) 677 (24.6%) 0.06
Vertebral wedging 74 (6.2%) 66 (4.2%) 140 (5.1%) 0.02
Endplate irregularity + vertebral wedging 66 (5.6%) 61 (3.9%) 127 (4.6%) 0.04
Scheuermann’s disease 54 (4.5%) 57 (3.6%) 111 (4.0%) 0.23
*P value χ2 males versus females.
Figure 2. Number of endplate irregularities observed per thoracic (T) and lumbar (L) vertebral level.
Next, we measured the kyphosis angle in the 127 potential cases of Scheuermann’s disease (Table 3). A 
kyphosis angle of 45° or more was found in 111 cases (87% of the participants prioritized by the triage 
procedure), resulting in a definitive diagnosis of Scheuermann’s disease. The prevalence of Scheuer-
mann’s disease was estimated to be 4.0% (95% confidence interval [CI]: 3.3%–4.7%), with no significant 
difference across sexes (P=0.23) (Table 2).
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Figure 3. Distribution of vertebral wedging of 3 adjacent vertebrae of 5° or more per thoracic (T) region.
Table 3. Frequencies per kyphotic angle interval for potential cases.
Kyphotic angle interval Frequency %
20–25 2 1.6
25–30 1 0.8
30–35 3 2.4
35–40 6 4.7
40–45 4 3.1
45–50 27 21.3
50–55 30 23.6
55–60 31 24.4
60–65 12 9.4
65–70 3 2.4
70–75 4 3.1
75–80 2 1.6
80–85 2 1.6
Total 127 100.0
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In addition, we evaluated whether a modification of the diagnostic criteria would influence the preva-
lence estimate of Scheuermann’s disease. By adjusting the kyphosis angle criterion from 45° to 40°, we 
found that this would increase the total number of Scheuermann’s disease cases to 115, resulting in no 
essential change in prevalence of 4.2% (95% CI: 3.3%– 4.7%). Similarly, no major difference was observed 
by using a kyphosis angle cutoff of 35°, in which the prevalence was 4.4% (95% CI: 3.6%–5.2%) after just 
adding 6 additional cases.
DISCUSSION
In this first epidemiological study in the Dutch population, we found a prevalence for radiographical 
Scheuermann’s disease of 4.0%, applying the criteria defined by Sørensen and Sachs. Although no “gold 
standard” for the radiographical definition exists, standardized scoring of independent features resulted 
in substantial interobserver agreement, and different definitions of diagnostic criteria did not alter 
disease classification.
The population-based study design with radiographs of the full thoracolumbar spine and a meticu-
lous scoring system enabled us to identify radiographical Scheuermann’s disease cases without clinical 
complaints, which would have been missed by a clinical-based study. We assessed a large number of 
radiographs specifically for Scheuermann’s disease and recorded each of the diagnostic criteria sepa-
rately and in detail with high interobserver agreement.
Usually, Scheuermann’s kyphosis becomes clinically overt during growth spurt and ceases to progress 
once axial skeletal maturity is reached.15, 16 Therefore, all participants with Scheuermann’s disease should 
have displayed radiographical features at the time of our examination. Nevertheless, our study in older 
individuals could have included some false positive cases because of the coexistence of degenerative 
disease. However, the most typical features of spine degeneration are disc disease, osteophytosis, and 
facet joint osteoarthritis,17 which are not diagnostic criteria for Scheuermann’s disease. Furthermore, 
these degenerative changes occur much less commonly in the thoracic spine than in the cervical and 
lumbar regions.18 As mortality rate is unchanged in Scheuermann’s disease,6 our prevalence estimates 
may also be extrapolated to younger populations.
Different expert opinion–based criteria have been used for diagnosing Scheuermann’s disease and 
these criteria remain controversial.8 Therefore, we evaluated the effect of modifying the kyphosis angle 
criterion and found that only few more would be classified as Scheuermann’s disease cases without 
affecting the prevalence. Composite standardized assessment of independent criteria seems to result in 
sufficient diagnostic consistency.
Our prevalence of 4.0% is within the previously reported range (0.4%–10%)1-6 and highlights that ra-
diographical Scheuermann’s disease is not infrequent in the general population. Each of the diagnostic 
criteria, that is, endplate irregularities and vertebral wedging, occurred most commonly at the midtho-
racic region. The frequency of both endplate irregularities and vertebral wedging was higher in males 
than in females; however, the sex difference in the prevalence was not statistically significant, which 
could be due to the limited study power with a relatively low number of cases. Some publications have 
reported prevalences of Scheuermann’s disease to be closely similar between the sexes,19-21 whereas 
others have observed Scheuermann’s disease to be more prevalent among males than in females.22, 23
An accurate and precise diagnosis of Scheuermann’s disease is important to provide proper treatment 
and hopefully to avert disability. Although coexistence with osteoporotic vertebral fractures can occur, 
the disorders should be distinguished as disease treatment is very different.6, 11, 24, 25 Radiographical find-
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ings should be correlated with clinical symptoms that typically started at adolescent age,26 nonetheless, 
taking into account recall bias. Some patients with adult Scheuermann’s kyphosis are only moderately 
affected by the disease;20, 27 future research might elucidate why some individuals have more complaints 
than others. In addition, the condition is generally not well known among clinical practitioners, which 
may cause diagnosis of Scheuermann’s disease to be missed or delayed. The fairly high disease preva-
lence underscores that Scheuermann’s disease should not be overlooked.
CONCLUSION
In sum, our study revealed a prevalence of 4.0% of Scheuermann’s disease in the Dutch population. 
Standardized scoring of independent features resulted in substantial interobserver agreement, and dif-
ferent applications of diagnostic criteria did not alter disease classification.
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KEy POINTS
– The prevalence of radiographical Scheuermann’s disease was 4.0% in a Dutch population sample 
aged 45 years and older.
– Vertebral wedging and endplate irregularities are significantly more prevalent among males.
– Standardized scoring of independent Scheuermann’s disease radiographical features shows sub-
stantial interobserver agreement.
– Current diagnostic criteria for Scheuermann’s disease seem sufficient, as different applications on a 
population level did not significantly alter disease classification.
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ABSTRACT
Purpose Osteoporotic vertebral fractures are a major health issue and should be diagnosed accurately. 
An important radiological differential diagnosis is Scheuermann’s disease. Our aim was to evaluate how 
different radiological assessment methods perform on independently ascertained cases of radiological 
Scheuermann’s disease.
Methods Two independent groups of trained research assistants applied the algorithm based qualitative 
(ABQ) or software-assisted quantitative morphometry (QM using SpineAnalyzer® software to measure 
vertebral height ratios, shape and severity of vertebral deformities classified according to Genant). These 
methods for osteoporotic vertebral deformities were compared on cases of radiological Scheuermann’s 
disease, which were diagnosed by a third group applying the radiological criteria by Sørensen and 
Sachs. In addition, thoracic spine indexes according to Masharawi were calculated from the raw QM 
data. Complete data was available for 2,656 lateral spine radiographs (T4–L4) from the population-based 
Rotterdam Study (43% men, age 45–89), an ongoing Dutch prospective cohort study.
Results Radiographic Scheuermann’s disease was present in 4.1% (95% CI: 3.3%–4.9%; N=109) of the 
sample. Of these participants identified with radiographic Scheuermann’s disease, QM scored 65.1% 
(95% CI: 56.2%–74.1%; N=71) as having an osteoporotic vertebral deformity, while ABQ classified only 
7.3% (95% CI: 2.4%–12.2%; N=8) of the participants with radiographic Scheuermann’s disease as having 
osteoporotic vertebral fractures. The QM-based Masharawi method was unable to discern between 
osteoporotic vertebral fractures, Scheuermann’s disease and controls.
Conclusions The inability of QM to rule out non-fracture deformities explains in part the higher number 
of osteoporotic vertebral deformities misclassified when applying QM as scoring method compared to 
ABQ.
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INTRODUCTION
Osteoporotic vertebral fractures embody a clinically and publicly relevant health issue1 as they occur 
relatively frequently2 and are associated with various adverse disease outcomes.3-6 Pharmacological 
treatment options include bisphosphonates 7-10, selective estrogen receptor modulators11, 12, deno-
sumab13 and (in Europe) strontium ranelate14.
Given the favorable efficacy of anti-osteoporotic therapy, it is important to adequately and accurately 
detect these spine fractures. Unfortunately, defining and diagnosing these fractures is not that simple as 
clinical work flows are too infrequently standardized nor is there a gold standard assessment method.15
Quantitative morphometry (QM)-based methods evaluate vertebral height loss by measuring the dis-
tance between points placed in the superior and inferior endplates at the anterior, middle and posterior 
aspects of the vertebral bodies.16 Next, ratios between these heights are calculated to classify vertebral 
fractures; this process may be (semi-) automated.17 Alternatively, the algorithm based qualitative (ABQ) 
method mainly judges endplate integrity visually by an expert reader, regardless of vertebral height 
reduction.18
A number of differential diagnoses complicate the diagnosis of vertebral fractures,19, 20 among which 
Scheuermann’s disease. Scheuermann’s disease, or vertebral osteochondrosis, is a developmental defect 
of the spine giving rise to morphological changes of the thoracic vertebral column in particular.21 The 
typical presentation is a frequently painful thoracic kyphosis and functional restriction of the spine, 
acquired mostly during adolescence.22 The pathogenesis is unknown and probably there is a contribu-
tion of both genetic and environmental factors.23 Scheuermann’s disease is diagnosed on the basis of 
radiographical criteria of which the criteria by Sørensen and Sachs24, 25 are the most commonly applied. 
There is a thoracic kyphosis greater than 45° and at least three adjacent wedge-shaped vertebral bodies 
of 5° or more and endplate irregularities with possible vertebral elongation and disc space narrowing. 
Also, Schmorl’s nodes are thought to be a common but not obligate manifestation of Scheuermann’s 
disease. Although coexistence of Scheuermann’s disease with osteoporotic vertebral fractures can oc-
cur, the disorders should be distinguished as disease treatments differ.26, 27
The vertebral wedging or short vertebral height in Scheuermann’s disease may be mistaken for mild 
vertebral fractures particularly by QM-based methods for vertebral fracture assessment, and Schmorl’s 
nodes may mimic endplate depression.28 The algorithm-based qualitative (ABQ) method for osteopo-
rotic vertebral fractures has introduced a decision-making algorithm, which provides a guideline for 
systematically assessing various non-fracture deformities. Masharawi et al. introduced a QM-based 
second derivative index for distinguishing osteoporotic thoracic vertebral fractures from Scheuermann’s 
disease. The aim of our study was to formally and objectively evaluate the discriminative performance 
for osteoporotic vertebral fractures of QM and ABQ on an independently assembled Scheuermann’s 
disease case collection.
METHODS
The Rotterdam Study
The Rotterdam Study is a population-based cohort that targets the investigation of determinants 
of numerous chronic diseases and disability in Dutch men and women. The study design has been 
described in great detail by Hofman et al.29 The present report describes results obtained from the Rot-
terdam Study-III cohort. In short, all inhabitants aged 45 years and over of the Ommoord district in 
the city of Rotterdam in The Netherlands were invited to participate from 2006 onwards. A baseline 
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home interview on medical history and risk factors for chronic diseases and medication use was taken 
by trained interviewers. Subsequently, participants were invited to the research center for clinical ex-
amination, including X-ray imaging of the spine. A trained research technician obtained standing lateral 
radiographs of the thoracolumbar spine of individuals visiting the research center. All radiographs were 
acquired digitally according to a standardized protocol, with a focus to detector distance of 120 cm. The 
Medical Ethics Committee of the Erasmus University Medical Center has approved the Rotterdam Study.
Vertebral fracture assessment
Radiographic examinations of the spine were obtained by a digitized Fuji FCR system (FUJIFILM Medical 
Systems). Two separate teams of trained research assistants assessed lateral spine radiographs (Th4–L4), 
using either ABQ or software-assisted QM (SpineAnalyzer®, Optasia Medical Ltd, Cheadle, UK) for the as-
sessment of osteoporotic vertebral fractures on the complete collection of radiographs. For QM, vertebral 
bodies with height loss ≥20% were considered fractured. Finally, an additional two research assistants, 
naive to any osteoporotic vertebral fracture assessment methods, were supervised by a musculoskeletal 
radiologist in the application of the radiological criteria by Sørensen and Sachs et al.,25 as described be-
fore30. To be established as Scheuermann’s disease case, the following criteria should be met: 1) thoracic 
kyphosis greater than 45°; 2) at least three adjacent wedge-shaped vertebral bodies of 5° or more; and 
3) endplate irregularities including optionally Schmorl’s nodes (Figure 1). All radiographs satisfying these 
criteria were re-evaluated and confirmed by the second reader. All Scheuermann’s disease cases were 
selected for the analyses presented in this article. A study diagram is presented in Figure 2.
vertebral wedging  
(≥3 adjacent vertebral bodies x5˚)  
 
 
 
 
 
 
 
 
 
 
 
increased thoracic kyphosis 
 
 
endplate irregularities  
(including Schmorl’s nodes) 
 
Figure 1.  Lateral radiograph showing Scheuermann’s disease with marked endplate irregularities (arrows) and mild 
anterior wedging of multiple midthoracic vertebrae (lines), resulting in increased thoracic kyphosis (dashed arc). The 
following criteria were applied to define Scheuermann’s disease cases: 1) thoracic kyphosis greater than 45°; 2) at 
least three adjacent wedge-shaped vertebral bodies of 5° or more; and 3) endplate irregularities including optionally 
Schmorl’s nodes.
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Statistical analysis
Prevalences of Scheuermann’s disease and of osteoporotic vertebral fractures according to both ABQ 
and QM were determined in the study population. For QM, vertebral bodies with height loss ≥20% were 
considered fractured, as defined above. As some believe that most of the grade 1 or mild deformities are 
not osteoporotic vertebral fractures31-33 and that Scheuermann’s disease may present with only minor 
height reductions,27 we performed secondary analyses by shifting the cut-off of 20% height loss to a 
more conservative threshold of 25% to compare results. Four indexes for the thoracic vertebrae T6-T10 
were calculated according to Masharawi et al.: anterior height/posterior height (hA/hP, abbreviated as 
A/P); anterior height/mid height (hA/hM, A/M); mid height/posterior height (hM/hP, M/P); and a secondary 
derivate index ((hA/hM)/(hM/hP), (A/M)/(M/P)) 27. Categories were created for participants: 1) satisfying the 
diagnostic characteristics of Scheuermann’s disease; 2) meeting the definition stated by either ABQ or 
QM applying different thresholds; 3) controls which were negative for the aforementioned criteria. After 
exclusion of cases satisfying criteria for more than one subgroup, t-tests were applied to the subgroup 
analyses for the QM-based methods. SPSS statistics software version 20 (IBM, Armonk, NY, USA) and R 
software version 3.0.1 (R Foundation for Statistical Computing, Vienna, Austria) were used for the analy-
ses. Receiver operating characteristic (ROC) and area under the receiver operating characteristic curve 
(AUC) statistics were calculated with the pROC R-software package.
  Datasets 
Rotterdam Study  
lateral spine X-rays (T4-L4) 
 
SpineAnalyzer® 
Genant 
 
Algorithm-Based 
Qualitative ABQ 
 
Musculoskeletal radiologist:  
Case confirmation &  
Discuss difficult X-rays 
QM VFx 
Final Dataset 
ABQ VFx 
Final Dataset 
 
Scheuermann’s 
Sørensen&Sachs  
Scheuermann’s 
Final Dataset 
Figure 2.  Study diagram: Lateral spine radiographs were assessed from levels T4 to L4 by separate trained assistant 
teams applying the two osteoporotic vertebral fracture methods, i.e., SpineAnalyzer® software-assisted quantitative 
morphometry (QM) and the algorithm-based qualitative method (ABQ). Thirdly, independent readers performed the 
readings for Scheuermann’s disease. A musculoskeletal radiologist performed case confirmation and was available to 
discuss difficult cases. This resulted in two individual datasets for osteoporotic vertebral fractures and a third dataset 
for Scheuermann’s disease describing the same study participants.
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RESULTS
In total, 2,656 lateral spine radiographs from the Rotterdam Study were assessed with the three separate 
workflows (43% men, age 45-89 with a mean of 57 years) for the diagnostic criteria of radiographic 
Scheuermann’s disease, osteoporotic vertebral fracture deformities according to ABQ and QM. Radio-
graphic Scheuermann’s disease was present in 4.1% (95% CI: 3.3%–4.9%; N=109) of the study sample. 
Of these participants identified with radiographic Scheuermann’s disease, QM scored 65.1% (95% CI: 
56.2%–74.1%; N=71) as having an osteoporotic vertebral deformity, while ABQ classified only 7.3% (95% 
CI: 2.4%–12.2%; N=8) of the participants with radiographic Scheuermann’s disease as having osteopo-
rotic vertebral fractures (Figure 3). For both methods, exclusion of the lumbar vertebral levels resulted 
in exactly the same outcomes as stated above. For QM, the proportion of radiographic Scheuermann’s 
disease cases with at least one vertebral body with height loss of 25% or greater was 40.4% (95% CI: 
31.1–49.6%; N=44).
    
 
 
 
 
 
 
             
  
 
QM VFx 
Final Dataset 
ABQ VFx 
Final Dataset 
 
Scheuermann’s 
Final Dataset 
 
2,656 lateral spine radiographs were assessed with all  
three separate workflows (43% men, age 45-89) 
 
109 cases 
65.1% VFx 
(95%CI: 56.2%-74.1%)  
n=71 
7.3% VFx 
(95%CI: 2.4%-12.2%)  
n=8 
Figure 3.  In total, 2,656 lateral spine radiographs were assessed with the three separate workflows for the diagnostic 
criteria of radiographic Scheuermann’s disease, which yielded 109 cases. Of these participants identified with radio-
graphic Scheuermann’s disease, QM scored 65.1% (95% CI: 56.2%-74.1%; N=71) as having an osteoporotic vertebral 
deformity, while ABQ classified 7.3% (95% CI: 2.4%-12.2%; N=8) as having osteoporotic vertebral fractures.
Next, indexes for the thoracic vertebrae T6-T10 were calculated according to the methodology by 
Masharawi et al., for which results are displayed in Table 1 for the different subgroups.27 No statistical 
differences were detected in any indexes of any of the thoracic vertebrae tested between the groups 
of Scheuermann’s disease cases and QM-based osteoporotic vertebral fracture cases regardless of the 
diagnostic definition applied (Supplementary Tables 1 and 2). The best discriminative ability for distin-
guishing Scheuermann’s disease cases from QM-based osteoporotic vertebral deformities reached was 
an AUC of 0.60 for a threshold of 0.99 for the (A/M)/(M/P) derivative of vertebra T7 applied to a vertebral 
height cut-off of 20%, as displayed in Figure 4. Under those conditions, the sensitivity would be 32% 
(95% CI: 18%–47%) with a specificity of 89% (95% CI: 88%–91%). Full results and ROC curves for the dif-
ferent diagnostic definitions and respective vertebral levels are available in the Supplementary materials.
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Table 1. Vertebral body height indices: mean and standard deviations
Studied groups
Thoracic 
vertebrae
Anterior/
Posterior
Anterior/
Middle
Middle/
Posterior
(Anterior/Middle)/ 
(Middle/Posterior)
(SD) (SD) (SD) (SD)
TOTAL T6 0.91 0.99 0.92 1.08
N=2,656 (N=2,545) (0.06) (0.05) (0.04) (0.08)
T7 0.89 0.98 0.92 1.07
(N=2,632) (0.06) (0.05) (0.04) (0.08)
T8 0.89 0.97 0.92 1.06
(N=2,643) (0.06) (0.05) (0.04) (0.07)
T9 0.92 0.99 0.93 1.07
(N=2,641) (0.06) (0.05) (0.04) (0.07)
T10 0.93 1.00 0.93 1.07
(N=2,643) (0.06) (0.05) (0.04) (0.06)
Total N=13,104
Control T6 0.91 0.99 0.92 1.08
N=2,547 (N=2,438) (0.05) (0.05) (0.04) (0.08)
T7 0.90 0.98 0.92 1.07
(N=2,523) (0.05) (0.05) (0.04) (0.07)
T8 0.90 0.98 0.92 1.07
(N=2,534) (0.06) (0.05) (0.04) (0.07)
T9 0.92 0.99 0.93 1.07
(N=2,532) (0.06) (0.05) (0.04) (0.06)
T10 0.93 1.00 0.93 1.07
(N=2,534) (0.06) (0.05) (0.04) (0.06)
Total N=12,561
Scheuermann T6 0.85 0.95 0.89 1.07
N=109 (N=107) (0.08) (0.06) (0.05) (0.08)
T7 0.82 0.93 0.88 1.06
(N=109) (0.08) (0.06) (0.07) (0.22)
T8 0.81 0.92 0.88 1.05
(N=109) (0.07) (0.05) (0.05) (0.08)
T9 0.85 0.95 0.90 1.06
(N=109) (0.08) (0.06) (0.05) (0.09)
T10 0.88 0.96 0.91 1.06
(N=109) (0.08) (0.05) (0.05) (0.07)
Total N=543
Osteoporosis QM T6 0.88 0.97 0.91 1.07
N=562 (N=534) (0.08) (0.06) (0.05) (0.08)
T7 0.86 0.95 0.90 1.07
(N=558) (0.08) (0.06) (0.05) (0.11)
T8 0.86 0.95 0.90 1.06
(N=560) (0.08) (0.06) (0.05) (0.07)
T9 0.89 0.97 0.92 1.06
(N=559) (0.07) (0.06) (0.04) (0.07)
T10 0.90 0.98 0.92 1.06
(N=559) (0.07) (0.05) (0.04) (0.07)
Total N=2,770
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Table 1. Vertebral body height indices: mean and standard deviations (continued)
Studied groups
Thoracic 
vertebrae
Anterior/
Posterior
Anterior/
Middle
Middle/
Posterior
(Anterior/Middle)/ 
(Middle/Posterior)
Osteoporosis ABQ T6 0.88 0.99 0.90 1.10
N=85 (N=80) (0.08) (0.06) (0.06) (0.09)
T7 0.85 0.96 0.88 1.12
(N=83) (0.11) (0.06) (0.09) (0.23)
T8 0.87 0.97 0.90 1.08
(N=83) (0.10) (0.06) (0.07) (0.08)
T9 0.91 0.98 0.92 1.07
(N=83) (0.06) (0.05) (0.04) (0.07)
T10 0.91 0.99 0.92 1.07
(N=83) (0.08) (0.06) (0.05) (0.07)
Total N=412
Osteoporosis QM T6 0.86 0.96 0.89 1.08
N=184 (N=174) (0.10) (0.07) (0.06) (0.09)
Moderate: >25% T7 0.84 0.94 0.89 1.08
(N=183) (0.10) (0.07) (0.07) (0.17)
T8 0.84 0.94 0.89 1.07
(N=183) (0.09) (0.07) (0.06) (0.09)
T9 0.88 0.96 0.91 1.06
(N=182) (0.09) (0.06) (0.05) (0.08)
T10 0.89 0.97 0.92 1.06
(N=182) (0.08) (0.06) (0.05) (0.06)
Total N=904
Standard deviation (SD); quantitative morphometry (QM); algorithm-based qualitative method (ABQ).
Figure 4. Receiver operating characteristic (ROC) curve for the secondary derivate index of anterior height/mid 
height relative to mid height/posterior height (A/M)/(M/P) of vertebra T7 applied to a quantitative morphometry 
(QM) vertebral height cut-off of 20%.
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DISCUSSION
Our study evaluated the discriminative performance for osteoporotic vertebral fractures of QM and ABQ 
on an independently assembled Scheuermann’s disease case collection. ABQ assessed a significantly 
larger proportion of the Scheuermann’s diseases cases as non-fractures, whereas QM was less able to 
differentiate from osteoporotic vertebral fractures, even when applying a specific quantitative method 
in addition. Sensitivity analyses excluding lumbar levels showed the exact results and adapting the QM 
cut-off to a moderate level changed the results to a limited extent.
It has been put forward that the vertebral wedging in Scheuermann’s disease could easily be dif-
ferentiated from osteoporotic vertebral fractures by using the derivative of the anterior and mid height 
divided by the mid and posterior height, because the height reduction in Scheuermann’s disease would 
be less severe and follows a different morphometry.27 Unfortunately, we were unable to replicate these 
results yielding an AUC of around 0.60, which may even be an overestimation in a discovery sample, with 
sensitivities and specificities which would be unsatisfactory in a clinical setting. Regarding the less severe 
height reduction, although true in a proportion of the cases, almost half of the Scheuermann’s disease 
cases have moderate or even severe vertebral height reduction, thus simply adjusting the vertebral 
height loss criterion in QM from 20% to for instance 25% will not simply solve the problem.
Limitations of current morphometry analyses include the inability of pattern recognition and the fact 
that morphometry is not be able to capture qualitative imaging features such as vertebral endplate 
irregularities, particularly the sclerotic margins34. ABQ as a qualitative method mainly assesses central 
endplate integrity, and unlike QM, is not that much affected by non-fracture deformities with vertebral 
height loss due to other causes, because there is no minimum requirement for vertebral height loss. 
ABQ further introduced an algorithm to systematically exclude these non-fracture deformities that may 
mimic osteoporotic spine fractures. Agreement between diagnostic methods improves by identifying 
non-fracture deformities such as Scheuermann’s disease and it has been demonstrated in the MrOS 
study that 17% of the discordant cases could be attributed to Scheuermann’s disease.33 Nonetheless, 
application of qualitative assessment methods on a large-scale is still much more labor-intensive than 
semi-automated quantitative measures and requires specific training and expertise, thus automation of 
qualitative means would be desirable.16, 30
Strengths of our study are the large-scale and impartial systematic evaluation of several radiological 
methods in a population-based cohort. The mean age in our study was younger with a more narrow 
range than in the case-control study sample of Masharawi et al.27 Nonetheless, our study has some 
limitations. More variability may have been introduced because of the greater number of readers, which 
was then again necessary to ensure an unbiased evaluation according to separate work flows. Although 
radiographs were assessed by well-trained reader teams, it was not feasible to have all radiographs as-
sessed by musculoskeletal radiologists. We are aware that more subtle disease cases could have been 
misclassified, even in spite of the availability of consensus readings attended by a musculoskeletal 
radiologist.
Although we cannot exclude that radiographic Scheuermann’s disease and osteoporotic vertebral 
fractures may co-exist, general consensus is that radiographic Scheuermann’s disease and osteoporotic 
vertebral fractures are two different entities that should be diagnosed differentially.26, 27 Differentiating 
Scheuermann’s disease from osteoporotic vertebral fractures is clinically relevant, thus it is important to 
be aware of the diagnostic discrepancies high-lighted by our study.35 Precise vertebral fractures diag-
nosis is needed to identify patients with high risk for future fractures to optimize patient management, 
nonetheless, overdiagnosis will result in overtreatment with anti-osteoporotic medication as there is 
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no evidence that osteoporosis treatment would be effective in Scheuermann’s disease. Radiographic 
Scheuermann’s disease and osteoporotic vertebral fractures should be accurately diagnosed differ-
entially by standardized assessments as this supports proper osteoporosis patient management.33 An 
increased awareness of the differential diagnoses of osteoporotic vertebral fractures among health 
professions including radiologists is desirable.
Accurate distinction between different disease entities such as osteoporosis and Scheuermann’s 
disease lays at the basis of etiological investigations. For example, genetics contribute to the occurrence 
of osteoporotic vertebral fractures.36, 37 A large-scale global meta-analytical effort found evidence for 
a vertebral fracture-associated genetic marker, however, the replication phase failed to validate this 
finding, which may have been due to phenotyping issues.38 Proper case classification will not only en-
able genetic studies, but also a myriad of other epidemiological and clinical studies into osteoporotic 
vertebral fractures. In this line of thinking, the heritability estimate of Scheuermann’s disease has been 
projected highly at 74%, which could encourage further genetic epidemiological studies.39 Extensive 
radiological assessments may refine phenotyping and even enable more and better research and unlock 
new traits worth follow-up.
In conclusion, a significantly higher proportion of radiographic Scheuermann’s disease cases were 
misclassified by SpineAnalyzer® software with Genant criteria (QM) as having vertebral fractures than 
with the ABQ qualitative method. No QM-based method is yet available to adequately differentiate 
between radiographic Scheuermann’s disease and osteoporotic vertebral fractures. This diagnostic 
discrepancy is both scientifically and clinically relevant; more developments are needed in this field.
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 Chapter 3.7
CLINICAL LESSON
Osteoporotic vertebral fractures or 
Scheuermann’s disease
Breda SJ, Oei L, Oei EHG, Zillikens MC
Dutch Journal of Medicine. 2013;157(45):A6479. PMID: 24191924
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ABSTRACT
Introduction Recent osteoporotic vertebral fractures are considered as a strong indication for anti-
osteoporotic treatment because they are highly predictive of future fracture risk. There are a number 
of differential diagnoses that have to be considered in individuals with vertebral deformities, including 
Scheuermann’s disease.
Case description A 56-year-old man was incidentally diagnosed with osteoporotic vertebral fractures 
on a chest radiograph taken for heavy cough and was prescribed bisphosphonate therapy. The patient 
visited our outpatient clinic for a second opinion because of gastrointestinal complaints. Our re-evalua-
tion with a DXA scan and lateral spine radiographs resulted in the diagnosis of Scheuermann’s disease. 
His gastrointestinal complaints resolved after stopping bisphosphonates. A 42-year-old man with limb-
girdle muscular dystrophy type 2B was analyzed because of back pain. Radiographs showed height loss 
of multiple thoracic vertebrae. Yet, bone mineral density measured by DXA was high-normal and MRI 
scans were suggestive for Scheuermann’s disease. Therefore, there was no indication for osteoporosis 
medical treatment or vertebroplasty.
Conclusion A number of differential diagnoses have to be considered in individuals with vertebral 
deformities, including Scheuermann’s disease. Recognition is important to avoid unnecessary medical 
treatment, which should be reserved for patients with osteoporosis. Refined vertebral fracture defini-
tions may help improve diagnostic accuracy.
- 219 -
M
isd
ia
gn
os
is 
of
 o
st
eo
po
ro
tic
 v
er
te
br
al
 fr
ac
tu
re
s d
ue
 to
 S
ch
eu
er
m
an
n’s
 d
ise
as
e
3.7
Ladies and Gentlemen,
The diagnosis of an osteoporotic vertebral fracture may have major consequences for the patient 
since these fractures in are an important criterion in various clinical guidelines for proceeding with drug 
therapy for osteoporosis.1,2 These fractures are associated with increased morbidity and mortality and 
are important predictors of future fractures.3 An accurate and timely diagnosis of osteoporotic vertebral 
fractures is therefore crucial. A disease that can lead to falsely diagnosed osteoporotic vertebral fractures 
is Scheuermann’s disease. We illustrate this with the following two case histories.
Patient A, a 56-year-old man consulted a general practitioner in response to periodic severe cough 
without sputum. The general practitioner had made a chest radiograph, in which as secondary finding 
vertebral were reported. The patient was known to have a scoliosis. Since childhood he had no pain 
and never fractured. The family history mentioned a wrist fracture and substantial loss of height with his 
mother after age 50, but not hip fractures. There were no other risk factors for osteoporosis.
The patient was referred to the department of internal medicine of a general hospital because of the 
clinical suspicion of osteoporosis. There therapy with alendronate was started based on the working 
hypothesis of osteoporotic vertebral fractures with a possible family history of osteoporosis. He was 
also advised to limit physical exertion to prevent the risk of fractures due to falling. Several months 
later, the patient was referred on his own request by the general practitioner to the Bone Center of 
our hospital for a second opinion. He had developed gastrointestinal complaints since the initiation 
of alendronate treatment and had become insecure by the recommended physical limitations. On 
physical examination, there was a slight scoliosis and a slightly increased thoracic kyphosis. For the first 
time, we performed dual-energy X-ray absorptiometry (DXA) scanning and made new radiographs of 
the thoracolumbar spine. The DXA scan showed normal bone density with a T score of +0.0 SD in the 
lumbar spine and +0.4 SD in the left femoral neck. An X-ray examination showed a thoracic scoliosis, and 
also increased kyphosis with a Cobb’s angle of 43 degrees with concomitant anterior height loss of the 
mid-thoracic vertebrae (T7,T8 and T9) of which at least one with more than 25% anterior height loss (T8) 
(Figure 1). The lumbar lordosis was largely lost and there were Schmorl’s nodes present in the endplates 
of the lumbar spine. We diagnosed the patient with Scheuermann’s disease and advised to discontinue 
the use of alendronate, after which the gastrointestinal symptoms of the patient resolved.
Patient B, a 42-year-old man, who was known with limb-girdle muscular dystrophy type 2B since about 
twenty years, had been wheelchair bound for three years. A progressive pain in the middle of the back had 
developed gradually in the last six months, and in recent weeks this had been so severe that he awakes at 
night. The patient had no prior history of fractures. His paternal grandmother had shrunk to a very small 
height in later life and she suffered from a hip fracture around her 80th year of life. In addition to the 
immobilization, the muscular disease and the positive family history, there were no other risk factors for 
osteoporosis. The rehabilitation physician had ordered radiographs because of the severe back pain, which 
revealed vertebral deformities of T10, T11 and T12 (Figure 2). The rehabilitation doctor referred the patient 
to the Bone Center of our hospital for further analysis and treatment. The laboratory examination showed 
no evidence of secondary osteoporosis. The DXA scan unexpectedly showed a high bone density of the 
lumbar vertebrae (+ 3.4 SD) and a normal femoral neck BMD (- 0.1 SD). Because of the strong discrepancy 
between the back pain, the risk factors and vertebral deformities on the one hand, and the (high) normal 
bone density on the other hand, an MRI of the spine was performed. The findings of this MRI appeared 
to support the diagnosis of Scheuermann´s disease more than osteoporotic vertebral fractures (Figure 3). 
There was no indication of drug treatment for osteoporosis or to perform a vertebroplasty. In retrospect, 
Schmorl´s nodes were also visible on the plain radiographs, but they were not as obvious as in patient A.
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Figure 1. Lateral radiographs of the thoracic and lumbar spine in patient A, a 56-year old man. There is enhanced 
kyphosis with anterior height loss of mid-thoracic vertebrae T6-9 and Schmorl’s nodes on vertebral levels T11 to L1 
(arrows). The thoracic vertebral endplates display irregularities and degenerative osteophyte formation.
Figure 2. Lateral radiographs of patient B, a 42-year old man, of the mid-thoracic up to the high lumbar spine. There 
is presence of a wedge deformity with 28% height loss of T11 and to a lesser extent of T10 and T12, with concomitant 
spondylarthrotic changes of the thoracic spine.
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DISCUSSION
A variety of disorders with morphological changes of the vertebrae can complicate the radiologic as-
sessment of the spine.4 The diagnosis of vertebral fractures on radiographs requires particular expertise 
in interpreting all possible deformations of the vertebrae. Especially in the mid-thoracic region the differ-
ential diagnosis of wedged vertebrae is wide. In addition to osteoporotic spinal fractures, Scheuermann’s 
disease, degenerative disorders and anatomical shape variations are also associated with wedging of 
the vertebrae. For an online course about osteoporotic vertebral fractures we refer to the website of the 
International Osteoporosis Foundation (www.iofbonehealth.org/vertebral-fractureteaching-program).
Scheuermann’s disease
Scheuermann’s disease, or juvenile osteochondrosis of the spine, is a growth disorder of the spinal 
column that is accompanied by morphological changes, especially of the thoracic spine. Prevalence 
Figure 3. Sagittal T2-weighted MR image of the middle and lower thoracic spine of patient B shows the known 
anterior wedging of vertebrae T11 and to a lesser extent of T10 and T12. Also, obvious endplate irregularities at the 
levels of T9 to T12 with multiple Schmorl’s nodes (arrows), fitting Scheuermann’s disease.
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estimates vary between 0.4% and 10% and the typical presentation is a (painful) thoracic kyphosis of the 
spine, evolving in adolescence.5,6 The pathogenesis is unknown and probably consists of both genetic 
and environmental factors. Radiological diagnostic criteria for Scheuermann’s disease on spinal radio-
graphs include wedging of three or more adjacent vertebrae of each at least five degrees with possible 
presence of additional criteria such as an enhanced kyphosis angle, narrowing of the intervertebral discs, 
irregularity of the endplates and Schmorl’s nodes. Our unpublished ‘Rotterdam Study’ data revealed that 
more than 40% of the patients with Scheuermann’s disease has a vertebral body with at least 25% height 
loss. Usually conservative treatment is sufficient because symptoms often disappear when skeletal de-
velopment is complete.5 Other treatment options include posture advice and exercise, wearing a corset, 
or surgical correction of severe cases.6
Osteoporotic vertebral fractures
Osteoporotic vertebral fractures also lead to morphological changes of the spine, however unlike 
Scheuermann’s disease, osteoporosis often is a metabolic bone disease of the elderly population.3 In the 
Netherlands it has been estimated that every year more than 80,000 patients aged 50 years and older 
suffer from a fracture.1 Vertebral fractures are the most common fractures related to osteoporosis.
There are several radiological assessment methods for the determination of osteoporotic vertebral 
fractures.4 The most common method is based on quantification of height loss of the vertebral body 
according to a modification of the method by Genant, where depressions are defined as wedge (front), 
biconcave (center) or crush (posterior).7 The recent CBO guideline ‘osteoporosis and fracture prevention’ 
and the NHG guideline ‘fracture prevention’ recommend a cut-off of at least 25% vertebral height loss for 
establishing a diagnosis of osteoporotic vertebral fracture.1,2 However, in addition to the measurement of 
vertebral height loss it is also important to pay attention to other abnormalities that may fit alternative di-
agnoses such as in this case Scheuermann’s disease. According to a recently propagated algorithm-based 
qualitative (ABQ) method anterior height loss of more than 20% and even of more than 25% without the 
collapse of the endplate can also be due to anatomical variants and degenerative conditions.8
On the other hand, osteoporotic vertebral fractures are also underreported.3 It is often difficult to 
establish the diagnosis of a spinal fracture, as they often occur without prior trauma, unlike the non-
vertebral fractures, such as those of the hip or wrist. Also, many of the osteoporotic vertebral fractures 
are asymptomatic; yet even these fractures are associated with negative health outcomes.3
After diagnosis of a vertebral fracture, the risk of a new vertebral fracture is increased 12.6 times and 
the chance to sustain a hip fracture within 10 years is 22%.9 Treatment options to reduce risks consist of 
lifestyle changes, such as increased exercise and sun exposure, quitting smoking and limiting alcohol 
consumption, adequate intake of calcium and vitamin D and drug therapy. Bisphosphonates are the first 
choice of pharmacotherapy, selective estrogen receptor modulators (SERMs), strontium ranelate and 
denosumab.10 In the Netherlands, PTH-analogs are only reimbursed in postmenopausal women and 
recently also in men with elevated fracture risk who sustained one or more fractures after already having 
had two vertebral fractures, or those that cannot tolerate other medication. Again, adequate diagnosis 
of vertebral fractures is essential.
EPICRISIS
Both guidelines (according to CBO less than one year and according to NHG less than two years ago) 
consider recent vertebral fractures in people older than 50 years an indication for drug therapy, indepen-
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dent of bone mineral density (BMD).1,2 Concerning fractures of earlier date, a risk assessment according 
to a points system is advised to decide whether or not to perform DXA scanning.
In patient A vertebral fractures have been reported as a secondary finding. If these were considered 
old fractures they could have been omitted for lack of a high risk score of >4 points.1,2 Additionally, 
according to both the CBO as the NHG guidelines there was no indication for further examinations. 
Therefore, no osteoporosis drug therapy would have been required. Evidence for the recent nature of 
the fracture could be found by good history taking including if there was back pain during coughing, 
comparing with previous radiological examinations, assessment of recent loss of standing height, the 
absence of trauma in the past, or possibly by evaluation of bone marrow edema on MRI.
Before patient A came to our center, it was assumed that the vertebral deformities had occurred 
recently during coughing, and therefore, pharmacological treatment was instituted. There were no old 
radiographs available and the patient could not remember any trauma in the past. A perfectly normal 
BMD, as was later found by us, would be an argument to doubt the diagnosis of osteoporotic vertebral 
fractures and to re-examine the radiographs critically.
Despite the fact that the two guidelines advise treatment of vertebral fractures independently of 
BMD, this case shows that when in doubt about whether or not fractures are recent, a DXA scan can 
provide additional diagnostic information. This especially concerns young men without an obviously 
high risk of fractures.
Although the CBO and the NHG guidelines only apply to patients aged 50 years and over, patient B 
would have most likely been treated with medication in second care because of the suspicion of clinical 
vertebral fractures with severe back pain. In addition, there was a greatly increased risk of osteoporotic 
fractures due to the combination of complete immobilization, a muscular disease and a positive fam-
ily history. The unexpectedly high BMD was reason to doubt the diagnosis of osteoporotic vertebral 
fractures and to proceed with performing an MRI scan to further examine the vertebrae.
Ladies and Gentlemen, both in the recent CBO guideline ‘osteoporosis and fracture prevention’ as the 
NHG guideline ’fracture prevention’ great importance is rightfully attached to the presence of vertebral 
fractures due to the increased risk of associated morbidity, mortality and new fractures. It is therefore 
important that the diagnosis of vertebral deformities is correct. As is shown in the case histories here, 
one needs to be aware that also other conditions such as Scheuermann’s disease, degenerative changes 
and anatomical shape variants are associated with wedge formation of the vertebrae. Clinical distinction 
is important to avoid incorrect treatment. Therefore, there is a need for expertise in evaluating vertebral 
deformities in both the radiologist and the treating physician who is occupied with fracture preven-
tion and takes into consideration the presence of vertebral fractures. Particularly if there is a clinical 
presentation atypical for osteoporosis, such as in relatively young men, a normal BMD on DXA scanning 
can be reason to critically re-examine radiographs and perform additional investigations. In this way, un-
necessary medical treatment can be prevented. If the abnormalities on the radiographs at re-evaluation 
still do not fit a diagnosis well, it could be useful to perform new radiographs or for example do MRI 
scanning. Finally, future refinements of radiological definitions might improve diagnostic accuracy.
EXPLANATION OF TERMINOLOGy
Dual energy X-ray absorptiometry (DXA)-scan
Method to measure bone density using two bundles of X-rays of different intensities. The results are 
usually reported as a T score by which bone density measured is compared to values of a reference 
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population consisting of young, healthy women. A T score of <-1.0 is considered abnormal. Osteoporosis 
is defi ned as a T score ≤-2.5.
Cobb’s angle
The degree of kyphotic curvature. It is the angle between the top of the upper vertebrae of the curvature 
and the bottom of lower vertebra of the curvature on a lateral radiograph.
Schmorl’s nodes
Protrusion of disc cartilage into a vertebral body, which can be noticeable on radiographs.
LESSONS LEARNED
– A disease that can falsely lead to the diagnosis of osteoporotic vertebral fractures is Scheuermann’s 
disease.
– A diff erential diagnosis for radiological vertebral fractures should be considered especially if the 
clinical presentation is atypical for osteoporosis and BMD is normal.
– Incorrect diagnosis of osteoporotic vertebral fractures can result in both under- and over-treatment 
of osteoporosis.
– Particularly in the mid-thoracic region, the diff erential diagnosis of vertebral deformities is wide.
– In practice it may be diffi  cult to assess whether or not vertebral fractures have occurred recently.
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ABSTRACT
Bone mineral density (BMD) is the most widely used predictor of fracture risk. We performed the largest 
meta-analysis to date on lumbar spine and femoral neck BMD, including 17 genome-wide association 
studies and 32,961 individuals of European and East Asian ancestry. We tested the top BMD-associated 
markers for replication in 50,933 independent subjects and for association with risk of low-trauma fracture 
in 31,016 individuals with a history of fracture (cases) and 102,444 controls. We identified 56 loci (32 new) 
associated with BMD at genome-wide significance (P<5×10-8). Several of these factors cluster within the 
RANK-RANKL-OPG, mesenchymal stem cell differentiation, endochondral ossification and Wnt signaling 
pathways. However, we also discovered loci that were localized to genes not known to have a role in 
bone biology. Fourteen BMD-associated loci were also associated with fracture risk (P<5×10-4, Bonferroni 
corrected), of which six reached P<5×10-8, including at 18p11.21 (FAM210A), 7q21.3 (SLC25A13), 11q13.2 
(LRP5), 4q22.1 (MEPE), 2p16.2 (SPTBN1) and 10q21.1 (DKK1). These findings shed light on the genetic 
architecture and pathophysiological mechanisms underlying BMD variation and fracture susceptibility.
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INTRODUCTION
Osteoporosis is a disease characterized by low bone mass and micro architectural deterioration of bone 
tissue leading to increased risk of fracture. The disease accounts for approximately 1.5 million new 
fracture cases each year, representing a huge economic burden on health care systems, with annual 
costs estimated to be $17 billion in the United States alone and expected to rise 50% by the year 2025.1 
Osteoporosis is defined clinically through the measurement of BMD, which remains the single best 
predictor of fracture.2, 3
Twin and family studies have shown that 50–85% of the variance in BMD is genetically determined.4 
Osteoporotic fractures are also heritable by mechanisms that are partly independent of BMD.5 Over the 
past 5 years, genome-wide association studies (GWAS) have revo lutionized the understanding of the 
genetic architecture of common, complex diseases.6 This approach is providing key insights into the 
mechanisms of disease, with prospects for the design of effective strate gies for risk assessment and the 
development of new interventions.7
Previous GWAS have identified 24 loci that influence BMD varia tion.8-14 Whereas several variants in 
these BMD-associated loci have also been nominally associated with fracture risk,15, 16 none have shown 
robust association with genome-wide significance (P<5×10-8). We report here the results of the largest 
effort to date searching for BMD-associated loci in >80,000 subjects and testing them for association 
with fracture in >130,000 cases and controls. In addition, we employed bioinformatics tools and gene 
expression analyses to place the identi fied variants in the context of pathways relevant to bone biology.
RESULTS
This study was performed across three main stages (Figure 1): (1) the discovery of BMD loci, (2) follow-up 
replication and (3) association of the BMD-associated loci with fracture.
Figure 1.  Description of study design. Stage 1: meta-
analysis of 17 genome-wide association studies for BMD. 
Stage 2: 96 top independent SNPs (82 autosomal SNPs 
with P<5×10−6, 5 SNPs on the X chromosome and 9 
SNPs from conditional analysis) were followed up in de 
novo and in silico replication of the BMD association in 
34 studies. Stage 3: the same 96 SNPs were tested for 
association with fracture in 50 studies with de novo and 
in silico data.
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Discovery of BMD loci (stage 1)
We first performed a meta-analysis of multiple GWAS for BMD of the femoral neck (FN-BMD; N=32,961) 
and lumbar spine (LS-BMD; N=31,800 cases), including ~2.5 million genotyped or imputed auto somal 
SNPs from 17 studies of populations across North America, Europe, East Asia and Australia, with a 
variety of epidemiologi cal designs and subject characteristics (Online Methods). We also performed 
meta-analysis in men and women separately to identify sex-specific associations. The quantile-quantile 
plots of the discov ery meta-analysis showed strong (and not early) deviation of the observed statistics 
from the null distribution of no association for both BMD traits (Supplementary Figure 1). After double 
genomic con trol correction of the overall (λFN-BMD pooled=1.112; λLS-BMD pooled=1.127) and sex-stratified (λFN-BMD 
women=1.091; λFN-BMD men=1.059; λLS-BMD women=1.086; λLS-BMD men=1.061) analyses, SNPs in 34 loci surpassed 
genome-wide significance, whereas a total of 82 loci were associated at P<5×10-6 (Supplementary Figs. 
2 and 3). Thirty-eight loci were associated with FN-BMD, 25 with LS-BMD and 19 with both. The overlap 
reflects correlation between the femoral neck and lumbar spine measurements (Pearson’s correla-
tion=0.53). Of these 82 loci, 59, 18 and 5 were prioritized from analyses in the sex-combined, female and 
male sample sets, respectively (Supplementary Table 1). The meta-analysis was extended to include the 
evaluation of 76,253 markers on the X chromosome imputed across 14 of the discovery GWAS, for a total 
of 31,801 participants (Online Methods). Five loci on the X chromosome were associated at P<5×10-5, 
with four of these derived from the sex-combined analysis and one identified in the analysis of men only 
(Supplementary Table 1). We further performed genome-wide conditional analyses in all sex-combined 
stage 1 studies. Each study repeated the GWAS analysis but also adjusted for 82 SNPs representing the 
autosomal loci associated at P<5×10-6 (Online Methods). We then performed meta-analysis on these 
studies in the same way as in the primary GWAS meta-analysis. Nine loci showed at least two inde-
pendent association signals in this conditional analysis (Supplementary Figure 4 and Supplementary 
Table 2), suggesting that allelic heterogeneity underlies BMD variation. We also assessed all possible 
pairwise interactions of the 82 SNPs, but none were significant after adjusting for the number of tests 
(Supplementary Figure 5 and Supplementary Table 3). A total of 96 independent SNPs (82 autosomal 
SNPs with P<5×10-6, 9 autosomal SNPs from condi tional analysis and 5 SNPs on the X chromosome) from 
87 genomic loci were selected for further replication (Figure 1).
Follow-up replication (stage 2)
We performed de novo genotyping of these 96 SNPs and tested them for association with BMD in up 
to 50,933 additional participants from 34 studies (Online Methods). Meta-analysis of the 96 SNPs in the 
dis covery and replication studies (N=83,894) yielded 64 replicating SNPs from 56 associated loci. Of 
these loci, 32 were newly found to show asso ciation (Table 1 and Supplementary Table 4A), and 24 were 
reported previously8-14 (Supplementary Table 4b). Thirty-two SNPs did not reach genome-wide signifi-
cance after replication (Supplementary Table 4C), including 10 markers that remained associated at a 
sug gestive level. Of all the SNPs analyzed, only one (rs9533090 mapping to 13q14.11 near TNFSF11 (also 
known as RANKL)) showed a high degree of heterogeneity of effects (I2>50%) across studies, despite be-
ing the marker that associated with highest significance (P=4.82×10-68) in the fixed-effect meta-analysis 
(Supplementary Table 4B). After applying random-effects meta-analysis, this marker was still associated 
with genome-wide significance (P=3.98×10-13).
Two of the newly identified loci were discovered in the sex-stratified meta-analysis: 8q13.3 in women 
and Xp22.31 in men; however, only the association at Xp22.31 showed significant evidence for sex 
specificity, as reflected by significant heterogeneity of effects across sex strata (Phet=1.62×10-8). Yet, we 
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acknowledge that the association at 8q13.3 in women may have been driven by a lower number of men 
in the discovery and replication data sets (Table 1 and Supplementary Table 5). Furthermore, evidence 
for BMD site specificity (Phet<5×10-4) was observed in a proportion of the loci, including 6 of the 32 new 
and 4 of the 24 known loci (Table 1 and Supplementary Figure 6). Among the newly identified loci, 
2q14 (INSIG2), 12p11.22 (PTHLH) and 16q12.1 (CYLD) showed site specificity with FN-BMD, and 8q13.3 
(LACTB2), 10p11.23 (MPP7) and 10q22.3 (KCNMA1) showed site-specificity with LS-BMD.
After replication, the conditional analysis provided significant evi dence of association (P<5×10-8) in 
eight of the nine loci contain ing secondary signals (Supplementary Figure 4 and Supplementary Table 
2). Three loci had variants located less than 40 kb from the initial main signal, suggesting allelic hetero-
geneity, including at 1p31.3 (represented by rs17482952 near WLS), 6q25.1 (rs7751941 near ESR1) and 
16q12.1 (rs1564981 near CYLD). The secondary signal at 16q12.1 (rs1564981) showed a strong associa-
tion with LS-BMD, whereas the main signal in this locus (rs1566045) was only associated with FN-BMD. 
The other five secondary signals were represented by variants localized more than 180 kb from the initial 
main signal and were located in different candidate genes, including at 1p36.12 (rs7521902 near WNT4), 
7p14.1 (rs10226308 near SFRP4), 7q31.31 (rs13245690 near C7orf58), 12q13.13 (rs736825 near HOXC6) 
and 17q21.31 (rs4792909 near SOST). The secondary signal mapping to the 13q14.11 locus (rs7326472) 
did not achieve genome-wide signifi cance after replication.
Association of the BMD loci with fracture (stage 3)
We tested the 96 markers for association with fracture in 31,016 cases and 102,444 controls from 50 
studies with fracture informa tion. This collection included 5,411 cases and 21,909 controls tested in the 
BMD GWAS discovery samples, 9,187 cases and 45,057 controls tested by in silico replication and 16,418 
cases and 35,478 controls tested by de novo genotyping (Figure 1 and Online Methods). In this fracture 
meta-analysis, 14 loci were significantly associated with any type of fracture at Bonferroni-corrected 
significance (P=5×10−4), of which five were new BMD-associated loci. None of the markers showed large 
estimates of heterogeneity (Table 2, Supplementary Figure 7 and Supplementary Table 6). Markers at 
six of these loci reached P<5×10-8, including at 18p11.21 (FAM210A; also known as C18orf19), 7q21.3 
(SLC25A13), 11q13.2 (LRP5), 4q22.1 (MEPE), 2p16.2 (SPTBN1) and 10q21.1 (DKK1). The proportion of the 
overall fracture risk explained by BMD ranged between 0.09 and 0.40 across markers (Supplementary 
Table 7) and was estimated in a subset of stage 2 samples (including N=8,594 cases and 23,218 controls) 
by modeling the effect of BMD-associated SNPs on fracture risk, with and without the inclusion of BMD 
as a covariate. In general, the effect of these SNPs on BMD was larger than on fracture risk (Figure 2A), 
except for the most significantly associated locus for fracture at 18p11.21 (Figure 2B). SNPs in genes of 
the RANK-RANKL-OPG path way (TNFRSF11A, TNFSF11 and TNFRSF11B, respectively), despite being the 
strongest loci associated with BMD, were not significantly associated with fracture. All 31 BMD-associat-
ed loci that had nominal association with fracture risk (P<0.05) showed consistent direc tion (the allele 
associated with decreasing BMD was associated with increased risk of fracture). When we performed 
subgroup analyses using cleaner phenotype definitions generated by limiting subjects to those with 
clinically validated fractures and stratifying by ana tomical site (for example, non-vertebral and vertebral 
fractures), we did not identify any additional signals (Supplementary Table 8). At a nominally significant 
level (P<0.05), only 3 loci were associated with vertebral fracture, and all 14 BMD-associated loci were 
associ ated with non-vertebral fracture, although the difference in effect between fracture sites was not 
significant. Therefore, the power of our study did not benefit from improving phenotype definitions at 
the cost of lower sample size.
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Figure 2.  Association of BMD loci with fracture risk. (A) Phenotype-wide effects for the BMD loci associated with 
fracture and those that are part of the RANK-RANKL-OPG pathway. Genetic effect estimates are shown for fracture 
(blue circles), LS-BMD (yellow squares) and FN-BMD (green diamonds) for the 14 loci associated with fracture risk. 
Horizontal lines represent 95% confidence limits. Effect estimates are shown after transformation of the standardized 
mean difference (SMD) in the BMD effect to odds ratio equivalents34 (for example, a 0.02 SMD in the BMD effect cor-
responds to an OR of 1.04). Secondary signals for rs227584 and rs6426749 are marked with an asterisk and the signals 
mapping to the TNFRSF11B (also known as OPG; rs2062377), TNFRSF11A (also known as RANK; rs884205) and TNFSF11 
(also known as RANKL; rs9533090) genes are marked with a double asterisk. (B) Regional association plot for the 
18p11.21 locus showing the P value for the top SNP associated with fracture (rs4796995) together with P values from 
the BMD discovery set (stage 1) and combined with the BMD replication (stage 1+2). SNPs are plotted by position in 
a 500 kb-window of chromosome 18 against association with FN-BMD (−log10 (P value)). Estimated recombination 
rates (from HapMap) are plotted in cyan to reflect the local LD structure. SNPs surrounding the most significant SNP 
are color-coded according to LD between these markers (pairwise r2). Genes, exons and transcription direction are 
derived from the UCSC Genome Browser.
Allele risk modeling for osteoporosis and fracture
The combined effect of all significant autosomal SNPs on BMD, osteoporosis and any type of fracture 
was modeled in the Prospective Epidemiological Risk Factor (PERF) study (N=2,836), a prospective study 
in postmenopausal Danish women aged 55–86 years.17 This study represents an independent validation 
setting, as it was excluded from the overall meta-analysis for this purpose (Supplementary Note). Risk 
alleles in the score (for example, BMD-decreasing alleles) were weighted by their individual effects on 
BMD and grouped into five bins (Supplementary Table 9). The difference in mean FN-BMD between 
individuals in the highest bin of risk score (9% of the popu lation; N=244) and those in the middle bin 
(34% of the population; N=978) was −0.33 SD (Figure 3A). This analysis was based on data at 63 SNPs 
and explained 5.8% (95% confidence interval (CI): 4.0%–7.6%) of the total genetic variance in FN-BMD.
The ability of this genetic score to predict the risk for osteoporosis (defined by a T score of≤−2.5) 
and for fracture was modeled in the PERF study using the middle bin as reference (odds ratio (OR)=1). 
Women in the highest bin had 1.56 (95% CI: 1.12–2.18) increased odds for osteoporosis (Figure 3B), 
whereas women in the lowest bin were protected from osteoporosis (OR=0.38, 95% CI: 0.23–0.63). A 
model based on the 16 BMD-associated SNPs that were also associ ated with fracture risk showed that 
women in the highest bin had 1.60 (95% CI: 1.15–2.24) increased odds for fracture, whereas women 
in the lowest bin had a decreased risk for fracture (OR=0.54, 95% CI: 0.36–0.83) (Figure 3C). Despite 
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serving as robust proof of the relationship between BMD-decreasing alleles and the risk of osteoporosis 
and fracture, prediction ability was modest. Receiver operat ing characteristics (ROC) analysis showed a 
significant but relatively small discrimination ability of the genetic score alone, with an area under the 
curve (AUC) of 0.59 (95% CI: 0.56–0.62) for osteoporosis (Supplementary Figure 8). Adding this score 
to a model with age and weight alone (AUC=0.75, 95% CI: 0.73–0.77) did not substantially increase 
discrimination (AUC=0.76, 95% CI: 0.74–0.78). A similar pattern was observed for fracture discrimination, 
with AUCs of 0.57 (95% CI: 0.55–0.59) in a model with the score alone and 0.62 (95% CI: 0.60–0.64) in a 
model with age, weight and height. A model considering all 63 SNPs did not change the AUC for fracture 
risk prediction (0.57, 95% CI: 0.54–0.59).
Functional annotations and pathway analyses
For the purpose of fine mapping and identifying additional SNPs with putative functional implication 
using linkage disequilibrium (LD), a subset of nine discovery studies (FN-BMD, N=21,699; LS-BMD, 
N=20,835) used 1000 Genomes Project data (Release June 2010) to re-impute genotypes at the 
55 autosomal BMD loci (Supplementary Note). In 13 of the 55 BMD-associated loci (the SNP on the 
X chromosome was not included), we identified markers in the surrounding 1-Mb region that were 
imputed from 1000 Genomes Project data and that were more significant than the original HapMap 
signals (Supplementary Tables 10 and 11), highlighting the benefit of using a denser reference panel of 
markers. All HapMap markers in LD with variants with functional annotation and showing higher signifi-
cance in the 1000 Genomes Project meta-analysis are shown (Supplementary Table 12). In 14 of the 56 
identified BMD-associated loci, a marker from HapMap imputation was highly correlated (r2>0.8) with at 
least one putative functional variant annotated in the 1000 Genomes Project reference. Three of the 14 
BMD-associated loci that also asso ciated with fracture contained putative functional variants tagged by 
Figure 3.  Combined effect of BMD-decreasing alleles and fracture risk–increasing risk alleles modeled in the pop-
ulation-based PERF study (N=2,836 women). (A–C) Effects are shown for baseline FN-BMD standardized residuals (Z 
scores) (A), risk for osteoporosis (B) and risk for any type of fracture (C). The genetic score of each individual in (A) and 
(B) was based on the 63 SNPs showing genome-wide significant association with BMD (55 main and 8 secondary 
signals) and in (C) was based on the 16 BMD SNPs associated with fracture. Both genetic scores are weighted for rela-
tive effect sizes estimated without the PERF study. Weighted allele counts summed for each individual were divided 
by the mean effect size, making them equivalent to the percent of alleles carried by each individual, and sorted into 
five bins. Histograms show the numbers of individuals in each genetic score category (left Y-axis). Diamonds (right 
Y-axis) represent mean FN-BMD standardized levels in (A), risk estimates in the form of odds ratios and osteoporosis 
(defined as NHANES T score of ≤–2.5) in (B) and any type of fracture in (C), using the middle category as reference 
(OR=1). Vertical lines represent 95% confidence limits.
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the top SNPs of the BMD meta-analysis. These included the known rs3736228 functional marker in LRP5 
(encoding p.Ala1330Val),16, 18 the intronic marker rs3779381 within a promoter and/or regulatory region 
of WNT16 and one intronic marker (rs4305309) within a pro moter and/or regulatory region of SPTBN1.
Expression profiles at the BMD loci associated with genome-wide significance were analyzed within 
four data sets (Supplementary Note). In transiliac bone biopsies, expression of five genes correlated with 
LS-BMD and/or FN-BMD of the donors with P<0.001, includ ing PSME4 (2p16.2), DKK1 (10q21.1), MIR22HG 
(also known as C17orf91; 17p13.3), SOST (17q21.31_1) and DUSP3 (17q21.31_1) (Supplementary Table 
13). Among these loci, the SNP at DKK1 (10q21.1) was the most significantly correlated with FN-BMD 
(P=1.3×10-5) and LS-BMD (P=3.2×10-4). Variants in all these BMD-associated loci (with the exception of 
MIR22HG at 17p13.3) were also associated with fractures.
SNP expression quantitative trait locus (eQTL) analyses were per formed across diverse tissues, examin-
ing the correlation between marker alleles and transcript levels at the associated BMD loci. Fourteen 
Figure 4.  Graphic representation of GRAIL connections between SNPs and corresponding genes for the 18 SNPs, as 
determined with GRAIL P<0.01. The top ten keywords linking the genes were bone, catenin, signaling, differentiation, 
rank, osteoblast, diacylglycerol, kappab, development and osteoclast. Thicker redder lines imply stronger literature-
based connectivity. Blue and black boxes depict loci boundaries represented for each top-associated marker (outer 
circle) and for each gene in the region (inner circle).
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of the BMD-associated SNPs correlated with the expression of one or more of the nearby genes with 
P<5×10−5 and were either the strongest cis variants or were good surrogates of these for the affected 
genes (Supplementary Tables 14 and 15). The most significant BMD-associated SNP eQTL was observed 
for rs10835187[T], resulting in reduced expression of the LIN7C gene at the 11p14.1 locus (P=2.8×10-39 
in adipose tissue). Of particular interest were BMD-associated SNP cis variants at three loci that were also 
associated with fracture, including 1p36.12, 4q22.1 and 17q21.31. At 1p36.12, rs6426749[G] correlated 
with reduced WNT4 expression in fibroblasts, osteoblasts and adipose tissue; at 4q22.1, rs6532023[G] 
correlated with reduced SPP1 (encoding osteopontin) expression in adipose tissue; and, at 17q21.31, 
rs227584[A] correlated with increased C17orf65 expression in monocytes, adipose tissue, whole blood 
and lymphoblasts.
We applied the Gene Relationships Across Implicated Loci (GRAIL) text-mining algorithm19 to inves-
tigate connections between genes in the 55 autosomal BMD-associated loci. This analysis revealed 
significant (P<0.01) connections between genes in 18 of the 55 input loci (Figure 4 and Supplementary 
Table 16). The strongest connections were seen for members of three key biological pathways: the 
RANK-RANKL-OPG path way (encoded by TNFRSF11A, TNFSF11 and TNFRSF11B, respectively); mesen-
chymal stem cell differentiation (RUNX2, SP7 and SOX9); and Wnt signaling (LRP5, CTNNB1, SFRP4, WNT3, 
WNT4, WNT5B, WNT16 and AXIN1), with the ten most frequently connecting terms being bone, catenin, 
sig naling, differentiation, rank, osteoblast, diacylglycerol, kappab, development and osteoclast. To assess 
the significance of this biological gene connection enrichment, we applied GRAIL to 2,000 randomly 
matched sets of 55 SNPs (Supplementary Note) and did not observe any set with 15 or more loci with 
significantly enriched connectivity (Supplementary Figure 9), providing strong statistical evidence of the 
significant clustering of our BMD-associated loci (P<0.0005).
DISCUSSION
In this report of the largest GWAS for osteoporosis traits to date, we iden tified 32 new genomic loci, 
bringing the total number of loci robustly associated with BMD variation to 56. Furthermore, we report 
that six of these BMD-associated loci are also associated with low-trauma fractures at P<5×10-8, an asso-
ciation that has not previously been detected. In terms of other complex traits, our results indicate that 
hundreds of variants with small effects may contribute to the genetic architecture of BMD and fracture 
risk.20 Our hypothesis-free assessment of common variants of the genome provides new insights into 
biology, implicating several factors that cluster in bone-active pathways.
Our results highlight the highly polygenic nature of BMD variation and the critical role of several 
biological pathways influencing osteoporosis and fracture susceptibility (Supplementary Figure 10). In 
addi tion to the Wnt factors known to be associated with BMD (CTNNB1, SOST, LRP4, LRP5, WLS, WNT4 
and MEF2C), several of the newly discovered loci implicate additional Wnt signaling factors (includ ing 
WNT5B, WNT16, DKK1, PTHLH, SFRP4 and AXIN1). Another clearly delineated pathway is that involved in 
mesenchymal stem cell differentiation, including the newly identified RUNX2, SOX4 and SOX9 BMD-
associated loci along with the previously known SP7. Another bone-relevant pathway includes that of 
endochondral ossification, which involves essential processes during fetal development of the mam-
malian skeleton and in which several of our identified BMD-associated loci are implicated, including 
SPP1, MEF2C, RUNX2, SOX6, PTHLH, SP7 and SOX9. In addition, the biological relevance of our associations 
is accentuated by the identification of genes underlying rare monogenetic forms of osteoporosis and/
or high bone mass, such as SOST, CLCN7 and LRP521-23 (Supplementary Table 17), which also contain 
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common variants involved in normal BMD variation at the population level11,14,16. This is supportive of 
a genetic architecture where both com mon and rare genetic variation may reside in the same locus.24 
Other genes have not been reported to be associated with monogenic forms of osteoporosis but have 
clear involvement in bone development in animal models. For example, SNPs in the BMD-associated 
locus at 16q12.1 map near CYLD. Human mutations in this gene have been described to cause familial 
cylindromatosis, a condition without phenotypic skeletal manifestations. However, it has been shown 
that Cyld knockout mice have significant bone loss, leading to a severe osteoporosis phenotype25 and 
also that CYLD regulates osteoclastogenesis26. Moreover, evidence from the GWAS and eQTL analyses 
also suggests that some loci contain more than one common variant with independent effects on BMD 
and fracture risk. On the other hand, when no correlation is observed between gene expression and a 
particular SNP, it is difficult to draw conclusions. A correlation might be missed if the expression of the 
transcript was not measured in a relevant tissue or if the expression of a particular splice variant was not 
measured.27
BMD and fracture genetic effects correlate to some extent, but some important risk variants for frac-
ture may have minimal impact on BMD and vice versa. This is the case for the signal at 18p11.21 (Figure 
2B), which, despite a modest effect on BMD (0.02% variance explained), showed the most significant 
association with fracture risk (OR=1.08, 95% CI: 1.06–1.10; P=8.8×10-13). This is in contrast to variants that 
are known to have stronger effects on BMD that were not significantly associated with fracture risk. For 
example, variants affecting the RANK-RANKL-OPG pathway that has a critical role in osteoclastogen-
esis had clear associations with BMD but not with fracture risk (Figure 2A). Even though loci discovery 
was based on the BMD phenotype, these findings reflect the heterogeneous and complex nature of 
the mechanistic pathways leading to fracture. Therefore, given our study design, we cannot rule out 
the possibility that unidentified genetic loci influence risk for fracture independently of BMD. Future 
well-powered GWAS meta-analyses on fracture risk will address this question, while corroborating the 
associations with fracture that we report for some of the BMD-associated loci (particularly those not 
associated with fracture at P<5×10-8).
Our study also provides indication that there is sex and site specificity underlying BMD variation. One 
of the GWAS signals (Xp22.31) was only significant in the sex-stratified analysis in men and showed 
significant sex heterogeneity (Phet=1.62×10-8). This is expected, considering the sexual dimorphism of 
bone.28, 29 In fact, in a recent GWAS, the rs5934507 SNP mapping to Xp22.31, which is associated with 
BMD in the current study, was previously associated with male serum testosterone levels30. Thus, it is 
likely that rs5934507 affects serum testosterone, which in turn regulates BMD. In line with the different 
types of bone composition at different skeletal sites (predominantly trabecular at the lumbar spine 
and cortical at the femoral neck), we observed some indication of site specificity in 10 of the 56 BMD 
loci, suggesting differential genetic influences on BMD determination across skeletal sites. As has been 
previously shown,31 we did not find in our results major differences in effect sizes between individuals 
of European and East Asian ancestry (Supplementary Figure 7). However, this may be due to reduced 
power, given the smaller number of individuals of East Asian ancestry. We tested a genetic risk score to 
identify individuals at risk for osteoporosis and fracture and showed that, cumulatively, the identified 
variants generate a gradient of risk. These gradients reach ORs of 1.56 for osteoporosis and 1.60 for 
fractures, when comparing participants with the highest risk scores to those having the mean score. Yet, 
at present, there is limited clinical usefulness for this score, as evidenced by its non-significant contribu-
tion to case discrimination when considering clinical risk factors with strong effects on osteoporosis 
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and fracture risk (like age and weight). This is not unexpected, given the small fraction of genetic risk for 
either BMD or fracture that has been identified thus far.
Our study has limitations. The identified SNPs are probably not the causal variants; it is more likely that 
these markers are in LD with the underlying causal variants. Additional analyses on potential functional 
SNPs identified in this study will be required to determine whether they are causal in these relationships 
with BMD. Moreover, the causal genes underlying the GWAS signals may be different from the candidate 
genes we describe, considering that our understanding of the role of these candidate genes in bone 
biology is limited. Further exploration of these loci with more detailed sequencing, gene expression and 
translational studies will be required. Such studies can also disentangle the diverse types of complex 
relationships we currently cannot distinguish in the BMD-associated loci with secondary signals to 
determine whether these are the result of true allelic heterogeneity or if they are driven by a second 
gene in the same region.32 Similarly, despite our large sample size, power limitations still influence the 
detection of additional associations with smaller effect sizes and/or those arising from rarer variants. 
Finally, given the different levels of data availability and the difficulty of standardization across studies, 
we did not evaluate the effect of additional risk factors for osteoporosis, such as menopausal status and 
smoking, which can influence genetic associations with BMD. Nonetheless, despite these limitations, we 
have identified many new and previously unsuspected associations with BMD variation and fracture risk.
Finally, the relatively weak effects of the variants discovered by GWAS do not undermine the bio-
logical relevance of the genes identified, for proteins currently targeted by new osteoporosis treatments 
(Supplementary Figure 10). The new genes identified in our study may represent new candidates to 
target for osteoporosis drug discovery. Most established treatments for osteoporosis focus on curtailing 
bone resorption (for example, bisphosphonates and RANKL inhibitors), whereas only a few anabolic 
treatments are currently approved for the treatment of osteoporosis (recombinant truncated or altered 
PTH). Other anabolic compounds undergoing Phase 2 development include PTHrP fragments and Wnt 
signaling enhancers, such as antibodies to sclerostin33. Several of the variants robustly associated with 
BMD map in or close to genes that encode proteins involved in these pharma cologic pathways, namely 
TNFRSF11B (encoding osteoprotegerin), TNFRSF11A (encoding RANK), TNFSF11 (encoding RANKL), PTHLH 
(encoding PTHrP), LRP5 (encoding low-density lipoprotein receptor–related protein 5), SOST (encoding 
sclerostin) and DKK1 (encoding Dickkopf-1).
In conclusion, these findings highlight the highly polygenic and complex nature of BMD variation, 
shed light on the pathophysio logical mechanisms underlying fracture susceptibility and may con tribute 
to the identification of future drug targets for the treatment of osteoporosis.
URLs. GEFOS Consortium, http://www.gefos.org/; GENOMOS Consortium, http://www.genomos.eu/; 
HapMap Project, http://hapmap.ncbi.nlm.nih.gov/; 1000 Genomes Project, http://www.1000genomes.
org/; LocusZoom, http://csg.sph.umich.edu/locuszoom/; METAL, http://www.sph.umich.edu/csg/
abecasis/Metal/.
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ONLINE METHODS
Study design
This study was conducted as part of the GEFOS Consortium, a coalition of teams of investigators 
dedicated to identifying the genetic determi nants of osteoporosis. The discovery samples comprised 
17 GWAS (N=32,961) from populations across North America, Europe, East Asia and Australia, with a 
variety of epidemiological designs (Supplementary Table 18A) and clinical characteristics of individuals 
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(Supplementary Table 18B); a subset of these had fracture information available (Supplementary Table 
18C). Subjects from 34 additional studies with BMD data (N=50,933) were used for replication, and as-
sociation with fracture was tested across 50 studies with fracture infor mation, most of which were also 
used for the BMD analysis (N=31,016 cases and 102,444 controls) (Figure 1 and Supplementary Tables 
19A-C and 20A-C). All studies were approved by their institutional ethics review committees, and all 
participants provided written informed consent.
BMD measurements and fracture definition
LS-BMD and FN-BMD were measured in all cohorts using dual-energy X-ray absorptiometry, following 
standard protocols (Supplementary Tables 18B, 19B and 20B). Three clinically distinct fracture defini-
tions were used: (1) any type, consisting of low-trauma fractures at any skeletal site (except fingers, toes 
and skull) occurring after age 18 years, assessed by X-ray, radiographic report, clinical record, clini cal 
interview and/or questionnaire, (2) validated non-vertebral, consisting of fractures occurring after age 50 
years, with diagnosis confirmed by hospital records and/or radiographs, and (3) radiographic vertebral 
fractures, from lateral morphometry scored on X-rays. The first definition is most-inclusive, whereas 
the latter two are more stringent fracture definitions that are com monly used in randomized trials.35, 36 
Controls were defined as individuals without a history of fracture, using for each fracture type the same 
age limit categories as for the cases.
Stage 1 genome-wide association analysis
Genotyping and imputation
GWAS genotyping was performed by each study following standard protocols, and imputation was 
then carried out on ~2.5 million SNPs from HapMap37 Phase 2 release 22 using Genome Build 36. Quality 
control was performed inde pendently for each study. To facilitate meta-analysis, each group performed 
genotype imputation with BIM-BAM,38 IMPUTE39 or MACH40 software using genotypes from HapMap 
Phase 2 release 22 (CEU or Han Chinese in Beijing (CHB) and Japanese in Tokyo (JPT) as appropriate). 
HapMap release 21 was used as a reference for SNPs residing on the X chromosome, and IMPUTE 
software was used for imputation. Overall, imputation quality scores for each SNP were obtained from 
IMPUTE (proper_info) and MACH (rsq_hat) statistics. Details of the genotyping platform, genotype 
quality control procedures and software for imputation that were used by each study are pre sented 
(Supplementary Tables 18D and 19D).
Association analysis with BMD
Each study performed genome-wide associa tion analysis for FN-BMD and LS-BMD, using sex-specific 
and age-, weight- and principal component–adjusted standardized residuals analyzed under an additive 
(per allele) genetic model. Analyses of autosomal and X-chromosome markers were performed sepa-
rately. The analysis of imputed genotype data accounted for uncertainty in each genotype prediction 
by using either the dosage information from MACH or the genotype probabilities from IMPUTE and 
BIM-BAM. Studies used MACH2QTL40 directly or via GRIMP41 (which uses genotype dosage value as 
a predictor in a linear regression framework), SNPTEST,39 Merlin,42 BIM-BAM or the linear mixed-effects 
model of the Kinship and ProbABEL43 (Supplementary Tables 18D and 19D). For analy sis of the X chro-
mosome, either SNPTEST or R software was used in each participating study. We coded ‘effect allele 
homozygous genotype’ as 2 and ‘other allele homozygous genotype’ as 0 in the genotyped SNPs in men 
on the X chromosome. The imputed genotypes were coded as continuous variables from 0 to 2 to take 
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into account imputation uncertainty. The genomic control method44 was used to correct the standard 
error (SE) by the square root of the genomic inflation factor (λ): SEcorrected=SEM×√λ.
Meta-analysis of the GWAS
Before performing meta-analysis on the genome-wide association data, SNPs with poor imputation 
quality scores (rsq_hat of <0.3 in MACH, proper_info of <0.4 in IMPUTE or a ratio of observed-to-expected 
dosage variance of <0.3 in BIM-BAM) and markers with a minor allele frequency (MAF) of <1% were 
excluded from each study. All individual GWAS were genomic control corrected before meta-analysis.44 
Individual study-specific genomic control values ranged from 0.98 to 1.08 (Supplementary Table 18D). 
A total of 2,483,766 autosomal SNPs were included in meta-analysis across 17, 16 and 13 studies for FN-
BMD (pooled, women-only and men-only analyses, respectively) and 16, 13 and 12 stud ies for LS-BMD 
(pooled, women-only and men-only analyses, respectively). A total of 76,253 X-linked SNPs were in-
cluded in meta-analysis across 14, 13 and 10 studies for LS-BMD and FN-BMD (pooled, women-only and 
men-only analyses, respectively). In our discovery analysis, we chose to implement a fixed-effects model, 
as it is generally preferable for the purposes of initial discovery, where the aim is to screen and identify 
as many of the true variants as possible.45, 46 SNPs present in less than three studies were removed from 
the meta-analysis, yielding ~2.2 million SNPs in the final results. The genomic inflation factors (λ) were 
1.11, 1.09 and 1.06 for FN-BMD (pooled, women-only and men-only analyses, respectively) and 1.13, 1.09 
and 1.06 for LS-BMD (pooled, women-only and men-only analyses, respectively). A second genomic 
control correction was applied to the overall meta-analysis results, although such a second correction is 
considered overly conservative.47 Significance for BMD association was set at P<5×10-8, and a Bonferroni 
correction was used for association with fracture.48
Selection of SNPs for replication
We took forward the most significant 96 SNPs for replication. With respect to power estimations, after 
adding 30,000 samples in stage 2, these variants had a priori power of ≥85% to reach P=5×10−8 in the 
meta-analysis. Loci were considered independent when separated by at least 1 Mb from a top GWAS 
signal. The 96 variants included the 82 index SNPs representing each of the 82 loci reaching P<5×10-6 
in stage 1, 9 SNPs that were within the same 2-Mb windows as the 82, which were independent from 
the main signals (secondary signals), and the top 5 most-associated SNPs on the X chromosome (with 
P<5×10-5).
Association analyses with fracture risk
Effect estimates (odds ratios) for asso ciation of allele dosage of the top signals with fracture risk were 
obtained from logistic regression models adjusted for age, age2, weight, sex, height and four principal 
components. The proportion of the fracture risk explained by FN-BMD was calculated from the regres-
sion coefficients as (βunadjusted−βBMDadjusted)/βunadjusted in a subset of replication samples for which both 
FN-BMD and complete fracture information was available.
STAGE 2 REPLICATION
Samples and genotyping
Fracture association results were also obtained for the 82 most-significant SNPs from 54,244 indi viduals 
of European ancestry from 7 GWAS (in silico genotyping) that had not been included in the stage 1 
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analyses (Supplementary Table 19A–C). Subjects from 34 studies of the GENOMOS Consortium with 
BMD and/or fracture information were studied in replication analysis (Supplementary Table 3A–C). De 
novo replication genotyping was performed in the UK (Kbiosciences), Iceland (deCODE Genetics), Aus-
tralia (University of Queensland Diamantina Institute) and the United States (WHI GeCHIP) using KASPar, 
Centaurus, OpenArray and iSelect assays, respectively (Supplementary Note). Minimum genotyping 
quality control criteria were defined as sample call rate of >80%, SNP call rate of >90%, Hardy-Weinberg 
Equilibrium P value of >1×10−4 and MAF of >1%.
Association analyses and meta-analysis
We tested the association between the 96 SNPs and BMD and fracture risk in each in silico and de 
novo stage 2 study separately, as described for the stage 1 studies. We subsequently performed meta-
analysis of effects and standard errors from the stage 2 studies and then carried out a meta-analysis of 
the summary statistics of stages 1 and 2 combined using the inverse-variance method in METAL. At the 
replication stage, where more than 30 studies were synthesized, we chose to first assess the underlying 
heterogeneity, considering both the Cochran’s Q statistic and the I2 metric. If the heterogeneity was 
not significant, fixed-effects model were applied. If the Cochran’s Q P value was <0.0005 and I2 was 
>50%, we used the more conservative random-effects model. Additional analyses. Further analyses were 
performed for the SNPs carried forward for replication. Each of these analyses is described in detail in 
the Supplementary Note.
In brief, we performed (1) a conditional genome-wide association analysis to determine whether any 
of the 82 BMD loci harbored additional independent signals, (2) tested gene-by-gene pairwise interac-
tions between these BMD loci, (3) assessed within the independent setting of the PERF study (for details 
on study design see Supplementary Table 20A–C) the predictive ability derived from the cumulative 
effect of the 63 autosomal SNPs associated with BMD with genome-wide significance in relation to BMD 
levels and osteoporosis risk and that of the 16 BMD SNPs also associated with fracture risk in relation to 
fracture risk, (4) identified SNPs with r2 of ≥0.80 with the lead SNP that were potentially functional (for ex-
ample, nonsense, non-conservative nonsynonymous, synony mous, exonic splicing, transcription factor 
binding), using regional imputation with 1000 Genomes Project data (June 2010 release), (5) tested the 
relationship between gene expression profiles from transiliac bone biopsies and BMD in 84 unrelated 
postmenopausal women49 and examined cis associations between each of the 55 significant BMD SNPs 
and expression of nearby genes in different tissues, including lymphoblastoid cell lines,50-52 primary hu-
man fibroblasts and osteoblasts,53 adipose tissue,54 whole blood54 and circulating monocytes,55 and (6) 
evaluated the connectivity and relationships between identified loci using literature-based annotation 
with the GRAIL19 statistical strategy.
Supplementary information is available at:
http://www.nature.com/ng/journal/v44/n5/extref/ng.2249-S1.pdf
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ABSTRACT
Background Bone fractures are considered the most clinically relevant clinical sequelae of osteoporosis. 
A positive family history is an important risk factor for fractures. The genes that contribute to risk for 
osteoporotic fractures are largely unknown.
Methods This meta-analysis on any-type of fracture risk included up to 163,292 participants (38,021 
cases) across 66 cohorts from Europe, USA, Asia and Australia. Cases were adults with fractures con-
firmed by medical, radiological or questionnaire reports. The discovery phase comprised 24 GWAS. SNPs 
surpassing P<5x10-6 and previously reported BMD-fracture SNPs were followed-up in a replication phase 
including both de-novo genotyping and in-silico look ups.
Results Common SNPs explained 0.19 (standard error: 0.09, P=0.02) of the variance in fracture risk. Ten 
loci replicated at genome-wide significance (P<5x10-8), with small to moderate effect sizes (OR 1.06–1.18; 
95% CI: 1.04–1.24). The signal on chromosome 21 has not been previously reported and maps upstream 
of the gene FLJ45139, which encodes a protein of yet unknown function. We confirmed the 7q21.3 and 
18p11.21 loci and replicated signals at genome-wide significant level at the SOST, CPED1/WNT16, SPTBN1, 
MEPE/IBSP/SPP1, MBL2/DKK1, CTNNB1 and RSPO3 loci.
Conclusions The top loci in our genome-wide screen were associated with both fracture risk and BMD, 
reinforcing BMD as a powerful endophenotype and suggesting a considerable proportion of genetic 
variance in fracture risk is through BMD. Mutations in some of the candidate genes cause skeletal abnor-
malities and many are involved in Wnt signaling, while the function and therapeutic potential of others 
remains to be explored.
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INTRODUCTION
Osteoporosis is a common skeletal disorder characterized by low bone mineral density (BMD), impaired 
bone quality, and fragility fractures. Osteoporotic fractures mainly occur at the vertebrae, wrist, pelvis 
and hip and constitute a major and costly public health problem, affecting hundreds of millions of 
people worldwide. One of the most important clinical risk factors for osteoporosis is a positive family 
history.1 Dozens of genetic loci have been identified by genome-wide association studies (GWAS) study-
ing BMD variation in populations,2-9 while only a few loci have been shown to underlie the occurrence 
of rare forms of osteoporosis in families10-12. Since only a fraction of the BMD loci have been shown to 
be associated with fracture we have embarked in performing the largest GWAS meta-analysis to date 
including 19,414 cases and 83,459 controls targeting the characterization of genetic determinants of 
osteoporotic fracture risk.
METHODS
Subjects
This study is part of the GEnetic Factors for OSteoporosis consortium (GEFOS), a coalition of teams 
of investigators dedicated to identify the genetic determinants of osteoporosis (http://www.gefos.
org/). The discovery samples comprised 24 GWA studies (N=102,873) from populations across North 
America, Europe, East Asia and Australia, with a variety of epidemiological designs (Table S1A-C in the 
Supplementary Appendix) and patient characteristics (Table S2A-C in the Supplementary Appendix). 
The replication phase including both de-novo genotyping and in-silico look ups in subjects from 42 
additional studies with fracture data (maximum N=18,779 cases and 41,845 controls) (Tables S3A-C in 
the Supplementary Appendix). All studies were approved by their institutional ethics review committees 
and all participants provided written informed consent.
Fracture definition
Cases were individuals (>18 years) with fractures confirmed by medical, radiological or questionnaire 
reports. When possible, fractures of the fingers, toes and skull were excluded from analyses. Also, high-
trauma fractures were excluded whenever possible, for example high-energy traffic accidents or falls 
from a height greater than standing height. Controls were defined as individuals without a known 
history of fracture.
Genotyping and imputation
GWAS genotyping was done by each study following standard manufacturer protocols followed by 
imputation to ~2.5 million SNPs from HapMap Phase II. De-novo replication genotyping was done in the 
UK (Kbiosciences). Details of the genotyping procedures are presented in the Supplementary Appendix 
(Tables S4A-C).
Statistical analysis
Association analyses
Each study performed genome-wide association analysis for fracture risk using logistic regression 
models adjusted for sex, age (simple and quadratic term), height, weight, testing additive (per allele) ge-
netic effects. Additionally, sex-stratified analyses were performed employing the same statistical models. 
Before performing meta-analysis, three meta-analytical centers checked the data files independently. 
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In addition, filtering was applied to each data file as described in detail in the Methods section of the 
Supplementary Appendix. Genomic control (GC) was applied to correct the SE for the genomic inflation 
factor (λ) to control for possible inflation of test statistics due to population stratification and cryptic 
family relations, targeting λ<1.05.13 Results were meta-analyzed with inverse variance fixed-effects in 
METAL.14
Additional analyses
GCTA analysis was used to estimate the variance explained by common SNPs in Rotterdam Study I and to 
detect secondary signals in the meta-analysis using individual-level genotype data of two discovery sets 
(Rotterdam Study-II and -III).15 Further analyses were performed including: association with dual-energy 
X-ray absorptiometry (DXA) femoral neck (FN-) and lumbar spine (LS-BMD),9 expression quantitative trait 
loci (eQTL), literature-based annotation with Gene Relationships across Implicated Loci (GRAIL) statistical 
strategy,16 functional, clinical and regional annotations. The variance explained by SNPs prioritized from 
the discovery screenings and correlated phenotypes was determined. These analyses are described in 
detail in the Methods section of the Supplementary Appendix.
RESULTS
Heritability estimate and association analyses
A moderate proportion of variance in fracture risk could be explained by genome-wide common SNPs 
(0.19; standard error: 0.09, P value: 0.02). Next, GWAS summary statistics from 24 cohorts (N=102,873, 
19,414 fractures) were meta-analyzed for ~2.5 million genotyped and imputed SNPs. In the discovery 
phase, 35 SNPs from the sex-combined and gender-stratified analyses surpassed P<5x10-6 at a satis-
factory genomic inflation level (Figures S1 and S2 in the Supplementary Appendix), mapping to 27 
distinct loci (Table S5 in the Supplementary Appendix). About half of these loci were also associated 
with BMD (Table S6 in the Supplementary Appendix) clustering in the Wnt signaling pathway, while 
others seemed to contain genes involved in hormonal and neurological pathways. No secondary signals 
were identified by GCTA.
These and previously reported BMD-fracture loci9 were followed-up in a replication phase, summing 
to 163,292 participants (38,021 cases) as illustrated in Figure 1. Loci replicating at genome-wide signifi-
cance are included below in Tables 1 and 2 and full results are available in Table S7 in the Supplementary 
Appendix). In sum, eight SNPs from the current genome-wide screening mapping to six distinct loci 
reached genome-wide significance, while six SNPs from the published BMD-fracture loci replicated 
at this level. Altogether, as two loci coincided, these add up to ten genome-wide significant fracture 
loci. The proportion of variance explained in fracture risk was 0.02 for the independent genome-wide 
significantly replicating SNPs in the meta-analysis, where results were validated in a genome-wide 
association study not part of the discovery screening; full results are shown in Table S8 in the Supple-
mentary Appendix. Including more fracture SNPs by lowering the significance threshold further added 
to the variance explained. Also, sets of SNPs from GWAS for correlated traits such as BMD and height 
significantly enlarged the variance explained, which was more than would expect by chance. This effect 
was not shown for SNPs for other known associated phenotypes such as vitamin D and metabolic traits 
such as type 2 diabetes mellitus and C-reactive protein.
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Remarkably, the loci replicating consistently were all previously reported as associated with BMD. 
The signal on chromosome 21q22.2 (P=3x10-10; OR=1.07; 95% CI: [1.05–1.10]) has not been previously 
reported and maps upstream of the gene FLJ45139 that encodes a protein of yet unknown function. 
Although not a previously known BMD locus, at least part of the association with fracture risk is probably 
through BMD as the SNP was associated with DXA FN- and LS-BMD in the GEFOS dataset (rs9982895 
PFN-BMD=0.01; BetaFN-BMD=-0.02; PLS-BMD=0.0001; BetaLS-BMD=-0.04).
Functional and clinical annotations
Annotations for the top markers from the fracture GWAS are available in Table S9 in the Supplementary 
Appendix.
The top signal in the novel locus on chromosome 21 has a strong DNase I-hypersensitive site (DHS) 
correlation (r=0.58) and is in the same topological domain with ETS2. ETS2 is a transcription factor and 
protooncogene, and is highly expressed in newly formed cartilage in murine development, including 
skull precursor cells and vertebral primordia. Mice with Ets2 overexpression developed neurocranial, 
visceral cranial, and cervical skeletal abnormalities. ETS2 has a role in skeletal development and that 
overexpression is involved in the genesis of some skeletal abnormalities that occur in Down syndrome.17
Several of the candidate gene products are part of or closely related to Wnt signaling. The signal 
replicating on 3p22.1 is in the vicinity of CTNNB1 (P=6x10-9; OR=1.06; 95% CI: [1.04–1.08]), which encodes 
the factor integral to Wnt signaling beta-catenin. The large linkage disequilibrium (LD) block harboring 
the 7q21.3 signal includes SLC25A13 and SHFM1 (P=1x10-12; OR=1.07; 95% CI: [1.05–1.10]). Slc25a13 is ex-
pressed in osteoblasts and osteoclasts in mice (Figure S6 in the Supplementary Appendix). The protein 
product, Citrin plays a role in transport across the mitochondrial membrane. However, expression of this 
gene was not correlated with BMD in our data. Genomic re-arrangements take place more frequently in 
GEFOS discovery (stage 1) 
meta-analysis of 24 
genome-wide association studies 
(n= 102,873, 19,414 fractures) 
GEFOS replication (stage 2A) 
in silico look-up in 3 additional 
genome-wide association studies 
(35 SNPs) 
(n= 14,459, 6,101 fractures) 
GENOMOS replication (stage 2B) 
de novo targeted genotyping  
in 26 DNA studies 
(24 selected SNPs) 
(n= 54,116, 16,573 fractures) 
35 SNPs with P < 5 x 10-6  
in 27 distinct loci 
8 SNPs with P < 5 x 10-8  
in 6 distinct loci 
Figure 1.  Study design diagram.
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this region, leading to deletion of DSS1, DLX5 and DLX6.18, 19 The latter two code for members of the Wnt 
signaling pathway, and when both are deleted or mutated, ectrodactyly (also known as split hand/foot 
malformation) with missing digits, a claw-like appearance of the distal extremities and hypoplasia of the 
long bones may occur.20 split hand/foot malformation has been reported with urogenital developmen-
tal defects,21 and double inactivation of Dlx5 and Dlx6 in mice leads to decreased testosterone levels and 
abnormal masculinization.22
The closest candidate genes for the association on chromosome 10q21.1 (P=8x10-9; OR=1.09; 95% CI: 
[1.06–1.12]) are MBL2 and DKK1. DKK1 encodes Dickkopf 1, an inhibitor of Wnt signaling, and anti-DKK1 
antibody treatment promotes bone fracture healing in mice.23 The 17q21.31 signal (P=1.2x10-8) is close 
to SOST. SOST encodes Sclerostin, which antagonizes bone formation by binding to LRP5/6 receptors 
and inhibiting Wnt signaling.24 Also, inactivating mutations of SOST have been reported to cause high 
bone mass syndromes comprising sclerosteosis,25, 26 van Buchem’s disease27 and craniodiaphyseal 
dysplasia28. Variants on chromosome 6q22.33 upstream from RSPO3 were first reported as associated at 
genome-wide significant level with BMD in Australian and Northern European populations,29 and our 
GWAS detected a signal for fracture risk (P=4x10-12; OR=1.07; 95% CI: [1.05–1.09]). RSpo proteins are acti-
vators and regulators of canonical Wnt signaling, with RSpo3 being one of the most potent members.30
The signal on chromosome 4q22.1 (P=2x10-9; OR=1.06; 95% CI: [1.04–1.08]) points to a cluster of 
phylogenetically-related genes encoding for matricellular phosphoglycoproteins important for bone 
formation and mineralization including MEPE (matrix extracellular phosphoglycoprotein), IBSP (integrin 
binding sialoprotein) and SPP1 (osteopontin). All three genes are expressed in bone and exhibit a skeletal 
phenotype when deleted in mice.31-33 The signal on 2p16.2 (P=6x10-9; OR=1.06; 95% CI: [1.04–1.08]) maps 
close to SPTBN1, which encodes a subform of β-spectrin a major cytoskeletal scaffold protein. In mice it 
is highly expressed (Figure S7 in the Supplementary Appendix)and targeted inactivation of the mouse 
homolog results in disruption of TGF-beta signaling.34 This gene is alternately spliced and expression of 
this gene yields a mixed correlation with BMD, dependent on the probe used to measure expression.
The CPED1/WNT16 locus repeatedly appears among the top hits in different GWAS for fracture-related 
traits,35, 36 and may thus indicate up to now unknown biological pathways for pharmacological interven-
tion for osteoporosis. Expression of Cped1 assessed by whole transcriptome RNA sequencing in mouse 
calvarial osteoblasts increased across differentiation (Figure S8 in the Supplementary Appendix). Expres-
sion of CPED1 in whole bone tissue obtained from iliac crest biopsies from post-menopausal women 
showed a significantly negative correlation with hip (r=-0.36) and spine (r=-0.32) T score. In addition, 
osteoblast-derived WNT16 inhibits human and mouse osteoclastogenesis both directly by acting on 
osteoclast progenitors and indirectly by increasing expression of osteoprotegerin (Opg) in osteoblasts 
and Wnt16-deficient mice develop spontaneous fractures as a result of low cortical thickness and high 
cortical porosity.37 Further, associated SNPs in the 18p11.21 locus map to three genes with unknown 
function, i.e., FAM210A, C18orf1 and RNMT (P=3x10-13; OR=1.07; 95% CI: [1.05–1.09]). Rnmt is expressed in 
mouse osteoblasts (Figure S9 in the Supplementary Appendix). The RNMT protein is involved in mRNA 
processing and this gene is most highly expressed in the brain. Expression of RNMT in whole bone 
tissue obtained from iliac crest biopsies from post-menopausal women showed a significantly positive 
correlation with whole body BMD T score (r=0.25).
To explore any sex-specific associations, additional analyses were performed stratified by gender and 
by formally testing for interaction effects. The gender-stratified results did not yield any replicating sex-
specific associations. The formal testing for sex-interaction effects did not show a significant difference 
for the genome-wide significant hits, but sex-specific effects may contribute to the high heterogeneity 
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observed in several suggestive signals, including those at the ELSPBP1, SHFM1, RASSF4, VLDLR, ALPK3 and 
LRP5 loci (Table S9 of the Supplementary Appendix).
DISCUSSION
In this study, the largest GWAS meta-analysis for osteoporosis traits to date, we are among the first to 
identify genetic loci associated with osteoporotic fracture risk. A significant proportion of the variance of 
risk of all-type of osteoporotic fracture can be explained by common genetic variants, yet this heritability 
estimate is of modest size. Additionally, our meta-analytical effort discovered and replicated multiple 
genetic loci associated with risk of fracture. Discovery analyses suggested the involvement of hormonal 
and neurological pathways, yet, this could not be replicated. Replicating loci were those found to be 
associated with BMD levels as well, of which several seem to be involved in Wnt signaling. Our data 
suggests a high degree of heterogeneity with suggestive evidence for specificity of effects for gender 
and population. Results were annotated by querying online databases and collaborating with functional 
biology groups.
In our previous work, we tested 96 BMD markers for association with fracture in 31,016 cases and 
102,444 controls from 50 studies with fracture information. In this fracture meta-analysis, 14 loci were 
significantly associated with any type of fracture at Bonferroni-corrected significance (P=5×10−4), of 
which six loci surpassed genome-wide significance (P=5×10−8). The genome-wide significant signals 
mapped to 18p11.21 (FAM210A), 7q21.3 (SLC25A13), 11q13.2 (LRP5), 4q22.1 (MEPE), 2p16.2 (SPTBN1) and 
10q21.1 (DKK1). The others at Bonferroni-corrected significance included: two independent signals at 
1p36.12 (ZBTB40 and WNT4), 3p22.1 (CTNNB1), 7p14.1 (STARD3NL), 7q31.31 (WNT16), 9q34.11 (FUBP3), 
11p14.1 (DCDC5), 14q32.12 (RPS6KA5) and two independent signals at 17q21.31 (SOST and C17orf53). 
In our current project we started out directly with GWAS meta-analyses for fracture risk. We confirmed 
the 7q21.3 and 18p11.21 loci, boosted the signals at the SOST, CPED1/WNT16, SPTBN1, MEPE/IBSP/SPP1, 
MBL2/DKK1 and CTNNB1 loci towards genome-wide significant level, and added the 6q22.33 (RSPO3) 
and 21q22.2 (FLJ45139) loci to the list of the now known fracture loci. Altogether, the GWAS design in 
a well-powered setting has pointed us to 16 loci for fracture risk so far. Compared to other quantitative 
traits that have been subject of GWAS, investigating BMD seems very promising and prolific (Figure S10 
in the Supplementary Appendix). On the other hand, GWAS taking dichotomous disease outcomes as 
a direct outcome, such as risk of osteoporotic fractures as described in this thesis, have been relatively 
more challenging (Figure S11 in the Supplementary Appendix). Compared to other GWAS employing a 
case-control design for different disease outcomes, osteoporotic fracture GWAS have been reasonably 
successful. From these graphs it becomes clear that generally the number of loci discovered increases 
along with increases in sample sizes as study power improves. However, the slopes of the graphs and the 
sample sizes investigated until now for the various phenotypes differ.
As the most prominent genetic loci associated with fracture risk coming out of a hypothesis-free 
genome-wide screen are also associated with BMD, this serves as proof of BMD being a very powerful 
endophenotype. From a different perspective, epidemiological studies have shown that a great pro-
portion of persons that fracture have abnormal BMD in either the osteoporotic or osteopenic range, 
with only 13% of women and 18% of men having a T score >-1.0.38 These observations bring us to 
the hypothesis that an abnormally decreased BMD is a prerequisite to fracture in the majority of cases, 
irrespective of additional mechanisms present. Further, those individuals with BMD in the normal range 
may have other confounding factors present such as type 2 diabetes mellitus and osteoarthritis.39, 40 
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Nevertheless, screening in view of primary prevention of osteoporotic fractures based only on BMD is 
not enough, because of the limited specificity as the relative risks are 1.3 for individuals with osteopenic 
BMD and 2.7 for individuals with osteoporotic BMD, respectively. 38
Pathway analyses applied to the information derived from our GWAS meta-analyses for BMD and frac-
ture risk highlighted connections between genes in the loci discovered. The discovery results pointed to 
hormonal and neurological pathways, possibly highlighting the multi-factorial etiology of fracture risk. 
It should be noted that the GRAIL annotation includes only information what is known so far, therefore, 
unknown gene functions and pathways will be missed. SOST, RSPO3, WNT16 and DKK1 are known Wnt 
signaling factors. Wnt signaling has been recognized as a key regulator of bone mass.41 It is tempting 
to speculate if defective Wnt signaling is detrimental to fracture risk at older age through a suboptimal 
peak bone mass established in earlier life. Alternative pathways would be defective maintenance of 
bone mass and compromised fracture healing at later stages42, 43.
However, few of the other initial fracture results remained after replication. Particularly the non-BMD 
loci not replicating could be due to false-positive associations, or the heterogeneity associated with the 
coarse phenotype definition and variety in study populations. Further, the biological relevance of our 
associations is accentuated by the identification of genes underlying rare monogenetic forms of mus-
culoskeletal defects or extreme bone mass syndromes which also contain common variants involved 
in normal BMD variation and fracture risk at the population level.5, 8, 44 This is supportive of a genetic 
architecture where both common and rare genetic variation may reside in the same locus.45
In contrast to the lack of population-specificity in previous work on BMD,9, 46 we found suggestive 
evidence for specificity of genetic variants for fracture risk in Asian versus Caucasian populations. 
Eurasian populations are efficient for genome scans, and populations of recent African origin (such as 
African Americans) are efficient for identification of causal polymorphisms within a candidate sequence 
because of their distinctive linkage disequilibrium (LD) structure.47 Nevertheless, larger sample sizes will 
be needed than currently available. Sexual dimorphism in various bone phenotypes is widely observed; 
however, sex-specific SNP effects, or gene-by-sex interactions, seem infrequent, as only one sex specific 
BMD variant (Xp22.31 chromosome) has been discovered to date.9, 48 Our current fracture meta-analysis 
showed signs of gender-interaction for a few of the loci. Nevertheless, our gender-specific analyses did 
not seem to be adequately powered to solidly corroborate sex-specific fracture loci in the stratified 
analyses. Population- and gender-specificity may have contributed to the high heterogeneity of effects 
present.
There were substantial age differences between studies, and exploring age-specific effects also seems 
of interest. Alternatively, phenotype measurement differences across studies are a known possible 
source of heterogeneity complicating replication successes due to non-differential misclassification 
leading to dilution of effect estimates. The signals we have now identified ought to be very strongly 
associated, while genetic variants that truly contribute to fracture risk but with small effect sizes may 
easily be missed, i.e., false negatives. Further, the statistical thresholds for significance in GWAS are very 
stringent.
For BMD it has been established that several loci display skeletal-site specific effects,9 and for fracture 
risk site-specific genetic effects have been proposed as well49. Intriguingly, different skeletal site-speci-
ficity for BMD has been demonstrated for variants in independent signals within the same locus but in 
different genes, i.e., WNT16 and CPED1.50 If genetic risk factors exist that may act only on certain skeletal 
sites, separate efforts taking specific fracture types as study outcomes may be worthwhile, as pursued 
in parallel by our consortia. However, so far these approaches have been challenging. For instance, our 
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GWAS for osteoporotic vertebral fractures identified a genome-wide significant signal in the discovery, 
however, this could not be convincingly replicated by de-novo genotyping the specific marker in 15 
studies world-wide.51 The current problem is that not enough studies are available with comparable 
or identical phenotyping procedures and there is a lack of means to harmonize data between cohorts. 
Analyzing the outcomes of non-vertebral fracture and vertebral fracture in addition to all-type of fracture 
did not produce any additional signals in our previous effort,9 demonstrating that the study power did 
not benefit from improving phenotype definitions at the cost of lower sample size at this stage.
Our study has limitations. The identified SNPs are probably not the causal variants; it is more likely that 
these markers are in LD with the underlying causal variants. Further, the causal genes underlying the 
GWAS signals may be different to the candidate genes we describe considering that our understanding 
of their role in bone biology is limited. Further exploration of these loci with more detailed sequencing, 
expression, and translational studies will be required. Despite our large sample size, power limitations 
still play a role for detecting additional associations with smaller effect sizes and/or rarer variants10, 12. 
Nonetheless, we have identified many novel and previously unsuspected associations with osteoporosis 
and fracture risk.
Future studies could expand on the types of genetic variation under investigation, such as for instance 
copy number variation.52 Also, genome-wide analysis of sex-chromosomes has not yet been performed 
for fracture risk. Analysis of rare variants and fine-mapping may be achieved by 1000 Genomes imputa-
tion, regional or whole genome sequencing. The first effort in our GEFOS and GENOMOS consortium 
encompassing a sequencing-based GWAS meta-analysis has discovered EN1 as a determinant of bone 
density and fracture.53 As microarray based GWAS relies on the principle of LD the SNPs found to be 
associated may not necessarily be the true causal variants or even map to the correct causative gene. 
Nowadays, advances in bioinformatics and genotyping technology are enabling studies with denser 
genotype data achieved through imputation, microarrays containing more SNPs or sequencing. New 
efforts utilizing these means are underway aimed at BMD and fracture risk, yet, the number of studies 
that have access to these techniques is still somewhat limited. More functional studies (e.g., animal ex-
periments and cell line work) are needed to increase our knowledge about the function of certain genes, 
for example those in the 7q21.3 and 18p11.21 loci. The genetic markers and loci may serve diagnostic 
or even therapeutic purposes.
Finally, the relatively weak effects of the variants discovered by GWAS do not undermine the biological 
relevance of the genes identified as exemplified by the identification of genetic signals at the location 
of genes coding for proteins currently targeted by novel osteoporosis treatments. From this perspective, 
one may consider also potential applications of these discoveries towards developing new interven-
tions of osteoporosis. Most established treatments for osteoporosis currently focus on curtailing bone 
resorption (e.g., bisphosphonates, RANKL inhibitors) while only few anabolic treatments are currently 
approved for the treatment of osteoporosis (i.e., recombinant truncated or altered PTH). Other anabolic 
compounds under Phase II development include PTHrP fragments and Wnt-signaling inhibitors such 
as anti-sclerostin antibodies.54 Interventional studies exploring the application of sclerostin monoclonal 
antibodies to osteoporosis treatment are currently ongoing. A significant decrease in bone resorption 
markers, significant increases in BMD and bone formation markers have been observed in phase 1 and 2 
clinical trials, whereas the efficacy to reduce fracture has not yet been studied.55, 56 Interventional studies 
exploring the application of sclerostin monoclonal antibodies to osteoporosis treatment are currently 
ongoing. A significant decrease in bone resorption markers, significant increases in BMD and bone for-
mation markers have been observed in phase 1 and 2 clinical trials, whereas the efficacy to reduce 
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fracture has not yet been studied. Most clinical trials benefit only those with low BMD; our current results 
have not evidenced otherwise, as from a genetic perspective the top loci from the first fracture screen 
are virtually all BMD-associated as well. BMD seems an excellent endophenotype for drug development.
In conclusion, this large-scale GWAS meta-analysis identified multiple genetic loci associated with 
risk of osteoporotic fracture, of which ten replicated at genome-wide significant level. Many of these 
loci contain genes involved in the regulation of bone mineral density through Wnt signaling, while the 
function and therapeutic potential of other candidate genes remains to be explored. These findings 
highlight the highly polygenic and complex nature underlying osteoporotic fracture risk, shedding light 
on the pathophysiological mechanisms underlying fracture susceptibility and harboring potential for 
the future identification of drug targets for the treatment of osteoporosis.
Supplementary information is available at:
http://www.glimdna.org/publicationdata.html
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ABSTRACT
Introduction Osteoporosis is a systemic skeletal disease characterized by reduced bone mineral density 
and increased susceptibility to fracture; these traits are highly heritable. Both common and rare copy 
number variants (CNVs) potentially affect the function of genes and may influence disease risk.
Aim To identify CNVs associated with osteoporotic bone fracture risk.
Methods We performed a genome-wide CNV association study in 5,178 individuals from a prospective 
cohort in the Netherlands, including 809 osteoporotic fracture cases, and performed in silico lookups 
and de novo genotyping to replicate in several independent studies.
Results A rare (population prevalence 0.14%, 95% confidence interval [CI]: 0.03%–0.24%) 210 kb deletion 
located on chromosome 6p25.1 was associated with the risk of fracture (OR 32.58, 95% CI: 3.95–1,488.89; 
P=8.69×10−5). We performed an in silico meta-analysis in four studies with CNV microarray data and 
the association with fracture risk was replicated (OR 3.11, 95% CI: 1.01–8.22; P=0.02). The prevalence of 
this deletion showed geographic diversity, being absent in additional samples from Australia, Canada, 
Poland, Iceland, Denmark, and Sweden, but present in the Netherlands (0.34%), Spain (0.33%), USA 
(0.23%), England (0.15%), Scotland (0.10%), and Ireland (0.06%), with insufficient evidence for association 
with fracture risk.
Conclusion These results suggest that deletions in the 6p25.1 locus may predispose to higher risk of 
fracture in a subset of populations of European origin; larger and geographically restricted studies will 
be needed to confirm this regional association. This is a first step towards the evaluation of the role of 
rare CNVs in osteoporosis.
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INTRODUCTION
Osteoporosis is a major public health problem in a rapidly aging population. This systemic skeletal disease 
is characterized by reduced bone mass and microarchitectural deterioration of bone tissue. The disease 
progresses ‘silently’ until the increase in bone fragility leads to increased fracture risk.1, 2 The importance 
of genetic variation in the regulation of bone mass and bone turnover was first highlighted by linkage 
analysis in severe Mendelian disorders such as osteoporosis-pseudoglioma syndrome and high bone 
mass syndrome.3 In the case of non-Mendelian forms of osteoporosis, common genetic variants have 
been found to be associated with fracture risk in well powered candidate gene settings.4 Meta-analysis 
of single nucleotide polymorphism (SNP) genome-wide association studies (GWAS) for bone mass have 
identified more than 56 loci independently associated with normal variation of bone mineral density, 
and some of these studies also found associations with fracture risk.5-12
In addition to SNPs, copy number variants (CNVs) have shown associations with complex phenotypes 
such as schizophrenia, autism, and obesity.13-16 A study in Chinese individuals suggested an associa-
tion of a common CNV with osteoporotic fractures;17 however, the same variant was not replicated in a 
follow-up study of individuals of European origin,18 potentially showing population specific effects. Most 
of the common CNVs are well tagged by common SNPs,19 and thus are easy to identify with a SNP based 
GWAS. On the other hand, rare CNVs are difficult to tag and rare and large CNVs have been found to be 
associated with different diseases.20 Nevertheless, it is not known whether rare CNVs play a significant 
role in fracture risk. Thus, we conducted a genome-wide CNV association study on a discovery dataset 
of 809 fracture cases and 4,369 controls drawn from a prospective cohort study. We further looked for 
in silico replication of the CNV region showing the most significant association in 1,096 fracture cases 
and 47,340 controls from four independent studies with CNV microarray data. Finally, using a breakpoint 
specific genotyping assay we evaluated the association of this deletion in an additional 9,760 fracture 
cases and 16,542 controls.
METHODS
Subjects
All studies were approved by the institutional ethics review committees of the respective organizations, 
and all participants provided written informed consent. The Rotterdam Study (RS-I) is a prospective 
population based cohort study of chronic disabling conditions in Dutch individuals aged 55 years or 
above (http://www.epib.nl/ergo.htm).21-23 The Rotterdam Study II (RS-II) is an extension of the Rotterdam 
Study, which started in 1999 and used the same inclusion criteria and design as the original cohort. 
Briefly, 3,011 individuals (response rate 67%) who had turned 55 years of age or had moved into the 
study district of Ommoord, Rotterdam, since the start of the original study in 1990 were included 
in the extension cohort. The Icelandic deCODE Genetics (dCG) study comprises a population based 
sample to identify the genetic basis of complex diseases.10 The Framingham Osteoporosis Study (FOS) 
is embedded in the Framingham Heart Study, a community based, longitudinal, prospective cohort 
comprising three generations of individuals in multigenerational pedigrees and additional unrelated 
individuals (http://www.framinghamheartstudy.org/). The PROSPER study is a randomized controlled 
clinical trial to test the effect of pravastatin on cardiovascular outcomes in the elderly at risk. In addition, 
we performed de novo genotyping —that is, targeted locus assessments because no CNV microarray 
data are available—in 15 studies with a variety of epidemiological designs that are part of the GENOMOS 
DNA collection (http://www.genomos.eu) across Canada, Europe, and Australia. Given the rarity of this 
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deletion event, we pursued genotyping only in those largest GENOMOS studies having at least 200 
fracture cases and a total sample size of at least 1,000 subjects with phenotype information concerning 
the fracture status. More information can be found in online Supplementary Tables S1 and S2. All study 
participants included were of Caucasian ancestry.
Fracture definition
Fracture cases were defined as fractures at any skeletal site (except fingers, toes, and skull) occurring after 
age 18 years assessed by X-ray screening, clinical radiographic report, clinical record, clinical interview, 
and/or questionnaire. High trauma fractures were excluded whenever possible, for example, motor 
vehicle accidents or falls from greater than standing height. Controls were defined as individuals without 
a history of fracture. Additional information for each study is available in online Supplementary Tables 
S3 and S4.
GWAS genotyping
The four studies were genotyped using the Illumina Infinium HumanHap550 Beadchip (RS-I, RS-II), 
Quad660 (PROSPER), the HumanCNV370 Beadchip (dCG) or the Affymetrix Dual NspI/StyI GeneChip 
2×250 K with 50 K gene centered MIP set (FOS), all according to manufacturer’s protocols and quality 
control standards. The exclusion/filtering criteria for individuals are described in online Supplementary 
Table S1A.
CNV analysis of microarray data
Studies used either QuantiSNP24 or PennCNV25 to segment CNVs as described below. Quality control 
(QC) steps for RS-I, RS-II, PROSPER, and FOS are summarized in online Supplementary Figure S1.
RS-I: Log R ratio (LRR) signal intensity and B allele frequency (BAF) were extracted from 5974 samples 
using BeadStudio 3.1.3. A Hidden-Markov model, implemented in the software QuantiSNP, was used to 
make CNV calls. A measure of confidence, log Bayes factor, was computed for each CNV call. A correction 
for local difference in GC content is implemented in the algorithm to adjust for irregularities in signal 
intensity. We excluded 547 samples with a mean autosomal LRR SD >0.3 or a BAF SD >0.15. We also 
excluded CNV calls that spanned the centromere (QC1, nCNVs=305,475). We discarded all CNV calls with 
a log Bayes factor value <10, a CNV size <1 kb or CNVs with less than two consecutive SNPs in the CNV 
event. This filter effectively reduces the majority of false positive calls, although it has the disadvantage 
that many putatively real CNV calls might be lost (QC2 nCNVs=58,866). Finally we removed 249 samples 
with an excess of CNV calls (expressed as upper quartile+1.5×(IQR))=20 CNVs (QC3, nCNVs=49,229 in 
5,178 samples).
RS-II: 2,157 samples were used for CNV analyses using QuantiSNP; 154 of these samples with a mean 
LRR SD >0.35 or a BAF SD >0.15 were excluded. We also excluded CNV calls that spanned the centromere 
(QC1, nCNVs=129,941). We discarded all CNV calls with a log Bayes factor value <10, a CNV size <1 kb, or 
only one consecutive SNP in the CNV event (QC2 N=15,266). For samples with a LRR SD between 0.3 and 
0.35, we applied a stricter threshold of log Bayes factor=15. Thirty-eight samples with >20 CNVs were 
excluded (QC3, 13,038 CNVs in 19,65 samples).
dCG: Illumina BeadStudio (V.2.0) was used to call genotypes, normalize the signal intensity data, and 
establish the LRR and BAF at every SNP according to standard Illumina protocols. All samples passed a 
standard SNP based QC procedure with an SNP call rate >0.97. PennCNV was used for detection of CNVs. 
The input data for PennCNV are LRR and BAF. PennCNV employs a hidden Markov model to analyze the 
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LRR and BAF values across the genome. CNV calls are made on the basis of the probability of a given 
copy state at the current marker, as well as on the probability of observing a copy state change from the 
previous marker to the current one.
FOS: A total of 8,734 Framingham participants with genome-wide genotypes using Affymetrix 550 k 
chips were used for CNV calling on autosomal chromosomes. The raw Affymetrix CEL files were read and 
normalized with Affymetrix power tools to estimate the LRR and BAF at every SNP probe. All samples 
passed a standard SNP based QC procedure with average genotype call rate >0.95. We excluded SNP 
probes with call rate <0.97. We first used PennCNV package (a hidden Markov model) to segment 
CNV and define the boundaries of a CNV on autosomal chromosomes. The estimated CNVs were then 
confirmed by another software package, GoldenHelix SVS, with an optimal segmenting algorithm (the 
Copy Number Analysis Method, CNAM). A principal component analysis was applied to correct for batch 
effects. We applied several QCs to filter out low quality or questionable quality samples as follows: aver-
age LRR SD value >0.35; high total length (10% per chromosome) of CNV; and high total number of CNV 
(CNV counts >50 per sample). A total of 1,300 samples were excluded. In addition, we excluded CNV with 
less than three consecutive SNPs; CNV with length <1 kb; CNV in the regions of high GC content (80%); 
and CNVs in the immunoglobulin regions. Among 7,434 high quality genotyped samples, 112,746 CNVs 
were assigned. Fracture data were available for 3,529 of these FOS samples.
PROSPER: LRR and BAF measurements were extracted from 5,244 samples using GenomeStudio 
V2009.1. QuantiSNP v2 was used to make CNV calls. We excluded 446 samples with a mean autosomal 
LRR SD>0.25 or a BAF SD>0.08. We also excluded CNV calls that spanned the centromere (QC1, nC-
NVs=2,683,302). We discarded all CNV calls with a log Bayes factor value <10, a CNV size <1 kb or CNVs 
with less than two consecutive SNPs in the CNV event (QC2 nCNVs=1,228,214). Finally, we removed 89 
samples with an excess of CNV calls (N>344 CNVs, QC3, nCNVs=1,195,162 in 4,709 samples).
Association analysis
The genome-wide association analysis on the discovery cohort was carried out using the rare CNV 
module implemented in Plink V.1.0.5 on binary copy number differences (deletion vs no deletion be-
tween cases and controls). Ten million permutations were performed to assess the significance of the 
genome-wide association results. Each study provided counts for case–control status among carriers 
and non-carriers. Odds ratio, confidence intervals and P values were calculated using study counts in 
an exact Cochran-Mantel-Haenszel exact test statistic implemented in the stats package within the R 
statistical framework.
Quantitative PCR analysis
We validated the deletion that was found to be associated with fractures using quantitative PCR (qPCR) 
in 12 RS samples where this deletion was found. The primers for the real-time
qPCR experiments were as follows (50–30 direction):
A. forward primer: GGCAGACAGAGAAAAATGTGGC
B. reverse primer: TGTCAGCTTGATGGATTTGTCC
qPCR assays were validated by demonstrating linearity over three orders of magnitude and by observa-
tion of a single melt peak by plotting relative fluorescence units (RFU) data with
time (T) (−d(RFU)/dT) on the Y-axis as a function of temperature on the X-axis. Reactions contained 200 
nM primer; 1X KAPA SYBR FAST qPCR Master Mix and 5 ng genomic DNA.
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All reactions were performed as triplicates on an Applied Biosystems 7300 Real-Time PCR System cycle 
conditions: 94°C 3 min initial denaturation followed by 30 cycles 5 s 94°C
denaturation and 30 s 60°C primer annealing, extension and RFU data collection. Two reference targets 
were used normalizing on genomic DNA obtained from healthy individuals.
SEL1L reference
Feb. 2009 (GRCh37/hg19) Assembly chr14:81952705-
81952790 86 bp
5’-GAATGTATGTGAACGAGGCCGttggtctgaaaggcttatgactgcctataacagctataaagatgGCGATTACAATGCTG-
CAGTGA-3’
RBM11 reference
Feb. 2009 (GRCh37/hg19) Assembly chr21:15587866
+15587951 86 bp
5’-ACAAAACTGGCTCACTCTCACCagtatatcccttggtatttgctttctcaagttccttttggagtCCACTTAAAACCTCTGC-
GACC-3’
Data were analyzed using Applied Biosystems RQ Study Software V1.2.3. A fold-change <0.7 (deletion) 
or >1.25 (duplication) was considered to constitute a true event. For two subjects the assay was incon-
clusive (DNA amount was not sufficient for full qPCR cycles).
Determination of the deletion breakpoints
Sanger sequencing was used to map the breakpoints of the 6p25 deletion in a population-control 
cohort. DNA was obtained from one individual from the SAGE cohort that was genotyped with the 
Illumina 1M array and was identified as a 6p25 deletion carrier (see online Supplementary Table S5). The 
cohort and array/CNV analysis have been described previously.26 The exact breakpoints were found at 
chromosome 6 in the positions: 4,198,453 and 4,418,843 (NCBI36 hg18).
De novo genotyping
The deletion was genotyped in 15 GENOMOS studies by K-Biosciences (http://www.kbioscience.co.uk) 
using a competitive allele specific PCR (KASPar) assay designed to identify those individuals with a differ-
ent sequence at the breakpoint identified by sequencing. Allele specific sequencing to design the probe 
was set as follows: allele X: 5’-AGGAAAAAAACATGTTAGCAGGCTTCT-3’; allele Y: 5’-GGAAAAAAACATGT-
TAGCAGGCTTCC-3’. Given the low frequency of this variant, three positive controls were included in each 
plate before genotyping. All genotyped plates were evaluated to show signals for the positive controls.
CNV population database query
We queried available CNV population databases to increase the precision for the prevalence estimate of 
the deletion on a general population level and to check for population specific differences. The resources 
available were SAGE, OHI, PopGen, WTCCC2, CHOP, the Pharmacogenomics and Risk of Cardiovascular 
Disease study (PARC), the National Institute for Neurological Disorders and Stroke (NINDS), and the Hu-
man Genome Diversity Panel (HGDP), which altogether included 13,441 individuals of European, African 
American, and Asian descent from various regions throughout the world (see online Supplementary 
Table S5).19, 20, 26-30
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RESULTS
We obtained the normalized intensity data on a discovery cohort composed of 5,974 Northwestern 
European individuals from the RS-I, a population based cohort of individuals aged 55 years and over 
who had been genotyped with the Illumina 550 K Array (see online Supplementary Table S1). After QC 
(see Methods), 49,229 CNVs (mapping to 26,162 genomic locations) were identified in 5,178 individuals 
using a hidden Markov model method to segment CNV regions from microarray DNA intensity data. 
As expected, we found an inverse correlation between the size and number of CNV events (Figure 1). 
Nevertheless, 90% of the analyzed subjects presented with at least one large CNV at some position in 
the genome (length >100 kb).
Figure 1. Copy number variant (CNV) type, length, and frequency. CNVs were plotted according to event type (col-
or), length (X-axis), and frequency in the Rotterdam Study (Y-axis, number of samples N=5,178).
First, we investigated if there was a difference in the global burden of CNV events between cases with 
fractures and controls in the RS-I study. Out of 5,178 individuals, with a mean follow-up of 7.7 years, 809 
subjects presented at least one osteoporotic fracture, of which most were fractures of the hip, spine, and 
wrist. While no difference was found in the overall burden of CNV events between fracture cases and 
controls, the proportion of fracture cases with at least one or more rare (frequency <1%) deletions was 
significantly higher compared to controls (OR 1.04, P=0.03).
Next, we tested the association of segmental rare deletions across the genome with fracture risk in 
the RS-I study. A rare (population prevalence 0.14%, 95% CI: 0.03%–0.24%) 210 kb deletion located on 
chromosome 6p25.1 (Figure 2A) was the only significantly associated locus with fracture risk after adjust-
ing for multiple testing based on permutations of individual level data (OR 32.58, 95% CI: 3.95–1,488.89; 
P=8.69×10−5; permuted P=0.027).
We then attempted to replicate this association of the 210 kb deletion on 6p25.1 with fracture in four 
additional cohort studies with CNV microarray data: the RS II (N=2,157, 161 cases), FOS (N=3,513, 367 
cases), deCode Genetics Study (dCG, N=38,250, 178 cases), and a multicenter randomized clinical trial 
entitled the PROspective Study of Pravastatin in the Elderly at Risk Study (PROSPER_SC, PROSPER_IR, 
PROSPER_NL, N=4,708, 390 cases). In FOS, we found four cases and 12 non-fracture controls with one 
copy deletion in the 6p25.1 region.
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c
Figure 2.  Identification and validation of deletions at 6p25.1. (A) 210 kb deletions were first identified in six fracture 
cases and one control from the Rotterdam Study I (RS-I). Additional carriers from the RS-II and Framingham Osteopo-
rosis Study are also depicted. Refseq genes and OMIM associated genes are depicted. (B) Quantitative PCR validation 
of 12 carriers in the RS (for two samples the assay failed). The third sample, labelled as ‘Duplication’, is a FISH (fluores-
cence in situ hybridization) validated complete 6p arm duplication. (C) Validation of a sequence based breakpoint 
detection of the 6p25.1 deletion. Twelve deletion carriers (wells A1, C1, E1, G1, A2, C2, E2, B2, B1, C1, E1, H1) show 
amplified PCR product exactly with the same length as the sequenced controls.
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Among them, two cases and six controls had a smaller deletion (~26 kb) inside the same 6p25.1 
region (Figure 2A). The remaining two cases and six controls had exactly the same size of deletion in the 
6p25.1 region. Both CNVs were aggregated in families and segregated from parents to offspring in FOS. 
We included samples with either one of the CNVs in the CNV-fracture association analyses.
The increased prevalence of this 6p25.1 deletion in fracture cases was replicated in RS-II (1.24% in 
cases, 0.17% in controls) and FOS (1.09% in cases, 0.38% in controls) studies (Table 1). The 6p25.1 deletion 
was present in three controls from the PROSPER study, but we did not find the 6p25.1 deletion either in 
Table 1. Association results of 6p25.1 deletion with increased fracture risk.
Stage Study Country Deletions/total cases Frequency in 
cases (%)
Deletions/total 
controls
Frequency in 
controls (%)
Discovery RS-I Netherlands 6/809 0.74 1/4,369 0.02
Frequency 
(95%CI)
0.74% (0.15–1.33) 0.02 (0–0.20)
32.58(3.95–1,488.89)
OR (95%CI) P=8.69x10-5
In silico dCG Iceland 0/178 0 0/38,072 0
Replication FOS USA 4/367 1.09 12/3,146 0.38
PROSPER_IR Ireland 0/141 0 1/1,650 0.06
PROSPER_NL Netherlands 0/57 0 0/756 0
PROSPER_SC Scotland 0/192 0 2/1,912 0.10
RS-II Netherlands 2/161 1.24 3/1,804 0.17
Total 6/1,096 0.55 18/47,340 0.04
Frequency 
(95%CI)
0.18% 
(0.11–0.98)
0.04 
(0.02–0.05)
OR (95%CI) 3.11(1.01–8.22) P=0.02
Breakpoint APOSS Scotland 0/531 0 0/2,129 0
Genotyping CABRIO-C Spain 1/327 0.31 3/1,018 0.29
Replication CABRIO-CC Spain 4/1,023 0.39 3/1,104 0.27
CAIFOS Australia 0/736 0 0/581 0
CAMOS Canada 0/235 0 0/1,732 0
DOPS Denmark 0/410 0 0/1,242 0
EDOS Scotland 0/1,500 0 0/193 0
EPICNOR England 0/227 0 1/1,127 0.09
EPOLOS Poland 0/231 0 0/446 0
EPOS England 1/686 0.15 2/1,289 0.16
HCS England 0/339 0 3/2,308 0.13
LASA Netherlands 0/313 0 3/562 0.53
MANMC Canada 0/750 0 0/0 0
NOSOS Scotland 0/342 0 0/740 0
UFO Sweden 0/2,110 0 0/2,071 0
Total 6/9,760 0.06 15/16,542 0.09
Frequency 
(95%CI)
0.06% (0.01–0.11) 0.09%(0.04–
0.14)
OR (95%CI) 0.78 (0.24–2.24) P=0.81
P, P value computed with an exact Cochran-Mantel-Haenszel test statistic.
dCG, Icelandic deCODE Genetics Study; FOS, Framingham Osteoporosis Study; RS, Rotterdam Study
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cases or in controls of the dCG study (Table 1). Combining the data from the in silico replication studies 
(RS-II, FOS, dCG, and PROSPER) using a Cochran-Mantel-Haenszel test yielded a significant threefold 
increase in the risk of fracture (OR 3.11, 95% CI: 1.01–8.22; P=0.02) (Table 1).
We validated the presence of this variant with qPCR (see Methods) in 12 6p25del carriers of the RS-I 
and RS-II cohorts. Ten of them showed clear evidence for deletion (Figure 2B). The microarray data in 
these 12 samples suggested a common breakpoint for all carriers (Figure 2A). To identify the breakpoint 
at a base pair resolution, we sequenced one sample in which the 6p25del had been identified (see 
Methods). Validation of the sequence level PCR gel to detect this deletion in the same 12 deletion carri-
ers and 12 controls showed perfect assignment of carrier status as determined from the microarray data 
(Figure 2B). Thus, we can conclude that all 12 carriers from the Rotterdam Study share exactly the same 
breakpoint at sequence level.
We then designed a Kaspar genotyping assay using the sequence level breakpoint information to per-
form de novo genotyping of this deletion in an additional set of 9,760 fracture cases and 16,542 controls 
from 15 independent studies across Europe, Australia, and Canada (Figure 2C and online Supplementary 
Table S1). Despite having a large sample size, we could only detect 21 additional 6p25del carriers (fre-
quency <0.1% in both cases/controls) with no significant association with fracture risk (P=0.81) (table 1).
We queried six available CNV population data bases for the prevalence of this deletion (see online 
Supplementary Table S5; SAGE N=1,287 European, 495 African Americans from USA; OHI N=1,234 
European from Canada; PopGen N=1,123 European from Germany; WTCCC2 N=4,783 European from 
UK; CHOP N=1,320 European, 694 African American, 12 Asian from USA; a combined dataset from PARC, 
NINDS, and the HGDP N=2,493 individuals from different ethnicities and countries of origin).19 20 26–30 
The deletion was identified in five out of six studies: SAGE (1/1,287), OHI (5/1,234), PopGen (0/1,123), 
WTCCC2=7/4,783, CHOP (4/1,320), PARC (2/936), NINDS (2/671), HGDP (0/886). All carriers were found 
in samples of European ancestry. The deletion was not found in 886 samples from the Human Genome 
Diversity Project (51 different world populations) or in two studies of African ancestry (see online Supple-
mentary Table S5).
DISCUSSION
We report here a genome-wide scan for CNVs and risk of fracture assessed in the RS-I cohort. A micro-
deletion in 6p25.1 was found to be associated with increased risk of fracture and remained significant 
after permutation testing. The deletion was validated with qPCR and was also replicated in silico in two 
additional studies: RS-II and FOS; the deletion was only found in three controls of the PROSPER study 
and it was not found in the deCode study. Combining all four in silico replication studies, the deletion is 
associated with a threefold higher risk of bone fracture in individuals of mainly Dutch and US American 
ancestry. Additional replication was pursued using breakpoint genotyping in 15 studies; however, the 
deletion was only found in six of the 15 studies with no replication of association with fracture risk.
The frequency of this deletion showed regional variation, being present in studies of the Netherlands 
(0.34%), Spain (0.33%), USA (0.23%), England (0.15%), Scotland (0.10%), and Ireland (0.06%) (Table 1). The 
deletion seems to be absent or in lower frequency in certain populations such as Iceland (dCG) and 
Sweden (UFO) where, despite having assessed more than 30,000 and 4,000 subjects for each popula-
tion, respectively, no additional carriers were found. Founder effects can effectively remove rare variants 
from the gene pool in a population. These population effects could explain why we did not detect the 
6p25.1 microdeletion in 30,000 individuals from a population with relatively similar genetic background 
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(Iceland) as the one in which we found the microdeletions (Northwestern European from Netherlands 
and USA).
While replication of the association with fracture risk in two cohorts was achieved using in silico data, 
the meta-analysis of de novo genotyped studies was not statistically significant. There are several poten-
tial explanations for the lack of replication in this subset of studies. First, limitations in study power could 
make it difficult to identify a significant association (at P<0.05) with a variant of such low frequency. 
Considering an OR=3, and a minor allele frequency (MAF)=0.05% in controls, almost 18,000 cases and an 
equal number of controls would be needed to reach 80% power. Secondly, it is possible that while 12 of 
the microarray based carriers in the Rotterdam Study share the same breakpoint, other 6p25del carriers 
may have different breakpoints (such as the eight carriers with a smaller 26 kb deletion detected in FOS) 
which were not detected by our specially designed genotyping probe. Thirdly, it may be possible that a 
two-hit model involving a yet unknown genetic variant is affecting the predisposition of 6p25del carriers 
to an increased risk for fracture. Finally, some degree of misclassification may have occurred, as carriers 
currently classified as controls may eventually develop a fracture later in life; this could have potentially 
affected our results.
The deletion is located in an intergenic region in the subtelomeric region of chromosome 6p (Fig-
ure 2A) in the proximity of the peroxisomal D3,D2-enoylCoA isomerase (PECI) gene which codes for an 
enzyme relevant for the metabolism of fatty acids. PECI was first cloned by using pooled antisera from 
autoimmune diabetes patients.31 Hence, it is possible that even though the 6p25.1 microdeletion is 200 
kb away from PECI, this region may be regulating the expression of PECI. Both type 1 and type 2 diabetes 
are associated with higher risk of fracture, even though bone density is not low.32-36 Thus, the increased 
risk we see with individuals with the 6p25del may be mediated by comorbidity with diabetes.
Another candidate hypothesis is that microdeletions in 6p25.1 are disrupting an unidentified gene in 
the critical region. A similar mechanism was shown in which microdeletions of 1q21.1 disrupted an ex-
pressed sequence tag (EST) that was in fact an unknown gene which subsequently increased the risk for 
neuroblastoma.37 There are two spliced ESTs that map to the 6p25 region covered by the microdeletions 
(Figure 2A). One of the ESTs, AL121205.1, shares 33% of its structure with the KREMEN1 gene. KREMEN1 
encodes a high affinity dickkopf homolog 1 (DKK1) transmembrane receptor that cooperates with DKK1 
to block Wnt/β-catenin signaling, which is an important pathway in bone biology.38 The second EST, 
DB318881.1, shares 38% structural similarity with WDR66, which does not have any clear connection to 
our findings. Further analyses are required to test whether the deletion of those ESTs are indeed related 
to the increased risk of fracture.
Other individuals have been reported with the same microdeletion in different populations of Cauca-
sian origin.20, 29 These reports provide further evidence of the existence of this rare microdeletion in other 
populations. Similarly, it has been reported that patients with 6p25 microdeletions present a variety of 
phenotypes such as ocular dysgenesis, hearing impairment, and craniofacial, skeletal, cardiac, and renal 
malformations.39-42 However, these deletions are much larger (from 1 to 13 Mb in size), and cover many 
genes. Therefore, the relation of those larger events with the association we found between the 6p25.1 
microdeletion and fractures is not direct.
Our study has three particular strengths: (1) samples from the discovery and in silico replication sets 
were drawn from cohort studies where cases and controls were genotyped at random in the same 
laboratory. This is important for avoiding the biases that occur when cases are genotyped at different 
time points or centers than controls are; (2) DNA was extracted from blood for samples used for the 
discovery of this CNV—the use of other DNA sources such as cell lines can introduce noise in CNV 
- 275 -
A 
ge
no
m
e-
w
id
e 
co
py
 n
um
be
r a
ss
oc
ia
tio
n 
st
ud
y o
f o
st
eo
po
ro
tic
 fr
ac
tu
re
s
4.3
analysis; (3) our discovery sample size was large enough to detect rare variants (~1%) with large effects 
(OR >3) and we also replicated the association in the independent studies in silico; (4) we validated the 
microdeletion using different technologies (qPCR, Sanger sequencing and Kaspar).
Performing a genome-wide scan for CNVs has limitations. Because the SNP arrays that we used for the 
discovery phase were not designed to evaluate CNVs, many CNV enriched regions were not covered in 
this study, and may not have been identified in our scan. Also, to minimize the rate of false positive CNV 
calls, we used stringent QC thresholds which may have filtered out real CNV calls.
In summary, we have shown that a microdeletion of 6p25.1 is associated with an increased risk of 
fracture in a group of populations mostly of Dutch origin. Further studies are needed to replicate this 
variant in populations of similar ancestral background and to identify the specific gene or genes in the 
region for which this deletion contributes to an increased risk for fracture. Although this event is rare, the 
effect on fracture risk was substantially greater than the effects usually observed for SNPs. If rare CNVs 
have similar degrees of effect as the one detected here, it might be possible to identify them with better 
powered genome scans, not only for fracture risk but also for other human traits and diseases.
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ABSTRACT
Vertebral fracture risk is a heritable complex trait. The aim of this study was to identify genetic suscep-
tibility factors for osteoporotic vertebral fractures applying a genome-wide association study (GWAS) 
approach. The GWAS discovery was based on the Rotterdam Study, a population-based study of el-
derly Dutch individuals aged 55 years; and comprising 329 cases and 2,666 controls with radiographic 
scoring (McCloskey–Kanis) and genetic data. Replication of one top-associated SNP was pursued by 
de-novo genotyping of 15 independent studies across Europe, the United States, and Australia and 
one Asian study. Radiographic vertebral fracture assessment was performed using McCloskey–Kanis or 
Genant semi-quantitative definitions. SNPs were analyzed in relation to vertebral fracture using logistic 
regression models corrected for age and sex. Fixed effects inverse variance and Han–Eskin alternative 
random effects meta-analyses were applied. Genome-wide significance was set at P<5×10−8. In the 
discovery, a SNP (rs11645938) on chromosome 16q24 was associated with the risk for vertebral fractures 
at P=4.6×10−8. However, the association was not significant across 5,720 cases and 21,791 controls 
from 14 studies. Fixed-effects meta-analysis summary estimate was 1.06 (95% CI: 0.98–1.14; P= 0.17), 
displaying high degree of heterogeneity (I2=57%; Qhet P=0.0006). Under Han–Eskin alternative random 
effects model the summary effect was significant (P=0.0005). The SNP maps to a region previously 
found associated with lumbar spine bone mineral density (LS-BMD) in two large meta-analyses from the 
GEFOS consortium. A false positive association in the GWAS discovery cannot be excluded, yet, the low-
powered setting of the discovery and replication settings (appropriate to identify risk effect size >1.25) 
may still be consistent with an effect size <1.10, more of the type expected in complex traits. Larger 
effort in studies with standardized phenotype definitions is needed to confirm or reject the involvement 
of this locus on the risk for vertebral fractures.
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INTRODUCTION
Vertebral fractures are the most common osteoporotic fractures and represent a significant health is-
sue.1, 2 Epidemiological measures derived from population-based studies vary between 1 and 3% per 
year for incidence and ~10 and 30% for the prevalence in elderly persons, varying by age, gender and 
geographic region.3-5 Vertebral fractures are associated with a high morbidity,6-11 mortality12, 13 and a con-
siderable financial burden. In the United States the costs of vertebral fractures were estimated to be 1.1 
billion dollars in the year 2005, and are expected to rise by more than 50% by the year 2025.14 A recent 
report estimated the costs of vertebral fractures in Europe at 1.5billion euros in 2010.15 Furthermore, 
vertebral fractures are likely to become an increasingly important health issue with the increasing age of 
populations1, 14, 15 and their association with increased risk of future osteoporotic fractures at other skel-
etal sites7, 16, 17. For all of these reasons, a better understanding of the genetic susceptibility to vertebral 
fracture has the potential to identify underlying biological mechanisms, improve risk prediction and lead 
to novel disease interventions.
Vertebral fracture risk is a heritable complex trait, also influenced by environmental, and gene–en-
vironment interactions.18, 19 A positive family history for vertebral fracture constitutes an independent 
risk factor for future fractures,20 emphasizing the importance of genetics in the pathogenesis of the 
disease. The hypothesis-free genome-wide association study (GWAS) approach has been particularly 
successful in identifying loci associated with many diseases and quantitative complex traits,21 including 
osteoporosis18, 22-24.
The aim of our study was to better understand the genetic architecture of radiographic vertebral 
fractures by conducting the first GWAS for this trait in a large population-based study of elderly Dutch 
individuals and pursuing replication in a large set of studies across Europe, the United States, Australia 
and Asia.
METHODS
Datasets assessed
Sample discovery phase
The discovery sample was confined to the original Rotterdam Study cohort, a large population-based 
study of Dutch men and women aged 55 years and over (mean age at vertebral fracture assessment: 
73.5 years). A detailed description of the Rotterdam Study has been reported previously.25 In short, the 
study aimed to assess the incidence and determinants of disease and disability in elderly persons. The 
study has been approved by the Medical Ethics Committee of the Erasmus University Medical Center 
Rotterdam.
Sample replication phase
The Genetic Factors for Osteoporosis (GEFOS), Genetic Markers for Osteoporosis (GENOMOS) and 
Anglo-Australasian Osteoporosis Genetics Consortium (AOGC) are three consortia studying the genetic 
determinants of osteoporosis-related skeletal phenotypes in populations with available DNA and/or 
GWAS data.23, 26-29 Within this setting, 15 studies with both DNA samples and lateral morphometry-
derived vertebral fracture data participated in the replication phase of this project (Supplementary Table 
1). More detailed descriptions are available in the Supplementary material.
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The AOGC — Geelong Osteoporosis Study (AOGC-GOS) is a cohort drawn from the Geelong general 
population. Vertebral fracture imaging was performed in case of a clinical indication.30, 31 The AOGC — 
Sheffield (AOGC-SHEFFIELD) study constitutes a large population-based cohort of community-dwelling 
elderly women aged ≥75 years in Sheffield, UK.32 AROS (Aarhus Osteoporosis Study) is a case–control 
study, including 462 osteoporotic patients (vertebral fracture and T score <−2.5) and 336 controls.33 AUS-
TRIOS is a prospective cohort study of elderly female patients above 70 recruited in 95 nursing homes in 
four counties in Austria. The AUSTRIOS-B cohort had vertebral fracture data available and was used for 
this project.34 The Cantabria-Camargo (CABRIO-C) and Cantabria Case–Control (CABRIO-CC) studies are 
based in Northern Spain. CABRIO-C is a community-based study designed to evaluate the prevalence of 
metabolic bone diseases in postmenopausal women and men older than 50 years attending a primary 
care center in Santander.35, 36 CABRIO-CC is a clinic-based study of control individuals and patients with 
osteoporosis living in Cantabria, a region in Northern Spain.37, 38 The Calcium Intake Fracture Outcome 
Study (CAIFOS) is a randomized-controlled trial investigating calcium carbonate supplementation 
Table 1. Vertebral fracture assessment.
Cut-off values used Fractures 
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by experta
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RS-I McCloskey-Kanis 329 2,666 0.11 YES YES YES NA YES
AOGC McCloskey-Kanis 686 3,411 0.17 YES NO YES NA YES
AROS Genant 335 130 1:0.39b NO NO NA 20% YES
AUSTRIOS-B Genant 803 1,261 0.39 NO NO NA 20% YES
CABRIO-C Genant 195 1,185 0.14 NO NO NA 20% YES
CABRIO-CC Genant 220 354 1:1.61b NO NO NA 20% YES
CAIFOS McCloskey-Kanis 428 600 0.42 YES NO YES NA YES
CaMos McCloskey-Kanis 243 1,785 0.12 YES NO NA NA YES
DOPS Genant 108 1,605 0.06 NO NO NA 20% YES
EDOS Genant 495 523 0.49 NO NO NA 20% YES
EPOS McCloskey-Kanis 313 1,779 0.15 YES YES YES NA YES
FOS Genant 417 2,291 0.15 NO NO NA 20% YES
KorAMC Genant 101 1,193 0.08 NO YES NA 20% YES
LASA Genant 237 268 0.47 NO NO NA 20% YES
MrOS 
Swedene
Genant 309 2,613 0.11 NO NO NA 20% NO
PERF Genant 830 2,793 0.23 NO NO NA 20% NO
aE.g., radiologist/clinician, to rule out artifacts and other etiologies, such as pathological fractures.
bPrevalence in population-based studies, case:control ratio in case–control studies.
cAny of the three vertebral heights (anterior, central, or posterior) shows a minimum decrease of at least 4mm.
d3 SD relative reduction of 2 out of 3 ratios: (ha/hp; hm/hp; hp/hp predicted).
ePrevalent X-ray verified vertebral fractures only available for about 1,425 subjects.
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in ambulatory women older than 70 years recruited in Perth, Australia.39 The Canadian Multicentre 
Osteoporosis Study (CaMoS) is a population-based prospective cohort of unrelated men and women 
followed for osteoporosis and osteoporotic fractures for the past 14 years.40-42 The Danish Osteoporosis 
Prevention Study (DOPS) is a population-based study of perimenopausal women. The women were 
followed for 10 years and approximately 35% were treated with hormone-replacement therapy (HRT).43 
The Edinburgh Osteoporosis Study (EDOS) consists of a clinical referral population of patients assessed 
for evaluation of osteoporosis in Edinburgh, United Kingdom. The European Prospective Osteoporosis 
Study (EPOS) is the prospective phase of the European Vertebral Osteoporosis Study (EVOS) in which 
population-based samples had paired duplicate spinal films. Men and women from 36 centers in 19 
European countries were recruited.5, 44, 45 The Framingham Osteoporosis Study (FOS) is an ancillary study 
of the Framingham Study, a multigenerational family based cohort study originally initiated to study 
the risk factors for cardiovascular disease.46-48 Vertebral fracture assessment was done on multidetector 
computed tomography (CT) lateral scout views. The Korean osteoporosis study at Asan Medical Center 
(KorAMC) study is a hospital registered, cross-sectional study of postmenopausal Korean women in 
Seoul.49 The Longitudinal Aging Study Amsterdam
(LASA) is an ongoing multidisciplinary cohort study in older persons. A random sample of men and 
women aged 55 years and over, stratified by age, sex, urbanization grade and expected 5-year mortality 
rate was drawn from the population register of Amsterdam, The Netherlands.50 The Osteoporotic Frac-
tures in Men Sweden (MrOS Sweden) study is a multicenter, prospective study including elderly men. 
Study subjects (men aged 69–80 years) were randomly identified using national population registers, 
contacted and asked to participate. Eligible subjects had to be able to walk without assistance, provide 
self-reported data, and sign an informed consent.51 The Prospective Epidemiological Risk Factor (PERF) 
Study is based on subjects who were screened for or enrolled into randomized controlled clinical trial to 
identify genetic and other risk factors of diseases in the elderly in Copenhagen, Denmark.52
Phenotyping
Osteoporosis-related skeletal phenotypes in the discovery sample
During the second follow-up visit between 1997 and 1999 all Rotterdam Study participants underwent 
radiographic screening. A trained research technician obtained lateral radiographs of the thoracolumbar 
spine following a standard protocol. Radiographs were evaluated morphometrically in Sheffield, UK, by 
the McCloskey–Kanis method as described previously.53 Using this method, central collapse, anterior 
and posterior wedge, and crush deformities were identified based on a cut point of 3 standard deviation 
height reductions. All vertebral fractures were confirmed by visual interpretation by an expert in the 
field to rule out artifacts and other etiologies, such as pathological fractures. Cases were defined as 
those individuals who had at least one vertebral fracture, and controls were defined as those who were 
free of vertebral fractures. Bone mineral density (BMD) of the femoral neck (FN) and lumbar spine (LS) 
was measured by dual-energy X-ray absorptiometry (DXA), using a Lunar DPX-L densitometer (Lunar 
Radiation Corporation, Madison, WI, USA).
Other measurements (covariates) in the discovery sample
An extensive baseline home interview on medical history, risk factors for chronic diseases, and medi-
cation use was performed on all participants by trained interviewers. Smoking habits were coded as 
“current”, “former” and “never”. Self-reported age at natural menopause between 40 and 60 years, defined 
as 12 months after periods ceased, was collected retrospectively. Information on medication use in-
Ch
ap
te
r 4
.4
- 284 -
cluded hormone replacement therapy and systemic corticosteroids. Alcohol intake was assessed from 
a validated semi-quantitative food frequency questionnaire. Height and weight were measured with 
indoor clothing and no shoes. Body mass index (BMI) was calculated as weight (in kg) / height (in m2).
Phenotyping replication phase
Vertebral fracture assessments differed by cohorts which applied either the McCloskey–Kanis53 or the 
Genant semi-quantitative method54. Detailed description of the methods and cut-offs applied by each 
study is available in Table 1. Four of the replication studies used the McCloskey–Kanis method, which is 
similar to the discovery (Rotterdam Study), of which one study applied the same additional criterion of 
absolute height reduction. Phenotyping for covariates was similar to that of the discovery sample.
Genotyping
Genome-wide association data
The Rotterdam Study participants were genotyped using the Illumina Infinium HumanHap550 Beadchip 
in the Genetic Laboratory of Erasmus MC Department of Internal Medicine, The Netherlands, following 
manufacturers’ protocols and quality control standards.
Single nucleotide polymorphism (SNP) genotyping
The top associated SNP from the discovery phase (rs11645938) was genotyped in 15 studies within 
three main genotyping centers: deCODE Genetics in Reykjavik, Iceland, Queensland University in Bris-
bane Australia and KBiosciences, Hertfordshire, U.K. (www.kbioscience.co.uk). Genotyping was carried 
out by personnel blinded to patient status in all centers. The samples genotyped by KBiosciences were 
part of the GENOMOS consortium DNA collection, and comprise most of the participating studies. For 
KBiosciences, a minimum of 1.5μl of DNA at 3.3ng/μl (when quantitated by PicoGreen analysis or 7 ng/
μl if quantitated by spectrophotometry) was required for one SNP to be assayed using their proprietary 
KASPar PCR technique and Taqman (also used by Brisbane University for AOGC samples). Genotype 
calling was carried out using an automated system, the results of which were checked manually by 
study personnel using SNPviewer software (KBiosciences). deCODE used the same KASPar assay from 
KBiosciences to genotype the PERF study samples. To ensure genotyping validity across study centers, 
a reference plate was shipped from KBiosciences to the AOGC coordinating center. To ensure correct 
genotyping deCODE Genetics genotyped 92 HapMap samples for comparison with the KASPar assay, 
and both positive and negative samples were present on all genotyping plates. Additionally, duplicate 
SNP genotyping was performed in the Rotterdam Study (all samples) and CABRIO-C (random selection 
of 187 samples) and no discrepancies were found.
Statistical methods
Within the discovery cohort, we tested 2,543,887 genotyped or imputed (HapMap CEU release 22, build 
36)55, 56 SNPs for association with risk of osteoporotic vertebral fractures using a logistic regression model 
(MACH2DAT)57, 58 adjusted for age, gender, and admixture principal components (PCs) derived using EI-
GENSTRAT to adjust for population substructure59. Potential effect modifiers for the relationship between 
genotype and vertebral fracture (i.e., height, weight, BMI, age at menopause, HRT use, corticosteroid use, 
>3 units alcohol use per day, current and ever smoking) were tested by adding them one at a time to the 
regression model and evaluating the change in both the effect estimate and significance. The GWAS was 
performed using a web-based interface (GRIMP) on scalable super-computing grid infrastructures.60 At a 
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genome-wide significant α-level of 5×10−8, the design had 0.80 power to detect risk effect sizes (OR) of 
1.8 to 2.1 for minor allele frequencies (MAF) of 20% to 10%, respectively.
Replication analyses
Except for the FOS and AOGC studies, all analyses were carried out centrally by the Rotterdam Coordinat-
ing Center. Again a logistic regression model adjusting for age and gender was used. Individuals with 
either missing genotype or phenotype data were excluded from analysis. Initially, fixed effects inverse 
variance meta-analysis was performed (METAL software61). The presence of statistically significant het-
erogeneity was assessed by Cochran’s Q statistic (Qhet P) and the extent of the observed heterogeneity 
was measured by the I2 metric. Han–Eskin alternative random effects meta-analysis was applied when 
the I2metric exceeded 50% as this model is optimized to detect associations under heterogeneity 
(Metasoft software62). SPSS 16.0, PLINK, and R software were used for the rest of the analyses. In addition, 
the Framingham Study analysis used population-based generalized estimating equation (GEE) approach 
correcting for correlations owing to family relationships and PCs. The replication setting incorporating 
5,720 cases and 21,791 controls from 14 studies was powered to identify a variant with a MAF of 0.10 and 
risk effect size >1.25, associated at P<5×10−8.
RESULTS
The description of the studies included in the discovery and replication phases is shown in Supplemen-
tary Table 1. Description of the vertebral fracture assessment done across studies is presented in Table 
1 while baseline characteristics of the study populations are shown in Supplementary Table 2. In the 
discovery set, 329 of the 2,995 Rotterdam Study participants had at least one vertebral fracture evident 
on the spinal radiographs. A genotyped SNP (rs11645938) on chromosome 16q24 (MAF=10%) was as-
Table 2. Descriptive information about genotyping of the rs11645938 SNP and association statistics per study.
Study SNP call rate P value Hardy-
Weinberg 
Equilibrium
Minor Allele 
Frequency
Effect estimate 
(Beta)
Standard error P value
RS-I 99.9% 0.52 9.65% 0.669 0.122 4.6×10−8
AOGC 93.7% 0.83 9.74% -0.11 0.11 0.33
AROS 99.3% 0.79 9.76% 0.22 0.31 0.61
AUSTRIOS-B 97.0% 0.96 11.74% -0.18 0.16 0.26
CABRIO-C 99.1% 0.84 7.71% -0.51 0.25 0.04
CABRIO-CC 99.1% 0.61 8.98% -0.16 0.26 0.53
CAIFOS 99.2% 0.02 10.01% -0.02 0.15 0.91
CaMos 99.0% 0.12 9.57% 0.09 0.16 0.50
DOPS 98.6% 0.17 10.01% -0.13 0.25 0.59
EDOS 99.4% 0.99 9.45% 0.07 0.16 0.65
EPOS 99.6% 0.80 9.62% 0.15 0.16 0.75
FOS 97.6% 0.86 9.97% -0.04 0.14 0.78
KorAMC 97.8% NA 0.00% NA NA NA
LASA 100.0% 0.82 11.16% -0.06 0.22 0.79
MrOS Sweden 98.6% 0.49 9.77% 0.07 0.16 0.69
PERF 100.0% 0.79 9.45% 0.04 0.10 0.70
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sociated at a genome-wide significant level (P=4.6×10−8) with an increased risk of vertebral fractures 
(Figure 1). Compared to the risk of non-carriers, the odds of the heterozygous carriers of the minor allele 
(C) was 1.7 times higher (95% confidence interval [CI]: 1.3–2.3) and that of the homozygous carriers was 
5.8 times higher (95% CI: 2.7–12.8) (Supplementary Figure 1). Figure 2 shows the regional association 
plot of the locus, where a cluster of FOX genes maps ~200 kb from the associated SNP, containing 
FOXF1, MTHFSD, FOXC2, and FOXL1. Further adjusting for potential confounders did not influence either 
the effect estimate or the significance of the association between genotype and vertebral fracture risk. 
Similarly, the association remained significant after adjustment for either LS- or FN-BMD. Sex-stratified 
association analysis for the SNP, showed similar effect estimates (OR heterozygote men: 1.8 [95% CI: 
1.2–2.8] and OR heterozygote women: 1.6 [95% CI: 1.1–2.3]; OR homozygote women: 8.4 [95% CI: 
3.0–23.0] and OR homozygote men 3.3 [95% CI: 0.9–12.7]).
The associated SNP rs11645938 was successfully genotyped in 14 of the replication studies (5,722 ver-
tebral fracture cases and 21,793 controls; MAF ~8–12%) while it was found to be monomorphic in the 
Korean population of the KorAMC study (Table 2). The summary effect estimate for vertebral fracture risk 
obtained from the meta-analysis was 1.06 (95% CI: 0.98–1.14; P=0.17) and the effect estimate displayed 
high degree of heterogeneity with I2=57% and Qhet P=0.0006 (Figure 3). When considering a Han–Eskin 
alternative random effects meta-analysis model the summary effect was significant (p = 0.0005). When 
applying more stringent genotyping criteria (call rate >95%; Hardy–Weinberg equilibrium P<0.05) the 
association became significant in both the fixed (P=0.045) and Han–Eskin alternative random effects 
meta-analysis (P=0.0002).When further restricting analyses only to those studies that used the Mc-
Closkey–Kanis assessment a consistent, nonetheless not a statistically significant, effect direction was 
observed (replication P=0.29).
DISCUSSION
To our knowledge, this is the first GWAS for radiographically determined vertebral fracture. A marker on 
chromosome 16q24 was genome-wide significantly associated with vertebral fracture in the Rotterdam 
Study discovery set. However, this association was not significant in a replication effort including 15 
studies world-wide using conventional statistical analysis techniques.
Figure 1.  Manhattan plot of negative logarithm P values plotted by chromosome, showing that a SNP on chromo-
some 16q24 was associated at a genome-wide significant level with osteoporotic vertebral fractures (P=4.6×10−8) in 
the Rotterdam Study (encircled).
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Work by Stankiewicz et al. implicated deletions/mutations in this 16q24 locus in the VACTERL as-
sociation (Vertebral anomalies, Anal atresia, Cardiovascular anomalies, TracheoEsophageal fistula, Renal 
and Radial anomalies, Limb defects), a non-random association of birth defects that includes vertebral 
defects.63FOXC2, mapping ~200 kb upstream from the associated SNP, is highly expressed in human 
bone tissue, and its expression is regulated by bone morphogenetic proteins64. The gene is involved in 
osteoblast differentiation through activation of canonical Wnt/β-catenin signals,65 and in mice Foxc2 
functions as a transcription factor essential for axial skeletogenesis66. The vertebral fracture associated 
SNP maps to a region previously found to be associated with LS-BMD in a meta-analysis of 19,125 
individuals23 and further replicated in 83,894 individuals22. However, the vertebral fracture SNP was not 
associated with either LS- or FN-BMD in our study and this signal was independent of the one previously 
reported for the BMD SNP rs10048146 (r2=0.002).
Despite the underlying biological plausibility supporting this association and even with identifying a 
genome-wide significant signal in the discovery GWAS, replication in independent studies is still need-
ed.21, 67, 68 Subsequently, de-novo direct genotyping of rs11645938 in 5,720 cases and 21,791 controls, 
from multiple independent studies around the world, did not provide robust evidence for replication 
of the association. Therefore, there is a high likelihood of the signal being a false-positive signal. It is 
expected that discoveries at underpowered settings would have low positive predictive value for true 
findings and this applies even for signals that pass a stringent genome-wide significance threshold.69 
However, other considerations might have also contributed to an apparent lack of replication of a 
potentially true association, and these will serve to inform the design of future GWAS of the vertebral 
fracture phenotype.
*
Figure 2.  Regional association plot showing position on chromosome 16 and association P values of the analyzed 
SNPs in the Rotterdam Study with neighboring genes. Included are genotyped, HapMap II and 1000 Genomes im-
puted SNPs. The rectangle is the SNP of interest, and the circles represent neighboring SNPs with their respective 
correlation with the topmarker. The spikes depict the recombination rates. The position of the rs10048146 SNP that 
has previously been found as associated with lumbar-spine bone mineral density is indicated with *.
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Signals in underpowered settings are likely to display inflated effects due to the “winner’s curse” phe-
nomenon, where the effect estimate observed in the first study overestimates the actual risk observed 
at the general population level.70-72 According to a post-hoc calculation for the replication phase, the 
current design had merely 0.42 power to detect an OR of 1.2. The study sample should have included 
more than 8,000 cases to achieve 0.80 power, and we know that typically GWAS of complex traits even 
requires close to 30,000 cases to identify truly associated SNPs with moderate allele frequencies (e.g., 
MAF=0.10) in a powered setting. Previous efforts have pointed out that SNPs with MAF<10% tend to 
be difficult to replicate due to the lack of statistical power.73 Thus, we cannot yet exclude the possibility 
that the identified association has a very small, yet genuine effect.74 Larger-scale GWAS meta-analyses 
for osteoporotic vertebral fractures are seriously needed.
GWA studies rely on the principle of linkage disequilibrium (LD) where markers are tested under the 
assumption they tag an underlying causal genetic variant. When the linkage disequilibrium structure 
in the region differs across populations this may result in decreased power and lack of replication.75-78 
The rs11645938 marker is not in LD with any other marker contained in HapMap and only in moderate 
LD with one marker (r2=0.41 with rs11647070) from the 1000 Genomes Project. This observation led 
us to conclude that existing GWAS without the rs11645938 on their arrays would be poorly imputed, 
which was the case in the FOS and AOGC studies, and therefore to overcome this, de-novo genotyping 
of the marker was performed in these studies. However, strictly speaking, genotyping in the Australian 
Figure 3.  Forest plot showing meta-analysis results of vertebral fracture risk for rs11645938 in discovery and replica-
tion studies. Effect estimates represented by squares are displayed on a logarithmic scale, with horizontal lines cor-
responding to 95% confidence intervals. The center line of the diamond stands for the overall summary measure, and 
its horizontal line indicates the 95% confidence interval.
- 289 -
G
en
om
e-
w
id
e 
as
so
ci
at
io
n 
st
ud
y f
or
 ra
di
og
ra
ph
ic
 v
er
te
br
al
 fr
ac
tu
re
s
4.4
AOGC and CAIFOS studies did not attain conventional criteria for unknown reasons. Further, the SNP is 
monomorphic in Asian populations.
Despite the fact that all studies used radiological assessments, a critical issue to bear in mind is the 
phenotype definition, considering that diverse methods and cut-offs exist for the assessment of ver-
tebral fractures.79 Phenotype measurement differences are a known possible source of heterogeneity, 
which might be reflected in our study by the great variation in vertebral fracture prevalences among the 
studies. Noticeably, prevalence estimates varied between 6% and 49% in the cohort studies. Further-
more, quantitative scoring is based on morphometry alone, which may result in inclusion of deformities 
into the phenotype definition that are not truly vertebral fractures.80 These non-fracture deformities are 
frequently labeled as Genant grade 1 or “mild vertebral fractures,” when, in fact, they may be normal 
variations in vertebral shape. Therefore, many studies assign an expert to filter out these non-fracture 
deformities. Nevertheless, this triage procedure may not have been sufficiently standardized, and this 
could have introduced the statistically significant heterogeneity between studies. Several methods exist 
to explore the existence of associations in heterogeneous data and when we applied a Han–Eskin ran-
dom effects model, more stringent genotyping criteria or sensitivity analyses for phenotype definition, 
the results became more consistent. Perhaps selecting Genant grade 2 and 3 types including “moderate” 
and “severe” vertebral fractures81 could provide a better phenotype definition for future genetic studies. 
In fact, Liu and colleagues demonstrated that the heritability of a stricter phenotype (when only more 
severe deformities counted) was higher than considering all vertebral deformities together.19 Therefore, 
phenotype standardization among meta-analysis participants can be a key in replication.71, 82 Unfor-
tunately, data harmonization was not possible because severity grading or qualitative standardized 
reading to enable data harmonization was not available for most of the studies included in our analysis. 
This consideration, along with the relatively small sample sizes across replication studies, is a major 
hurdle to be overcome in future studies focusing on radiographic vertebral fractures. Clinical vertebral 
fracture is an alternative phenotype definition for future genetic studies, though achieving sufficient 
sample sizes will be also challenging; considering that only a small fraction of vertebral fractures come 
to clinical attention (i.e., are symptomatic). In addition, it would be valuable to gain more insight into 
incident vertebral fractures. Nevertheless, definition of incident vertebral fractures is accompanied by 
different and possibly greater precision errors than identification of prevalent vertebral fractures. On the 
other hand, by comparing images at different follow-ups, the radiological reader has the opportunity 
to correct possible misclassifications, including misattributions of baseline deformities as fracture cases 
caused by erroneous vertebral height readings due to for example superimposition of other structures 
or magnification errors.83-86
In conclusion, although a GWAS in the population-based Rotterdam Study identified a marker map-
ping to the 16q24 (FOXC2) BMD locus as being genome-wide significantly associated with radiographic 
vertebral fracture in that population, this could not be conclusively replicated by de-novo genotyping 
across 15 studies worldwide. A false positive association in the GWAS discovery cannot yet be excluded. 
However, these results from a low-powered setting may still be consistent with a small true effect size 
as is common in complex traits. Larger efforts in subsequent GWAS for radiographic vertebral fracture 
with standardized phenotype definitions may confirm or reject the involvement of this locus on the risk 
for vertebral fractures.
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ABSTRACT
We explored the role of transient receptor potential vanilloid 4 (TRPV4) in murine bone metabolism and 
association of TRPV4 gene variants with fractures in humans. Urinary and histomorphometrical analyses 
demonstrated reduced osteoclast activity and numbers in male Trpv4−/− mice, which was confirmed 
in bone marrow-derived osteoclast cultures. Osteoblasts and bone formation as shown by serum 
procollagen type 1 amino-terminal propeptide and histomorphometry, including osteoid surface, 
osteoblast and osteocyte numbers were not affected in vivo. Nevertheless, osteoblast differentiation 
was enhanced in Trpv4−/− bone marrow cultures. Cortical and trabecular bone mass was 20% increased 
in male Trpv4−/− mice, compared to sex-matched wild type (Trpv4+/+) mice. However, at the same time 
intracortical porosity was increased and bone matrix mineralization was reduced. Together, these 
lead to a maximum load, stiffness and work to failure of the femoral bone, which were not different 
compared to Trpv4+/+ mice, while the bone material was less resistant to stress and less elastic. The 
differential impacts on these determinants of bone strength were likely responsible for the lack of any 
changes in whole bone strength in the Trpv4−/− mice. None of these skeletal parameters were affected 
in female Trpv4−/− mice. The T-allele of rs1861809 SNP in the TRPV4 locus was associated with a 30% 
increased risk (95% CI: 1.1–1.6; P=0.013) for non-vertebral fracture risk in men, but not in women, in the 
Rotterdam Study. Meta-analyses with the population-based LASA study confirmed the association with 
non-vertebral fractures in men. This was lost when the non-population-based studies Mr. OS and UFO 
were included. In conclusion, TRPV4 is a male-specific regulator of bone metabolism, a determinant of 
bone strength, and a potential risk predictor for fractures through regulation of bone matrix mineraliza-
tion and intra-cortical porosity. This identifies TRPV4 as a unique sexually dimorphic therapeutic and/or 
diagnostic candidate for osteoporosis.
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INTRODUCTION
The bone is an organ undergoing continuous remodeling, requiring a tight balance between bone 
resorption (by osteoclasts) and formation (by osteoblasts). The bone stores 99% of total body Ca2+, mak-
ing it a vital player in Ca2+ homeostasis. Members of the transient receptor potential (TRP) superfamily, 
predominantly the transient receptor potential vanilloid channels (TRPVs), have been implicated in both 
Ca2+ homeostasis and bone metabolism. We have demonstrated earlier in mice that the epithelial Ca2+ 
channel TRPV5 is crucial for renal Ca2+ reabsorption and for proper bone resorption.1, 2 Moreover, mice 
lacking TRPV6 display disturbed intestinal Ca2+ uptake and reduced bone mass.3-5 In contrast to TRPV5 
and TRPV6, TRPV4 is permeable to Ca2+ in a non-selective manner.6 TRPV4 responds to a wide variety of 
stimuli, including hypotonicity, pH, pain, cell swelling, endocannabinoids and mechanical stretching.7, 8 
Recently, it was shown that activating mutations in the TRPV4 gene lead to several skeletal phenotypes 
in humans, including several dysplasias of the brachyolmia, spondylometaphyseal, Kozlowski and 
metatropic types.9, 10 Two reports have investigated the role of TRPV4 in the murine skeleton but the 
data obtained are yet inconclusive.11, 12 Although both studies used the same mouse model, one study 
examined male mice while the other study examined female mice. This may implicate that TRPV4 is a 
potential driver of skeletal sexual dimorphism such as differences in size and strength.13
In order to address this, we studied a head-to-head comparison of male and female Trpv4−/− mice 
with respect to the bone phenotype as well as bone cell differentiation patterns. In addition, we tested 
genetic variants in the TRPV4 gene locus for association with fracture risk and bone parameters in human 
cohorts within a meta-analysis.
METHODS
Mice, tissue collection and serum/urine analyses Mice lacking TRPV4 were generated as described 
extensively.14 Briefly, cross-breeding of C57Bl/6 TRPV4+/+ and TRPV4−/− mice resulted in offspring that 
were heterozygous for TRPV4. This offspring, bred within the Radboud University Nijmegen Medical 
Centre animal facility, was inter-crossed to obtain TRPV4−/− mice. These were subsequently inter-crossed 
and compared to age-matched TRPV4+/+ mice. Male and female 20-week-old mice, fed ad libitum, were 
placed in metabolic cages to collect 24 hour urine. Next, mice were sacrificed and serum was collected. 
Bones were collected for microcomputed tomography and histomorphometry (left femurs), 3-point 
bending tests (right femurs) and bone marrow cultures (tibiae). Serum Ca2+ was colorimetrically deter-
mined with a Ca2+ assay kit (Sigma, St. Louis, MO, USA) according to the manufacturer’s description at 595 
nm, using a Bio-Rad microplate reader (Bio-Rad, Hercules, CA, USA). Urinary deoxypyridinoline (DPD) as a 
marker for bone resorption was analyzed using a MetraDPD enzyme immunoassay (Quidel, San Diego, 
CA, USA). Serum procollagen type 1 amino-terminal propeptide (P1NP) as a marker for bone formation 
was measured with an EIA (IDS, Boldon, UK). The animal ethics board of the Radboud University Medical 
Centre Nijmegen approved all experimental procedures.
Microcomputed tomography (μCT)
Femurs from female and male TRPV4+/+ and TRPV4−/−mice (N=6) were scanned at a resolution of 9 μm, 
using a SkyScan 1172 system (Bruker MicroCT, Kontich, Belgium). According to guidelines recently pub-
lished,15 the following settings were used: X-ray power and tube current were 40 kV and 0.25 mA, respec-
tively. Beam hardening (20%) was reduced using a 1 mm aluminum filter, ring-artifacts were reduced (set 
at 5), exposure time was 5.9 s and an average of three pictures was taken at each angle (0.9°) to generate 
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final images. Using different software packages from Bruker MicroCT (NRecon, CtAn and Dataviewer), 
bone microarchitectural parameters were assessed in trabecular and cortical bone of all mice (N=14 for 
both genotypes). The trabecular bone parameters trabecular tissue volume, bone volume, trabecular 
volume fraction (BV/TV), trabecular thickness, trabecular number and trabecular patterning factor (con-
nectivity of trabeculae) were determined in the distal metaphysis of the femur (scan area 0–4 mm of 
proximal femur). In the mid-diaphysis (scan area 4–6.2 mm from trochanter), cortical volume, cortical 
thickness, polar moment of inertia (MOI; proxy for bone strength) and perimeter were analyzed. For 
image processing, trabecular bone was manually selected and cortical bone was automatically selected. 
We used a Hamming filter and global thresholding was applied for segmentation, followed by using 
threshold levels of 150 (lower) and 194 (higher) for trabecular and levels of 0 and 31 for cortical bone 
measurements. In addition, trabecular and cortical bone mineral density (BMD) was measured on basis 
of calibration scanning, using two phantoms with known density (0.25 mg/cm2 and 0.75 mg/cm2; Bruker 
MicroCT) under identical conditions as for the femurs (method note from SkyScan provided on website).
Bone mechanical properties (3-point bending)
Femurs were stored in phosphate-buffered saline at −20 °C until further use. Before the 3-point bending 
test, femurs were scanned according to the settings mentioned above. The procedure was carried out 
as previously described in detail.16 Briefly, femurs were placed in a custom made 3-point bending device, 
with the loading posts 10 mm apart. Mechanical testing was performed, using a Single Column Lloyd 
LRX System (Lloyd Instruments, Fareham, UK). Displacement (mm) and force (N) were registered. Using 
the same settings for filtration, segmentation and binarization as mentioned above in the microCT sec-
tion, the MOI, reflecting the ability of the bone to withstand torsion, was calculated using CtAnalyzer 
software (Bruker MicroCT). It is the integral of the product of the distance between the area of the 
cortical bone and the center of gravity on one hand and the cortical bone itself on the other. This was 
determined in the μCT scan-derived crosssection that corresponded to the fracture site resulting from 
the bending test. From the resulting displacement to force graphs as well as the MOI values, ultimate 
force (N), stiffness (N/mm), work to failure (mJ), ultimate stress (N/mm2) and elastic modulus (GPa) were 
determined as described before.17
Quantitative backscattered electron imaging
The distal half of femoral bone samples were fixed in 70% v/v ethanol, dehydrated in ethanol, and 
embedded in polymethylmethacrylate. Sample blocks containing grinded and polished surfaces of 
longitudinal femoral sections were manufactured. Bone mineralization density distribution (BMDD) from 
the trabecular metaphyseal and epiphyseal as well as from the cortical mid-shaft region was determined 
using quantitative backscattered electron imaging (qBEI). A digital scanning electron microscope (DSM 
962, Zeiss, Oberkochen, Germany) operated at an accelerating voltage of 20 kV, a probe current of 110 
pA and equipped with a four-quadrant semiconductor backscattered electron detector, was used. Im-
ages with spatial resolution of 1 μm per pixel were acquired for BMDD measurements. This technique is 
well established and validated and the details of the method have been published elsewhere.18, 19 The 
following BMDD parameters were calculated 1) CaMean is the weighted average Ca concentration of the 
mineralized tissue area, obtained from the integrated area under the BMDD curve. 2) CaPeak is the peak 
position of the BMDD histogram showing the most frequently occurring wt.% Ca of the measured areas. 
3) CaWidth is the width at half-maximum of the BMDD histogram curve indicating the heterogeneity of 
mineralization and 4) CaLow is the percentage of bone area with a calcium concentration of less than 
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17.68 wt.% Ca, which reveals the amount of bone area undergoing primary mineralization; and CaHigh, 
the portion of bone area with a calcium concentration higher than 25.30 wt.% Ca.
Bone histomorphometry
After excision, femurs were routinely embedded in methylmetacrylate as described before.2 Sections of 
6 μm were subjected to tartrate-resistant acid phosphatase (TRAP) staining. Sections were deacrylated, 
hydrated and rinsed in 0.2 M sodium acetate/50 mM tartaric acid for 5 min. Naphtol AS-MX (0.5 mg/ml) 
and 1.1 mg/ml Fast red TR salt (both from Sigma, St. Louis, MO, USA) were added and incubated for 120 
min at 37 °C. Counterstaining was performed with hematoxylin for 5 s and after air-drying, the sections 
were embedded in Permount (Thermo Fischer Scientific, Waltham, MA, USA). For osteoid measurements, 
a von Kossa staining was used. After incubation with 2% w/v silver nitrate (ICN Biomedicals, Irvine, CA, 
USA) for 5 min in daylight, the sections were counterstained with eosin. The sections were dehydrated 
and embedded in Entellan (Electron Microscopy Sciences, Hatfield, PA, USA). Eosin-stained osteoid was 
specifically visualized, using fluorescent imaging with a 365 nm excitation/420 nm emission filter. For 
osteoblast and osteocyte measurements, sections were stained with a Goldner staining as described 
before.20 Images were taken from the TRAP and Goldner stainings with a Nikon Eclipse E400 system 
(Nikon, Lijnden, the Netherlands) and a Zeiss Axiovert 200 MOT system (Carl Zeiss BV, Jena, Germany) 
was used for osteoid stainings. Measurements were performed, using the software package Bioquant 
(Version 7.20; Bioquant image analysis corporation, Nashville, Tennessee, USA).
Quantitative PCR analysis (Q-PCR)
RNA isolation, cDNA syntheses, and Q-PCR were performed as described previously.21 Primer and probe 
sequences and concentrations used for Q-PCR are listed in Supplementary Table 1.
Bone marrow cultures
Bone marrow cells derived from TRPV4+/+ and TRPV4−/− mice directed towards osteoclasts and osteo-
blasts were cultured as described in detail.2, 22 After 6 days of culture, TRAP and coomassie brilliant blue 
stainings were used to stain for osteoclasts and resorption pits on bone slices left behind by osteoclasts, 
respectively.2 Osteoclast number and resorption surface were measured as well as resorption surface per 
osteoclast, using the freely available ImageJ software (version 1.41; http://rsbweb.nih.gov/ij/). Alkaline 
phosphatase and alizarin red staining were performed on osteoblast cultures at days 9 and 21 of culture, 
respectively, as described earlier.2 Colony numbers and mineralized area were quantified using Bioquant.
Genetic association studies in humans
To evaluate the effect of genetic variants in TRPV4 on bone outcomes we first focused on the Rotterdam 
Study where deep phenotyping on bone parameters is available followed by replication assessment of 
fracture outcomes in three additional studies.
Rotterdam Study
Individuals were derived from the Rotterdam Study (N=7,983), a single-center prospective population-
based cohort study of determinants of disabling chronic diseases in the elderly. The Medical Ethics 
Committee of Erasmus University Medical School approved the Rotterdam Study, and participants pro-
vided written informed consent. Both the rationale and the design of the study have been extensively 
described previously.23, 24 In brief, the Rotterdam Study was designed in the mid-1980s as a response to 
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the demographic changes that were leading to an increase of the proportion of elderly people in most 
populations. It was clear that this would produce a strong rise in elderly people living with diseases, as 
most diseases cluster at the end of life, and that to discover the causes of diseases in the elderly one 
would have to study the risk factors of those diseases. The design of the Rotterdam Study is that of a 
prospective cohort study among, initially, 7,983 persons living in the well-defined Ommoord district in 
the city of Rotterdam in The Netherlands (78% of 10,215 invitees). They were all 55 years of age or over 
and the oldest participant at the start was 106 years. The participants were all examined in some detail 
at baseline. They were interviewed at home and then had an extensive set of examinations in a specially 
built research facility in the center of their district. These examinations focused on possible causes of 
invalidating diseases in the elderly in a clinically state-of the-art manner, as far as the circumstances 
allowed. The emphasis was put on imaging (of heart, blood vessels, eyes, skeleton and later brain) and 
on collecting bodily fluids that enabled further in-depth molecular and genetic analyses.
Height and weight were measured in a standing position wearing indoor clothing without shoes. 
BMI was computed as weight in kilograms divided by height in meters squared (kg/m2). During the 
home interview, female participants were asked to recall their age at menopause, and responses were 
validated as described previously.25 Assessment of vertebral fracture, incident non-vertebral fractures, 
bone mineral density (BMD) and bone geometry measurements has been described in detail previ-
ously.26 In short, fractures where derived from general practitioner records and validated by two trained 
physicians. BMD and hip structural analysis measurements were derived from DXA scans acquired with 
a GE_Lunar DPX-L scanner.
TRPV4 SNP genotyping
Markers present in the TRPV4 gene region of interest (chromosome 12q24, positions 108,705,277 to 
108,755,595) plus 50 kb up- and downstream of the gene (HapMap release 27, February 2009) were 
extracted from Illumina HumanHap 550 K beadchip arrays as described earlier27 and included 32 hap-
lotype tagging SNPs. These cover most of the common genetic variance in the TRPV4 region spanning 
chromosome 12 positions 108,623,000 to 108,801,400 and including 78 markers. Markers were excluded 
if: 1) they deviated significantly from Hardy–Weinberg equilibrium (P<1×10−4; N=0), 2) the low minor 
allele frequency (MAF) was below 5% (N=2), or 3) they had a call rate <95% (N=3). The exclusion of 5 
tagging markers due to low MAF or genotyping call rate did not substantially affect coverage in the 
region as only 3 additional markers would be missed. This resulted in 27 SNPs from the Illumina array 
in the TRPV4 locus area available for gene-wide association analyses, using PLINK v1.05 (Supplementary 
Figure 1 and Supplementary Table 2). Genomic control was used to correct for potential population 
stratification using genome-wide data.28 The genomic inflation factor (based on median chi-squared) 
ranged between 1.015 (non-vertebral fracture) and 1.049 (femoral neck BMD) across all bone trait analy-
ses providing evidence against the presence of significant population stratification affecting the results.
Association analysis
Association of the rs1861809 SNP with bone mineral density (BMD; femoral neck and lumbar spine 
BMD) were analyzed. Furthermore, association with osteoporotic, non-vertebral, fragility, hip, wrist and 
vertebral fracture risk as well as hip structural parameters, including narrow neck (NN) width, NN cortical 
thickness (Ct.Th), NN cross-sectional moment of inertia (CSMI) and NN buckling ratio (BR) was assessed.
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Replication cohorts
For replication, men and women from the prospective population-based cohort study LASA (Longi-
tudinal Aging Study Amsterdam, N=904), the prospective study MrOS Sweden (N=2,829) and the 
nested case–control study UFO (Umeå Fracture and Osteoporosis, N=2,807) cohorts were genotyped 
for rs1861809, the most significantly associated marker in the Rotterdam Study using TaqMan Allele 
discrimination assay (Applied Biosystems, Nieuwerkerk a/d IJssel, the Netherlands) and included in 
the analysis. The Longitudinal Aging Study Amsterdam (LASA) is an ongoing multidisciplinary cohort 
study in older persons. A random sample of men and women aged 55 years and over, stratified by age, 
sex, urbanization grade and expected 5-years mortality rate was drawn from the population register of 
Amsterdam, The Netherlands.29 Follow-up time of the fractures was 6 years. The Osteoporotic Fractures 
in Men (MrOS) study is a multicenter, prospective study including elderly men. Study subjects (men 
aged 69–80 years) were randomly identified using national population registers, contacted and asked to 
participate. Eligible subjects had to be able to walk without assistance, provide self-reported data, and 
sign an informed consent. For this study data from the MrOS Sweden cohort was used.30 Assessments of 
incident fractures have been described before.31 The UFO study is a nested case–cohort study investigat-
ing associations between genes, lifestyle and osteoporotic fractures (average age 65 years of age). The 
study is based on the prospective and population-based Northern Sweden Health and Disease Study 
cohort, initiated to assess risk factors for diabetes and cardiovascular disease.32, 33
Statistical analyses
If not stated otherwise, SPSS 15.0 (SPSS, Chicago, IL, USA) was used for the statistical analyses. In all 
non-genetic experiments values were expressed as mean ± SEM unless stated otherwise. Differences 
between groups were tested for significance using the Student-t-test. Baseline parameters and bone 
geometric data from the genetic studies were expressed as mean ± SD. Differences between groups 
were tested for significance using ANOVA. Values were considered significantly different at P<0.05. To 
estimate the risk of fractures, odds ratios with 95% confidence intervals (95% CI) were calculated using 
logistic regression models. Trend analysis assuming an underlying additive genetic model was done for 
the presence of zero, one, or two copies of the associated allele.34 Since we took only one SNP forward for 
the replication studies no multiple testing penalty was applied, hence P values <0.05 were considered 
statistically significant.
RESULTS
Bone phenotype of male and female TRPV4-/- mice
μCT analyses demonstrated a positive effect on bone mass following TRPV4 deficiency in male but not 
in female mice. Male Trpv4−/− mice displayed increased femoral trabecular (Figures 1A and B) and cortical 
(Figures 1C–E) bone mass compared to female Trpv4+/+ mice. Femoral bone size was also increased in male 
Trpv4−/− mice as exemplified by larger femoral head volume, diaphyseal volume, perimeter (Figures 1F–H, 
respectively) and femoral length (Supplementary Table 3). In females, all parameters described above were 
unaffected. A summary of these and additional μCT parameters are listed in Supplementary Table 3.
We first studied osteoclast function in these Trpv4−/− mice. Urinary DPD analysis showed reduced bone 
resorption in male Trpv4−/− mice compared to Trpv4+/+ (Figure 2A). Histomorphometrical analyses of 
TRAP staining on bone sections confirmed this (Figure 2B). In femurs from male Trpv4−/− mice, osteoclast 
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Figure 1.  Bone microarchitecture in male and female Trpv4+/+ and Trpv4−/− mice. In the femoral head, (A) trabecular 
thickness, (B) trabecular bone volume fraction and (F) femoral head volume were determined. Cortical bone param-
eters included (C) cortical thickness, (D) cortical volume, (G) diaphyseal volume and (H) perimeter. (E) Representative 
3D reconstructions for the mid-diaphyseal cortices for each group are shown (arrows indicate thicker cortices in male 
Trpv4−/− mice). White bars: Trpv4+/+ mice; black bars: Trpv4−/− mice. Data are presented as means ± SEM. *P<0.05 versus 
male Trpv4+/+ mice (N=6).
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number (Figure 2C) and surface area resorbed (data not shown) was significantly reduced. In contrast, 
no differences in bone resorption and osteoclast number were observed between the female Trpv4+/+ 
and Trpv4−/− mice (Figure 2A and data not shown).
Figure 2. Osteoclast function in Trpv4−/− mice. (A) Urinary deoxypyridinoline (DPD) was measured in male and female 
Trpv4+/+ and Trpv4−/− mice. (B) Representative bone sections were stained for TRAP. (C) Osteoclast numbers corrected 
for total bone surface (Oc.N/BS) were quantified, using Bioquant software. In osteoclast cultures, (D) number of TRAP 
positive colonies and (E) coomassie brilliant blue-positive resorption area were quantified as well as (F) resorption 
surface per osteoclast (Trpv4+/+ set to 1). White bars: Trpv4+/+ mice; black bars: Trpv4−/− mice. *P<0.05 versus male 
Trpv4+/+ mice (N=6).
Bone marrow-derived osteoclast cultures supported the in vivo observations that osteoclast number 
and resorption is disturbed in male Trpv4−/− but not female mice. Fewer osteoclasts developed from male 
Trpv4−/− bone marrow compared to that of Trpv4+/+ mice (Figure 2D), which is paralleled by a significantly 
reduced resorption surface area (Figure 2E). Resorption surface per osteoclast analyses demonstrated 
that osteoclast activity from Trpv4−/− cultures is impaired (Figure 2F). None of these differences were 
found in female Trpv4−/− bone marrow-derived osteoclast cultures (e.g., osteoclast numbers: 35.1 ± 3.3 
versus 29.6 ± 5.4, P=0.44 for female Trpv4+/+ versus Trpv4−/− mice).
When osteoclast–osteoblast coupling during bone remodeling is intact, reduced osteoclast function 
should lead to attenuated osteoblast activity. In male Trpv4−/− mice, bone formation was unaffected 
despite reduced bone resorption as shown by serum P1NP analyses (Figure 3A). This is supported by 
histomorphometrical assessment of bone sections showing no differences in number of osteoblast 
lining trabecular bone (Figure 3B), percentage osteoid surface (Figure 3C) and osteocytes in cortices 
(Figure 3D) between male Trpv4+/+ and Trpv4−/− mice.
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Figure 3. Osteoblast function in Trpv4−/− mice. Serum was collected for measurement of P1NP (A). Bone sections 
were stained for osteoid, using a von Kossa/eosin staining. (B) Osteoblast number along the bone surface (N.Ob/
BS), (C) osteoid surface as a percentage of total bone surface (OS/BS)was quantified as well as (D) osteocytes num-
bers in cortical bone (N.Ot/B.Ar), using Bioquant software. Osteoblast cultures were stained for (E) number of al-
kaline phosphatase colonies and (F) alizarin red-positive mineralized surface area. White bars: Trpv4+/+ mice; black 
bars: Trpv4−/− mice. (G) TRPV4 gene expression in bone marrow-derived osteoblasts from male and female mice, (H) 
human osteoblast cell-line (SV-HFO), (I) bone marrow-derived osteoclasts from male and female mice (day 6) and 
(J) human peripheral blood mononuclear cells-derived osteoclasts (day 21). Total RNA was isolated and assessed for 
TRPV4 mRNA expression. *P<0.05 versus male Trpv4+/+ mice (N=5). Abbreviations: NM, no mineralization; OM, onset of 
mineralization; FM, full mineralization.
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While the in vivo findings strongly suggest that osteoblast differentiation and function remain unaffected 
in Trpv4−/− mice, osteoblast differentiation was enhanced in bone marrow cultures. Trpv4−/− osteoblast 
cultures showed a significant increase in the number of alkaline phosphatase positive colonies (Figure 
3E) as well as elevated Ca2+ deposition, although this did not reach significance (Figure 3F). Colony size 
was not affected in cultures from male Trpv4−/− mice (0.10 ± 0.02 mm versus 0.15 ± 0.02 mm, P=0.1 for 
male Trpv4+/+ mice). TRPV4 may directly affect osteoblast and osteoclast function as it is abundantly 
expressed in both cell types (Figures 3G–J). No differences in alkaline phosphatase positive colony 
numbers and Ca2+ deposition were observed between osteoblast cultures from female Trpv4+/+ and 
Trpv4−/− mice bone marrow (data not shown).
Resistance to stress and elastic modulus is reduced in male Trpv4−/− mice
To assess whether increased bone mass led to improved bone strength, 3-point bending tests were 
performed on femurs from male and female Trpv4+/+ and Trpv4−/− mice (Figures 4A–E). Maximum load, 
stiffness and work to failure were not different between Trpv4+/+ and Trpv4−/− mice (Figures 4A–C). Inter-
estingly, the femurs from Trpv4−/− mice were less resistant to stress (Figure 4D) and less elastic (Figure 4E). 
However, polar moment of inertia was increased in the Trpv4−/− mice at the site of fracture (Figure 4F). 
None of these differences were seen in bones from female mice (e.g., stress: 87.6 ± 2.9 GPa versus 75.0 ± 
3.4 GPa, P=0.31 for female Trpv4+/+ versus Trpv4−/− mice).
We assessed cortical porosity by quantifying the holes appearing in the cortical bone (Figure 4G–H). 
Cortical porosity was more than doubled in the male Trpv4−/− mice compared to Trpv4+/+ mice (Figure 
4 and Supplementary Table 3). The diameter of these holes varied between 40 and 160 μm. Increased 
cortical porosity was not observed in the female mice (Supplementary Table 3). Bone mineral density of 
the femoral trabecular and cortical compartment was unaltered and slightly but significantly increased, 
respectively, in the Trpv4−/− mice (Figures 4J–K).
Finally, we measured bone mineralization density distribution at three positions in femurs of the 
male Trpv4+/+ and Trpv4−/− mice (Figure 5A). The bone matrix of Trpv4−/− mice was significantly lower 
mineralized compared to Trpv4+/+ mice at all skeletal sites analyzed (metaphysis, epiphysis and corticalis) 
as shown by the significant reduction of CaMean, CaPeak and CaHigh (Figures 5B, C and D). The width 
of the BMDD curve (CaWidth) is not altered indicating that the heterogeneity in mineralization is not 
different between the genotypes (Figure 5E). The fraction of lowly mineralized bone areas (CaLow), i.e., 
areas of ongoing bone formation (primary mineralization), in the Trpv4−/− mice is not different from that 
in Trpv4+/+ mice (Figure 5F).
Human genetic association studies on TRPV4 and fracture risk
We investigated the contribution of TRPV4 to bone phenotypes in humans by studying the association 
of genetic variants in the TRPV4 gene locus with skeletal phenotypes and fracture risk. Baseline char-
acteristics for the Rotterdam Study population are provided in Supplementary Table 4. Using PLINK 
software, we tested 27 tagging single nucleotide polymorphisms (SNPs) in the TRPV4 locus for potential 
association with bone mineral density (BMD), hip geometry and fracture risk in the Rotterdam Study 
(Supplementary Table 2 and Supplementary Figure 1) as a discovery cohort. Two intronic tagging SNPs 
located between exons 2 and 3 of the TRPV4 gene (rs10850783, C to A, MAF=27.4% and rs1861809, C to 
T, 27.3%; Supplementary Table 2 and Supplementary Figure 1) were found to be associated with osteo-
porotic fractures (P=0.002). These SNPs were in complete linkage disequilibrium and so rs1861809 was 
chosen for further analyses. No association was observed for rs1861809 with femoral neck and lumbar 
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Figure 4. Bone material strength is reduced in mice lacking Trpv4. Three-point bending tests were performed in 
Trpv4+/+ and Trpv4−/− mice to assess femoral mechanical properties. Besides (A) maximum load, (B) stiffness, (C) work to 
failure, (D) elastic modulus and (E) ultimate stress were analyzed from the displacement–force curves and (F) moment 
of inertia was determined from the μCT analyses. Representative images from binarized μCT cross-sections through 
cortices from male (G) Trpv4+/+ (WT) and (H) Trpv4−/− mice (KO). (I) The percentage volume of the cortices representing 
holes (white) was quantified as a proxy for cortical porosity. (J) Trabecular and (K) cortical bone mineral density (BMD).
White bars: Trpv4+/+ mice; black bars: Trpv4−/− mice. *P<0.05 versus male Trpv4+/+ mice (N=5).
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spine BMD in either men or women (Supplementary Table 5). The hip bone geometric parameters’ nar-
row neck (NN) width and NN cross-sectional moment of inertia (CSMI) were significantly higher in men 
with the TT genotype (P=0.006 and P=0.02, respectively), but this effect was not observed in women 
(P=0.2 and 0.14, respectively; Supplementary Table 5). NN cortical thickness (Ct.Th) and buckling ratio 
(BR) were not significantly different between the genotypes in either men or women (Supplementary 
Table 5).
Risk of osteoporotic fractures was 1.9 times higher in men homozygous for the T-allele of rs1861809 
(Table 1). Men had a 40% increased risk for osteoporotic fractures per T-risk allele (95% CI: 1.1–1.7, 
P=0.005). For fragility and hip fractures the risk was 1.6 times (95% CI: 1.1–2.2, P=0.005; and 1.1–2.4, 
P=0.011, respectively) higher per risk allele, while for wrist fractures the risk was 2 times (95% CI: 1.1–3.5, 
P=0.014) higher per risk allele. In contrast to men, no association with any type of fracture was observed 
for women (Table 1).
Next, we sought replication of our genetic associations in other cohorts, including LASA, MrOS and 
UFO (baseline characteristics in Supplementary Tables 6 and 7). In men from the LASA study the same 
trend for increased risk for osteoporotic fracture was observed in carriers of the T-allele (OR=1.5, 95% CI: 
0.9–2.5, P=0.11) (Supplementary Table 8). Meta-analyses of the Rotterdam and LASA studies together 
were consistent with a 40% increase in risk for osteoporotic fracture (OR=1.4, 95% CI: 1.1–1.7, P=0.001) 
per risk allele (Figure 6). However, in the Swedish MrOS and UFO studies, no evidence for association 
with osteoporotic fracture risk was observed in either study. (Supplementary Table 8 and Figure 6). In the 
meta-analysis, including all four cohorts, the association of the polymorphism with osteoporotic fracture 
was lost for men (OR=1.1, 95% CI: 1.0–1.3, P=0.167; Figure 6). As expected, for women the association 
with osteoporotic fractures remained absent (OR=1.0, 95% CI: 0.9–1.0, P=0.303; Figure 6) nor were any 
signification associations found for other types of fractures (data not shown).
Figure 5. Bone matrix mineralization is reduced in mice lacking Trpv4. Using qBEI, BMDD was measured at 3 loca-
tions in femurs from male Trpv4+/+ and Trpv4−/− mice (A). CaPEAK (B), CaMEAN (C), CaHIGH (D), CaWIDTH (E) and 
CaLOW (F) were measured in the trabecular compartment of the femoral metaphysis and epiphysis as well as in the 
diaphyseal cortex (corticalis). Data are presented as means ± SEM. *P<0.05 versus Trpv4+/+ controls (N=6).
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DISCUSSION
In this multidisciplinary study, using Trpv4−/− mice, ex vivo cell biological analyses and genetic associa-
tion data from human cohorts, we demonstrate that TRPV4 is an important sexually dimorphic factor 
for determining bone strength, with potentially clinically relevant implications at the population level.
Male Trpv4−/− mice display reduced osteoclast function and osteoclast–osteoblast 
uncoupling
TRPV4 deficiency leads to an increased bone mass phenotype in male, but not in female mice. This 
predominantly results from decreased osteoclast formation/differentiation and activity, which has.11, 12, 35 
Considering the importance of osteoblast–osteoclast coupling in bone turnover it was anticipated that 
impaired osteoclast differentiation would lead to reduced osteoblast differentiation. However, bone for-
mation is not affected in the male Trpv4−/− mice in this study, although it is enhanced in ex vivo cultures. 
This implies that TRPV4 acts indirectly in vivo, through mesenchymal stem cells (MSCs) and limits their 
differentiation into osteoblasts. TRPV4 is also abundantly expressed on osteoblasts, which suggests a 
direct effect; the mechanism through which TRPV4 acts on osteoblasts remains elusive. In contrast to 
our data, it was demonstrated very recently that bone marrow-derived MSCs from Trpv4−/− mice actu-
ally were less osteogenic compared to wild type MSCs, whereas the opposite was seen for adipose 
tissue-derived MSCs.36 However, these findings are difficult to directly correlate with our data, due to 
the methodological differences in cell collection (cell sorting), additional passaging of the cells before 
osteogenic differentiation and culturing under hypoxic conditions, which has been shown to have pro-
found effects on osteogenic differentiation.37 The reduced bone resorption (DPD as a marker) together 
with the unchanged bone formation marker (P1NP) demonstrates osteoblast–osteoclast uncoupling 
following TPRV4 deficiency in male mice only. A summary of the results and a more detailed reasoning 
Figure 6. Meta-analysis for osteoporotic fracture risk. Forest plot of the group-wise genotype meta-analysis for os-
teoporotic fracture risk in men across studies for rs1861809. Provided are the odds ratios for TT versus CC genotype in 
males and females from the Rotterdam Study, LASA, MrOS Sweden and UFO. All associations were adjusted for age, 
height and weight.
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for this conclusion is shown in panels 1–6 in Figure 7. Based on the current data we propose that lack of 
TPRV4 in male mice, but not female mice, enhances osteoblast development via an osteoblast-intrinsic 
mechanism (observed: in vitro enhanced osteoblast development; panel 5) that (partially) overrules the 
in vivo osteoclast–osteoblast coupling signal (observed: in vivo unchanged bone formation; panels 4 
and 6) that would have led to reduced osteoblast activity as a consequence of the reduced osteoclast 
activity and bone resorption (observed: in vivo and in vitro; panels 2 and 6). Overall, these analyses dem-
onstrate a clear sex-specific effect of TRPV4 on bone phenotype, which is due to impaired osteoclast 
function and disturbed coupling between osteoclasts and osteoblasts.
Figure 7. Osteoclast–osteoblast uncoupling in male Trpv4−/− mice. Trpv4+/+ bone function is characterized by a bal-
ance between osteoclastic (OC) bone resorption and osteoblastic (OB) bone formation (panel 1). In male Trpv4−/− 
mice, osteoclast differentiation and function is reduced in vivo and ex vivo (panel 2). In healthy bone metabolism, 
bone formation is reduced to achieve a new balance (panel 3). However, in the male Trpv4−/− mice, bone formation 
was unaffected (panel 4) and osteoblast differentiation was even enhanced ex vivo (panel 5). Together, these data 
clearly indicate that uncoupling between bone resorption and formation exists (panel 6), leading to the increased 
bone mass phenotype observed in male Trpv4−/− mice.
Male Trpv4−/− mice have increased cortical porosity and reduced matrix mineralization
Despite reduced osteoclast activity, male Trpv4−/− mice have increased cortical porosity, an important 
predictor in diagnosing osteoporosis.38 In fact, non-vertebral fractures at predominantly cortical sites 
account for 80% of all fracture age-related osteoporosis.39 In several mouse models where osteoclast 
function is increased, such as one where the PTH receptor is constitutively active, or one that overex-
presses cathepsin K, intracortical porosity is abundant.40, 41 In addition, mice lacking the gastrin receptor 
Cckbr associated with hypochlorhydria also suffer from increased cortical porosity due to low intestinal 
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Ca2+ absorption and secondary hyperparathyroidism.42 However, cortical porosity may well arise from 
insufficient bone remodeling during bone development. For bone remodeling, osteoclast activity 
is required, which is defective in the male Trpv4−/− mice. An alternative, intriguing explanation is the 
process of osteocytic osteolysis, a mechanism by which osteocytes are able to resorb their surrounding 
perilacunar extracellular matrix, which may lead to intracortical porosity (Reviewed in:43, 44). Although 
osteocyte density was not altered in femoral cortices of our male Trpv4−/− mice (Figure 3D) the pres-
ence of osteocytic osteolysis remains to be established. However, to achieve this yet robust means to 
quantitatively assess osteocytic osteolysis need to be developed.
The reduction in matrix mineralization in Trpv4−/− mice demonstrates a role for this ion channel in 
mineralization of bone. The maintenance of cortical bone strength observed in Trpv4−/− male mice 
despite an increased cortical porosity and the observed reduced bone matrix mineralization can be 
best explained by a compensatory effect of the increase in bone mass, as reflected by an enhanced 
moment of inertia. In general, reduced bone matrix mineralization causes a lower ultimate stress and 
elastic modulus and increased intracortical porosity weakens additionally the mechanical competence 
of whole cortical bone.45, 46 Interestingly, BMD was only slightly increased in these mice. However, taken 
into account, that a change in BMD has to be considered as the sum of changes in bone volume and 
bone matrix mineralization,47 it seems that the extent of the increase in bone volume fairly compensated 
for the increase in porosity and the reduction in bone matrix mineralization in these Trpv4−/− mice.
The T-allele of rs1861809 is associated with increased fracture risk in men
In the Rotterdam Study we observed that the rs1861809 polymorphism between exons 2 and 3 of 
TRPV4 harbors BMD-independent sex-specific effects on osteoporotic fracture risk. Our study and others 
claim that it is crucial to study men and women independently to determine sex-specific genetic fac-
tors that contribute to osteoporosis risk.48 Similarly, it has been proposed that including bone structural 
parameters can aid the assessment of fracture risk.49-51 Nevertheless, performing sex-stratified analysis is 
a limiting approach resulting in a lower power setting.
Male-specific skeletal findings arising from Trpv4−/− mice and the ex vivo cell biology analyses were 
in line with those observed in men from the Rotterdam Study. In addition, including the LASA study 
(also of Dutch ancestry) resulted in a consistent, albeit smaller, effect estimate, which is most probably 
a natural consequence of smaller sample size and less power. The association in two additional studies 
of Swedish origin and lower number of fracture cases did not follow the same trend observed in the 
studies of Dutch origin. We do not foresee population-specific effects as allele frequencies of the Rot-
terdam and LASA studies were similar to those observed in the MrOS Sweden cohort. We did observe 
different allele frequencies in the UFO cohort as compared to the prospective nature of the other three 
cohorts, which may be attributable to its case/cohort design. Indeed, having a set of controls enriched 
with osteoporotic subjects may be an explanation for the observed deviant allele frequencies and also 
a potential explanation for the lack of association in the UFO cohort. We did not see an effect on BMD 
but a lower BMD may potentially reflect an enriched set of controls with fracture. Even though the 
male-specific effect of variants in TRPV4 in relation to fracture was observed in populations of Dutch 
origin, further scrutiny of these associations in additional prospective cohorts is warranted to confirm 
potential translation of the effects seen in mice to men.
TRPV4 has been shown to respond to alterations in osmolarity as well as to hypotonicity (reviewed 
in:52). Of interest, we previously demonstrated in the Rotterdam Study that patients with hyponatremia 
had a 40% increased risk of getting a non-vertebral fracture.53 In concordance, others showed a role 
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for hyponatremia in osteoporosis, most likely through activation of osteoclasts.54, 55 Future work should 
point out whether TRPV4 may be a gateway between hyponatremia and fracture risk in the elderly.
Phenotype consistencies and inconsistencies across species
The consistency between the genetic association data in the Rotterdam and LASA Studies and the 
findings in the Trpv4−/− mice – that bone strength is affected in males but not in females – is striking. An 
explanation for increased fracture risk in men despite an increase in bone mass may reside in reduced 
bone matrix mineralization and/or increased cortical porosity, as was shown in the male mice. Although 
there are studies describing the assessment of cortical porosity in the distal radius,38 we currently have 
no bone matrix mineralization and cortical porosity data from the Rotterdam Study to corroborate this 
hypothesis at the population level. Interestingly, increased midpubertal cortical thickness is associated 
with an increase in forearm fractures but also with elevated cortical porosity,56 which is more pronounced 
in boys than in girls.57 These processes evolve from endocortical bone resorption, most likely due to 
excess Ca2+ requirements in the growing adolescent.58, 59 It is tempting to speculate that this transient 
‘weakness’ of the long bones, in combination with DNA variations in the TRPV4 locus may lead to more 
permanent alterations in bone structure and/or composition resulting in an increased fracture risk for 
elderly men. There is recent supporting data that reduction in bone matrix mineralization can contribute 
to the increased fracture risk in men.60, 61
Childhood fractures may actually better reflect the porosity phenotype we observe in the male 
Trpv4−/− mice, being bone growth related rather than bone loss related, which occurs in the human 
aging cohorts that we assessed in this study. Although fracture incidence seems to show a bimodal 
pattern with an increased fracture incidence during puberty, the incidence is still very low compared 
to that of the elderly population and studies will lack power. With recently initiated population studies 
such as the Generation R cohort focusing on children from birth to adulthood,62 we may be able to study 
childhood fractures in the forthcoming years.
Dominant mutations in the TRPV4 gene lead to a comprehensive family of bone dysplasia’s, ranging 
from lethal metatotropic dysplasia to familial arthropathy with brachydactyly.63 The range and severity of 
the skeletal conditions together with the knowledge that a single mutation in the TRPV4 gene leads to 
different dysplasias, suggests modulation by other parts of the genome. Despite the human mutations, 
which so far are all dominant and activating of nature, ablation of the whole gene in murine studies 
(thereby inactivating the gene) displays a surprisingly
mild skeletal phenotype (11 and our data). Potentially, activating TRPV4 function by introducing the 
mutations leading to the various human bone dysplasias in a murine setting will phenocopy what we 
see in man but this requires extensive mouse genetic approaches.
TRPV4 deficiency is sexually dimorphic
The current study demonstrates a role for TRPV4 in explaining sexual dimorphism in bone metabolism 
and maintenance of bone strength. The underlying mechanism is unclear and currently purely specula-
tive but other examples of a gender-specific bone phenotype have been described, for example in 
myeloid-specifically ablated leptin receptor knockout mice.64 A role for sex steroid hormones such as an-
drogens or estrogens seems logical but there is no data to support an interaction with TRPV4. It has been 
reported that TRPV4 is expressed in the testes of male rats6, 65 but a relation with sex steroid production 
has not been shown. Although we cannot fully explain the current sex-specific findings in the Trpv4−/− 
animals we did find an induction of TRPV4 mRNA expression by 17β-estradiol in cultured osteoblasts 
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from male, but not female mice, suggesting a difference in sensitivity to sex steroids between males 
and females. It is worth mentioning that although sex was not mentioned in the majority of the reports 
describing a phenotype in Trpv4−/− mice, the ones that did, actually used male mice in their studies.11, 66, 67 
Of interest, in a recent review it was stated that sex differences also occur in the absence of hormonal 
changes through sex chromosome-mediated epigenetic regulation of autosomal chromosomes, such 
as DNA methylation and histone modifications68.
CONCLUSION
In conclusion, TRPV4 is a male-specific determinant of bone strength. TRPV4 influences bone by uncou-
pling of osteoclast and osteoblast activity and increase in bone mass in a sexually dimorphic manner. 
In addition, TRPV4 plays a role in bone matrix mineralization, which is reduced, and together with en-
hanced cortical porosity, may lead to reduced elasticity of bone. The increased bone mass and moment 
of inertia observed in the male Trpv4−/− mice seem to preserve bone strength, but this compensation 
mechanism may be lost during aging, potentially leading to reduced bone strength and fracture risk. 
Finally, the human genetic association analyses, which support a role of TRPV4 in male but not female 
osteoporosis, need to be replicated and verified. Supplementary data to this article can be found online 
at http://dx.doi.org/10.1016/j.bone.2013.09.017.
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Osteoporotic vertebral fractures during 
pregnancy: be aware of a potential 
underlying genetic cause
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ABSTRACT
Introduction Although the baby growing in its mother’s womb needs calcium for skeletal develop-
ment, osteoporosis and fractures very rarely occur during pregnancy.
Case Presentation A 27-year-old woman in the seventh month of her first pregnancy contracted 
midthoracic back pain after lifting an object. The pain was attributed to her pregnancy, but it remained 
postpartum. Her past medical history was uneventful, except for severely reduced vision of her left eye 
since birth. Family history revealed that her maternal grandmother had postmenopausal osteoporosis 
and her half-brother had three fractures during childhood after minor trauma. Her height was 1.58 m; 
she had no blue sclerae or joint hyperlaxity. Laboratory examination including serum calcium, phos-
phate, alkaline phosphatase, creatinine, β-carboxyterminal cross-linking telopeptide of type I collagen, 
25-hydroxyvitamin D, and TSH was normal. Multiple thoracic vertebral fractures were diagnosed on X-ray 
examination, and dual-energy X-ray absorptiometry scanning showed severe osteoporosis (Z scores: 
L2–L4, -5.6 SD; femur neck, -3.9 SD). DNA analyses revealed two compound heterozygous missense 
mutations in LRP5.The patient’s mother carried one of the LRP5 mutations and was diagnosed with 
osteoporosis. Her half-brother, treated with cabergoline for a microprolactinoma, also had osteoporosis 
of the lumbar spine on dual-energy X-ray absorptiometry and carried the same LRP5 mutation. The 
patient was treated with risedronate for 2.5 years. Bone mineral density and back pain improved. She 
stopped bisphosphonate use 6 months before planning a second pregnancy.
Conclusion Our patient was diagnosed with osteoporosis pseudoglioma syndrome/familial exudative 
vitreoretinopathy. Potential underlying genetic causes should be considered in pregnancy associated 
osteoporosis with implications for patients and relatives. More studies regarding osteoporosis treatment 
preceding conception are desirable.
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INTRODUCTION
Pregnancy- and lactation-associated osteoporosis (PLO) with the occurrence of fragility fractures 
mainly of the vertebral bodies was first described as a syndrome by Nordin and Roper in 1955.1 It is 
most commonly observed in the third trimester or early postpartum in women presenting with severe 
and prolonged back pain and sometimes height loss. The prevalence is unknown, and so far about 
120 case reports have been reported.2 The etiology is also not known, although a role of calciotropic 
hormones such as PTHrP has been suggested.3, 4 Most of the cases have been reported in primigravid 
women.3 There are no guidelines for treatment due to the lack of controlled trials. Another form of rare 
pregnancy-associated osteoporosis is called transient osteoporosis of pregnancy. Transient osteoporosis 
of pregnancy usually presents in the third trimester of pregnancy, sometimes with very severe pain while 
walking or standing, usually localized in the hip, and sometimes leading to hip fracture.5 Radiographs 
can show severe localized loss of bone mass, whereas only edema may be visible in magnetic resonance 
imaging in early stages. This condition usually fades within a few months after delivery.
Additionally, pregnancy and lactation might lead to bone loss in patients with pre-existent osteoporo-
sis attributable to genetic causes of low bone mineral density (BMD). As a consequence, these patients 
may become clinically manifest and develop fractures during this period. In this case report, we describe 
the clinical picture of a 27-year-old woman diagnosed with vertebral fractures and osteoporosis shortly 
after pregnancy. We will discuss potential causes of pregnancy-associated osteoporosis, its clinical 
consequences, and issues to take into account concerning patient management.
CASE PRESENTATION
A 27-year-old Caucasian woman in the seventh month of her first pregnancy complained of midthoracic 
back pain after bending over to lift a nonheavy object. The pain remained with differing intensity and 
was attributed to her pregnancy. After the delivery of a healthy child, the back pain prevented her from 
lifting her baby. She breastfed her baby for about 4 weeks. Because physical therapy had no effect on 
the pain, she was referred to an internist about 3 months after delivery. Her past medical history was 
uneventful without fractures, but she reported a severely reduced vision of her left eye since birth of 
unknown etiology, treated unsuccessfully with patches on the right eye. She consumed two to three 
dairy products daily. There was no history of abnormal menstrual cycle, smoking, alcohol, or medication 
use (such as corticosteroids) except for over-the-counter calcium and vitamin D supplements. Family 
history revealed that her maternal grandmother had postmenopausal osteoporosis, her grandfather had 
ankylosing spondylitis, and her only sibling (a half-brother) had experienced three fractures during child-
hood after minor trauma. On physical examination, her height was 1.58m (5 ft 2 in), her weight was 53 
kg (117 lb), and she had no blue sclerae and no joint or skin hyperlaxity. Her maximally corrected visual 
acuity was 0.16 + + left (S-6.50=C-2.75×22) and 1.0- right (S-5.75=C-1.25×170). Further ophthalmological 
examination revealed amblyopia in the left eye and changes compatible with a mild form of familial exu-
dative vitreoretinopathy (FEVR) in both eyes. There was normal form and function of the spinal column, 
which was slightly painful during flexion and extension. Except for an increase in bone-specific alkaline 
phosphatase and low urinary calcium excretion, there were no abnormalities on laboratory examination 
(Table 1). Spinal X-ray showed endplate compressions of thoracic vertebrae (T7, -9, -10, and -12; Figure 
1). Dual-energy X-ray absorptiometry (DXA) scanning performed approximately 3 months after delivery 
showed severe osteoporosis (Z scores: L2–L4, -5.6 SD; femur neck, -3.9 SD) (Table 1). A biopsy of the 
iliac crest revealed coarse trabeculae with loss of connectivity and a strongly increased bone turnover, 
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but no evidence for mastocytosis or osteomalacia. After obtaining informed consent, DNA analysis was 
performed and showed no mutations in the COL1A1 or COL1A2 genes, only a polymorphism in the 
COL1A1 gene that has been reported in juvenile osteoporosis but also in nonaff ected family members. 
This makes a mild form of osteogenesis imperfecta unlikely. It is important, however, to notice that 
10% of patients with clinical osteogenesis imperfecta have no detectable mutations in the exons for 
COL1A1 and COL1A2.6 DNA analyses of the LRP5 gene revealed two compound heterozygous mutations, 
c.1519G>A (p.Gly507Ser) and c.3758G>T (p.Cys1253Phe). Subsequently, family screening with DXA and 
DNA analyses were performed (Figure 2). The mother of the patient, recently postmenopausal, is a carrier 
of the LRP5 c.3758G>T mutation and was diagnosed with osteoporosis on a DXA scan (Z scores: lumbar 
spine, -2.8 SD; femoral neck, 0.0 SD). Spine radiography showed mild anterior wedging (less than 25%) 
of three thoracic vertebrae. The patient’s half-brother, treated with cabergoline for a microprolactinoma, 
carried the same LRP5 c.3758G>T mutation. He also had osteoporosis on the DXA scan (Z scores: lumbar 
spine, -2.1 SD; femoral neck, 0.0 SD) and had sustained three fractures after minimal trauma at a young 
age, as described before. He had no vertebral fractures on spine radiography. The mother and half-
brother had no visual impairments. The father of the patient was deceased and could therefore not be 
tested. Surprisingly, the c.3758G>T mutation was not detected in DNA from the maternal grandmother 
with osteoporosis. This indicates that the mutation was inherited from the maternal grandfather or a de 
novo mutation and that the grandmother may have had common osteoporosis. The patient was treated 
with risedronate for 2.5 years. BMD and back pain improved. She stopped the use of bisphosphonate 6 
months before planning a second pregnancy.
Figure 1.  Lateral spinal X-ray image of the index pa-
tient. The black arrows show endplate compressions of 
thoracic vertebrae at T7, T9, T10, and T12.
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Table 1. Laboratory and imaging studies.
Lab Values Reference values Index patient, III:2 Patient’s mother, 
II:2
Patient’s half-
brother, III:4
Serum
Calcium, mmol/L 2.25-2.65 2.35 2.26 2.31
Phosphate, mmol/L 0.8-1.4 1.39 0.96 1.19
Creatinine, μmol/L 55-90 67 66 82
TSH, mU/L 0.4–4.3 1.26 4.10 0.55
ALP, U/L <97 83 76 71
Bone-specific ALP, μg/L <20.1 22.6 NA 21.8
25-Hydroxyvitamin D, nmol/L >50 59 101 46
bCTX, μg/L <0.56 0.11 NA 0.88
Urine
24-h calcium, mmol/24 h 2.5-7.5 1.9 7.2 NA
Urine spot sample, mmol/L NA NA 3.55
DXA scan Cut-off for 
osteoporosis
Lumbar spine L2-L4 (T score) ≤-2.5 SD -5.7 -3.2 -1.4
Lumbar spine L2-L4 (Z score) ≤-2.0 SD -5.6 -2.8 -2.1
Femoral neck (T score) ≤-2.5 SD -3.9 -0.5 0.0
Femoral neck (Z score) ≤-2.0 SD -3.9 0.0 -0.8
Abbreviations: ALP, alkaline phosphatase; bCTX, β-carboxyterminal cross-linking telopeptide of type I collagen; NA, 
measurement not available. Values outside of reference range are marked bold.
Figure 2.  Pedigree and 
genotypes of the family. 
Index patient (III:2) is indi-
cated with an arrow. She is 
compound heterozygous 
for the c.1519G>A and 
the c.3758G>T mutations. 
Subjects II:2 and III:3 are 
carriers of the c. 3758G>T 
mutation. Black squares 
within circles and square 
represent low BMD (below 
left) and mild exudative 
vitreoretinopathy (above 
right).
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DISCUSSION
In this case report we describe the clinical picture of a young woman without a history of fractures. She 
presented in the third trimester of her first pregnancy with disabling back pain that persisted after deliv-
ery and was caused by fractures of multiple thoracic vertebrae. She had a severely reduced BMD on DXA 
scanning. We considered the diagnosis of PLO, but we identified a genetic cause underlying her condi-
tion. PLO is a rare heterogeneous disorder of unknown etiology. It is characterized by the occurrence of 
fragility fractures mostly in the spine and severe back pain presenting typically in the third trimester of 
gestation or early postpartum period.3 In PLO, whereas some patients improve spontaneously after giv-
ing birth or stopping lactation, others need medical treatment and continue to have decreased BMD.7 
Pre-existing secondary causes of osteoporosis, such as vitamin D deficiency, celiac disease, anorexia 
nervosa, mastocytosis, and hyper(para)thyroidism, should always be ruled out. Pregnancy and lactation 
may lead to up to 5–10% loss of mainly trabecular bone, especially during breast-feeding. However, 
almost complete recovery occurs in most cases within 6 to 12 months8 and thus cannot explain the 
very low BMD in our patient unless BMD was already compromised before pregnancy due to other 
reasons. In patients with PLO, a high prevalence of fractures has been reported in their mothers9 and of 
osteopenia in their offspring,10 leading to the suggestion of an underlying (genetically determined) low 
peak bone mass8, 9.
In our patient, we suspected an underlying monogenetic bone disease due to the severity of her 
osteoporosis. Analysis of her half-brother and mother confirmed a familial component. The history of 
severely reduced vision in one eye since birth led to suspicion of osteoporosis pseudoglioma (OPPG) 
syndrome, an autosomal recessive disorder characterized by early onset osteoporosis and blindness 
(OMIM no. 259770). OPPG is a rare disease with an estimated incidence of 1:2,000,000 and a carrier fre-
quency of 1:700,11 caused by biallelic loss of function mutations in LRP512. LRP5 (low-density lipoprotein 
receptor-related protein 5) is a cell-surface protein receptor that plays a key role in several intracellular 
signaling pathways, mainly Wnt and Norrin signaling.12 Mutations in LRP5 are also involved in FEVR13 
(FEVR/exudative vitreoretinopathy 4, OMIM no. 133780), a hereditary blinding disorder with a highly 
variable phenotype even within the same family14. Both autosomal recessive and autosomal dominant 
inheritance can occur. FEVR caused by LRP5 mutations is associated with low bone mass, in contrast 
to FEVR caused by mutations in other genes (e.g., FZD4 or NDP).14 OPPG and FEVR caused by LRP5 
mutations are therefore disorders with an overlapping phenotype. It has been suggested by Qin et 
al.14 that OPPG and FEVR caused by mutations in LRP5 are part of a single phenotypic spectrum with 
both ocular and bone manifestations. DNA analysis in our patient showed compound heterozygosity 
for two missense mutations in the LRP5 gene. The c.1519G>A (p.Gly507Ser) mutation is predicted to 
induce a minor chemical change of an evolutionary strongly conserved amino acid with introduction of 
an alternate splice acceptor site, and when present in homozygous state induces OPPG with very low 
BMD levels.15 On the other hand, c.3758G>T (p.Cys1253Phe) is predicted to induce a major chemical 
change of an evolutionary strongly conserved amino acid and has been previously described in reces-
sive FEVR.13 Because most patients with OPPG are congenitally blind or become blind by the age of 25 
years,11, 15-17 it is remarkable that our patient had relatively mild signs of exudative vitreoretinopathy, and 
a diagnosis of recessive FEVR might be considered as well,18 although osteoporosis is usually less severe 
than in OPPG11, 14, 15. The mother and half-brother carrying the LRP5 c.3758G>T mutation that has been 
previously described in recessive FEVR also had decreased BMD. Although OPPG follows an autosomal 
recessive pattern of inheritance, heterozygous carriers can exhibit mildly reduced BMD19.
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Heterozygous mutations in LRP5 are associated with primary osteoporosis in children.20 Moreover, in 
genome-wide meta-analyses the LRP5 locus was significantly associated with BMD and fracture risk,21 
broadening the spectrum of bone abnormalities related to genetic variation in LRP5.
We treated our patient with risedronate after she told us she did not want to get pregnant for at 
least 2 years, and she continued the use of oral contraceptives. Bisphosphonates are contraindicated 
in pregnancy. Animal studies with high doses have shown maternal and fetal toxicity, and there is 
concern of treating premenopausal women with these drugs because they are retained in bone for 
several years.22 A recent study of the literature that identified 78 cases of pregnancies involving exposure 
to bisphosphonates before conception or during pregnancy did not demonstrate serious adverse ef-
fects. Despite this, cases of increased spontaneous abortions, shortened gestational age, low neonatal 
birth weight, and transient hypocalcemia of the newborn were reported.23 Although bisphosphonates 
share the same core structure, their binding affinity to hydroxyapatite crystals varies among them; 
those with higher affinity display longer skeletal retention. It has been found that the ranking order for 
hydroxyapatite affinity from highest to lowest is zoledronate > alendronate > ibandronate > risedronate 
> etidronate.24 We chose a bisphosphonate with relatively low skeletal retention. We advised the patient 
to stop treatment at least 6 months before stopping birth control because risedronate levels have not 
been detected in urine 5 months after cessation of therapy.25 We would nevertheless advise close moni-
toring of pregnancy and intrauterine growth, check for neonatal hypocalcemia, and report on outcome. 
Also, we advised our patient to limit or avoid lactation after a subsequent pregnancy to prevent further 
maternal bone loss associated with breast-feeding.8 Alternatively, newer medications without long-term 
bone retention could be considered as off-label treatment in premenopausal women at very high risk 
for fractures who wish to become pregnant. However, in theory, stopping these drugs before becoming 
pregnant could lead to increased bone loss during pregnancy.
CONCLUSION
We report the clinical picture of a 27-year-old woman who suffered from disabling back pain during 
pregnancy and was diagnosed with multiple vertebral fractures and severe osteoporosis after delivery. 
We made the diagnosis of severe osteoporosis due to compound heterozygous mutations in the LRP5 
gene with mild exudative vitreoretinopathy as part of a spectrum of diseases named “osteoporosis 
pseudoglioma syndrome” and “familial exudative vitreoretinopathy.” Thus, our patient was genetically 
predisposed, and pregnancy further exacerbated her osteoporosis, resulting in vertebral fractures. We 
propose screening for an underlying monogenetic bone disorder in patients with PLO and one of the 
following features: a severely reduced BMD (Z scores < -2.0 SD); a family history of osteoporosis or 
fragility fractures, joint hypermobility, blue sclerae, congenital blindness, or severely reduced vision; or 
a history of fractures before pregnancy (e.g., testing for mutations in collagen 1A1 and 1A2 genes, LRP5, 
WNT1,26 and LGR4,27 and for the recently reported PLS3 gene28). A genetic diagnosis has implications for 
the patient and relatives. More studies regarding bisphosphonate treatment and newer osteoporosis 
drugs preceding conception are desirable.
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ABSTRACT
Our understanding of the genetic control of skeletogenesis and bone remodeling is increasing, and in 
addition to various non-genetic risk factors, a positive family history confers an increased risk of fracture. 
Vertebral fractures are the most common osteoporotic fractures and they are often a first manifestation 
of osteoporosis. This review presents the current state of knowledge on the genetic basis of osteopo-
rotic vertebral fractures and, additionally, of structural vertebral deformities resembling osteoporotic 
vertebral fractures but which may have their own genetic basis. We conclude that, apart from tentative 
screening for rare monogenic forms of osteoporosis in very unusual case presentations, not enough is 
currently known to encourage routine genetic screening in regular osteoporotic vertebral fracture cases.
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INTRODUCTION
Our understanding of the genetic control of skeletogenesis and bone remodeling is increasing. Normally, 
bone resorption and bone formation are balanced and regulated by hormones, growth factors and 
cytokines. In addition to various non-genetic risk factors, a positive family history confers an increased 
risk of fracture.1
Vertebral fractures are the most common osteoporotic fractures and often a first manifestation of 
osteoporosis. They represent a significant health issue2 being associated with a high morbidity3, 4. There 
may be skeletal-site specific effects of fracture determinants, meriting the study of vertebral fractures 
independently of non-vertebral fractures, as discussed below.
In this review, we discuss the genetics of osteoporotic vertebral fractures and touch on other structural 
vertebral deformities. This is important because these conditions may have their own genetic basis, and 
an accurate diagnosis is important to prevent case misclassification that may in turn hamper genetic 
discoveries.
Structural vertebral deformities and fractures
Several methods for radiological assessment of vertebral fractures exist, but a gold standard is lacking.5 
Traditionally, conventional radiography has been the imaging modality of choice. Two advantages of 
DXA-based vertebral fracture assessment over conventional radiography are the lower radiation dose 
and capture of the whole spine in one image with virtually no parallax distortion particularly because 
DXA imaging resolution has improved immensely. However, a number of diseases complicate the diag-
nosis of vertebral fractures, including degenerative disease, anatomical variation, and anomalies.6 More 
is becoming known about these conditions and their possible inter-relationships with osteoporosis and 
fractures, as discussed subsequently. Therefore, we begin by discussing the definition of osteoporotic 
vertebral fractures and mimics that should not be confused with vertebral fractures.
Non-fractural deformities represented by anatomical variation and developmental abnormalities have 
been reviewed by Ferrar et al.7 On a lateral view, the spine has a natural curvature such that vertebrae in 
the mid-thoracic region tend to be wedge-shaped, in keeping with the normal mild kyphosis. Lumbar 
vertebrae have a relatively shorter posterior height and tend to be biconcave. Some individuals have 
developmentally smaller or shorter vertebrae (Figure 1), particularly anteriorly and most commonly in 
the mid-thoracic region. This is thought to be because of either congenital variation or inhibited growth 
of the vertebral body during childhood or adolescence and it is believed that this variant is not because 
of fracturing8. In so-called ‘‘step-like’’ or “step-off” endplates (Figure 2) the central endplate is deeper with 
an abrupt transition to the more normal periphery. This is in contrast to the appearance of the fractured 
endplate in osteoporosis, in which a concave depression usually extends from corner to corner of the 
vertebral body.7 These “step-off” endplates seem to be the consequence of growth retardation in the 
central portion of the endplate. In contrast, the periphery of the growth plate has a different blood sup-
ply through short arteries, in which vaso-occlusion and microinfarction may lead to avascular necrosis 
and further developmental disruption of the vertebral body.9 Implicated in such a process are Gaucher’s 
disease, hemolytic anemias including hereditary spherocytosis, and sickle cell and thalassemia among 
the hemoglobinopathies.10 The cortical margins of the inferior endplates of lumbar vertebral bodies 
also frequently have paired parasagittal concavities, when viewed in the frontal projection, resembling 
the curvature of an aimed bow11 (Figure 3). When viewed in the lateral projection, the concavities are 
superimposed and lie in the posterior portion of the inferior endplate and might be confused with frac-
tures.7 This anomaly called “cupid’s bow” is a normal anatomic variant. Histologic examination in cadavers 
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reveals thickened bone in the cupid’s bow endplate with annular fibers inserting into this region, which 
was detected at multiple lumbar and thoracic levels, with the highest frequency in the lower lumbar 
spine in 34 out of 64 thoracolumbar spines.12 Furthermore, the endplate indentations tend to become 
progressively deeper distally. Other commonly seen normal variants are a deep inferior endplate (Figure 
4) and a balloon disc, where there is an occurrence of an unusually concave disc-vertebral border at 
multiple levels. A Japanese study has reported a prevalence of balloon disc up to 14% in the healthy 
population, with an association with male gender and height but a lack of a relation with back pain or 
age, yet, to our knowledge no replication and validation studies have been published.
A specific example of a vertebral abnormality that might be confused with fracturing is Scheuermann’s 
disease (SD) (Figure 5). With reported prevalence rates of up to 10%, the disease is frequently men-
tioned in the differential diagnosis of osteoporotic vertebral fractures.7 It is a form of osteochondrosis 
of the spine characterized by increased thoracic kyphosis in association with structural deformity.13, 14 
SD usually first appears during adolescence at the time of puberty, resulting in permanent vertebral 
distortion and back pain in many cases. The etiology is unknown, but heredity may well be important15: 
genetic surveys are underway. SD is diagnosed on the basis of radiographic criteria of which those 
defined by Sørensen and Sachs are the most commonly applied: a thoracic kyphosis >45°; at least three 
adjacent wedge-shaped vertebral bodies of ≥5°; endplate irregularities with possible vertebral elonga-
tion; and disc space narrowing. Schmorl’s nodes 
are thought to be a common but not obligate 
manifestation of SD (Figure 6).16-19 In a popula-
tion survey by Makurthou et al. the frequency 
of the separate radiological criteria of endplate 
irregularities and vertebral wedging was higher 
in males than in females.16 Some studies suggest 
SD to be more prevalent in men,20, 21 whereas 
others have reported no significant difference 
between the sexes16, 22-24. Although coexistence 
Figure 1. Lateral thoracic spine radiograph demonstrat-
ing an example of a developmentally short vertebra (ar-
row). This vertebra was unchanged for 15 years and the 
patient had no other evidence of disease. Therefore it 
was presumed to be a developmentally short vertebra.
Figure 2. Lateral radiography showing a ‘‘step-like’’ or 
“step-off” endplate (arrow). An osteoporotic vertebral 
fracture is also visible one level below.
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of SD with osteoporotic vertebral fractures 
may occur, it is thought that the disorders and 
their treatment are different.25 Nonetheless, 
few data exist on a possible connection. Some 
studies with small patient numbers have been 
conducted a long time ago, some of which 
suggest that patients with SD have generalized 
lower bone mineral density (BMD)26, 27. This may 
be a transient effect that resolves in adulthood,28 
whereas other analyses have found no difference in BMD between those with SD and controls29, 30. 
However, no investigations have looked into osteoporotic vertebral fracture risk in SD.
A few percent of the general population has a scoliosis as diagnosed by a Cobb angle of >10⁰ in 
the frontal plane.31, 32 A scoliosis may impair DXA BMD measurement and assessment for vertebral 
fractures.7, 33 Scoliosis can be categorized according to the etiology:
– It may occasionally be congenital, arising during embryonic development and oftentimes part of 
other abnormalities.34
– Adolescent idiopathic scoliosis represents most cases and is the most common pediatric skeletal 
disease. The etiology remains largely unknown, but population and twin studies strongly suggest 
a genetic contribution.35 So far, findings from linkage and candidate gene association studies im-
plicate genes related to connective tissue structure, bone formation and metabolism, melatonin 
signaling pathways, puberty and growth, and axon guidance pathways, but these results remain 
to be replicated.36 Two genome-wide association studies (GWAS) containing a replication phase 
have been published and describe associations with loci containing the candidate genes ladybird 
homeobox 1 (LBX1) and G protein–coupled receptor 126 (GPR126), of which the functions remain 
to be elucidated further. Bone quality deterioration and lower bone mass have been reported at 
Figure 3. “Cupid’s bow” anomaly shown on a vertebral 
fracture assessment image (arrow).
Figure 4. Lateral radiograph of the lumbar spine dem-
onstrates deep inferior endplates at multiple levels (ar-
rows).
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the hip, spine and other peripheral sites in adult idiopathic scoliosis patients.33, 37-40 Whether this 
decrease in bone mass is associated with an increased risk of osteoporotic spine fractures has not 
yet been investigated.
– Third, the clinically most important factors in adult scoliosis are primary and secondary degenerative 
scoliosis.41 In the so-called primary degenerative scoliosis (de novo form) there is asymmetric disc 
and facet joint degeneration, mostly located at the thoracolumbar junction or lumbar spine, and 
associated with aging.42 Secondary degenerative scoliosis may appear as a consequence of pelvic 
obliquity because of a leg length discrepancy, hip disease or a neuromuscular disorder.
– Finally, osteoporotic vertebral fractures may bring about an asymmetric configuration with the ap-
pearance of kyphosis, scoliosis or both.41
Figure 5. Scheuermann’s disease demonstrated on a 
lateral thoracic spine radiograph. There is increased ky-
phosis, mild wedging of multiple adjacent thoracic ver-
tebral bodies that demonstrate irregular endplates.
Figure 6. Scheuermann’s disease and Schmorl’s node 
(arrow) visualized on a sagittally reconstructed comput-
ed tomography image.
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Genetics of vertebral fractures
As mentioned, an important risk factor for osteoporosis and fractures is a positive family history.43 Studies 
have reported estimates of heritability of BMD and fractures of up to 66% and 46%, respectively.44, 45 
Furthermore, a recent report has found a mixture of shared and specific genetic influences for distinct 
BMD traits, where the strength of genetic variants may differ in their association and magnitude of effect 
across different skeletal sites and, moreover, some loci seem to act in certain skeletal locations while they 
are irrelevant at others.46 Such a difference in genetic basis had previously been proposed for lumbar 
BMD compared with femoral neck BMD in GWAS.47 Although a fracture is the most important clini-
cal outcome in osteoporosis, identifying genetic determinants contributing to the risk of fracture has 
been difficult because of its multifactorial nature and occurrence late in life. For this reason, correlated 
intermediate phenotypes such as BMD have attracted the interest of researchers. The most recent GWAS 
meta-analysis concluded that genetic factors related to BMD measured in the spine and proximal femur 
by dual-energy X-ray absorptiometry cluster in 3 key biologic pathways: mesenchymal stem cell differ-
entiation; Wnt signaling; and RANK-RANKL-OPG (receptor activator of nuclear factor kappa-B–receptor 
activator of nuclear factor kappa-B ligand–osteoprotegerin).48 Mesenchymal stem cells are multipotent 
stromal cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, and 
adipocytes. Wnt signaling consists of a group of signal transduction pathways in which proteins that 
pass signals from the extracellular space through cell surface receptors to the inside of the cell. It plays 
an essential role in development and maintenance of numerous organs and tissues including bone, 
especially in osteoblastogenesis.49 The RANK-RANKL-OPG system is crucial for well-balanced bone re-
modeling through activation of osteoclasts by osteoblasts.50 Another critical process highlighted in this 
study was endochondral ossification and the accumulation of intracellular calcium by chondrocytes to 
form calcified bone tissue in the developing skeleton.
A growing number of GWAS have revealed genetic loci for fracture risk of any type.48, 51, 52 A study by 
Liu et al. has found heritability estimates of prevalent moderate and severe vertebral fractures (semi-
quantitative (SQ) grade ≥2) as assessed on computed tomography (CT) ranging from 43% to 53% 
and increasing to approximately 69% when adjusted for volumetric BMD and cross-sectional area.53 
The very first GWAS for radiographic vertebral fractures discovered a single nucleotide polymorphism 
SNP on chromosome 16q24 at genome-wide significant level.54 The single nucleotide polymorphism 
maps to a region previously found associated with DXA LS-BMD in two large meta-analyses.47, 48 From 
a biomedical perspective, deletions/mutations in this 16q24 locus are implicated in a combination of 
birth defects that includes vertebral defects in both humans and mice.55 Furthermore, the forkhead box 
C2 (FOXC2) candidate gene located nearby in the locus encodes a transcription factor essential for axial 
skeletogenesis in mice.56 However, this GWAS association could not be convincingly replicated by de 
novo genotyping the specific marker in a large-scale global replication effort, displaying a high degree 
of heterogeneity of effects54. It was speculated that, apart from the possibility of the signal being a false 
positive association, phenotype definition as discussed elsewhere in this issue may have undermined 
establishment of a firm correlation. For instance, it is thought that many mild vertebral deformities are 
not caused by fractures but by degenerative changes, etc. Indeed in the study by Liu et al., after adding 
mild grade 1 vertebral deformities into the analyses, the heritability was much lower (aforementioned 
43% to 69% dropping to 19% to 27%) with a lower intrareader agreement (kappa =0.56–0.59 versus 
kappa=0.68–0.72 for grade ≥2).53
There are a multitude of additional candidate genes that might be screened for in very unusual clinical 
presentations of vertebral fractures, for instance genetic mutations that are known to cause monogenic 
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forms of osteoporosis or osteogenesis imperfecta, for example: COL1A1,57COL1A2, LRP5,58WNT1,59LGR4,60, 
PLS361, CRTAP, FKBP10, LEPRE1, PLOD2, PPIB, SERPINF1, SERPINH1 and SP762.
In conclusion, vertebral fractures are associated with high morbidity, mortality and costs. Radiologi-
cal diagnosis is not always straightforward. We have reviewed what is known so far about the genetic 
basis of osteoporotic vertebral fractures, and, additionally, other spinal conditions that have phenotypes 
resembling osteoporotic vertebral fractures while the underlying genetics are probably different. Recent 
discoveries in this field are likely to be the tip of the iceberg. Apart from tentatively screening for rare 
monogenic forms of osteoporosis in very unusual case presentations, not enough is currently known to 
encourage routine genetic screening in typical patients with osteoporotic vertebral fractures.
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ABSTRACT
The potential for personalized sequencing to individually optimize medical treatment in diseases such 
as cancer and for pharmacogenomic application is just beginning to be realized, and the utility of 
sequencing healthy individuals for managing health is also being explored. The data produced requires 
additional advancements in interpretation of variants of unknown significance to maximize clinical ben-
efit. Nevertheless, personalized sequencing, only recently applied to clinical medicine, has already been 
broadly applied to the discovery and study of disease. It is poised to enable the earlier and more ac-
curate diagnosis of disease risk and occurrence, guide prevention and individualized intervention as well 
as facilitate monitoring of healthy and treated patients, and play a role in the prevention and recurrence 
of future disease. This article documents the advancing capacity of personalized sequencing, reviews its 
impact on disease-oriented scientific discovery and anticipates its role in the future of medicine.
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INTRODUCTION
In the 10 years since the official completion of the Human Genome Project (HGP)1 technological 
advances in the speed and scale of sequencing analysis have maintained an accelerating pace. The 
tools produced by these advances now enable holistic analysis of individual human genomes at a cost 
and within a timeframe to allow practical and productive application to research questions and, more 
recently, personalized clinical evaluations.
Targeted, single gene sequence analysis of individual patients has been a clinically applicable diag-
nostic tool since before completion of the Human Genome Project. However, such testing has always 
been limited to thoroughly characterized genes, for which a phenotype is recognizable and clinically 
certified testing is available. Current next-generation sequencing technologies, including whole-exome 
sequencing (WES) and whole-genome sequencing (WGS) now allow analyses beyond a handful of 
genes, to include a more comprehensive genetic analysis. These sequencing tools are being actively 
applied to well-studied, but as yet unconquered diseases such as cancer, where significant advances 
in understanding the pathophysiology, diagnostics, treatment and surveillance are likely to greatly 
benefit patients; they are also being applied to the analyses of unsolved diseases in children and adults, 
and more recently to the analyses of healthy individuals. It is expected that genetic information will 
play an ever increasingly important role in helping us to better predict, diagnose and treat diseases. 
Here, we present a perspective on how next-generation sequencing may change pharmacogenomics 
and medicine as a whole through discovery and treatment of many types of disease and personalized 
pharmacological intervention.
Cancer genome sequencing
Many of the most innovative tools of biomedical investigation have been based on understanding the 
various presentations of cancer. Accordingly, soon after the completion of the HGP and the advent of 
new sequencing technologies, genome sequencing was applied to the analysis of cancer. Cancer has 
long been recognized as being caused by acquisition of multiple genetic mutations, which are thought 
to ‘drive’ cells toward uncontrollable growth. Studies have described driver gene versus passenger 
gene mutations in many forms of cancer2. Driver gene mutations are classically defined as mutations 
that, when they occur in a cell, confer a selective growth advantage and drive the cell’s progression to 
malignancy3. Some driver mutations are inherited at birth (e.g., APC and mutations) whereas others are 
acquired somatically and may be heavily influenced by environmental exposure.
Personalized sequencing impacts cancer in several ways. The first is cancer cell DNA sequencing. One 
of the first genomic studies to apply WGS to cancer involved analysis of the DNA of an acute myeloid 
leukemia patient in which both tumor and normal cells were sequenced.4 Ten mutations were identi-
fied in the tumor DNA and not in the normal DNA. Two of these had been previously described as 
linked to acute myeloid leukemia and the remaining eight were novel. This proof of principle study put 
forward WES/WGS as a tool to discover novel mutations and potential therapeutic targets. This effort 
has now been expanded on a very large scale. One large project is The Cancer Genome Atlas (TCGA), 
which is systematically analyzing WGS and WES of more than 20 types of human cancer.5 One of the 
biggest outcomes of these efforts is the discovery that most cancers are very different from one other, 
although common mutated pathways can often be observed. For example, in ovarian cancer patients 
mutations in the BRCA1 and the BRCA2 pathways, affecting homologous recombination, are frequently 
observed. Moreover, cancer from different tissues of origin can often have the same types of mutations. 
For example, the EGFR gene, previously known to be commonly mutated in breast cancer patients, is 
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often amplified or mutated in other cancer types. As such, cancers are now being classified based on 
their genetic changes rather than their tissue of origin.
Another active area in the pathophysiology of cancer is the clonal evolution theory of cancer. In 1976 
Peter Nowell posited that cancer develops as differently mutated clonal cells out-compete each other, 
with the expectation that less fit variant clones die, leaving one clone to comprise the majority of a 
tumor.6 However, genomic analyses in recent years have demonstrated that for many cases, there is 
a significant level of genetic diversity within single tumors, suggesting that tumors are more mosaic, 
rather than being dominated by a predominant clone.7 These observations have raised the profile of 
several aspects of tumoral genetic heterogeneity, and the role heterogeneity plays in diagnosis and 
treatment of cancer. For example, intratumoral, intermetastatic, intrametastatic and interpatient tumor 
heterogeneity each impact our efforts to achieve early diagnosis and successful therapeutic interven-
tion.3
New methods have emerged that use DNA sequencing to monitor cancer progression. Tumor DNA 
sequencing is rapidly expanding its capacity to produce a clinically relevant tumor profile. This is cur-
rently focused on somatic DNA variations, but there is growing effort to analyze RNA expression and 
DNA methylation patterns. Such information can help determine which signaling pathways are active 
in tumor cells, which may not have been suggested by histological assessment alone, and thereby sug-
gests therapeutic avenues that would not be uncovered by conventional methods.8
Cancer sequencing treatment implications
Personalized tumor DNA sequencing can directly impact treatment by identifying mutations that can 
suggest therapeutic treatments. In some cases the information from DNA sequencing can identify a 
known cancer target or pathway for which an existing pharmacological treatment is available (often 
initially used for a cancer involving a different tissue) and sometimes even new potential targets are 
uncovered. For example, researchers recently found through WES, a loss of function mutation in TSC1 in 
approximately 5% of advanced bladder cancers. This specific mutation correlated with tumor sensitivity 
to everolimus, suggesting that this subgroup of bladder cancer patients might benefit from everolimus 
therapy.9 Other examples of genome sequencing based clinical interventions include utilization of EGFR 
kinase inhibitors in cancers with EGFR gene mutations (found in many different types of cancers), and 
BRAF inhibitors in tumors with BRAF mutations (often found in melanomas).10, 11 In these situations appli-
cation of pharmacogenomic principles to individual tumors is critical to determine their susceptibility to 
these specific drug therapies, as only a fraction of patients will respond to these targeted therapies and 
treating patients prior to confirming their tumor’s sensitivity would expose patients to drug side effects
while allowing their cancers to advance.3 For example, identification of KRAS alterations in codons 12 
or 13, which occurs in approximately 30% of colon cancer patients, suggest some toxicity risk and no 
particular treatment benefit with EGFR specific antibodies.12
Despite these advances with clear impact on current patient care, tumor somatic mutation assess-
ment has impacted clinical intervention for a limited number of cancers. Currently, less than 10% of 
oncology drugs approved by the US FDA have documented molecular
predictors of efficacy, and there is tremendous potential for progress in this area.8
Even as sequencing has led to these advances in cancer therapy, new targets are emerging, such as 
within the pathways of tumor suppressor genes, which individually can be difficult to impact therapeuti-
cally. For example, BRCA1 and BRCA2 gene defects impact
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downstream DNA repair pathways and make cells more susceptible to drugs that inhibit repair of 
DNA damage, such as PARP, and clinical trials with this strategy are in underway.13 Individual cancer ge-
nomes have been noted to contain highly variable numbers (often 30–70 mutations) in coded proteins. 
Each of these changes is foreign to the native immune system and exploiting these changes has been 
suggested to lead to the development of highly tumor-specific antigens as a powerful tool for cancer 
directed therapies.8 This is one example of advances in the development of molecularly targeted cancer 
therapies enabled by genomic sequencing. This is especially important in the context of the substantial 
problem of cancer drug resistance, in which resistance causing events in tumors appear to be selected 
for in a Darwinian fashion.14, 15 The mechanism of cancer drug resistance can be influenced by genetic 
and histological background of the tumor as well as previously applied treatments.14, 16 One of the strate-
gies to combat drug resistance may eventually include using simultaneous drug combinations.14, 17
Cancer pharmacogenomics
Another major area of impact of cancer genome sequencing is germline sequencing. Germline 
sequencing enables the estimation of underlying patient risk arising from known alterations causing 
characterized syndromes of cancer predisposition, such as familial adenomatous polyposis or Li Frau-
meni syndrome, which facilitates implementation of prophylactic interventions and screening protocols 
to optimize early detection. Familial predisposition is estimated to account for up to 10% of melanoma, 
breast, colon and gastric cancers and up to 25% of ovarian cancer. Among these, testing is available 
to identify known predisposing genes in approximately 2–3% of colon cancer, 3–5% of gastric cancer, 
5–10% of breast cancer, up to 10% of melanoma and up to 25% of endometrial cancer.18-23 Germline 
testing can potentially impact an estimated 40,000 new cases of these types of cancer alone,24 in addi-
tion to the thousands of family members who benefit from germline sequencing by finding they do not 
carry the genetic predisposition. While germline sequencing currently impacts a minority of cancer, it 
is clear that significant potential remains for personal sequencing to discover novel genetic etiologies 
that account for the thousands of familial and individual cases of cancer for which a molecular etiology 
remains unclear. For example, WGS and WES analysis of individuals with pancreatic cancer identified 
segregating variants of the ATM gene, implicating it as a pancreatic cancer predisposition gene.25 WGS 
of patients with multiple adenomas and/or colorectal adenocarcinoma (CRC) found mutations in POLE 
and POLD, identifying them as CRC susceptibility genes.26
These same technologies are being applied to address pharmacogenomic issues, such as the etiology 
of chemotherapeutic failure, clinical side effects, drug metabolism or drug resistance. The identification 
of a germline variant of TPMT was found to result in life-threatening toxicity in patients treated with 
mercaptopurine (a treatment for acute lymphoblastic leukemia). This led the FDA to recommend ge-
notyping of patients prior to treatment, and reduce the dosage for those with appropriate genotypes.27 
The FDA currently recommends genotyping prior to treatment with other chemotherapeutics, such as 
irinotecan for CRC.28 Patient-specific drug metabolism can also lead to inadequate dosing, as in the case 
of tamoxifen for estrogen receptor positive breast carcinoma. Tamoxifen is metabolized into multiple 
metabolites, including endoxifen, which is central to treatment efficacy. Germline patient sequencing 
found variants in the CYP2D6 gene, which are associated with lower serum concentrations of endoxifen 
due to decreased enzyme activity and lead to risk of drug failure due to inadequate dosing.29 In addi-
tion to the clear potential for cancers to mutate and develop resistance to particular chemotherapeutic 
interventions,8 germline sequence analysis has found patients whose tumors are inherently resistant. 
For example, a study of chronic myeloid leukemia patients found a deletion of BCL2-like (also known as 
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BIM) in patients whose cancer treatment was resistant to tyrosine kinase inhibitors. Further analyses con-
firmed presence of the BIM deletion in the germline of the patients resistant to treatment, and that the 
proapoptotic domain affected by the deletion was the mechanism of the patients’ inherent resistance 
to tyrosine kinase inhibitor therapeutics.28 Each of these circumstances demonstrates the increasingly 
important role of pretreatment, germline personalized sequencing in successful cancer intervention.
Although the benefit of genetic information is clear, the overall impact of these advances on patient 
care currently remains limited. To date, approximately 40 FDA approved oncology drugs (Table 1) have 
been updated to include clinically relevant pharmacogenomics information in their package inserts.30 
Similarly, only approximately 40 known cancer genes have FDA approved drugs, some with multiple 
drugs per gene target. However, greater than 30 additional cancer genes have experimental drugs 
under development, which will greatly enhance the impact of genome sequencing in the future.31
Cancer sequencing & surveillance
Following intervention for a diagnosed malignancy, such as CRC, personalized sequencing will likely 
also play a role in guiding ongoing surveillance for recurrence. With one WGS costing the approximate 
equivalent of one to two colonoscopies,32 post-treatment identification of known genetics suscepti-
bilities can inform individualized management and follow-up protocols. An area of promise for future 
monitoring of remission and recurrence is that of cell-free DNA (cfDNA) sequencing through which it is 
possible to detect cancer mutations in body fluids such as blood, urine and stool, which enables moni-
toring of response to treatment and tumor evolution.33 Developed and clinically applied in the realm 
of prenatal diagnostics, the analysis of cell-free fetal DNA, as collected from maternal plasma collection, 
has recently lead to noninvasive WGS of a fetus at 18.5 weeks gestation, enabled in part by the capacity 
to distinguish maternal from fetal DNA sequence.34 The observation of significant levels of tumor DNA 
in the blood of patients with cancer has led to the idea of monitoring tumor cfDNA levels as a marker of 
disease.35 The presence of tumor specific mutations offers an additional opportunity for cfDNA analysis, 
with post-treatment sequencing of cfDNA having the potential to identify those mutations unique to 
the eradicated primary tumor, as a marker of remission and sentinel indicator of recurrence.35 In light 
of the advances made in cfDNA analysis in the prenatal realm to the point of WGS of an actively grow-
ing fetus, it seems reasonable to envision a future ability to obtain WGS of a patient tumor at an early 
stage of recurrence, as a noninvasive form of surveillance that potentiates early re-intervention. It is 
crucial to emphasize here that surveillance strategies require tests with high sensitivity and specificity, 
the establishment of which will require large randomized control trials. This is necessary to avoid the 
potential harm from false positives or ambiguous results. Overall, this could lead personalized sequenc-
ing to become an integral part of the full spectrum of clinical cancer care, including risk assessment, 
prevention, disease screening and diagnostics, personalized pharmacogenomic-based therapy, and 
post-therapy surveillance (Figure 1).
Sequencing the unknown: rare diseases
Multiple genome sequencing studies have already uncovered novel relationships for genetic variants 
with monogenetic Mendelian disorders and complex diseases.36-41 Approximately 7000 well-defined 
Mendelian disorders are currently known, of which the corresponding allelic variants underlying fewer 
than half of these monogenic disorders have been discovered, and the etiology of many monogenic 
diseases is still unknown.41, 42 Furthermore, genome sequencing enables us to decipher the causes and 
even guide treatment of an evergrowing number of “mystery” diseases, of which many cluster in families 
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but can also involve individual probands, such as Charcot–Marie–Tooth neuropathy, Miller’s syndrome, 
and dopa (3,4-dihydroxyphenylalanine)-responsive dystonia.36, 40, 41 Sequencing has shown the potential 
Table 1. US FDA-approved oncology drugs with package inserts containing pharmacogenetics and pharmacoge-
nomics information.
Drug Pharmacogenomic biomarker(s)
Ado-trastuzumab emtansine ERBB2
Afatinib EGFR
Anastrozole ESR1, PGR
Arsenic trioxide PML/RARA
Bosutinib BCR/ABL1
Brentuximab vedotin TNFRSF8
Busulfan Ph chromosome
Capecitabine DPYD
Cetuximab EGFR, KRAS
Cisplatin TPMT
Crizotinib ALK
Dabrafenib BRAF, G6PD
Dasatinib BCR/ABL1
Denileukin diftitox IL2RA
Erlotinib EGFR
Everolimus ERBB2, ESR1
Exemestane ESR1
Fluorouracil DPYD
Fulvestrant ESR1
Ibritumomab tiuxetan MS4A1
Imatinib KIT, BCR/ABL1, PDGFRB, FIP1L1/PDGFRA
Irinotecan UGT1A1
Lapatinib ERBB2
Letrozole ESR1, PGR
Mercaptopurine TPMT
Nilotinib BCR/ABL1, UGT1A1
Obinutuzumab MS4A1
Ofatumumab MS4A1
Omacetaxine BCR/ABL1
Panitumumab EGFR, KRAS
Pazopanib UGT1A1
Pertuzumab ERBB2
Ponatinib BCR-ABL T315I
Rasburicase G6PD
Rituximab MS4A1
Tamoxifen ESR1, PGR, F5, F2
Thioguanine TPMT
Tositumomab MS4A1
Trametinib BRAF
Trastuzumab ERBB2
Tretinoin PML/RARA
Vemurafenib BRAF
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to provide a solution in cases where there is an initial inability to make a clinical diagnosis of the disease 
and in rare cases has been shown to subsequently direct a course of treatment.43
A notable example was reported by Worthey et al. A male infant presented with proctitis. This pro-
gressed to pancolitis, which was concerning for a Crohn’s disease-like affliction. The severity of disease 
was suggestive of underlying immune dysfunction, however, substantial clinical evaluation was unable 
to determine a definitive diagnosis. Utilization of WES in this patient identified over 16,000 variants 
which, after further analysis observed a novel mutation in the X-linked inhibitor of the apoptosis gene, 
not previously connected with Crohn’s disease but known to be involved in the proinflammatory re-
sponse.44 Functional analyses confirmed the deleterious nature of the mutation and the diagnosis of 
X-linked inhibitor of apoptosis deficiency. Indicated treatment was hematopoetic cell transplant, after 
which the patient experienced resolution of the symptoms of colitis.44 Another example is described 
by Bainbridge et al., in two fraternal twins afflicted by clinical symptoms of dystonia whose diagnostic 
evaluation was unrevealing until one of the twins experienced symptomatic improvement with L-dopa 
treatment, at which time they were diagnosed with dopa-responsive dystonia (DRD), based on this clini-
cal response. Even with L-dopa treatment, the patients continued to experience a combination of mild 
tremor, dystonic posturing, unsteady gait, dysphonia and bradykinesia.36 The twins’ DNA, as well as their 
parents and an unaffected sibling, were subjected to WGS and, after shared mutation analysis, filtering 
and genetic annotation, three genes with significant nonsynonymous mutations were found, one of 
which, SPR, had been previously associated with DRD. SPR encodes an enzyme important to the genera-
tion of BH4, a cofactor for dopamine and serotonin. Functional studies confirmed the deleterious impact 
of the compound heterozygous SPR mutations found in the patients, and their treatment was modified 
to include a serotonin precursor, which is recommended in patients with DRD due to SPR mutations. 
Figure 1. Personalized sequencing in cancer: current and future medical applications. This includes applications 
that are currently clinically available, those applied in research protocols and those envisioned for the future, such 
as preventional management. WES: Whole-exome sequencing; WGS: Whole-genome sequencing; VUS: Variants of 
unknown significance.
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Two weeks after therapeutic modification, the patients both experienced symptomatic improvement 
including increased ability to participate in athletic activities at school.36 Though a minority of cases 
result in successful treatment interventions, even a diagnosis without a current therapy provides a fam-
ily with important information regarding a patient’s prognosis, medical management and allows for 
informed family planning.
Challenges of sequence interpretation
Despite these clear successes, many challenges make these successes less frequent than is desirable. 
In one of the above examples, multiple individuals in addition to the probands underwent WGS to 
facilitate filtering of the thousands of identified variants, which are not relevant to the clinical question 
in the proband. However in many clinical scenarios, only a single proband is under evaluation and, even 
with sequencing of both of the proband’s parents, thousands of variants will segregate in a fashion that 
makes it difficult to unequivocally identify the causative variant. Filtering of identified variants is also 
dependent on the clarity of the phenotype, as candidate gene lists are developed based on known 
disease gene associations. If a patient’s phenotype is too broadly defined or nonspecific, then the identi-
fication of likely candidate genes, from thousands of sequence variants, is significantly complicated. The 
clarity of a patient’s phenotype may also be difficult to describe in the setting of monogenic conditions 
with decreased penetrance or variable expressivity. Finally, once a promising candidate is distilled from 
the filtering process, there is no standardized approach to functionally verify that the causative genetic 
mutation has been ascertained. In the examples noted, in vitro functional analyses were performed to 
obtain supportive evidence, though the true confirmation of the diagnosis was observed in the patients’ 
response to genomic sequence based treatment. Unfortunately, there remain many genetic diseases 
without a known treatment, for which these means of confirmation is unavailable.
Sequencing & the potential for discovery
Nevertheless, the application of WES/WGS appears well suited to the elucidation of genetic diseases 
of Mendelian inheritance, as outlined in Figure 2. It is a powerful approach to the discovery of novel 
causative genes underlying Mendelian disorders where conventional strategies have failed. Even in con-
ditions where conventional approaches are expected to find the genetic etiology, WES/WGS provides 
a means to accelerate discovery.45 WES in particular is anticipated to accelerate the discovery of genes 
causing rare Mendelian disorders as: many known alleles of these conditions disrupt protein-coding 
sequences; a large fraction of rare protein impacting variants are predicted to have deleterious effects; 
and the exome represents an enriched genomic subset in which to search for these alterations with 
large effect sizes providing the opportunity to capture nearly all of the protein-coding gene rare al-
leles present in a sample.45 This includes diagnostic application to pediatric patients with rare diseases, 
like the examples already described. There is also potential to impact other inherited disease, such as 
the wide range of inherited cardiovascular diseases. Nonsyndromic cardiomyopathies such as dilated 
cardiomyopathy (DCM), hypertrophic cardiomyopathy, arrhythmogenic right ventricular dysplasia and 
left ventricular noncompaction, among others, have been attributed to mutations in over 40 genes.46 
Among these known cardiomyopathy genes, it is estimated that the specific genetic cause is identified 
in as many as 65% of familial hypertrophic cardiomyopathy cases, 50% of arrhythmogenic right ventricu-
lar dysplasia cases and 30% of DCM cases; however, lower identification rates are achieved in sporadic 
cases. Of the remaining undiagnosed cases of familial cardiomyopathy, application of WES/WGS has 
identified rare variants, for example, in the DCM gene TTN, with 25% of familial cases demonstrating 
Ch
ap
te
r 5
.1
- 350 -
potentially causative variants.46 With such an extensive, and growing, collection of genes accounting 
for the various inherited cardiomyopathies, many of which overlap between categories, personalized 
sequencing is a promising tool for streamlining of diagnostics, via both WES/WGS as well as targeted 
sequencing panels. It also demonstrates ongoing promise in delineating the underlying rare variants 
responsible for those cases of heritable cardiomyopathy yet to be elucidated.
Clinical personalized sequencing
The process of performing WES began to be offered on a clinical basis in 2011. There are currently a 
number of CLIA-certified laboratories that offer WES as a diagnostic test for patients with a phenotype 
for which an underlying molecular etiology has not yet been defined. While WES can be performed 
on the patient only, various sites offer, and recommend, testing of family trios, including the patient 
Figure 2. Investigation of rare diseases: potential and pitfalls. As the obstacles facing WES/WGS in the diagnosis of 
rare diseases are overcome, they can ultimately guide medical management. WES: Whole-exome sequencing; WGS: 
Whole-genome sequencing.
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and both parents, to facilitate subsequent sequence interpretation. In all cases of clinically available 
WES, identified mutations thought to be of clinical relevance are confirmed via Sanger sequencing 
prior to being reported. The output of clinical WES includes disruptive mutations to which the patient’s 
phenotype is attributable, mutations which appear unrelated to the observed phenotype, and variants 
of unknown significance (VUS).
There can also be mutations and incidental findings discovered during WGS and WES studies that 
predispose to conditions unrelated to the original indication, the reporting of which has been addressed 
by the American College of Medical Genetics and Genomics (ACMG) and remains a subject of ongoing 
evaluation.47 Though early estimates of the success of WES/WGS in diagnosing rare disease have been 
as high as 50%,48 recent studies suggest the success rate to be closer to 20–30%,49, 50 with chief obstacles 
being efficient and accurate clinical interpretation of the genomic variants51 and the fact that many 
genes have yet to be associated with a specific disorder, an obstacle WES itself will help to overcome. 
Nevertheless, it is probably just a matter of time until pharmacogenomic sequencing studies experience 
similar successful discoveries in the realm of rare Mendelian diseases.
Sequencing the “healthy”
Future steps will involve integration of established disease variants into clinical decision-making for as-
ymptomatic, healthy individuals. Several pilot projects have been published where sequenced genomes 
from single individuals were annotated for known genetic risk factors.52-54 The Varimed database, which 
contains published knowledge on hundreds of thousands of genetic variations in relation to thousands 
of traits, formed the reference for annotation with the Risk-OGram algorithm.53 Other examples of an-
notation databases are: Online Mendelian Inheritance in Man (OMIM),55, 56 the Human Gene Mutation 
Database (HGMD),57, 58 NCBI ClinVar55, 59 the European Genome-phenome Archive,60 dbGaP61, 62 and 
the GWAS catalog63, 64. Ashley et al. provided the first example where a patient with a family history of 
vascular disease and early sudden death was clinically assessed, including the patient’s full genome 
sequence, to provide risk prediction for coronary artery disease and screening for causes of sudden 
cardiac death.52 The ‘Snyderome’ paper revealed that genome sequencing can be used to assess vari-
ous medical risks, direct the monitoring of specific diseases (in this study, aplastic anemia and Type 2 
diabetes) and successfully guide lifestyle interventions and pharmacotherapy.53 The subject carried a 
TERT mutation, predicted to be damaging, which has been associated with aplastic anemia.65 However, 
measurements of telomere length suggested little or no decrease in telomere length and a modest 
increase in numbers of cells with short telomeres. Importantly, the patient and his mother share the 
same mutation but neither exhibit symptoms of aplastic anemia, indicating that this mutation does not 
always result in disease and is likely context specific in its effects. This illustrates that previously reported 
statistically significant associations of genetic variants with diseases may have imperfect positive predic-
tive values. The subject was predicted to have significantly elevated risk levels for hypertriglyceridemia 
and diabetes, including associated variants in GCKR (homozygous),66KCNJ11 (homozygous)67 and TCF7 
(heterozygous)68. Consistent with the elevated hypertriglyceridemia risk, triglycerides were found to be 
high (321 mg/dl) at the beginning of the study and these levels were reduced (81–116 mg/dl) after 
regularly taking simvastatin (20 mg/day). Although the subject lacked many known factors associated 
with diabetes (nonsmoker, normal BMI) and for that reason usually would not have been screened, 
monitoring of glucose levels and glycated hemoglobin revealed the onset of Type 2 diabetes during 
study follow-up as diagnosed by the subject’s physician. Interestingly, the participant possessed two 
genotypes in the LPIN1 and SLC22A1 genes associated with favorable responses to two diabetic drugs 
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(rosiglitazone and metformin). Nonetheless, after dramatic changes in diet, exercise and ingestion of 
low doses of acetylsalicylic acid, gradual decreases in glucose and glycated hemoglobin levels were 
observed and no auxiliary pharmacological agents were prescribed.
Pharmacogenomic sequencing
In addition to drugs relevant to diabetes, the subject described by Chen et al. had pharmacogenomic 
variants such as that of VKORC1 (C/T) associated with a low maintenance dose of warfarin and CYP2C19, 
which has been associated with increased risk of bleeding on standard doses of clopidogrel. There 
were also variants associated with slow metabolism of codeine, increased risk of neurological adverse 
events and Stevens–Johnson syndrome with carbamazepine and increased risk of adverse effects with 
methotrexate, among others.53 The subject described by Ashley et al. similarly carried the VKORC1 vari-
ant (C/T) for low warfarin maintenance dose, and variants in CYP4F2 associated with reduced warfarin 
dosing, ADRB1 suggesting favorable response to atenolol, HMGCR associated with favorable response 
to statins, and CDKN2A/B suggesting reduced likelihood of response to metformin and troglitazone, 
among others.52 In each case, these findings could impact the choice or dosing of medications in these 
individuals, should any of the impacted drugs be indicated in future medical management. In both 
cases, the pharmacogenomics variants were annotated based on the Pharmacogenomics Knowledge 
Base (PharmGKB), a publicly available web-based knowledge base.69 It contains data from approximately 
2,500 variants, from which approximately 650 are specifically related to drug response phenotypes, each 
of which are assigned levels of evidence through literature review by database curators.52 It represents 
one of the most up to date sources of human genetic variation as relevant to drug response. There 
are a number of databases accumulating pharmacogenomic information, including PharmaADME,70, 71 
the human cytochrome P450 (CYP) allele nomenclature website,70, 72 the human arylamine N-acetyl-
transferase (NAT) gene nomenclature website,70, 73 Pharmacogenetics of Membrane Transporters (PMT) 
database,70, 74 Transporter Database (TP-search),70, 75 the UDP-glucuronosyltransferase (UGT) Allele 
Nomenclature Page,70, 76 and PACdb,77, 78 among others. The information compiled by these and other 
sources is anticipated to play an ever growing role in guiding patient care in conjunction with personal 
sequencing. While these pilot studies were performed in ostensibly healthy individuals, similar sequence 
analysis has clear potential relevance in individuals for whom any one of the above mentioned drugs 
may be indicated for a known medical condition.
The described pilots in single individuals should be replicated in greater numbers, potentially lead-
ing the way towards more specific upstream screening for risk factors and diseases. Additional genetic 
variants are known and have been validated to be of potential clinical relevance, such as the Val174Ala 
allele in the SLCO1B1 gene for statin-induced myopathy.79, 80HLA B*5701 has been associated with slow 
or nonprogression of HIV infection and with hypersensitivity reactions to abacavir.81-83 Therefore, most 
treatment guidelines recommend that upon considering administration of abacavir, patients should be 
tested for the presence of this allele, and that those who are positive should not receive the drug. Since 
the widespread introduction of HLA B*5701 testing, the incidence of hypersensitivity reactions in those 
receiving abacavir has dropped substantially.84 Recently, it was shown in a large cohort that HLA B*5701-
positive patients were more likely to achieve viral suppression than negative patients on a nonabacavir 
regimen and less likely to experience viral rebound.85 Clinical Pharmacogenetics Implementation Con-
sortium (CPIC) guidelines have been published regarding the use of CYP2D6 and CYP2C19 genotyping 
test results to modify patient dosing of tricyclic antidepressants, such as amitriptyline and nortriptyline.86 
The effect of an individual patient’s CYP genotype on metabolism of these tricyclic agents can be taken 
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into consideration at initial dosing, in an effort to maximize the efficacy in utilizing these medications for 
such indications as depression, obsessive compulsive disorder, migraine prophylaxis and neuropathic 
pain management while minimizing the associated anticholinergic, CNS and cardiac adverse effects.86 
With these and other examples of pharmacogenomic indications, the FDA currently includes pharma-
cogenomic information in the drug labels of approximately 100 approved drugs (Table 2), in addition to 
the 40 oncology drugs mentioned previously (Table 1).
Information derived from personalized genome sequencing could point to undeveloped or concealed 
monogenic/oligogenic phenotypes where lifestyle and pharmacological interventions may minimize 
disease risks and future complications. Additionally, genome sequencing may provide evidence sup-
porting the elevated risk for, or diagnosis of, complex disorders such as Alzheimer’s disease and prostate 
cancer, where genome sequencing has contributed novel findings.37-39 Where multiple pharmacological 
options are available, the pharmacogenomics profile may guide more effective and less deleterious 
treatment decisions. To this end are more pharmacogenomic studies needed, as the associated variants 
form the basis for prediction of treatment response. It may become of increasing interest to invest in 
drug-response sequencing studies within clinical trials. Though it may seem unattractive to the pharma-
ceutical industry to identify those individuals genetically prone to adverse effects, this information can 
provide opportunities for the development of drugs with application to a broader population and drugs 
uniquely effective for significant individual cohorts, both in terms of tolerance and drug metabolism 
related individualized dosing.
Personal sequencing & family history
The patient interest and demand for personal sequencing seems poised to grow, for example in those 
individuals with a known family history of a particular condition as well as healthy, proactive individu-
als curious to learn about their genomic health and corresponding disease risks. Indeed on-demand 
genetic testing has already been commercially available for some time, including personal sequencing. 
As such, we anticipate increasing examples, such as those described above, of sequence analysis in 
individuals with subclinical or nondisease status, some having traditional risk factors (such as family 
history), which could contribute to improved prediction of who will not and who will ultimately develop 
disease and allow preventive measures to potentially avert disease in some (Figure 3).
Table 2. US FDA-approved drugs with package inserts containing pharmacogenetics and pharmacogenomics in-
formation.
Drug Disease type Pharmacogenomic biomarker(s)
Abacavir Infectious diseases HLA-B
Amitriptyline Psychiatry CYP2D6
Aripiprazole Psychiatry CYP2D6
Atomoxetine Psychiatry CYP2D6
Atorvastatin Endocrinology LDLR
Azathioprine Rheumatology TPMT
Belimumab Autoimmune diseases BTG3
Boceprevir Infectious diseases IFNL3
Carbamazepine Neurology HLA-B, HLA-A
Carglumic acid Metabolic disorders NAGS
Carisoprodol Rheumatology CYP2C19
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Table 2. US FDA-approved drugs with package inserts containing pharmacogenetics and pharmacogenomics in-
formation. (continued)
Drug Disease type Pharmacogenomic biomarker(s)
Carvedilol Cardiology CYP2D6
Celecoxib Rheumatology CYP2C9
Cevimeline Dermatology CYP2D6
Chloroquine Infectious diseases G6PD
Chlorpropamide Endocrinology G6PD
Citalopram Psychiatry CYP2C19, CYP2D6
Clobazam Neurology CYP2C19
Clomipramine Psychiatry CYP2D6
Clopidogrel Cardiology CYP2C19
Clozapine Psychiatry CYP2D6
Codeine Anesthesiology CYP2D6
Dapsone Dermatology, infectious diseases G6PD
Desipramine Psychiatry CYP2D6
Dexlansoprazole Gastroenterology CYP2C19, CYP1A2
Dextromethorphan and quinidine Neurology CYP2D6
Diazepam Psychiatry CYP2C19
Doxepin Psychiatry CYP2D6
Drospirenone and ethinyl estradiol Neurology CYP2C19
Eltrombopag Hematology F5, SERPINC1
Esomeprazole Gastroenterology CYP2C19
Fluorouracil Dermatology DPYD
Fluoxetine Psychiatry CYP2D6
Flurbiprofen Rheumatology CYP2C9
Fluvoxamine Psychiatry CYP2D6
Galantamine Neurology CYP2D6
Glimepiride Endocrinology G6PD
Glipizide Endocrinology G6PD
Glyburide Endocrinology G6PD
Iloperidone Psychiatry CYP2D6
Imipramine Psychiatry CYP2D6
Indacaterol Pulmonary UGT1A1
Isosorbide and hydralazine Cardiology NAT1–2
Ivacaftor Pulmonary CFTR
Lansoprazole Gastroenterology CYP2C19
Lenalidomide Hematology del (5q)
Lomitapide Endocrinology LDLR
Mafenide Infectious diseases G6PD
Maraviroc Infectious diseases CCR5
Methylene blue Hematology G6PD
Metoclopramide Gastroentrology CYB5R1–4
Metoprolol Cardiology CYP2D6
Mipomersen Endocrinology LDLR
Modafinil Psychiatry CYP2D6
Mycophenolic acid Transplantation HPRT1
Nalidixic acid Infectious diseases G6PD
Nefazodone Psychiatry CYP2D6
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Table 2. US FDA-approved drugs with package inserts containing pharmacogenetics and pharmacogenomics in-
formation. (continued)
Drug Disease type Pharmacogenomic biomarker(s)
Nitrofurantoin Infectious diseases G6PD
Nortriptyline Psychiatry CYP2D6
Omeprazole Gastroenterology CYP2C19
Pantoprazole Gastroenterology CYP2C19
Paroxetine Psychiatry CYP2D6
PEG-3350 Gastroenterology G6PD
Peginterferon alfa-2b Infectious diseases IFNL3
Pegloticase Rheumatology G6PD
Perphenazine Psychiatry CYP2D6
Phenytoin Neurology HLA-B
Pimozide Psychiatry CYP2D6
Prasugrel Cardiology CYP2C19
Pravastatin Endocrinology LDLR
Primaquine Infectious diseases G6PD
Propafenone Cardiology CYP2D6
Propranolol Cardiology CYP2D6
Protriptyline Psychiatry CYP2D6
Quinidine Cardiology CYP2D6
Quinine sulfate Infectious diseases G6PD
Rabeprazole Gastroenterology CYP2C19
Rifampin, isoniazid and pyrazinamide Infectious diseases NAT1–2
Risperidone Psychiatry CYP2D6
Rosuvastatin Endocrinology LDLR
Simeprevir Infectious diseases IFNL3
Sodium nitrite Antidotal therapy G6PD
Sofosbuvir Infectious diseases IFNL3
Succimer Hematology G6PD
Sulfamethoxazole and trimethoprim Infectious diseases G6PD
Telaprevir Infectious diseases IFNL3
Terbinafine Infectious diseases CYP2D6
Tetrabenazine Neurology CYP2D6
Thioridazine Psychiatry CYP2D6
Ticagrelor Cardiology CYP2C19
Tolterodine Genitourinary CYP2D6
Tramadol Analgesic CYP2D6
Trimipramine Psychiatry CYP2D6
Valproic acid Neurology POLG, NAGS, CPS1, ASS1, OTC, ASL, 
ABL2
Velaglucerase alfa Metabolic disorders GBA
Venlafaxine Psychiatry CYP2D6
Voriconazole Infectious diseases CYP2C19
Vortioxetine Neurology CYP2D6
Warfarin Cardiology, hematology CYP2C9, VKORC1, PROC
F2: Prothrombin; F5: Factor V Leiden. Data taken from 104.
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Understandably, there remains a significant amount of trepidation in the clinical community regarding 
genome sequencing in individuals as an adjunctive screen for risk of various types of disease. However, 
information obtained via a family history has long been an accepted and critical part of an individual’s 
clinical evaluation as a potent predictor of risk for certain diseases. WES/WGS represents a potentially 
more accurate means of determining what portion of the family history is specifically relevant to a par-
ticular individual’s health, and should be seen as a powerful supplement to the clinical family history. 
Limitations of personalized sequencing Nevertheless, WES and WGS are often performed with relatively 
low read depth, which results in data of insufficient quality to be directly used in clinical practice. Conse-
quently, they can return thousands or tens of thousands of false-positive variants, necessitating valida-
tion by a separate platform such as Sanger sequencing or targeted amplicon sequencing with high 
read depth. As an example, for the Snyderome a variety of technologies and platforms manufactured by 
different distributors were applied to achieve deep sequencing. WGS by Complete Genomics (CA, USA; 
35 nt paired end; 150-fold total coverage) and Illumina (CA, USA; 100 nt paired end; 120-fold total cover-
age). WES by Agilent (CA, USA), Illumina (CA, USA) and Nimblegen (WI, USA) at 80- to 100-fold coverage; 
crossvalidation with Illumina Omni1-Quad genotyping arrays (99.3% sensitivity); stringent data quality 
control and calling criteria; RNA sequencing by Illumina HiSeq with high depth; Sanger sequencing of 
randomly selected variants (36/36 single nucleotide variations validated; 14/15 indels validated).
In the majority of cases of clinically available WES, identified mutations thought to be of clinical 
relevance are confirmed via an independent platform prior to being reported with Sanger sequencing 
being the predominantly applied confirmatory platform. Sanger sequencing is held by many as the gold 
Figure 3. Profiling rare diseases. Issues and pipeline for personal genome sequencing in disease risk profiling of the 
“healthy” state.
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standard,87 while some have suggested conventional Sanger may no longer be the gold standard.88 This 
appears in part related to the observation that some variants identified by WES/WGS are not confirmable 
by Sanger sequencing.89-91 It should be noted that no platform is perfect as each has its own systematic 
weaknesses.88, 92 Nevertheless, while one clinical laboratory has begun to forgo Sanger confirmation for 
WES/WGS variants identified above a specified quality threshold, Sanger sequencing remains a relevant 
technique for validation of variants found by WES/WGS, as the systematic errors associated with each 
are different.93
It is also important to realize that previously reported associations of genetic variants with disease may 
have suboptimal positive- and negative-predictive values. Some variants have been evaluated in this 
context with sufficient sample sizes in independent studies, but for many associations these statistics 
remain to be adequately determined. More research is needed to support high-quality evidence-based 
genomic medicine.
Sequencing & VUS: benefit-to-harm ratio
As application of personal sequencing expands, WES/WGS will yield an abundance of data includ-
ing VUS.94, 95 Inadequate in silico prediction algorithms and incomplete penetrance are among the 
factors complicating clinical interpretation of these findings.43 A ‘binning system’ has been proposed 
by which genetic variants can be ‘triaged’ in the clinical diagnostic setting to help address the field’s 
limited, though growing, understanding about most genetic variants, to facilitate focused attention on 
those variants demonstrated to have clinical implications.96 Additional in vitro investigations, such as 
RNA expression and proteomic analyses, will be needed to confidently disregard a VUS or establish 
its association with a condition. As more sequencing data are becoming available, variants previously 
designated disease causing, benign or of uncertain significance are being reclassified. This theoretically 
adds to healthcare costs and the practical and mental burden of patients tested; these aspects need to 
be taken into consideration and require further investigation.
Ethical discussions surrounding DNA sequencing are ongoing and confidentiality of patient health 
information has become a serious issue.97 Patients, but also the general public, should be properly 
educated about genome sequencing, its applications and limitations, enabling them to make informed 
health decisions. Informed consent and data sharing agreements should include clauses specifying to 
whom a patient wishes to grant access to his or her genomic data, while taking into consideration the 
individuals for whom the patient’s genomic data represents actionable clinical information. While these 
issues remain to be resolved, we are convinced that correct application of information resulting from 
personal sequencing will prove to be cost effective with a favorable benefit-to-harm ratio.
Sequencing patients: integration into clinical care
The genome is believed to be relatively stable throughout life and it will gradually become more 
attractive to retain data resulting from genome sequencing for future use. The cost–effectiveness of 
personalized exome and genome sequencing will improve with time, as the costs of sequence data 
generation, processing and storage decline and we will learn how to best utilize this information. For 
clinical care, it may become relevant to integrate genomic information into medical health records. Any 
information to be integrated into the electronic medical record (EMR) needs to be of high quality and 
accuracy, and the current quality of genomic sequence does not meet that level of rigor. An interim 
strategy would be to establish a clinical research database in which the full genome sequence and 
downstream analyses are stored and selected results from established, clinically related follow-up tests 
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would get into the EMR (Figure 4). The selection criteria would require regular updating per advancing 
scientific understanding and the patients’ sequences would need to be regularly re-evaluated, gradually 
enriching the genomic information in the EMR. A pharmacogenomic example could be that automated 
alerts would notify the treating physician of genetically determined sensitivity to certain medications 
or suboptimal metabolism requiring drug dose adjustment, such as the Snyderome related variants 
impacting clopidogrel and warfarin efficacy.53
Figure 4. Incorporation of the personal genome sequence into healthcare. As genome sequence quality improves, 
future direct incorporation into the EMR will be possible, as indicated by the dashed arrows. EMR: Electronic medical 
record.
Studies have also been designed for genotype-driven scans of the interaction of numerous non-genetic 
factors. A group of investigators lead by Atul Butte devised a design where a set of well-established 
genetic variants are screened for interactions with a great variety of non-genetic factors, termed 
‘environment-wide association study’.98-100 One of the published studies found an association between 
SNP genotypes and β-carotenes, where β-carotenes seem to negate certain detrimental genetic ef-
fects and prevent genetically predisposed persons from getting Type 2 diabetes.99 Whether β-carotene 
administration to persons with risk genotypes for Type 2 diabetes could actually prevent them from 
getting the disease remains to be proven. In the future it may even be possible to isolate cells from 
patients known to carry detrimental alleles and test responses to different compounds in vitro, which 
may support eventual medical decision-making.
Obstacles to EMR implementation
While personalized sequencing provides us with a wealth of genomic data including single nucleotide 
variations or SNPs and structural variations, it is key to keep in mind the current limitations of the tech-
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nology, such as read depth and data quality, when interpreting the results. Confirmation by another 
reliable platform with high read depth remains necessary. Moreover, there is additive value in combining 
genomic sequencing information with RNA sequencing, transcriptomic, proteomic and metabolomic 
data. These omics analyses yield independent information about dynamic changes in health and disease 
states and are critical to correct interpretation of genomic variation and its clinical application.53, 101, 102
Many of these clinical applications for personal sequencing remain in the near and distant future, as 
we continue to unravel the mysteries of the human genome.95 As our understanding grows through dis-
covery and validation studies the accuracy of medical genetic sequencing will improve. This will increase 
the need for carefully curated databases with wellcorroborated genetic variants and reference genomes 
to support sequence interpretation. Analytical validation and evaluation studies with adequate study 
sample sizes and performed in different population groups are necessary to translate findings from 
the research realm into clinically validated tests. While the clinical applications of personal sequencing 
and validated medically actionable variants remains limited, their growing application to the practice of 
medicine is anticipated to accelerate.
CONCLUSION
Personalized sequencing has fast evolved to become a tool broadly applied in the study of disease and 
of increasing value in medical application to the diagnosis and treatment of disease. There is a growing 
need for improved methods, both in silico and in vitro, to predict the clinical impact of VUS identified 
in the process of large-scale sequencing. The quality of the currently generated WES and WGS is also 
in need of improvement, if it is to be incorporated in the future into an individual’s EMR as a reference.
Even with these obstacles, personalized sequencing has already begun to demonstrate its applica-
bility to the practice of medicine. With it we have begun to better understand the etiologies of rare 
diseases and long studied diseases, such as cancer. Successes have been most evident in the field of 
rare Mendelian disorders where a single variant is sought to explain the phenotype in a patient, and 
can guide disease management by establishing the diagnosis. It demonstrates utility in refining and 
expanding our current diagnostic capacity such as through individual tumor DNA sequencing. Germline 
sequencing has also produced actionable information able to indicate lifestyle changes for an individual 
at risk for diabetes, as well as guiding pharmacologic interventions for the treatment of cancer, attuned 
to both tolerance of the patient and effectiveness of therapy, in a step towards personalized medicine. 
The application of personalized sequencing to clinically healthy individuals awaits the replication of 
recent studies in larger cohorts, but has the potential to be a medically valuable application in the not 
too distant future. As implementation of personalized sequencing on a large-scale is becoming progres-
sively achievable, and accuracy of interpretation is significantly improved, we expect a transformation of 
healthcare in its current form.
FUTURE PERSPECTIVE
With the rapid advances that have taken place in personalized sequencing over the past 5 years, it is diffi-
cult to predict its overall impact on the field of medicine in the coming 5–10 years, though we expect its 
impact to be significant. For example, while current WES data quality and interpretation remain currently 
inadequate to the task, there exists the future possibility that personal sequencing technology might be 
applied in clinically healthy individuals, both with and without known predispositions to disease, as a 
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screening method to detect preclinical conditions, such as cancer, and facilitate pre-emptive treatment, 
with the potential to abrogate progression of otherwise clinically undetectable disease. It should be 
noted that, while we feel the current sequence quality and associated interpretative capacity require 
significant advancement prior to this type of clinical application, asymptomatic adult whole-exome 
screening tests are already being offered by CLIA-certified facilities (i.e., ‘adult screening exome sequenc-
ing’),103 emphasizing the urgent need for advancement in sequence quality and interpretive acuity. 
Where WES is currently available on a clinical basis, we would predict WGS to be clinically available in 
5–10 years’ time, as an evaluation that is routinely ordered by physicians. As broader utilization of EMRs 
takes hold in the practice of medicine and the quality of WGS continues to improve, we envision an 
individual’s genomic sequence becoming archived as an accessible part of their EMR in as little as 10 
years’ time, for physicians to reference as a part of patient care.
In this era of medicine where medical practitioners include intensivists who treat diseases at their 
critical extremity and interventionalists who utilize invasive techniques, often at significant expense and 
morbidity, to ameliorate the complications of advanced sequelae of preventable disease, we envision 
a future in which personalized genomic sequencing enables the emergence of a new breed of medi-
cal practitioner: the preventional geneticist. Personalized sequencing portends a future for medicine 
where specialized healthcare providers, preventional geneticists, carefully interpreting and applying an 
individual’s genomic profile can foresee their potential for various major diseases, such as diabetes and 
cancer. This information can then be used by preventional geneticists, possibly prior to clinical onset of 
these conditions, to institute surveillance, lifestyle changes and even preemptive pharmacogenomic-
based therapeutics, with the potential to delay disease sequelae, and ultimately prevent disease onset 
in its entirety, defeating disease. Personalized sequencing represents a first major step toward this 
revolutionary future for medicine.
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EXECUTIVE SUMMARy
Background
– Personalized sequencing has advanced in scale, speed and affordability to become a powerful tool 
in the study of individuals and their diseases.
Cancer genome sequencing
– The diagnosis and management of various forms of cancer has benefited from two forms of person-
alized sequencing: tumor DNA and germline. These have enabled the beginning of individualized 
therapy of cancer.
Sequencing the unknown: rare diseases
– Rare and “mystery” diseases as targets for personalized sequencing have yielded etiologies for previ-
ously undiagnosed diseases, in rare cases capacitating effective treatment.
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Sequencing the “healthy”
– At least one study analyzing the genomic sequence of a clinically healthy individual found a 
predisposition to diabetes, pharmacological interventions to which the individual would favorably 
respond, and allowed lifestyle changes to prevent the disease’s onset.
– Several obstacles impede the current clinical application of personalized sequencing, one of which 
is the technological limitations of sequencing accuracy, where much progress is needed to allow 
transition to clinical medicine.
– Interpretation of the genomic sequence currently remains a significant impediment to clinical ap-
plications. While many approaches are under development, new in silico and in vitro strategies are 
critical to understanding genomic data with acuity sufficient for clinical decision-making.
– Variant(s) of unknown significance uncovered during sequencing will require additional inter-
rogation via RNA expression, proteomic, metabolomic and other functional analyses, to facilitate 
accurate classification as benign and disease causing.
Sequencing patients: integration into clinical care
– An individual’s personalized sequence may eventually become a valuable part of their electronic 
medical record, to be referenced periodically in the identification and management of disease.
Future perspective
– Personalized sequencing represents a major step toward a revolutionary future of disease treatment, 
prediction and prevention in the practice of medicine.
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In this thesis, various genetic and metabolic factors were investigated to characterize the determinants 
underlying skeletal endocrine and degenerative diseases. These included alterations in bone leading to 
increased fracture risk in osteoporosis and diabetic bone disease. The main objective of this thesis was to 
identify novel risk factors including genetic markers and to further characterize known determinants of 
fracture risk. This chapter places the main findings under a unifying perspective together with a discus-
sion and suggestions for future research.
EPIDEMIOLOGICAL ASPECTS OF ENDOCRINE BONE DISEASES
Fracture is a “complex” clinical event, or phenotype, with environmental and genetic factors influencing 
risk of fracture. Fractures can be classified according to skeletal site, shape, etiological mechanism and 
clinical expression. Table 1 shows an overview of various fracture definitions used. Here, it has to be 
noted that the definition of fracture is not uniform and difficult to standardize, and is based on different 
criteria in different studies. The studies in this thesis include mainly two phenotypes: 1) the all-type of 
fracture phenotype, further stratified according to fracture site, and 2) radiographic vertebral fractures, 
further characterized by shape. These fracture definitions were selected, because the all-type of fracture 
phenotype and radiographic vertebral fractures maximize sample size, and the latter can be diagnosed 
on population imaging by radiographs.
RADIOLOGICAL ASPECTS OF VERTEBRAL FRACTURES AND ENDOCRINE BONE 
DISEASES
Currently, clinical scores available for osteoporosis only predict incident non-vertebral fracture risk. It 
would be desirable to devise a clinical risk score for vertebral fractures as well. Risk factors for incident 
vertebral fractures have previously been identified, such as: prevalent vertebral fractures, age, gender, 
height, weight, smoking history, height loss1 and use of a walking aid.2, 3 Further studies may identify 
additional risk factors for osteoporotic vertebral fractures.
Vertebral fractures may go misdiagnosed as the clinical presentation can be aspecific. Moreover, as two 
thirds of vertebral fractures do not give clinical symptoms, these may be only detected on radiological 
imaging.4 Nevertheless, vertebral fractures increase the risk of new vertebral fracture up to five-fold and 
the risk of other fragility fractures two- to four-fold.4, 5 Drugs available for the treatment of osteoporosis 
are highly effective, with the most potent bisphosphonate zoledronic acid reducing the risk of vertebral 
fractures by 76% and of non-vertebral fractures by 24%.6
Therefore, accurate diagnosis is crucial, however, at present, a gold standard is lacking. The Dutch 
national multi-disciplinary osteoporosis guideline of 2011 recommends performing DXA-BMD measure-
ments and Vertebral Fracture Assessments (DXA-VFA or lateral radiographs) in persons: 1) aged 50 years 
and over with clinical suspicion of vertebral fractures; 2) having recent non-vertebral fracture; 3) with 
diseases or medication use with potential bone loss; and 4) aged 60 years and over with multiple risk 
factors.7 A clear and correct fracture definition is crucial, because vertebral fractures form an integral part 
of clinical decision making to initiate anti-osteoporotic drugs. In addition, switching to the expensive os-
teoanabolic agent teriparatide for two years is indicated in patients who have sustained three fractures 
of which at least two are located in the spine while treated with other osteoporosis drugs.7
Various morphometric methods are currently used to diagnose vertebral fractures and we compared 
the algorithm based qualitative (ABQ) method with quantitative morphometry (QM) in a dataset of 
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Table 1. Description of various fracture-related definitions (alphabetical order).
Fracture terminology Definition
All-type or any-type Break in any bone of the skeleton resulting from the application of excessive force. In most studies 
focusing on osteoporosis, fractures by high-trauma and of the skull, toes and fingers are excluded 
from the definition.
Asymptomatic Fracture which does not present with any clinical signs. Versus clinical fractures.
Atypical Refers to fractures that occur at an unusual site for osteoporosis, and principally concerns Atypical 
Femoral Fractures (AFF) located in the subtrochanteric region and diaphysis of the femur. They 
have been reported in patients taking bisphosphonates or denosumab, but they also occur in 
patients with no exposure to these drugs.
Avulsion A fragment of bone tears away from the main mass by traumatic traction.
Biconcave Vertebral fracture with middle height loss.
Burst Severe vertebral fracture with compression of the posterior height due to a high-energy axial load.
Clinical Coming to clinical attention and diagnosed by a physician and confirmed by radiological imaging.
Colles Fracture of the distal radius in the forearm with dorsal (posterior) and radial displacement of the 
wrist and hand. Most common causal mechanism is falling onto a hard surface and breaking of the 
fall with outstretched arms.
Comminuted Breaking of the bone in more than two pieces.
Complicated Fracture in which the broken bone fragment(s) cause damage to neighboring structures.
Compression Collapse of the vertebral body
Crush Vertebral fracture with posterior height loss.
Fragility Occurs spontaneously or after minimal trauma, such as a fall from standing height. This definition 
arises because a normal human being ought to be able to fall from standing height without 
breaking any bones, and a fracture therefore suggests weakness of the skeleton. There are three 
fracture sites said to be typical of fragility fractures: vertebral fractures, fractures of the neck of the 
femur, and Colles fracture of the wrist.
Hip Refers to fracture of the femur bone.
Malunion Healing of a fracture in an abnormal (nonanatomic) position
Nonunion Fractured bone fails to heal completely and a space remains between the fragments
Osteoporotic Occurring as a consequence of deterioration of bone quantity and qualities, where decreased BMD 
(World Health Organization definition: 2.5 standard deviations or more below the mean peak bone 
mass of average young, healthy adults as measured by dual-energy X-ray absorptiometry[DXA]) 
and deteriorated microarchitecture may be present. Major osteoporotic fractures comprise clinical 
vertebral, hip, forearm or proximal humerus fractures. Fractures of the skull, hands and toes are 
often excluded, as they are often associated with trauma and not with osteoporosis.
Pathologic Caused by disease that led to weakness of the bone structure.
Radiographic Diagnosed on imaging studies. Particularly applies to vertebral fractures, as a majority of these 
fractures are asymptomatic and thus can only be comprehensively captured by radiological 
surveys.
Spiral The bone has been twisted apart and the line of break is helical; also called torsion fracture.
Stress Caused by the repetitive application of force resulting in microcracks in bone which may eventually 
progress to larger fractures; often by overuse and sometimes in combination with osteoporosis.
Traumatic versus 
low-trauma or non-
traumatic
Traumatic fractures are caused by a significant external force, such as traffic accidents or falls from 
heights; low-trauma or non-traumatic fractures occur spontaneously or after minimal trauma, such 
as a fall from standing height, and are considered fragility fractures.
Unstable Fracture with a high risk to displace.
Vertebral or spinal 
versus non-vertebral
Occurring in the spinal column versus not occurring in the spine. This traditional distinction 
arose due to clinical and epidemiological differences in diagnostic methodology and underlying 
mechanisms in a substantial number of cases.
Wedge Vertebral fracture with anterior height loss.
Wrist Commonly refers to fractures of the distal radius bone.
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2,827 subjects of the Rotterdam Study (RS-III cohort). QM-based methods evaluate vertebral height,8 
while the ABQ method9 mainly judges endplate integrity, regardless of vertebral height reduction (Table 
2). Our study showed that osteoporotic vertebral fractures prevalence rates are significantly different 
when applying either software-assisted QM or ABQ. Both QM and ABQ identify a considerable number 
of deformities that were assessed as normal by the other: 16.9% were assessed as QM deformities but 
not ABQ fractures; 1.2% were judged fractured according to ABQ but not QM. Further work is needed 
to reveal which of the discordant cases are actually clinically relevant: association studies evaluating the 
predictive ability of the different definitions with different relevant outcomes like future non-vertebral 
and vertebral fractures, and mortality are desirable. Merely measuring vertebral heights in clinical prac-
tice (which is the current recommendation in the Dutch osteoporosis guideline),7 frequently leads to 
misdiagnosis of fracture in non-osteoporotic conditions including Scheuermann’s disease, as illustrated 
by our case examples. Simultaneous assessment of vertebral heights together with endplate integrity 
may correctly differentiate these cases. One of the major advantages of software-assisted QM is the 
detailedness of the data recording. If more evidence supporting the ABQ method will be put forward, 
it will be worthwhile to explore if endplate integrity can be captured in software-assisted assessments 
based on computer-based morphometric recognition or if necessary also assess qualitative parameters. 
In addition to improvement of the radiological vertebral fracture definition by itself, clearer criteria for 
non-fracture deformities differential diagnosis, are necessary. Also, the relevance of more quantitative 
measures that could be derived from the raw X-ray data can be investigated, such as the kyphosis or 
lordosis angle or vertebral wedging, intervertebral disc space, and spondylolisthesis.
Table 2. Comparison of vertebral fracture definitions across quantitative morphometry (QM) and algorithm based 
qualitative (ABQ) methods.
Algorithm based qualitative (ABQ) Quantitative morphometry (QM)b
Vertebral body height reduction + or - +
Endplate depression +a -
aThe algorithm based qualitative (ABQ) method offers an approach for the differentiation of non-fracture deformities 
(e.g., degenerative changes in spine osteoarthritis such as vertebral wedging and intervertebral disc space narrow-
ing) from osteoporotic vertebral fractures.
bOne kind of quantitative morphometry-based method is SpineAnalyzer®.
The extensive imaging-based phenotyping effort of the Rotterdam Study has over 100,000 radiographs 
of the spine, hips, hands and knees available. All spine radiographs from 11,344 participants from the 
4-yearly visits were assessed for vertebral fractures with a comprehensive range of quantitative and 
qualitative methods (Figure 1). Assessments have been performed for osteoporotic vertebral fractures 
according to QM with the McCloskey-Kanis method, ABQ methods, and semi-automated morphometry 
using SpineAnalyzer software. It is also an excellent setting to expand our knowledge about other 
spine diseases through readings that have been done for Scheuermann’s disease, various degenera-
tive traits for osteoarthritis, etc. For instance, Rotterdam Study results revealed a prevalence of 4.0% of 
radiographic Scheuermann’s disease in Dutch individuals aged 45 years and over, indicating that the 
disorder is underappreciated.
TBS seems a promising osteoporosis quantitative imaging parameter, to some extent independent 
of DXA-BMD. DXA-BMD is a measure of bone quantity, while TBS provides information on the biome-
chanics and microarchitecture which reflects trabecular structure. Studies with larger sample sizes and 
aiming at additional phenotype associations are underway in the Rotterdam Study. TBS is less expensive 
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and better accessible than CT or MRI imaging for wide-spread implementation. The very fi rst TBS reports 
showed applications for the prediction of fracture risk in osteoporosis,10-12 have added value in those in-
dividuals with bone density outside of the osteoporosis range13 and monitoring of treatment eff ects,14, 15 
and similarly, TBS may fi nd an application in other conditions such as primary hyperparathyroidism,16 
hypercortisolism,17 rheumatoid arthritis,18 and diabetes-related bone disease19. A major advantage is that 
it can be easily derived from DXA scans, similar to VFA, which is already being applied in the clinic as 
recommended in the Dutch national guideline7.
DIABETES, DEGENERATION AND BONE
Intuitively, a higher BMD should be protective against fracture. For instance, an individual with 5% higher 
femoral neck BMD would have a 10% decrease in fracture risk. Intriguingly, the contrary seems true 
in lumbar disc degeneration (LDD) and type 2 diabetes. Our studies showed that subjects with LDD 
have systematically higher BMD at the lumbar spine, femoral neck, skull, and consequently, at the total 
body measurement. In spite of this systematically higher BMD, persons with LDD are at higher risk of 
osteoporotic fractures, particularly males in whom LDD seems more severe. Second, De Liefde et al. were 
Figure 1. Diagram of the radiographic osteoporotic vertebral fracture data for the examination cycles of the Rot-
terdam Study (RS). These are part of a series of over 100,000 radiographs of the spine, hips, hands and knees. Five visit 
cycles have been conducted until now for the fi rst original cohort RS-I and are indicated by RS-I-1 to RS-I-5. RS-II-1 and 
RS-II-2 relate to the extension of the cohort and RS-III-1 denotes the baseline examination of the second extension co-
hort. The total sample sizes per cohort counting the participants that have had a radiographic examination for assess-
ment of their vertebral fracture status at least once are depicted on the left, comprising N=11,344 individuals of which 
2,868 participants with vertebral fractures and 8,476 controls. The center shows total sample sizes and osteoporotic 
vertebral fracture status per assessment method for the separate examination cycles. Abbreviations: N=total sample 
size; VFx=vertebral fracture cases; Ctr=controls without vertebral fractures; ABQ=vertebral fracture case according to 
the algorithm based qualitative method; QM=vertebral fracture case according to quantitative morphometry.
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among the first to show, using Rotterdam Study data, that individuals with type 2 diabetes have 69% 
higher fracture risk than those without diabetes despite having higher BMD at the femoral neck and 
lumbar spine.20 Schwartz and colleagues established that the World Health Organization’s fracture risk 
assessment tool (FRAX) underestimates osteoporotic fracture risk in individuals with diabetes;21 this is 
why diabetes as a risk factor should be considered for inclusion in future iterations of FRAX.22
Abnormal alterations of bone may be mediated by processes such as glycemic load and inflamma-
tion. The main biomarker to clinically monitor glycemic load is glycated hemoglobin (HbA1C). Individuals 
with higher levels of HbA1C and CRP have been found to suffer from more cardiovascular disease,23 and as 
we have shown also more bone complications. From these results, we were among the first to postulate 
that an inefficient redistribution of bone mass, accumulation of microcracks and cortical porosity reflect-
ing impaired bone repair give rise to fragility in apparently “strong” bones in inadequately controlled 
diabetes. A study using high-resolution peripheral quantitative computed tomography (HR-pQCT), 
reported that the cortical porosity in type 2 diabetic patients was up to twice that of controls at the 
radius.24 Subsequently, Patsch et al. showed in a four-group comparison of type 2 diabetes patients with 
and without fragility fractures to controls with and without fractures that cortical porosity is specific 
to those type 2 diabetes patients that fracture.25 Moreover, an innovative investigation utilizing in vivo 
microindentation testing of the tibia showed that patients with type 2 diabetes have reduced serum 
markers of bone turnover and lower bone material strength than controls.26 In this same study the aver-
age HbA1C level over the previous ten years was negatively correlated with bone material strength.26 As 
hip structural analysis gives limited information, it would be desirable to investigate these phenomena 
on a larger population scale applying (pQ)CT and magnetic resonance imaging (MRI) in future work.
These data indicate that the first line of action for fracture prevention in diabetes is targeting adequate 
glycemic control. However, results from a randomized trial did not find changes in fracture or fall risk 
between standard glycemia and intensive glycemia.27 Nevertheless, the study group may represent 
mostly less severe diabetes and average follow-up was less than 4 years. Hence, inference of long-term 
effects, i.e., from long-standing control and diminishing carryover of pretreatment glycemic exposure, 
is not yet possible. In sum, there is a need for adequate imaging and laboratory biomarkers to aid 
diagnosis and monitoring of diabetic bone disease. Additionally, this contention opens the possibility 
for alternative treatments that consider different pathophysiologic mechanisms than those present in 
typical osteoporosis processes, such as osteo-anabolic therapies like teriparatide, to overcome low bone 
formation and accumulation of microcracks.28 More studies including randomized controlled trials in 
this area are needed.
GENETIC ASPECTS OF ENDOCRINE BONE DISEASES
Genome-wide screening as achieved in GWAS has advantages over the candidate gene approach. 
The traditional candidate gene approach is largely limited by its reliance on the a priori knowledge 
about the physiological, biochemical or functional aspects of possible candidates.29 On the other 
hand, genome-wide genotyping is unbiased in the sense that by surveying the whole genome in a 
hypothesis-free manner, involvement of unexpected candidates or even loci with unknown function 
could be revealed.30 Nonetheless, meta-analysis can unite the best of both worlds, including follow-up 
of top loci and genes prioritized by GWAS in candidate gene studies or use of existent GWAS for look-ups 
of functional biological hypotheses, as performed in a few of the studies in this thesis.
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Family history has been shown to be an adequate predictor of risk across varied health conditions as 
heart disease, colorectal cancer, breast cancer, ovarian cancer, atopy or asthma, type 2 diabetes, among 
many others.31 Similarly, a positive family history is one of the most important risk factors for osteoporosis 
and fractures.32 The risk ratio (RR) for any fracture is 1.17, and for hip fracture is 1.49 (95% CI: 1.17-1.89). 
Parental hip fracture has been incorporated as a risk factor in the FRAX clinical score. Hence, the underly-
ing possibilities provided by genomics make genetic studies appealing.
Compared to other quantitative traits that have been subject of GWAS, investigating BMD seems 
very prolific (Figure 2), while GWAS for dichotomous disease as a direct outcome including osteoporotic 
fractures, have yielded relatively lower numbers of loci discovered (Figure 3). Identifying the specific 
genetic determinants contributing to the risk of fracture has been difficult due to its multifactorial nature 
and occurrence late in life. High phenotype heterogeneity and ascertainment bias reduce the power to 
detect association. Studying correlated endophenotypes, such as in this case DXA-BMD, have shown to 
be a good alternative to study the genetic basis of osteoporosis. Endophenotypes may be nearer to the 
coding DNA in the chain of events at the basis of multifactorial diseases, and, homogeneous determina-
tion of endophenotypes may be simpler than defining certain diseases. Indeed, our hypothesis-free 
genome-wide screens have shown that the most prominent and consistently replicating genetic loci 
associated with fracture risk are also associated with BMD, which serves as proof of BMD being a very 
powerful endophenotype for fracture prediction. An underlying fragility component mediated through 
genetic predisposition seems to form the basis for fracture risk.
From the graphs it becomes clear that, first a trait-specific minimum sample-size threshold needs to be 
reached, and thereafter, the number of loci discovered increases along with growing sample sizes as 
study power improves.33 Mega-sized biobanks, such as 23andMe and UK Biobank, including hundreds of 
thousands participants with GWAS of adequate quality are increasingly becoming available to in include 
in meta-analyses.34, 35 A drawback is that phenotype data may be of variable quality and detailedness, 
however there is a trade-off where the huge numbers may boost study power tremendously and 
overcome measurement error to a certain extent. In addition, the success rate of unraveling underlying 
genetic mechanisms may be influenced by the complexity of the genetic architecture of the trait of 
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Figure 2. The number of associated loci discovered by GWAS at genome-wide significance (P<5x10−8) on the Y-axis 
by the total number of study participants included in the discovery stage for different complex quantitative traits.
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interest, including imperfect penetrance, allelic heterogeneity, and gene-environment and epigenetic 
effects.
At the beginning of the GWAS era, the field was dominated by the common disease-common variant 
hypothesis, which states that common diseases are caused by common genetic variants.36 Yet, the list 
of rare genetic variants influencing common disease is growing.37 In between these two categories are 
SNPs with minor allele frequency (MAF) of 0.5-5%. In our study of fracture risk, evidence was presented 
that the study of rare CNVs (defined as MAF<0.5% in some studies) deserves follow-up. The propor-
tion of fracture cases with at least one deletion was significantly higher compared to controls and a 
210 kb deletion located on chromosome 6p25.1 was associated with fracture risk (OR=32.58). Also, 
the first effort in our GEFOS and GENOMOS consortium encompassing a sequencing-based GWAS 
meta-analysis has discovered EN1 as a determinant of bone density and fracture (OR=0.85).38 Likewise, 
deCODE investigators have discovered common sequence variants in PTCH139 (MAF= 11.4–22.6%) and 
less frequent (MAF=0.14%–0.18%) variants in LGR440 associated with BMD and fractures (OR=1.09 and 
OR=3.12). Discovery of rare variants is hindered by the large sample sizes required to attain sufficient 
study power, where research consortia prove their worth through ever-increasing sized meta-analyses. 
Larger imputation reference panels and sequencing-based genotyping are becoming progressively 
available, facilitating examination of lower-frequency SNPs and other type of genetic variants such as 
indels and larger deletions.41 Furthermore, genetic variance estimation with imputed variants found that 
the missing heritability for human height and body mass index is negligible;42 this might apply to other 
(quantitative) traits such as BMD as well, for studies are needed. Until now, rare variant association studies 
have found variants with large effects that each explains only a tiny proportion of the phenotypic vari-
ance, because the heritability explained is dependent on the effect size and allele frequency.43 Therefore, 
arguments can be found to study common and rare variants in the occurrence of common diseases,43 
as confirmed by our experiences. Additionally, the osteoporosis field has started to explore non-coding 
variation and epigenetics for for instance microRNA,44 long non-coding RNA,45 and DNA methylation46.
I believe that there are skeletal-site specific effects for fracture risk, for example cortical versus tra-
becular bone, which would justify separate GWAS efforts for specific fracture types. This thinking comes 
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Figure 3. The number of associated loci discovered by GWAS at genome-wide significance (P<5x10−8) on the Y-axis 
by the number of study participants with the disease (cases) included in the discovery stage for different complex 
diseases.
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from the observations that heritability of BMD varies across skeletal sites due to a mixture of shared 
and specific genetic and environmental influences as quantified by the genetic correlations,47 which 
supports the findings that some genetic loci display skeletal-site specific effects.48 Furthermore, it has 
been hypothesized that using stricter phenotype definitions and taking into account fracture mecha-
nisms, while preserving sample size, may increase study power. Efforts for clinical vertebral, hip and 
wrist fractures are underway, but struggle with attaining sufficient study samples to enable discoveries. 
Therefore, the all-type of fracture GWAS approach seems the starting point to attain maximum sample 
size for power to perform the first screening for genetic variants that contribute to osteoporotic fracture 
risk in general. Until now, sample sizes for the subtypes of fractures have been insufficient to perform 
explorative studies, comparable to those by Kemp, Medina-Gomez et al. for BMD,47 into genetic correla-
tions of fracture risk. This information could guide the joint selection and exclusion of sub-phenotypes 
for GWAS. Other even more specific subjects of clinical studies could be atypical (femoral) fractures or 
fracture healing, which could yield insight into differences in natural healing mechanisms and efficacy 
of medical treatment between patients.
CLINICAL ASPECTS OF ENDOCRINE BONE DISEASES
The occurrence of fracture is without doubt the most important clinical outcome in osteoporosis. 
Although fracture risk prediction tools such as FRAX® and Garvan Fracture Risk Calculator may predict 
which patients will sustain a fracture, these algorithms still underestimate observed fracture risk in 
at least half of patients.49 The number of associated conditions with corresponding biomarkers and 
medications with reported adverse effects on skeletal health continues to expand.50 A high predicted 
risk justifies preventative treatment. Clinical measurement of BMD by dual energy X-ray absorptiometry 
(DXA) is currently the most widespread method to diagnose osteoporosis and evaluate the risk of 
fracture. Sensitivity and specificity for incident osteoporotic fractures are limited with an area under the 
ROC curve of 0.63,51, 52 as most fractures occur in mildly to moderately decreased BMD, i.e., osteopenia, or 
even at normal BMD values.53 A moderate proportion (0.19) of variance in risk in the all-type of fracture 
GWAS meta-analysis could be explained by genome-wide common SNPs and the proportion of variance 
explained by the independent genome-wide replicating SNPs was 0.02. More genetic and non-genetic 
fracture determinants remain to be discovered.54
Furthermore, GWAS holds the potential to identify novel therapeutic targets and genetic biomarkers 
that will be useful for drug discovery.55 We have identified multiple brand-new candidate loci and genes 
associated with BMD and fracture risk and postulate that these could be potential novel drug targets for 
osteoporosis. Several of the current drug targets for osteoporosis are detected in our unbiased GWAS 
approach (Table 3). Theoretically, novel understanding of underlying osteoporosis biology may also 
be hypothesis-generating to explore new indications for existing drugs which are already applied in 
other conditions if a common genetic basis would be found. In such cases many phases of costly drug 
development could be shortened. Nelson et al. estimated that selecting genetically supported targets 
could double the success rate in clinical drug development.56 Further, among our top fracture associa-
tions were signals in the vicinity of the genes encoding sclerostin (SOST) and DKK1, known Wnt signal-
ing antagonists, and RSPO3 and low-density lipoprotein receptor-related protein 5 (LRP5), activators 
and regulators of canonical Wnt signaling.57 This is an exciting era in which novel promising drugs are 
becoming available, for example romosozumab,58 a monoclonal antibody that binds to SOST. However, 
it has been difficult to obtain specific Wnt signaling modulators because of the ubiquitous expression 
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of genes across tissue types and the importance of Wnt signaling in diverse physiological processes, 
thereby increasing the likelihood of systemic side-effects.59 Anti-DKK1 monoclonal antibodies BHQ880 
are currently under investigation as a potential therapeutic agent for multiple myeloma.60 No human 
trials in osteoporosis have been published to date; in animal models, anti-DKK1 antibody increases BMD 
in mice61 and macaques62 and promotes fracture healing through activation of beta-catenin signaling63. 
Perhaps potentially most exciting, the rest of our all-type of fracture loci, 18p11.21 (FAM210A), 7q21.3 
(SLC25A13), 7q31.31 (CPED1) and 21q22.2 (FLJ45139), repeatedly appear among the top hits in different 
GWAS for fracture-related traits, such as DXA-BMD and heel bone properties.64 These may thus indicate 
until now unknown biological pathways deserving functional follow-up. A good example of this is the 
follow-up of WNT16, which was prioritized from the findings of BMD GWAS,65-67 in functional biological 
studies. WNT16 is highly expressed in cortical bone but for unknown reasons is only moderately ex-
pressed in trabecular bone,68 and Wnt16−/− mice have a substantial loss of cortical bone, whereas mice 
with Wnt16 overexpression display an increase in trabecular bone.69
FUTURE RESEARCH DIRECTIONS
1. Phenotypes
More research would be desirable to gain insight into the pathophysiology and acquire a wider and 
optimized diagnostic and therapeutic arsenal for endocrine and musculoskeletal diseases, including 
osteoporosis. Deeper phenotyping to better understand underlying disease mechanisms is necessary. 
In parallel, increasing sample size is clearly a key factor for the identification of more genetic factors of 
complex diseases, which is evidently illustrated by Figures 2 and 3. Larger-scale integrative and col-
laborative systematic screening of genetic and non-genetic factors, together with development of more 
advanced genotyping including sequencing, bioinformatic and statistical analysis techniques is the way 
forward. The work described in this thesis has contributed to these aspects of osteoporosis research, but 
further studies are needed.
There may be value in examining longitudinal follow-up assessments within a cohort throughout time, 
such as for example change in levels of BMD or height. Eventually, as ingeniously demonstrated with the 
Snyderome,77 monitoring many different types of measurements of high quality throughout time even 
in a single individual can be powerful. On the longer term, this longitudinal -omics study design may be 
Table 3. Drugs applied to the field of osteoporosis with corresponding signals from genome-wide association stud-
ies (GWAS).
Drugs Company Candidate genes and
protein products
GWAS
Loci
GWAS
References
Raloxifene Daiichi Sankyo ESR1 estrogen receptor alpha 6q25.1 48, 64, 70, 71
GEFOS-2
Bazedoxifene Pfizer
Denosumab Amgen TNFRSF11A receptor activator of nuclear 
factor kappa B; TNFRSF11B osteoprotegerin
18q21.33; 
8q24.12
47, 48, 70-74
GEFOS-2
Romosozumab Amgen SOST sclerostin; LRP5 low-density 
lipoprotein receptor-related protein 5; 
MEF2C myocyte enhancer factor 2C
17q21.31; 
11q13.2;
5q14.3
47, 48, 70, 72, 74-76
GEFOS-2
BHQ880 Novartis DKK1Dickkopf-1; LRP5 low-density 
lipoprotein receptor-related protein 5
10q21.1; 
11q13.2
47, 48, 64, 72, 74
GEFOS-2
GEFOS-2 denotes the BMD and all-type of fracture GWAS meta-analysis described in Chapter 4.1.
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transferrable to cohort studies, including whole genome sequencing data as a backbone of thousands 
of individuals with millions of datapoints comprising different -omics such as transcriptomics and me-
tabolomics repeated during study follow-up. At present, analytical and computing power are limiting 
factors. Statistical methods for GWAS of longitudinal BMD have been explored in work by Sikorska et al.,78 
with proposals for statistical methodology to apply for expedite computations79, 80. In the specific case 
of BMD, a life-course approach may be appropriate where for peak bone mass attained at younger ages 
the emphasis should be on genetic studies because of the high heritability (h2~50%–85%),81 whereas for 
bone loss non-genetic factors become more prominent especially with advanced age (h2~0%–70%)82 
and possibly the focus should be more on metabolic and environmental factors.
2. Imaging
Histomorphometry is the gold standard for assessing bone, because it is the only method for the direct 
analysis of bone cells and their activities.83 Yet, even in the clinical setting bone biopsies are rarely used 
to diagnose and manage patients with osteoporosis, because of their invasiveness.84 Molecular imaging, 
the in vivo characterization and measurement of biologic processes at the cellular and molecular level, is 
being hailed as the next great advance for imaging.85 Technical improvements are necessary for human 
application and minimization of invasiveness and radiation exposure are prerequisites for the introduc-
tion into large-scale population imaging studies in the future to aid the analysis of a large variety of 
musculoskeletal disorders including osteoporosis. In the meantime, alternative innovations may provide 
fair results to minimally invasively measure bone material properties of human bone in vivo, such as 
microindentation by the Osteoprobe®,86, 87 for which the very first results look promising in osteoporotic 
fractures88, 89 and type 2 diabetes26. Such techniques need to be further validated in clinical studies.
Aforementioned DXA innovations such as TBS and “3D-DXA”90 with a C-arm can accomplish 3D recon-
structions. TBS may be recognized as an independent endophenotype and may have potential to guide 
clinical decision making similar to DXA-BMD in the future, which again would justify investigations into 
the determinants of TBS. Nonetheless, there is still a need for additional and more refined radiological 
imaging investigations for osteoporosis, such as assessments based on CT or MRI, where MRI does not 
require radiation. However, CT is more costly and requires more radiation than DXA and conventional 
radiography; MRI, is even more costly and time consuming, produces a limited spatial resolution, and, 
importantly, there is no signal from cortical bone with conventional MRI pulse sequences. This may 
be overcome with novel ultrashort or zero echo time (UTE/ZTE) MRI techniques. A concession is QCT, 
which utilizes low dose scan protocols on a standard CT scanner or (HR-)pQCT by a dedicated extrem-
ity scanner.91 This allows more sophisticated analysis of cortical and trabecular bone, the imaging of 
trabecular structure and the application of finite element analysis (FEA) to biomechanically estimate 
bone strength.92-94 pQCT is also used in exploratory analyses for muscle.95 However, medical evidence is 
still too limited to warrant implementation in clinical practice at this point.96, 97 In the future, diagnostics 
and therapeutics may separately target cortical versus trabecular bone compartments. Currently ap-
plied teriparatide works osteoanabolic for trabecular surfaces, but at the same time it increases cortical 
porosity.98
In population imaging, images of areas of interest or even of the whole body are acquired and 
analyzed in hundreds to thousands of participants in population-based cohort studies. This approach 
increases our understanding of natural variation and the natural history of diseases, and may point us to 
novel risk factors and biomarkers. In the Rotterdam Study, radiography, ultrasound, CT and MRI images 
are available of for example brain, abdominal organs, cardiovascular and locomotor systems in a total 
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of almost 15,000 individuals.99 Population imaging groups will need to join forces in research consortia 
to pool sample sizes. By banding together, knowledge and experiences could be exchanged more 
intensively, furthermore, common research databases systems can be set-up containing de-identified 
participant data including image biobanks. In that case, close to perfect data harmonization would 
become conceivable through central measurements by expert investigators employing a single clearly 
defined protocol.
3. Genomics
However, some of the measurement methods currently available are simply too expensive or invasive 
to apply on a population level at present. Yet, current limits are being challenged, with the very first suc-
cessful large-scale applications of whole-genome sequencing and deep imputation using sequencing-
based reference panels.38 The Haplotype Reference Consortium (HRC) is creating a large reference panel 
of human haplotypes by combining together sequencing data from multiple cohorts. However, the ge-
nome may be too distant in the cascade from the disease of interest to detect clinically relevant patterns, 
therefore, screening the transcriptome, epigenome, metabolome, proteome and even microbiome at 
certain time points may prove necessary. This, again, can be followed-up by typing only a selection 
of markers, possibly by custom content on microarrays, in a select replication sample of succinctly 
phenotyped individuals or several distinct clinical states in fewer individuals. This may change with the 
continuing drop in costs of technologies in the long term, particularly next-generation sequencing. 
Improved quality and increased density of genotyping and imputations will increase confidence in 
genetic information and will further enhance examination of structural variation and rarer variants.
Oftentimes the function of genes contained in the associated loci are not (completely) known. Func-
tional follow-up studies are needed, yet, the development of animal knock-out-models may take years. 
Establishment of multi-disciplinary research consortia world-wide may be beneficial to efficiently take 
GWAS discoveries to functional follow-up in a harmonized research pipeline. Also, publicly available 
databases are being launched to enhance interpretation of genomic sequence information, promoting 
mutual data sharing between expert consortia, professional organizations, health care providers, and 
patients.100 Moreover, the GWAS association signal in the radiographic vertebral fracture GWAS did not 
lie within a gene, and the same was true for some of the signals in the BMD and all-type of fracture 
GWAS. An inventory of the GWAS catalog in 2009 revealed that 88% of the GWAS associations are in 
either intergenic or intronic regions,101 regions of the genome we still understand little about, but to 
which GWAS has contributed by indicating regulatory sites. The Encyclopedia of DNA Elements (EN-
CODE) project, aiming to identify all functional elements in the human genome, has drastically enriched 
our comprehension about regions outside of the exome and showed that many GWAS SNPs overlap 
transcription-factor-occupied regions whereas or DNase I hypersensitive sites and are particularly 
enriched in the segmentation classes associated with enhancers and transcription start sites.102 A strik-
ing finding is that obesity-associated noncoding sequences within the FTO locus are associated with 
expression of the homeobox gene IRX3 at megabase distances, but not with FTO itself;103 this association 
seems to be driven by a topologically associated domain (TAD) structure encompassing the FTO and 
IRXB genes cluster.104 Such genomic explorations remain to be performed for osteoporosis-related traits.
GWAS for various osteoporosis-related traits have shown that targeting quantitative endophenotypes 
with excellent measurement properties (root mean square standard deviation expressed as coefficient 
of variation of 1.0 1.2% for the spine and 1.1 2.2% for the femoral neck by DXA)105 is efficient in the number 
of loci discovered. An exception may be when extreme phenotypes76, 106 display threshold effects, then 
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fewer subjects may be needed with enrichment for highly penetrant variants,107, 108 but still adequate 
sample sizes should be collected to achieve sufficient discovery power.109 However, the tough start of 
the fracture GWAS may be rooted in the complex phenotype definition and heterogeneity of the trait 
and its underlying genetics. A better understanding of the genetic architecture seems necessary. More 
clarity is needed which fracture phenotypes should be studied together because they have a joint ge-
netic etiology, and which do not and thus should be analyzed separately. Then robust selection criteria 
should be defined for an optimal fracture phenotype definition of interest. Research ideas include data 
enrichment for cases that have a known family history for osteoporosis, fractured at relatively young age 
or sustained multiple fractures, etc. Perhaps further exclusion criteria need to be established for cases 
that are thought to be caused by non-genetic mechanisms. Refinement and automatization of mea-
surements may enhance the richness, quality and quantity of research data available. Combination into 
multivariate GWAS of multiple disease-related traits could further exploit the detection of pleiotropic 
effects110 and novel statistical methods may be able to better utilize the richer phenotype information 
that will become available.111, 112
4. Drugs and pharmacogenetics
So far, therapies used to increase bone strength in individuals with osteoporosis are mainly antiresorp-
tives.113 Bisphosphonates are the most widely used first-line because of their effectiveness, reasonable 
safety, and a low cost price.114 However, no single antiresorptive therapy is currently appropriate for all 
patients, as a subgroup of patients put on anti-fracture medication responds suboptimally, e.g., small 
gain in bone mass or new fractures occur in spite of treatment, or negative side-effects including as 
osteonecrosis of the jaw or Atypical Femoral Fractures (AFF).115 To our knowledge no pharmacogenetic 
studies examining these phenomena in osteoporosis have been published to date. In the future, results 
from pharmacogenomics studies may aid in assigning the most effective therapy to specific patient 
groups and it has been hypothesized that genetic biomarkers can be identified to pinpoint those pa-
tients most vulnerable to side-effects of certain agents. Nevertheless, because interaction studies tend 
to involve more parameters, up to four times as many subjects are needed;116 unless extremely large 
effects are in place, as we have witnessed for a few pharmacogenomic successes, such as anticoagulant 
dosing according to VKORC1 haplotypes and HLA-B*5701 screening for the risk of hypersensitivity reac-
tion to abacavir in HIV.117 Until now in genetic osteoporosis research, solely candidate gene studies have 
appeared investigating genetically-based variation in treatment response to raloxifene, teriparatide and 
bisphosphonates.118 One of the reasons for this is that the coverage of pharmacogenomics variants 
is limited on current GWAS genotyping platforms,119, 120 but this may improve with novel microarrays 
becoming available.
5. Risk prediction and personalized medicine
Finally, our clinical practice is in need for improved prediction of fracture risk and more effective preven-
tion and treatment options. Populations at increased risk of fractures should be identified in time and 
subgroups of patients may require different approaches. To be able to initiate precision medicine for 
osteoporosis and other conditions associated with fractures, we will require better performing yet fea-
sible and cost-effective investigations. Eventually, applying an integrative personal omics profile (iPOP)77 
approach to osteoporosis may be the Holy Grail. Clinical risk assessments and treatment evaluations may 
be enhanced with integrated diagnostics utilizing novel biomarkers incorporating possibly (molecular) 
imaging, minimally invasive measurements of bone material properties, genomic, transcriptomic, and 
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metabolomic information.121 Standardized storage and longitudinal follow-up of these parameters inte-
grated into the electronic medical record will be required. We should not be afraid to acquire these data 
in clinic, transfer them to the research bench to get to understand the meaning and clinical relevance 
of this data, and then bring this new knowledge back to the bedside to actually help our patients. 
Knowledge is required about what findings are normal and what is abnormal, and how to interpret what 
is clinically relevant. Then, medical education about this methodology is needed to have this imple-
mented in practice. Choices for osteoporosis therapy have and are still expanding; GWAS findings may 
point to even more potential drug targets remaining to be explored. Hence, it will become increasingly 
important to apply the optimal individualized treatment strategy as our patients deserve the right drug 
at the right time.
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An abnormally low bone mineral density and/or a disrupted bone microarchitecture predispose to 
increased fracture risk, as is the case in osteoporosis and diabetes-related bone disease. These disease 
entities are known to have a multifactorial etiology and have a high population prevalence, particularly 
in the elderly. In this thesis, different aspects of musculoskeletal diseases were investigated, i.e., epidemi-
ology, radiology, and genetics.
Chapter 2 describes several epidemiological studies of osteoporotic fractures performed in the Rotter-
dam Study. In chapter 2.1 we found that in women, short term use of loop diuretics is associated with an 
increased level of free deoxypyridinoline, most likely reflecting increased bone resorption by osteoclasts. 
In chapter 2.2 we learned that cases with lumbar disc degeneration have a systemically higher bone 
mineral density, but this does not protect them from getting vertebral and non-vertebral fractures. In 
chapter 2.3 we explored the association between C-reactive protein levels and increased fracture risk. 
The following two sub-chapters focus on the epidemiology of diabetes-related bone disease. In chapter 
2.4 we studied the literature available for the association between bone mineral density and type 2 
diabetes mellitus. Our meta-analysis of these observational studies confirmed that bone mineral density 
is elevated at multiple skeletal sites in patients with type 2 diabetes mellitus compared to individuals 
without diabetes. As our meta-regression indicated that glycated hemoglobin (HbA1C) modifies this 
relationship, we decided to explore this further in the Rotterdam Study in chapter 2.5. Here we found 
that the group with type 2 diabetes mellitus and poor glucose control had a higher fracture risk than 
the group with type 2 diabetes mellitus and good glucose control or the group without diabetes. 
Intriguingly, at the same time the group with type 2 diabetes mellitus and poor glucose control had a 
higher bone mineral density, narrower neck width and thicker cortices at the femoral neck. Chapter 2.6 
contains a review article on diabetic bone complications. Chapter 2.7 is a review describing osteoporotic 
vertebral fractures as part of systemic disease.
Chapter 3 brings a comparative appraisal of radiological scoring methods for osteoporotic vertebral 
fractures. In chapter 3.1 we review different radiological scoring methods of osteoporotic vertebral 
fractures for clinical and research settings. When applying two of the most commonly used radiological 
scoring methods to the Rotterdam Study we found that prevalences vary widely between these two 
methods, as described in chapter 3.2. The data in chapter 3.3 demonstrate that trabecular bone scores 
are strongly associated with prevalent vertebral fractures in women, and that this measure provides 
information independent of bone mineral density analyzed by dual energy X-ray absorptiometry. Chap-
ter 3.4 illustrates that the data acquired in vertebral fracture morphometry analyses provide multiple 
quantitative parameters, which could be relevant for different musculoskeletal disorders. In chapter 3.5 
we evaluated the radiological criteria and disease prevalence in the Rotterdam Study. In chapter 3.6 we 
assessed how many of Scheuermann’s disease cases would be incorrectly diagnosed as osteoporotic 
vertebral fractures, where we found that the algorithm-based qualitative method performs better than 
quantitative morphometry. Chapter 3.7 contains case series, which emphasizes the need to differentiate 
osteoporotic vertebral fractures from Scheuermann’s disease in daily clinical practice.
Chapter 4 presents various genetic epidemiological studies for fracture risk, with the majority being 
large-scale projects executed within the framework of the genetic factors for osteoporosis (GEFOS) 
and genetic markers for osteoporosis (GENOMOS) consortia. In Chapter 4.1 we identified 56 genetic 
loci for femoral neck bone mineral density and lumbar spine bone mineral density measured by dual 
energy X-ray absorptiometry through a world-wide genome-wide association study meta-analysis of 
83,894 individuals. Furthermore, additional analyses in 133,460 participants revealed that fourteen of 
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these bone mineral density loci are also associated with fracture risk. In chapter 4.2 we directly applied a 
hypothesis-free genome-wide approach for fracture risk, meta-analyzing data from 102,873 persons. This 
effort highlighted 35 genetic signals as associated with fracture risk. Interestingly, half of these loci (i.e., 
eighteen) were among the previously discovered bone mineral density loci, while other gene regions 
have been implicated in neurological and hormonal processes. This seems to illustrate the complex 
interplay of factors contributing to an increased fracture risk. In the end, ten loci replicated at genome-
wide significant level. In chapter 4.3 a genome-wide copy number association study of osteoporotic 
fractures highlighted the 6p25.1 locus. A rare (minor allele frequency [MAF]=0.1%) 210 kb deletion in 
6p25 was associated with increased fracture risk in the Rotterdam Study and further replicated in other 
array-based studies In chapter 4.4 we did the first genome-wide association study for radiographic 
vertebral fractures in the Rotterdam Study finding a marker on chromosome 16q24 as genome-wide 
significantly associated. Although the 16q24 locus has been found associated with bone mineral density 
and vertebral defects at birth before, our association with vertebral fracture risk could not be replicated 
by de-novo genotyping across 15 studies worldwide. In chapter 4.5 we tested single nucleotide poly-
morphisms in the TRPV4 gene for association with osteoporotic fracture risk in human Rotterdam Study 
participants, as these genetic variants were found to have male-specific skeletal effects on osteoblast – 
osteoclast uncoupling in mice. In spite of finding an association in our Rotterdam Study as well, analyses 
of three more studies did not yield the same results. Chapter 4.6 shows the case of a young woman 
with severe osteoporosis and vertebral fractures due to osteoporosis pseudoglioma syndrome/familial 
exudative vitreoretinopathy due to compound heterozygous missense mutations in LRP5, which illus-
trates that genetic screening should be considered in pregnancy associated osteoporosis. The review 
in chapter 4.7 presents the current state of knowledge on the genetic basis of osteoporotic vertebral 
fractures and, additionally, of structural vertebral deformities resembling osteoporotic vertebral fractures 
but which may have their own genetic basis.
Chapter 5 is a future perspective on personalized sequencing and the future of medicine in general.
Finally, in chapter 6 a general discussion is presented of the studies presented in this thesis, and find-
ings are placed in a broader context. Additionally, future directions are proposed at the end of chapter 6.
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Een abnormaal lage botmineraaldichtheid en/of een verstoorde bot microarchitectuur predisponeren 
voor een verhoogd risico op botbreuken, zoals het geval is bij osteoporose en diabetes-gerelateerde 
botziekte. Deze ziektebeelden hebben een multifactoriële etiologie hebben en hebben een hoge 
prevalentie in de algemene bevolking, met name bij ouderen. In dit proefschrift worden verschillende 
aspecten van musculoskeletale aandoeningen onderzocht, namelijk de epidemiologie, radiologie, en 
genetica.
Hoofdstuk 2 beschrijft een aantal epidemiologische studies van osteoporotische fracturen uitgevoerd 
in de Rotterdam Studie. In hoofdstuk 2.1 vonden we dat in vrouwen, kortdurend gebruik van lisdiuretica 
is geassocieerd met een verhoogd niveau van vrij deoxypyridinoline, wat waarschijnlijk weer het gevolg 
is van toegenomen botresorptie door osteoclasten. In hoofdstuk 2.2 hebben we gedemonstreerd dat 
mensen met lumbale degeneratie een systemisch hogere botdichtheid hebben, maar dit resulteert 
bij hen niet in bescherming tegen het krijgen van wervel- en niet-wervelfracturen. In hoofdstuk 2.3 
hebben we de associatie tussen C-reactief proteïne en een verhoogd risico op fracturen onderzocht. 
De volgende twee sub-hoofdstukken richten zich op de epidemiologie van diabetes-gerelateerde 
botziekte. Hoofdstuk 2.4 is een literatuurstudie naar de associatie tussen botdichtheid en type 2 diabetes 
mellitus. Onze meta-analyse van observationele studies bevestigde dat de botmineraaldichtheid op 
meerdere plaatsen van het skelet verhoogd is bij patiënten met type 2 diabetes mellitus in vergelijking 
met mensen zonder diabetes. Uit onze meta-regressie bleek dat geglycolyseerd hemoglobine (HbA1C) 
hierin een rol speelt, en wij hebben dit verder onderzocht in de Rotterdam Studie in hoofdstuk 2.5. 
Hier vonden we dat de groep met type 2 diabetes mellitus en een slechte glycemische controle een 
hoger risico heeft op botbreuken dan de groep met type 2 diabetes mellitus en een goede glycemische 
controle of de groep zonder diabetes. Intrigerend was ook dat de groep met type 2 diabetes mellitus 
met slechte glucosecontrole een hogere botdichtheid had, smallere femurhals breedte en een dikker 
cortex. Hoofdstuk 2.6 bevat een overzichtsartikel over diabetische botcomplicaties. Hoofdstuk 2.7 is een 
beschrijvend overzicht over osteoporotische wervelfracturen als onderdeel van systemische ziekte.
Hoofdstuk 3 geeft een vergelijkend overzicht van de radiologische scoren methoden voor osteopo-
rotische wervelfracturen. In hoofdstuk 3.1 bespreken we verschillende radiologische scoren methoden 
van osteoporotische wervelfracturen voor klinisch onderzoek en de klinische praktijk. Bij de toepassing 
van twee van de meest gebruikte radiologische scoringsmethoden in de Rotterdam Studie vonden we 
dat prevalenties enorm verschilden tussen deze twee methoden, zoals beschreven in hoofdstuk 3.2. 
De gegevens in hoofdstuk 3.3 tonen dat de trabeculaire botscore sterk is geassocieerd met prevalente 
vertebrale fracturen bij vrouwen, en dat deze indicator informatie onafhankelijk van botdichtheid van 
dual energy X-ray absorptiometrie oplevert. Hoofdstuk 3.4 illustreert dat de bij vertebrale morfometrie 
verkregen data meerdere kwantitatieve parameters geeft die relevant kunnen zijn voor verschillende 
musculoskeletale aandoeningen. In hoofdstuk 3.5 onderzochten we de radiologische criteria en de 
prevalentie van de ziekte van Scheuermann in de Rotterdam Studie. In hoofdstuk 3.6 onderzochten 
we hoeveel ziekte van Scheuermann gevallen verkeerd worden gediagnosticeerd als osteoporotische 
wervelbreuken, waar we vonden dat de algoritme gebaseerde kwalitatieve methode beter presteert dan 
kwantitatieve morfometrie. Hoofdstuk 3.7 bevat een case serie, die de noodzaak om osteoporotische 
wervelfracturen te onderscheiden van de ziekte van Scheuermann in de dagelijkse klinische praktijk 
benadrukt.
Hoofdstuk 4 presenteert verschillende genetische epidemiologische studies naar risico op botbreu-
ken, waarvan de meesten grootschalige projecten zijn, uitgevoerd in het kader van de genetische 
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factoren voor osteoporose (GEFOS) en genetische merkers voor osteoporose (GENOMOS) consortia. 
In hoofdstuk 4.1 identifi ceerden we 56 genetische loci voor femurhals botmineraaldichtheid en de 
lumbale wervelkolom botmineraaldichtheid gemeten met dual energy X-ray absorptiometrie door 
middel van een wereldwijde genoom-wijde associatie studie meta-analyse van 83.894 personen. Uit 
aanvullende analyses in 133.460 deelnemers is gebleken dat veertien van deze botmineraaldichtheid 
loci ook geassocieerd zijn met risico op botbreuken. In hoofdstuk 4.2 pasten we direct een hypoth-
esevrije genoom-brede analyse toe voor het risico op botbreuken, door middel van meta-analyse van 
gegevens van 102.873 personen. Deze studie leverde 35 genetische signalen op in associatie met het 
risico op botbreuken. Interessant is dat de helft van deze loci (18) behoorden tot de eerder ontdekte 
botmineraaldichtheid loci, terwijl andere gengebieden zijn betrokken bij neurologische en hormo-
nale processen. Dit lijkt de complexe interactie van factoren die bijdragen aan een verhoogd risico op 
botbreuken te illustreren. Uiteindelijk repliceerden tien signalen op genoom-wijde signifi cantie. De in 
hoofdstuk 4.3 beschreven genoom-wijde kopie nummervariatie studie van osteoporotische fracturen 
wees op het 6p25.1 locus. Een zeldzame (minor allel frequentie [MAF]=0,1%) 210 kb deletie in 6p25 werd 
geassocieerd met een verhoogd risico op botbreuken in de Rotterdam Studie en verder gerepliceerd 
in andere array-gebaseerde studies. In hoofdstuk 4.4 hebben we de eerste genoom-brede associatie 
studie voor radiografi sche wervelfracturen in de Rotterdam Studie, waarin een marker op chromosoom 
16q24 genoom-breed signifi cant geassocieerd bleek te zijn. Hoewel het 16q24 locus eerder geasso-
cieerd was bevonden met botdichtheid en congenitale wervelkolom afwijkingen, kon de associatie met 
wervelfractuur risico niet worden gerepliceerd door de-novo genotypering in 15 studies over de hele 
wereld. In hoofdstuk 4.5 testten we single nucleotide polymorfi smen in het TRPV4 gen voor associatie 
met osteoporotische fracturen in Rotterdam Studie deelnemers, omdat deze genetische varianten in 
mannen skeletale eff ecten op de osteoblast bleken te hebben – namelijk osteoclasten ontkoppeling 
bij muizen. Ondanks het vinden van de associatie in de Rotterdam Studie, leverden analyses van drie 
andere studies niet dezelfde resultaten op. Hoofdstuk 4.6 toont de beschrijving van een jonge vrouw 
met ernstige osteoporose en wervelfracturen te wijten aan het osteoporose pseudoglioom syndroom 
/ familiale exsudatieve vitreoretinopathie door compound heterozygote missense mutaties in LRP5, 
dat aantoont dat genetische screening in zwangerschap-gerelateerde osteoporose moet worden 
overwogen. De review in hoofdstuk 4.7 presenteert de huidige stand van kennis over de genetische 
basis van osteoporotische wervelfracturen, en van de structurele werveldeformaties die kunnen lijken 
op osteoporotische wervelfracturen, maar die hun eigen genetische basis kunnen hebben.
Hoofdstuk 5 is een toekomstperspectief over persoonlijke sequencing en de toekomst van de ge-
neeskunde in het algemeen.
Tenslotte wordt in hoofdstuk 6 een algemene discussie gegeven van de studies in dit proefschrift, en 
de bevindingen worden in een bredere context geplaatst. Daarnaast worden toekomstige richtingen 
voorgesteld aan het einde van hoofdstuk 6.
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A, Jones G, Dailiana Z, Giroux S, Lacroix AZ, Frost M, Lorentzon M, McCloskey E, Robbins J, Liu Y, Breda SJ, Tang 
NL, Szulc P, Husted LB, Prince RL, Lewis JR, Nethander M, Rousseau F, Luben R, Cauley JA, Arnold A, Reppe S, 
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A, Lewis JR, Masi L, Shen J, van Meurs JBJ, Lee SH, Sham PC, Psaty BM, Harris TB, Reeve J, Jukema JW, Metspalu 
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D**, Orwoll E**, Forgetta V**, Kiel DP**, Ohlsson C**, Richards JB**, Rivadeneira F**, for the GEFOS consortium. 
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Summary of PhD training and teaching
Name PhD student: H. Ling D.W. Oei
Erasmus MC Departments: Internal Medicine and Epidemiology
Research School: NIHES / MolMed Erasmus University
PhD period: 2010- 2016
Promotor(s): Prof. dr. A.G. Uitterlinden
Supervisor: Dr. F. Rivadeneira
1. PhD training
year Workload
General courses
-  Laboratory animal science (functionary, article 9) 2007
-  Radiation protection, competence level 5B 2007
-  BROK (‘Basiscursus Regelgeving Klinisch Onderzoek’) 2012 1.0 ECTS
-  Biomedical English Writing and Communication 2012 4.0 ECTS
Specific courses
NIHES:
-  Advances in Genome-Wide Association Studies (GE03) 2010 1.4 ECTS
-  Principles of Research in Medicine (ESP01) 2010 0.7 ECTS
-  Principles of Genetic Epidemiology (ESP43) 2010 0.7 ECTS
-  Genomics in Molecular Medicine (ESP57) 2010 1.4 ECTS
-  Master class: Advances in Genomics Research (ESP63) 2010 0.3 ECTS
-  Genome Wide Association Analysis (ESP29) 2010 1.4 ECTS
-  Study Design (CC01) 2010 4.3 ECTS
-  Classical Methods for Data-analysis (CC02) 2010 5.7 ECTS
-  Modern Statistical Methods (EP03) 2010 4.3 ECTS
-  Courses for the Quantitive Researcher (EP17) 2010 1.4 ECTS
-  Genetic Linkage Analysis: Model-free analysis (GE05) 2011 1.4 ECTS
-  Mendelian Randomization (GE10) 2011 0.9 ECTS
-  Missing Values in Clinical Research (EP16) 2011 0.7 ECTS
-  Topics in Meta-analysis (ESP15) 2011 0.7 ECTS
-  Clinical Decision Analysis (ESP04) 2011 0.7 ECTS
-  Conceptual Foundation of Epidemiologic Study Design (ESP38) 2011 0.7 ECTS
-  Cohort Studies (ESP39) 2011 0.7 ECTS
-  Demography of Ageing (ESP59) 2011 0.7 ECTS
-  Health Economics (ESP25) 2011 0.7 ECTS
-  Genetic-epidemiologic Research Methods (GE02) 2011 5.7 ECTS
-  Linux for scientists 2010, 2011 0.9 ECTS
-  Introduction to Clinical and Public Health Genomics (EWP11) 2012 1.9 ECTS
-  A first encounter with next-generation sequencing data (GE13) 2012 1.4 ECTS
Molmed:
-  SNPs and Human Diseases (GE08) 2010 1.4 ECTS
-  Basic and translational endocrinology 2011 2 ECTS
-  Annual Molmed Course 2011 0.7 ECTS
-  Annual Molmed Day 2011 0.3 ECTS
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-  Workshop Browsing Genes and Genomes with UCSC 2011 0.4 ECTS
-  Biobase course: principles of NGS data analysis and interpretation 2012 0.4 ECTS
Seminars and workshops
-  Joint Valorisation Workshop NCHA/CGC (Rotterdam, The Netherlands) 2010 March 10
-  Clinical Translation of Bone Biology (Rhoon, The Netherlands) 2010 April 8
-  Critical Appraisal of Osteoporosis Treatment (Delft, The Netherlands) 2010 April 13
-  Imaging Workshop for MDs (MolMed) (Rotterdam, The Netherlands) 2010 May 17
-  Endocrine Fellows Foundation/American Diabetes Association (EFF/ADA) Fellows 
Forum
2011 September 14-15
-  Weekly scientific seminars at department of Epidemiology 2010-2012
-  Erasmus lectures on endocrinology 2010-2012
-  Erasmus course endocrinology 2009, 2014
-  Osteoporosis Symposium 2016
Presentations
Genome-wide Association In the Rotterdam Study Implicates the 16q24 Locus As 
Determinant of Osteoporotic Vertebral Fractures.
-  (oral) 32nd American Society for Bone Mineral Research Annual Meeting (Canada, 
Toronto).
2010 October 15-19
-  (oral) 20th Dutch Society for Calcium and Bone Metabolism Annual Meeting (Zeist, 
The Netherlands).
2010 November 11-12
-  (poster) Dutch Society for Human Genetics Meeting (Amsterdam, The Netherlands). 2010 November 19
-  (poster) 15th Belgian Society of Internal Medicine (BVIG-SBMI) Annual Congress 
(Leuven, Belgium).
2010 December 3-4
-  (poster) Erasmus MC Internal Medicine Annual Science Day, (Antwerp, Belgium). 2011 January 13-14
-  (poster) 15th Molecular Medicine Day (Rotterdam, The Netherlands). 2011 February 3
-  (poster) 13th European Congress of Endocrinology (Rotterdam, The Netherlands). 2011 April 30-May 4
Challenges on phenotype definition: the case osteoporotic vertebral fractures.
-  (poster) 6th CHARGE Consortium Investigators Meeting (Boston, United States). 2011 February 9-11
The first genome-wide association study for osteoporotic vertebral fractures.
-  (poster) Netherlands Consortium for Healthy Ageing outreach and kick-off meeting 
(Amersfoort, The Netherlands).
2011 March 14-15
Women with inadequately controlled type 2 diabetes are at increased risk of 
osteoporotic fractures despite higher bone mineral density: the Rotterdam Study.
-  (poster) 3rd Joint Meeting of the European Calcified Tissue Society and the 
International Bone and Mineral Society (Athens, Greece).
2011 May 7-11
-  (plenary poster) 33rd American Society for Bone Mineral Research Annual Meeting 
(San Diego, United States).
2011 September 16-20
Large-scale meta-analyses of genome-wide association studies for fracture risk: the 
GEFOS consortium.
-  (oral) 33rd American Society for Bone Mineral Research Annual Meeting (San Diego, 
United States).
2011 September 16-20
-  (poster) 12th International Congress of Human Genetics (Montreal, Canada) 2011 October 11-15
Review of radiological scoring methods of osteoporotic vertebral fractures for clinical 
and research settings.
-  (poster) 97th Annual Meeting of the Radiological Society of North America (Chicago, 
United States)
2011 November 27- 
December 2
Degree of glucose control and risk of fracture in type 2 diabetes: the Rotterdam Study
-  (poster) Erasmus MC Internal Medicine Annual Science Day, (Antwerp, Belgium). 2012 January 12-13
-  (oral) Dutch Association of Endocrinology (NVE) Annual Meeting (Noordwijkerhout, 
The Netherlands)
2012 February 10-11
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-  (poster) Netherlands Consortium for Healthy Ageing outreach phase II Meeting 
(Amersfoort, The Netherlands).
2012 March 12-13
-  (oral and poster) Meeting of the European Calcified Tissue Society (Stockholm, 
Sweden).
2012 May 19-23
-  (poster) Dutch annual conference on Epidemiology (WEON) (Rotterdam, The 
Netherlands).
2012 June 14-15
Osteoporotic Vertebral Fracture Prevalences Vary Widely Between Radiological Scoring 
Methods: The Rotterdam Study
-  (poster) Dutch annual conference on Epidemiology (WEON) (Rotterdam, The 
Netherlands).
2012 June 14-15
-  (oral) Dutch Society for Calcium and Bone Metabolism Meeting (Zeist, The 
Netherlands).
2012 November 1-2
-  (oral) American Society for Bone Mineral Research Annual Meeting (Minneapolis, 
United States).
2012 October 12-15
Genetic Epidemiology of Diabetes and Bone Disease
-  (seminar) Stanford University, Department of Genetics (Stanford, United States). 2012 June 26
Brief Introduction to The Rotterdam Study
-  (invited presentation) University of California at San Francisco (San Francisco, United 
States).
2012 November 9
Genome-Wide Association Studies Meta-Analysis For Fracture Risk
-  (invited presentation) University of California at San Francisco (San Francisco, United 
States).
2012 November 9
Scheuermann’s Disease: Evaluation of Radiological Criteria and Population Prevalence
-  (poster) World Congress on Osteoarthritis (Philadelphia, United States). 2013 April 18-21
Painful Vertebral Fractures During Pregnancy: Be Aware Of A Potentially Underlying 
Genetic Cause
-  (oral) Endocrine Society (San Francisco, United States) 2013 June 15-18
Dissecting the Relationship Between High-Sensitivity Serum C-Reactive Protein and 
Increased Fracture Risk: The Rotterdam Study
-  (oral) Endocrine Society (San Francisco, United States) 2013 June 15-18
-  (oral poster) American Society for Bone Mineral Research Annual Meeting 
(Baltimore, United States).
2013 October 4-7
Large-scale Genetic Studies and Personalized Medicine in Osteoporotic Fractures
-  (invited seminar) University of California at San Francisco (San Francisco, United 
States).
2013 July 12
The genetic basis of cross-phenotype correlation with bone fracture risk: the GEFOS 
consortium
-  (poster) American Society for Bone Mineral Research Annual Meeting (Baltimore, 
United States).
2013 October 4-7
Differentiating Osteoporotic Vertebral Fractures from Scheuermann’s Disease using 
Different Radiological Assessment Methods for Osteoporotic Vertebral Fractures: The 
Rotterdam Study
-  (oral) American Society for Bone Mineral Research Annual Meeting (Baltimore, 
United States).
2013 October 4-7
Prediction of vertebral fracture by Trabecular Bone Score in elderly women of The 
Rotterdam Study
-  (oral) American Society for Bone Mineral Research Annual Meeting (Baltimore, 
United States).
2013 October 4-7
Genes, Hormones and Bones: Genetic Epidemiology of Endocrine and Skeletal Disease
-  (invited seminar) Veterans Affairs Medical Center, University of California at San 
Francisco (San Francisco, United States).
2013 October 15
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-  (grand rounds) Stanford University, Department of Endocrinology (Stanford, United 
States).
2013 November 6
Type 2 Diabetes, Inflammation, Genetics and Bone Fractures
-  (invited seminar) University of California at San Francisco (San Francisco, United 
States).
2013 November 22
Large-scale Population Imaging to Investigate the Genetic Epidemiology of 
Radiographic Scheuermann’s Disease: the Rotterdam Study
-  (poster) 99th Annual Meeting of the Radiological Society of North America 
(Chicago, United States).
2013 December 1-6
-  (poster) World Congress on Osteoarthritis (Philadelphia, United States). 2013 April 18-21
Genome-Wide Association Studies (GWAS) meta-analysis for fracture risk points to loci 
related to hormonal and neurological pathways: the GEFOS Consortium
-  (poster) American Society for Bone Mineral Research Annual Meeting (Minneapolis, 
United States).
2012 October 12-15
-  (oral) Dutch Society for Calcium and Bone Metabolism Meeting (Zeist, The 
Netherlands).
2012 November 1-2
-  (oral) American Society of Human Genetics (San Francisco, United States). 2013 November 6-10
-  (poster) Erasmus MC Internal Medicine Annual Science Day (Antwerp, Belgium). 2014 January 9-10
Reninoma: a Rare Cause of Curable Hypertension and Hypokalemia
-  (oral) Rotterdam Regional Clinical Conference of Internal Medicine (Rotterdam, The 
Netherlands).
2015 November 19
-  (oral) Netherlands Internal Medicine Annual Meeting (Maastricht, The Netherlands). 2016 April 20-22
(Inter)national conferences
-  Dutch Association of Endocrinology (NVE) Annual Meeting, Noordwijkerhout, The 
Netherlands.
2010 January 29-30
-  Dutch Internist Association Annual Meeting (Maastricht, The Netherlands). 2010 April 21-23
-  CHARGE Consortium Investigators Meeting (Houston, United States). 2010 April 28-30
-  European Symposium on Calcified Tissues (Glasgow, Great Britain). 2010 June 26-30
-  GEFOS/GENOMOS Consortia Investigators Meeting (Glasgow, Great Britain). 2010 June 27
-  American Society for Bone Mineral Research Annual Meeting (Toronto, Canada). 2010 October 15-19
-  GEFOS/GENOMOS Consortia Investigators Meeting (Toronto, Canada). 2010 October 19
-  Belgian Society of Internal Medicine (BVIG-SBMI) Annual Congress (Leuven, 
Belgium).
2010 December 3-4
-  CHARGE Consortium Investigators Meeting (Boston, United States) 2011 February 9-11
-  International Networking Conference: ‘From DNA to phenotype’ (Rotterdam, The 
Netherlands)
2011 March 9-11
-  European Congress of Endocrinology (Rotterdam, The Netherlands). 2011 April 30 -
May 4
-  Joint Meeting of the European Calcified Tissue Society and the International Bone 
and Mineral Society (Athens, Greece).
2011 May 7-11
-  GEFOS/GENOMOS Consortia Investigators Meeting (Athens, Greece). 2011 May 7
-  American Society for Bone Mineral Research Annual Meeting (San Diego, United 
States).
2011 September 16-20
-  GEFOS/GENOMOS Consortia Investigators Meeting (San Diego, United States) 2011 September 19
-  Radiological Society of North America Annual Meeting (Chicago, United States) 2011 November 27 
-December 02
-  Dutch Association of Endocrinology (NVE) Annual Meeting (Noordwijkerhout, The 
Netherlands)
2012 February 10-11
-  Meeting of the European Calcified Tissue Society, Stockholm, Sweden. 2012 May 19-23
-  Dutch annual conference on Epidemiology (WEON) (Rotterdam, The Netherlands). 2012 June 14-15
- 405 -
8
Ap
pe
nd
ic
es
-  American Society for Bone Mineral Research Annual Meeting (Minneapolis, United 
States).
2012 October 12-15
-  American Society of Human Genetics Annual Meeting (San Francisco, United 
States).
2012 November 6-10
-  Radiological Society of North America Annual Meeting (Chicago, United States) 2012 November 25-30
-  Personalized Medicine World Conference (Mountain View, United States). 2013 January 28-29
-  Osteoarthritis Research Society International (Philadelphia, United States). 2013 April 18-21
-  ENDO Endocrine Society Annual Meeting (San Francisco, United States). 2013 June 15-18
-  American Society for Bone Mineral Research Annual Meeting (Baltimore, United 
States).
2013 October 4-7
-  GEFOS/GENOMOS Consortia Investigators Meeting (Baltimore, United States). 2013 October 5
-  Radiological Society of North America Annual Meeting (Chicago, United States) 2013 December 1-6
-  Dutch Internist Association Annual Meeting (Maastricht, The Netherlands). 2014 April 23-25
-  Dutch Internist Association Annual Meeting (Maastricht, The Netherlands). 2015 April 22-24
-  European Calcified Tissue Society Meeting (Rotterdam, The Netherlands). 2015 April 25-28
-  Dutch Internist Association Annual Meeting (Maastricht, The Netherlands). 2016 April 20-22
-  European Congress of Internal Medicine Annual Meeting (Amsterdam, The 
Netherlands).
2016 September 2-4
Other
Associate Editor for journals:
-  Gene 2013-2014 16 manuscripts
Peer-reviewing for journals:
-  European Journal of Epidemiology 2010, 2012 2 manuscripts
-  Gene 2011, 
2012, 
2013
12 manuscripts
-  Plos One 2012, 2013 3 manuscripts
-  New England Journal of Medicine 2012 1 manuscript
-  Calcified Tissue International 2012 2 manuscripts
-  Osteoporosis International 2012, 2016 2 manuscripts
-  Joint Bone Spine 2013 1 manuscript
-  Journal of Bone and Mineral Research 2013, 2015 2 manuscripts
-  Journal of Clinical Endocrinology and Metabolism 2014 1 manuscript
-  BMC Musculoskeletal Disorders 2014 1 manuscript
-  British Medical Journal 2015 1 manuscript
-  Bone 2016 1 manuscript
Service positions for scientific organizations:
-  American Society for Bone and Mineral Research: Annual Meeting peer-reviewing of 
abstracts
2014, 2015
-  European Calcified Tissue Society: Annual Meeting session moderator 2015
Grants and awards
-  American Society of Bone Mineral Research (ASBMR) Travel Grant 2013
-  Dutch Association of Endocrinology “Goodlife Healthcare Travel Grant” 2013
-  Simons Fund Foundation. Fellowship subsidy 2013
-  Erasmus University Trust Fund. Postdoctoral fellowship subsidy 2013
-  Dutch Society for Calcium and Bone Metabolism Best Presentation Award 2012
-  Endocrine Fellows Foundation/American Diabetes Association (EFF/ADA) Fellows 
Forum Meeting Support
2012
-  American Society of Bone Mineral Research (ASBMR) Travel Grant 2012
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-  Endocrine Fellows Foundation/American Diabetes Association (EFF/ADA) Fellows 
Forum Meeting Support
2011
-  American Society of Bone Mineral Research (ASBMR) Travel Grant 2011
-  Gordon Research Conference Travel Support 2011
-  European Calcified Tissue Society Travel Grant 2011
-  Dutch Association of Endocrinology “Goodlife Healthcare Travel Grant” 2011
-  American Society of Bone Mineral Research (ASBMR) Young Investigator Award 2010
2. Teaching
year Workload
Lecturing
Teacher for Erasmus University medical school:
-  journal club (diabetes) 2011 0.2 ECTS
-  compulsory education (thyroid disease) 2011, 2012 0.6 ECTS
Supervising practicals and excursions, tutoring
-  Supervision of abstract writing (Student: Felisia Ly) 2011
-  Supervision of a student working team working on data cleaning of DXA scans in 
Erasmus Rotterdam Health Research (ERGO) and Generation R studies. (Students: 
Rodinde Bloot, Mette Offerhaus)
2010-2011
-  Supervision of a student working team working on digitization of radiographs in 
the ERGO study. (Students: Emma Dogterom, Laura de Kok, Mette Offerhaus, Felisia 
Ly, Hanna Ning, Florian Buisman, Nadia Rbia, Burak Kalin, Nuray Cakici, Stephan 
Breda, Bart Hazemeijer, Evelien van Meel, Nienke Bart)
2010-2011
-  Supervision of a student working team working on vertebral fracture assessment in 
the ERGO study. (Students: Rodinde Bloot, Laura de Kok, Mette Offerhaus, Felisia Ly, 
Hanna Ning, Stephan Breda, Bart Hazemeijer, Evelien van Meel, Nienke Bart, Khadija 
Moumni, Maarten Meijer, Sebastian Valk Bonila, Sander Verkade, Maria Tihaya, 
Lisanne van de Koevering)
2010-2012
-  SNP course practical 2012
-  Supervision of medical interns in internal medicine 2014-2016
Supervising Master’s theses
-  Medical student Salih El Saddy 2011 6 ECTS
-  Medical student Ater Andrew Makurthou 2011 6 ECTS
-  Medical student Stephan Breda 2012 6 ECTS
-  Medical student Khadija Moumni 2013 Co-supervision
-  Medical student Sema Ozdemir 2013 Co-supervision
-  Medical student Sebastian Valk Bonilla 2013 Co-supervision
Other
-  GEnetic Factors for OSteoporosis (GEFOS) Consortium: general coordination, co-
organizing meetings, set-up and coordination of vertebral fracture and all-type of 
fracture working groups
2010-2014
-  GENOMOS Consortium: general coordination, co-organizing meetings 2010-2014
-  CHARGE Consortium: participation in musculoskeletal working group 2010-2014
-  ERGO Rotterdam Study: coordination of musculoskeletal research findings that are 
potentially clinically relevant
2010-2014
-  Visiting scholar at dr. Michael Snyder’s lab Stanford University, Department of 
Genetics
2013
-  Educational committee member IJsselland hospital 2015-2016
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